<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />


<meta name="author" content="Yina Liu" />

<meta name="date" content="2020-10-13" />

<title>PM566-Assignment3</title>

<script>/*! jQuery v1.11.3 | (c) 2005, 2015 jQuery Foundation, Inc. | jquery.org/license */
!function(a,b){"object"==typeof module&&"object"==typeof module.exports?module.exports=a.document?b(a,!0):function(a){if(!a.document)throw new Error("jQuery requires a window with a document");return b(a)}:b(a)}("undefined"!=typeof window?window:this,function(a,b){var c=[],d=c.slice,e=c.concat,f=c.push,g=c.indexOf,h={},i=h.toString,j=h.hasOwnProperty,k={},l="1.11.3",m=function(a,b){return new m.fn.init(a,b)},n=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g,o=/^-ms-/,p=/-([\da-z])/gi,q=function(a,b){return b.toUpperCase()};m.fn=m.prototype={jquery:l,constructor:m,selector:"",length:0,toArray:function(){return d.call(this)},get:function(a){return null!=a?0>a?this[a+this.length]:this[a]:d.call(this)},pushStack:function(a){var b=m.merge(this.constructor(),a);return b.prevObject=this,b.context=this.context,b},each:function(a,b){return m.each(this,a,b)},map:function(a){return this.pushStack(m.map(this,function(b,c){return a.call(b,c,b)}))},slice:function(){return this.pushStack(d.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},eq:function(a){var b=this.length,c=+a+(0>a?b:0);return this.pushStack(c>=0&&b>c?[this[c]]:[])},end:function(){return this.prevObject||this.constructor(null)},push:f,sort:c.sort,splice:c.splice},m.extend=m.fn.extend=function(){var a,b,c,d,e,f,g=arguments[0]||{},h=1,i=arguments.length,j=!1;for("boolean"==typeof g&&(j=g,g=arguments[h]||{},h++),"object"==typeof g||m.isFunction(g)||(g={}),h===i&&(g=this,h--);i>h;h++)if(null!=(e=arguments[h]))for(d in e)a=g[d],c=e[d],g!==c&&(j&&c&&(m.isPlainObject(c)||(b=m.isArray(c)))?(b?(b=!1,f=a&&m.isArray(a)?a:[]):f=a&&m.isPlainObject(a)?a:{},g[d]=m.extend(j,f,c)):void 0!==c&&(g[d]=c));return g},m.extend({expando:"jQuery"+(l+Math.random()).replace(/\D/g,""),isReady:!0,error:function(a){throw new Error(a)},noop:function(){},isFunction:function(a){return"function"===m.type(a)},isArray:Array.isArray||function(a){return"array"===m.type(a)},isWindow:function(a){return null!=a&&a==a.window},isNumeric:function(a){return!m.isArray(a)&&a-parseFloat(a)+1>=0},isEmptyObject:function(a){var b;for(b in a)return!1;return!0},isPlainObject:function(a){var b;if(!a||"object"!==m.type(a)||a.nodeType||m.isWindow(a))return!1;try{if(a.constructor&&!j.call(a,"constructor")&&!j.call(a.constructor.prototype,"isPrototypeOf"))return!1}catch(c){return!1}if(k.ownLast)for(b in a)return j.call(a,b);for(b in a);return void 0===b||j.call(a,b)},type:function(a){return null==a?a+"":"object"==typeof a||"function"==typeof a?h[i.call(a)]||"object":typeof a},globalEval:function(b){b&&m.trim(b)&&(a.execScript||function(b){a.eval.call(a,b)})(b)},camelCase:function(a){return a.replace(o,"ms-").replace(p,q)},nodeName:function(a,b){return a.nodeName&&a.nodeName.toLowerCase()===b.toLowerCase()},each:function(a,b,c){var d,e=0,f=a.length,g=r(a);if(c){if(g){for(;f>e;e++)if(d=b.apply(a[e],c),d===!1)break}else for(e in a)if(d=b.apply(a[e],c),d===!1)break}else if(g){for(;f>e;e++)if(d=b.call(a[e],e,a[e]),d===!1)break}else for(e in a)if(d=b.call(a[e],e,a[e]),d===!1)break;return a},trim:function(a){return null==a?"":(a+"").replace(n,"")},makeArray:function(a,b){var c=b||[];return null!=a&&(r(Object(a))?m.merge(c,"string"==typeof a?[a]:a):f.call(c,a)),c},inArray:function(a,b,c){var d;if(b){if(g)return g.call(b,a,c);for(d=b.length,c=c?0>c?Math.max(0,d+c):c:0;d>c;c++)if(c in b&&b[c]===a)return c}return-1},merge:function(a,b){var c=+b.length,d=0,e=a.length;while(c>d)a[e++]=b[d++];if(c!==c)while(void 0!==b[d])a[e++]=b[d++];return a.length=e,a},grep:function(a,b,c){for(var d,e=[],f=0,g=a.length,h=!c;g>f;f++)d=!b(a[f],f),d!==h&&e.push(a[f]);return e},map:function(a,b,c){var d,f=0,g=a.length,h=r(a),i=[];if(h)for(;g>f;f++)d=b(a[f],f,c),null!=d&&i.push(d);else for(f in a)d=b(a[f],f,c),null!=d&&i.push(d);return e.apply([],i)},guid:1,proxy:function(a,b){var c,e,f;return"string"==typeof b&&(f=a[b],b=a,a=f),m.isFunction(a)?(c=d.call(arguments,2),e=function(){return a.apply(b||this,c.concat(d.call(arguments)))},e.guid=a.guid=a.guid||m.guid++,e):void 0},now:function(){return+new Date},support:k}),m.each("Boolean Number String Function Array Date RegExp Object Error".split(" "),function(a,b){h["[object "+b+"]"]=b.toLowerCase()});function r(a){var b="length"in a&&a.length,c=m.type(a);return"function"===c||m.isWindow(a)?!1:1===a.nodeType&&b?!0:"array"===c||0===b||"number"==typeof b&&b>0&&b-1 in a}var s=function(a){var b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u="sizzle"+1*new Date,v=a.document,w=0,x=0,y=ha(),z=ha(),A=ha(),B=function(a,b){return a===b&&(l=!0),0},C=1<<31,D={}.hasOwnProperty,E=[],F=E.pop,G=E.push,H=E.push,I=E.slice,J=function(a,b){for(var c=0,d=a.length;d>c;c++)if(a[c]===b)return c;return-1},K="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",L="[\\x20\\t\\r\\n\\f]",M="(?:\\\\.|[\\w-]|[^\\x00-\\xa0])+",N=M.replace("w","w#"),O="\\["+L+"*("+M+")(?:"+L+"*([*^$|!~]?=)"+L+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+N+"))|)"+L+"*\\]",P=":("+M+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+O+")*)|.*)\\)|)",Q=new RegExp(L+"+","g"),R=new RegExp("^"+L+"+|((?:^|[^\\\\])(?:\\\\.)*)"+L+"+$","g"),S=new RegExp("^"+L+"*,"+L+"*"),T=new RegExp("^"+L+"*([>+~]|"+L+")"+L+"*"),U=new RegExp("="+L+"*([^\\]'\"]*?)"+L+"*\\]","g"),V=new RegExp(P),W=new RegExp("^"+N+"$"),X={ID:new RegExp("^#("+M+")"),CLASS:new RegExp("^\\.("+M+")"),TAG:new RegExp("^("+M.replace("w","w*")+")"),ATTR:new RegExp("^"+O),PSEUDO:new RegExp("^"+P),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+L+"*(even|odd|(([+-]|)(\\d*)n|)"+L+"*(?:([+-]|)"+L+"*(\\d+)|))"+L+"*\\)|)","i"),bool:new RegExp("^(?:"+K+")$","i"),needsContext:new RegExp("^"+L+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+L+"*((?:-\\d)?\\d*)"+L+"*\\)|)(?=[^-]|$)","i")},Y=/^(?:input|select|textarea|button)$/i,Z=/^h\d$/i,$=/^[^{]+\{\s*\[native \w/,_=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,aa=/[+~]/,ba=/'|\\/g,ca=new RegExp("\\\\([\\da-f]{1,6}"+L+"?|("+L+")|.)","ig"),da=function(a,b,c){var d="0x"+b-65536;return d!==d||c?b:0>d?String.fromCharCode(d+65536):String.fromCharCode(d>>10|55296,1023&d|56320)},ea=function(){m()};try{H.apply(E=I.call(v.childNodes),v.childNodes),E[v.childNodes.length].nodeType}catch(fa){H={apply:E.length?function(a,b){G.apply(a,I.call(b))}:function(a,b){var c=a.length,d=0;while(a[c++]=b[d++]);a.length=c-1}}}function ga(a,b,d,e){var f,h,j,k,l,o,r,s,w,x;if((b?b.ownerDocument||b:v)!==n&&m(b),b=b||n,d=d||[],k=b.nodeType,"string"!=typeof a||!a||1!==k&&9!==k&&11!==k)return d;if(!e&&p){if(11!==k&&(f=_.exec(a)))if(j=f[1]){if(9===k){if(h=b.getElementById(j),!h||!h.parentNode)return d;if(h.id===j)return d.push(h),d}else if(b.ownerDocument&&(h=b.ownerDocument.getElementById(j))&&t(b,h)&&h.id===j)return d.push(h),d}else{if(f[2])return H.apply(d,b.getElementsByTagName(a)),d;if((j=f[3])&&c.getElementsByClassName)return H.apply(d,b.getElementsByClassName(j)),d}if(c.qsa&&(!q||!q.test(a))){if(s=r=u,w=b,x=1!==k&&a,1===k&&"object"!==b.nodeName.toLowerCase()){o=g(a),(r=b.getAttribute("id"))?s=r.replace(ba,"\\$&"):b.setAttribute("id",s),s="[id='"+s+"'] ",l=o.length;while(l--)o[l]=s+ra(o[l]);w=aa.test(a)&&pa(b.parentNode)||b,x=o.join(",")}if(x)try{return H.apply(d,w.querySelectorAll(x)),d}catch(y){}finally{r||b.removeAttribute("id")}}}return i(a.replace(R,"$1"),b,d,e)}function ha(){var a=[];function b(c,e){return a.push(c+" ")>d.cacheLength&&delete b[a.shift()],b[c+" "]=e}return b}function ia(a){return a[u]=!0,a}function ja(a){var b=n.createElement("div");try{return!!a(b)}catch(c){return!1}finally{b.parentNode&&b.parentNode.removeChild(b),b=null}}function ka(a,b){var c=a.split("|"),e=a.length;while(e--)d.attrHandle[c[e]]=b}function la(a,b){var c=b&&a,d=c&&1===a.nodeType&&1===b.nodeType&&(~b.sourceIndex||C)-(~a.sourceIndex||C);if(d)return d;if(c)while(c=c.nextSibling)if(c===b)return-1;return a?1:-1}function ma(a){return function(b){var c=b.nodeName.toLowerCase();return"input"===c&&b.type===a}}function na(a){return function(b){var c=b.nodeName.toLowerCase();return("input"===c||"button"===c)&&b.type===a}}function oa(a){return ia(function(b){return b=+b,ia(function(c,d){var e,f=a([],c.length,b),g=f.length;while(g--)c[e=f[g]]&&(c[e]=!(d[e]=c[e]))})})}function pa(a){return a&&"undefined"!=typeof a.getElementsByTagName&&a}c=ga.support={},f=ga.isXML=function(a){var b=a&&(a.ownerDocument||a).documentElement;return b?"HTML"!==b.nodeName:!1},m=ga.setDocument=function(a){var b,e,g=a?a.ownerDocument||a:v;return g!==n&&9===g.nodeType&&g.documentElement?(n=g,o=g.documentElement,e=g.defaultView,e&&e!==e.top&&(e.addEventListener?e.addEventListener("unload",ea,!1):e.attachEvent&&e.attachEvent("onunload",ea)),p=!f(g),c.attributes=ja(function(a){return a.className="i",!a.getAttribute("className")}),c.getElementsByTagName=ja(function(a){return a.appendChild(g.createComment("")),!a.getElementsByTagName("*").length}),c.getElementsByClassName=$.test(g.getElementsByClassName),c.getById=ja(function(a){return o.appendChild(a).id=u,!g.getElementsByName||!g.getElementsByName(u).length}),c.getById?(d.find.ID=function(a,b){if("undefined"!=typeof b.getElementById&&p){var c=b.getElementById(a);return c&&c.parentNode?[c]:[]}},d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){return a.getAttribute("id")===b}}):(delete d.find.ID,d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){var c="undefined"!=typeof a.getAttributeNode&&a.getAttributeNode("id");return c&&c.value===b}}),d.find.TAG=c.getElementsByTagName?function(a,b){return"undefined"!=typeof b.getElementsByTagName?b.getElementsByTagName(a):c.qsa?b.querySelectorAll(a):void 0}:function(a,b){var c,d=[],e=0,f=b.getElementsByTagName(a);if("*"===a){while(c=f[e++])1===c.nodeType&&d.push(c);return d}return f},d.find.CLASS=c.getElementsByClassName&&function(a,b){return p?b.getElementsByClassName(a):void 0},r=[],q=[],(c.qsa=$.test(g.querySelectorAll))&&(ja(function(a){o.appendChild(a).innerHTML="<a id='"+u+"'></a><select id='"+u+"-\f]' msallowcapture=''><option selected=''></option></select>",a.querySelectorAll("[msallowcapture^='']").length&&q.push("[*^$]="+L+"*(?:''|\"\")"),a.querySelectorAll("[selected]").length||q.push("\\["+L+"*(?:value|"+K+")"),a.querySelectorAll("[id~="+u+"-]").length||q.push("~="),a.querySelectorAll(":checked").length||q.push(":checked"),a.querySelectorAll("a#"+u+"+*").length||q.push(".#.+[+~]")}),ja(function(a){var b=g.createElement("input");b.setAttribute("type","hidden"),a.appendChild(b).setAttribute("name","D"),a.querySelectorAll("[name=d]").length&&q.push("name"+L+"*[*^$|!~]?="),a.querySelectorAll(":enabled").length||q.push(":enabled",":disabled"),a.querySelectorAll("*,:x"),q.push(",.*:")})),(c.matchesSelector=$.test(s=o.matches||o.webkitMatchesSelector||o.mozMatchesSelector||o.oMatchesSelector||o.msMatchesSelector))&&ja(function(a){c.disconnectedMatch=s.call(a,"div"),s.call(a,"[s!='']:x"),r.push("!=",P)}),q=q.length&&new RegExp(q.join("|")),r=r.length&&new RegExp(r.join("|")),b=$.test(o.compareDocumentPosition),t=b||$.test(o.contains)?function(a,b){var c=9===a.nodeType?a.documentElement:a,d=b&&b.parentNode;return a===d||!(!d||1!==d.nodeType||!(c.contains?c.contains(d):a.compareDocumentPosition&&16&a.compareDocumentPosition(d)))}:function(a,b){if(b)while(b=b.parentNode)if(b===a)return!0;return!1},B=b?function(a,b){if(a===b)return l=!0,0;var d=!a.compareDocumentPosition-!b.compareDocumentPosition;return d?d:(d=(a.ownerDocument||a)===(b.ownerDocument||b)?a.compareDocumentPosition(b):1,1&d||!c.sortDetached&&b.compareDocumentPosition(a)===d?a===g||a.ownerDocument===v&&t(v,a)?-1:b===g||b.ownerDocument===v&&t(v,b)?1:k?J(k,a)-J(k,b):0:4&d?-1:1)}:function(a,b){if(a===b)return l=!0,0;var c,d=0,e=a.parentNode,f=b.parentNode,h=[a],i=[b];if(!e||!f)return a===g?-1:b===g?1:e?-1:f?1:k?J(k,a)-J(k,b):0;if(e===f)return la(a,b);c=a;while(c=c.parentNode)h.unshift(c);c=b;while(c=c.parentNode)i.unshift(c);while(h[d]===i[d])d++;return d?la(h[d],i[d]):h[d]===v?-1:i[d]===v?1:0},g):n},ga.matches=function(a,b){return ga(a,null,null,b)},ga.matchesSelector=function(a,b){if((a.ownerDocument||a)!==n&&m(a),b=b.replace(U,"='$1']"),!(!c.matchesSelector||!p||r&&r.test(b)||q&&q.test(b)))try{var d=s.call(a,b);if(d||c.disconnectedMatch||a.document&&11!==a.document.nodeType)return d}catch(e){}return ga(b,n,null,[a]).length>0},ga.contains=function(a,b){return(a.ownerDocument||a)!==n&&m(a),t(a,b)},ga.attr=function(a,b){(a.ownerDocument||a)!==n&&m(a);var e=d.attrHandle[b.toLowerCase()],f=e&&D.call(d.attrHandle,b.toLowerCase())?e(a,b,!p):void 0;return void 0!==f?f:c.attributes||!p?a.getAttribute(b):(f=a.getAttributeNode(b))&&f.specified?f.value:null},ga.error=function(a){throw new Error("Syntax error, unrecognized expression: "+a)},ga.uniqueSort=function(a){var b,d=[],e=0,f=0;if(l=!c.detectDuplicates,k=!c.sortStable&&a.slice(0),a.sort(B),l){while(b=a[f++])b===a[f]&&(e=d.push(f));while(e--)a.splice(d[e],1)}return k=null,a},e=ga.getText=function(a){var b,c="",d=0,f=a.nodeType;if(f){if(1===f||9===f||11===f){if("string"==typeof a.textContent)return a.textContent;for(a=a.firstChild;a;a=a.nextSibling)c+=e(a)}else if(3===f||4===f)return a.nodeValue}else while(b=a[d++])c+=e(b);return c},d=ga.selectors={cacheLength:50,createPseudo:ia,match:X,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(a){return a[1]=a[1].replace(ca,da),a[3]=(a[3]||a[4]||a[5]||"").replace(ca,da),"~="===a[2]&&(a[3]=" "+a[3]+" "),a.slice(0,4)},CHILD:function(a){return a[1]=a[1].toLowerCase(),"nth"===a[1].slice(0,3)?(a[3]||ga.error(a[0]),a[4]=+(a[4]?a[5]+(a[6]||1):2*("even"===a[3]||"odd"===a[3])),a[5]=+(a[7]+a[8]||"odd"===a[3])):a[3]&&ga.error(a[0]),a},PSEUDO:function(a){var b,c=!a[6]&&a[2];return X.CHILD.test(a[0])?null:(a[3]?a[2]=a[4]||a[5]||"":c&&V.test(c)&&(b=g(c,!0))&&(b=c.indexOf(")",c.length-b)-c.length)&&(a[0]=a[0].slice(0,b),a[2]=c.slice(0,b)),a.slice(0,3))}},filter:{TAG:function(a){var b=a.replace(ca,da).toLowerCase();return"*"===a?function(){return!0}:function(a){return a.nodeName&&a.nodeName.toLowerCase()===b}},CLASS:function(a){var b=y[a+" "];return b||(b=new RegExp("(^|"+L+")"+a+"("+L+"|$)"))&&y(a,function(a){return b.test("string"==typeof a.className&&a.className||"undefined"!=typeof a.getAttribute&&a.getAttribute("class")||"")})},ATTR:function(a,b,c){return function(d){var e=ga.attr(d,a);return null==e?"!="===b:b?(e+="","="===b?e===c:"!="===b?e!==c:"^="===b?c&&0===e.indexOf(c):"*="===b?c&&e.indexOf(c)>-1:"$="===b?c&&e.slice(-c.length)===c:"~="===b?(" "+e.replace(Q," ")+" ").indexOf(c)>-1:"|="===b?e===c||e.slice(0,c.length+1)===c+"-":!1):!0}},CHILD:function(a,b,c,d,e){var f="nth"!==a.slice(0,3),g="last"!==a.slice(-4),h="of-type"===b;return 1===d&&0===e?function(a){return!!a.parentNode}:function(b,c,i){var j,k,l,m,n,o,p=f!==g?"nextSibling":"previousSibling",q=b.parentNode,r=h&&b.nodeName.toLowerCase(),s=!i&&!h;if(q){if(f){while(p){l=b;while(l=l[p])if(h?l.nodeName.toLowerCase()===r:1===l.nodeType)return!1;o=p="only"===a&&!o&&"nextSibling"}return!0}if(o=[g?q.firstChild:q.lastChild],g&&s){k=q[u]||(q[u]={}),j=k[a]||[],n=j[0]===w&&j[1],m=j[0]===w&&j[2],l=n&&q.childNodes[n];while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if(1===l.nodeType&&++m&&l===b){k[a]=[w,n,m];break}}else if(s&&(j=(b[u]||(b[u]={}))[a])&&j[0]===w)m=j[1];else while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if((h?l.nodeName.toLowerCase()===r:1===l.nodeType)&&++m&&(s&&((l[u]||(l[u]={}))[a]=[w,m]),l===b))break;return m-=e,m===d||m%d===0&&m/d>=0}}},PSEUDO:function(a,b){var c,e=d.pseudos[a]||d.setFilters[a.toLowerCase()]||ga.error("unsupported pseudo: "+a);return e[u]?e(b):e.length>1?(c=[a,a,"",b],d.setFilters.hasOwnProperty(a.toLowerCase())?ia(function(a,c){var d,f=e(a,b),g=f.length;while(g--)d=J(a,f[g]),a[d]=!(c[d]=f[g])}):function(a){return e(a,0,c)}):e}},pseudos:{not:ia(function(a){var b=[],c=[],d=h(a.replace(R,"$1"));return d[u]?ia(function(a,b,c,e){var f,g=d(a,null,e,[]),h=a.length;while(h--)(f=g[h])&&(a[h]=!(b[h]=f))}):function(a,e,f){return b[0]=a,d(b,null,f,c),b[0]=null,!c.pop()}}),has:ia(function(a){return function(b){return ga(a,b).length>0}}),contains:ia(function(a){return a=a.replace(ca,da),function(b){return(b.textContent||b.innerText||e(b)).indexOf(a)>-1}}),lang:ia(function(a){return W.test(a||"")||ga.error("unsupported lang: "+a),a=a.replace(ca,da).toLowerCase(),function(b){var c;do if(c=p?b.lang:b.getAttribute("xml:lang")||b.getAttribute("lang"))return c=c.toLowerCase(),c===a||0===c.indexOf(a+"-");while((b=b.parentNode)&&1===b.nodeType);return!1}}),target:function(b){var c=a.location&&a.location.hash;return c&&c.slice(1)===b.id},root:function(a){return a===o},focus:function(a){return a===n.activeElement&&(!n.hasFocus||n.hasFocus())&&!!(a.type||a.href||~a.tabIndex)},enabled:function(a){return a.disabled===!1},disabled:function(a){return a.disabled===!0},checked:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&!!a.checked||"option"===b&&!!a.selected},selected:function(a){return a.parentNode&&a.parentNode.selectedIndex,a.selected===!0},empty:function(a){for(a=a.firstChild;a;a=a.nextSibling)if(a.nodeType<6)return!1;return!0},parent:function(a){return!d.pseudos.empty(a)},header:function(a){return Z.test(a.nodeName)},input:function(a){return Y.test(a.nodeName)},button:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&"button"===a.type||"button"===b},text:function(a){var b;return"input"===a.nodeName.toLowerCase()&&"text"===a.type&&(null==(b=a.getAttribute("type"))||"text"===b.toLowerCase())},first:oa(function(){return[0]}),last:oa(function(a,b){return[b-1]}),eq:oa(function(a,b,c){return[0>c?c+b:c]}),even:oa(function(a,b){for(var c=0;b>c;c+=2)a.push(c);return a}),odd:oa(function(a,b){for(var c=1;b>c;c+=2)a.push(c);return a}),lt:oa(function(a,b,c){for(var d=0>c?c+b:c;--d>=0;)a.push(d);return a}),gt:oa(function(a,b,c){for(var d=0>c?c+b:c;++d<b;)a.push(d);return a})}},d.pseudos.nth=d.pseudos.eq;for(b in{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})d.pseudos[b]=ma(b);for(b in{submit:!0,reset:!0})d.pseudos[b]=na(b);function qa(){}qa.prototype=d.filters=d.pseudos,d.setFilters=new qa,g=ga.tokenize=function(a,b){var c,e,f,g,h,i,j,k=z[a+" "];if(k)return b?0:k.slice(0);h=a,i=[],j=d.preFilter;while(h){(!c||(e=S.exec(h)))&&(e&&(h=h.slice(e[0].length)||h),i.push(f=[])),c=!1,(e=T.exec(h))&&(c=e.shift(),f.push({value:c,type:e[0].replace(R," ")}),h=h.slice(c.length));for(g in d.filter)!(e=X[g].exec(h))||j[g]&&!(e=j[g](e))||(c=e.shift(),f.push({value:c,type:g,matches:e}),h=h.slice(c.length));if(!c)break}return b?h.length:h?ga.error(a):z(a,i).slice(0)};function ra(a){for(var b=0,c=a.length,d="";c>b;b++)d+=a[b].value;return d}function sa(a,b,c){var d=b.dir,e=c&&"parentNode"===d,f=x++;return b.first?function(b,c,f){while(b=b[d])if(1===b.nodeType||e)return a(b,c,f)}:function(b,c,g){var h,i,j=[w,f];if(g){while(b=b[d])if((1===b.nodeType||e)&&a(b,c,g))return!0}else while(b=b[d])if(1===b.nodeType||e){if(i=b[u]||(b[u]={}),(h=i[d])&&h[0]===w&&h[1]===f)return j[2]=h[2];if(i[d]=j,j[2]=a(b,c,g))return!0}}}function ta(a){return a.length>1?function(b,c,d){var e=a.length;while(e--)if(!a[e](b,c,d))return!1;return!0}:a[0]}function ua(a,b,c){for(var d=0,e=b.length;e>d;d++)ga(a,b[d],c);return c}function va(a,b,c,d,e){for(var f,g=[],h=0,i=a.length,j=null!=b;i>h;h++)(f=a[h])&&(!c||c(f,d,e))&&(g.push(f),j&&b.push(h));return g}function wa(a,b,c,d,e,f){return d&&!d[u]&&(d=wa(d)),e&&!e[u]&&(e=wa(e,f)),ia(function(f,g,h,i){var j,k,l,m=[],n=[],o=g.length,p=f||ua(b||"*",h.nodeType?[h]:h,[]),q=!a||!f&&b?p:va(p,m,a,h,i),r=c?e||(f?a:o||d)?[]:g:q;if(c&&c(q,r,h,i),d){j=va(r,n),d(j,[],h,i),k=j.length;while(k--)(l=j[k])&&(r[n[k]]=!(q[n[k]]=l))}if(f){if(e||a){if(e){j=[],k=r.length;while(k--)(l=r[k])&&j.push(q[k]=l);e(null,r=[],j,i)}k=r.length;while(k--)(l=r[k])&&(j=e?J(f,l):m[k])>-1&&(f[j]=!(g[j]=l))}}else r=va(r===g?r.splice(o,r.length):r),e?e(null,g,r,i):H.apply(g,r)})}function xa(a){for(var b,c,e,f=a.length,g=d.relative[a[0].type],h=g||d.relative[" "],i=g?1:0,k=sa(function(a){return a===b},h,!0),l=sa(function(a){return J(b,a)>-1},h,!0),m=[function(a,c,d){var e=!g&&(d||c!==j)||((b=c).nodeType?k(a,c,d):l(a,c,d));return b=null,e}];f>i;i++)if(c=d.relative[a[i].type])m=[sa(ta(m),c)];else{if(c=d.filter[a[i].type].apply(null,a[i].matches),c[u]){for(e=++i;f>e;e++)if(d.relative[a[e].type])break;return wa(i>1&&ta(m),i>1&&ra(a.slice(0,i-1).concat({value:" "===a[i-2].type?"*":""})).replace(R,"$1"),c,e>i&&xa(a.slice(i,e)),f>e&&xa(a=a.slice(e)),f>e&&ra(a))}m.push(c)}return ta(m)}function ya(a,b){var c=b.length>0,e=a.length>0,f=function(f,g,h,i,k){var l,m,o,p=0,q="0",r=f&&[],s=[],t=j,u=f||e&&d.find.TAG("*",k),v=w+=null==t?1:Math.random()||.1,x=u.length;for(k&&(j=g!==n&&g);q!==x&&null!=(l=u[q]);q++){if(e&&l){m=0;while(o=a[m++])if(o(l,g,h)){i.push(l);break}k&&(w=v)}c&&((l=!o&&l)&&p--,f&&r.push(l))}if(p+=q,c&&q!==p){m=0;while(o=b[m++])o(r,s,g,h);if(f){if(p>0)while(q--)r[q]||s[q]||(s[q]=F.call(i));s=va(s)}H.apply(i,s),k&&!f&&s.length>0&&p+b.length>1&&ga.uniqueSort(i)}return k&&(w=v,j=t),r};return c?ia(f):f}return h=ga.compile=function(a,b){var c,d=[],e=[],f=A[a+" "];if(!f){b||(b=g(a)),c=b.length;while(c--)f=xa(b[c]),f[u]?d.push(f):e.push(f);f=A(a,ya(e,d)),f.selector=a}return f},i=ga.select=function(a,b,e,f){var i,j,k,l,m,n="function"==typeof a&&a,o=!f&&g(a=n.selector||a);if(e=e||[],1===o.length){if(j=o[0]=o[0].slice(0),j.length>2&&"ID"===(k=j[0]).type&&c.getById&&9===b.nodeType&&p&&d.relative[j[1].type]){if(b=(d.find.ID(k.matches[0].replace(ca,da),b)||[])[0],!b)return e;n&&(b=b.parentNode),a=a.slice(j.shift().value.length)}i=X.needsContext.test(a)?0:j.length;while(i--){if(k=j[i],d.relative[l=k.type])break;if((m=d.find[l])&&(f=m(k.matches[0].replace(ca,da),aa.test(j[0].type)&&pa(b.parentNode)||b))){if(j.splice(i,1),a=f.length&&ra(j),!a)return H.apply(e,f),e;break}}}return(n||h(a,o))(f,b,!p,e,aa.test(a)&&pa(b.parentNode)||b),e},c.sortStable=u.split("").sort(B).join("")===u,c.detectDuplicates=!!l,m(),c.sortDetached=ja(function(a){return 1&a.compareDocumentPosition(n.createElement("div"))}),ja(function(a){return a.innerHTML="<a href='#'></a>","#"===a.firstChild.getAttribute("href")})||ka("type|href|height|width",function(a,b,c){return c?void 0:a.getAttribute(b,"type"===b.toLowerCase()?1:2)}),c.attributes&&ja(function(a){return a.innerHTML="<input/>",a.firstChild.setAttribute("value",""),""===a.firstChild.getAttribute("value")})||ka("value",function(a,b,c){return c||"input"!==a.nodeName.toLowerCase()?void 0:a.defaultValue}),ja(function(a){return null==a.getAttribute("disabled")})||ka(K,function(a,b,c){var d;return c?void 0:a[b]===!0?b.toLowerCase():(d=a.getAttributeNode(b))&&d.specified?d.value:null}),ga}(a);m.find=s,m.expr=s.selectors,m.expr[":"]=m.expr.pseudos,m.unique=s.uniqueSort,m.text=s.getText,m.isXMLDoc=s.isXML,m.contains=s.contains;var t=m.expr.match.needsContext,u=/^<(\w+)\s*\/?>(?:<\/\1>|)$/,v=/^.[^:#\[\.,]*$/;function w(a,b,c){if(m.isFunction(b))return m.grep(a,function(a,d){return!!b.call(a,d,a)!==c});if(b.nodeType)return m.grep(a,function(a){return a===b!==c});if("string"==typeof b){if(v.test(b))return m.filter(b,a,c);b=m.filter(b,a)}return m.grep(a,function(a){return m.inArray(a,b)>=0!==c})}m.filter=function(a,b,c){var d=b[0];return c&&(a=":not("+a+")"),1===b.length&&1===d.nodeType?m.find.matchesSelector(d,a)?[d]:[]:m.find.matches(a,m.grep(b,function(a){return 1===a.nodeType}))},m.fn.extend({find:function(a){var b,c=[],d=this,e=d.length;if("string"!=typeof a)return this.pushStack(m(a).filter(function(){for(b=0;e>b;b++)if(m.contains(d[b],this))return!0}));for(b=0;e>b;b++)m.find(a,d[b],c);return c=this.pushStack(e>1?m.unique(c):c),c.selector=this.selector?this.selector+" "+a:a,c},filter:function(a){return this.pushStack(w(this,a||[],!1))},not:function(a){return this.pushStack(w(this,a||[],!0))},is:function(a){return!!w(this,"string"==typeof a&&t.test(a)?m(a):a||[],!1).length}});var x,y=a.document,z=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]*))$/,A=m.fn.init=function(a,b){var c,d;if(!a)return this;if("string"==typeof a){if(c="<"===a.charAt(0)&&">"===a.charAt(a.length-1)&&a.length>=3?[null,a,null]:z.exec(a),!c||!c[1]&&b)return!b||b.jquery?(b||x).find(a):this.constructor(b).find(a);if(c[1]){if(b=b instanceof m?b[0]:b,m.merge(this,m.parseHTML(c[1],b&&b.nodeType?b.ownerDocument||b:y,!0)),u.test(c[1])&&m.isPlainObject(b))for(c in b)m.isFunction(this[c])?this[c](b[c]):this.attr(c,b[c]);return this}if(d=y.getElementById(c[2]),d&&d.parentNode){if(d.id!==c[2])return x.find(a);this.length=1,this[0]=d}return this.context=y,this.selector=a,this}return a.nodeType?(this.context=this[0]=a,this.length=1,this):m.isFunction(a)?"undefined"!=typeof x.ready?x.ready(a):a(m):(void 0!==a.selector&&(this.selector=a.selector,this.context=a.context),m.makeArray(a,this))};A.prototype=m.fn,x=m(y);var B=/^(?:parents|prev(?:Until|All))/,C={children:!0,contents:!0,next:!0,prev:!0};m.extend({dir:function(a,b,c){var d=[],e=a[b];while(e&&9!==e.nodeType&&(void 0===c||1!==e.nodeType||!m(e).is(c)))1===e.nodeType&&d.push(e),e=e[b];return d},sibling:function(a,b){for(var c=[];a;a=a.nextSibling)1===a.nodeType&&a!==b&&c.push(a);return c}}),m.fn.extend({has:function(a){var b,c=m(a,this),d=c.length;return this.filter(function(){for(b=0;d>b;b++)if(m.contains(this,c[b]))return!0})},closest:function(a,b){for(var c,d=0,e=this.length,f=[],g=t.test(a)||"string"!=typeof a?m(a,b||this.context):0;e>d;d++)for(c=this[d];c&&c!==b;c=c.parentNode)if(c.nodeType<11&&(g?g.index(c)>-1:1===c.nodeType&&m.find.matchesSelector(c,a))){f.push(c);break}return this.pushStack(f.length>1?m.unique(f):f)},index:function(a){return a?"string"==typeof a?m.inArray(this[0],m(a)):m.inArray(a.jquery?a[0]:a,this):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(a,b){return this.pushStack(m.unique(m.merge(this.get(),m(a,b))))},addBack:function(a){return this.add(null==a?this.prevObject:this.prevObject.filter(a))}});function D(a,b){do a=a[b];while(a&&1!==a.nodeType);return a}m.each({parent:function(a){var b=a.parentNode;return b&&11!==b.nodeType?b:null},parents:function(a){return m.dir(a,"parentNode")},parentsUntil:function(a,b,c){return m.dir(a,"parentNode",c)},next:function(a){return D(a,"nextSibling")},prev:function(a){return D(a,"previousSibling")},nextAll:function(a){return m.dir(a,"nextSibling")},prevAll:function(a){return m.dir(a,"previousSibling")},nextUntil:function(a,b,c){return m.dir(a,"nextSibling",c)},prevUntil:function(a,b,c){return m.dir(a,"previousSibling",c)},siblings:function(a){return m.sibling((a.parentNode||{}).firstChild,a)},children:function(a){return m.sibling(a.firstChild)},contents:function(a){return m.nodeName(a,"iframe")?a.contentDocument||a.contentWindow.document:m.merge([],a.childNodes)}},function(a,b){m.fn[a]=function(c,d){var e=m.map(this,b,c);return"Until"!==a.slice(-5)&&(d=c),d&&"string"==typeof d&&(e=m.filter(d,e)),this.length>1&&(C[a]||(e=m.unique(e)),B.test(a)&&(e=e.reverse())),this.pushStack(e)}});var E=/\S+/g,F={};function G(a){var b=F[a]={};return m.each(a.match(E)||[],function(a,c){b[c]=!0}),b}m.Callbacks=function(a){a="string"==typeof a?F[a]||G(a):m.extend({},a);var b,c,d,e,f,g,h=[],i=!a.once&&[],j=function(l){for(c=a.memory&&l,d=!0,f=g||0,g=0,e=h.length,b=!0;h&&e>f;f++)if(h[f].apply(l[0],l[1])===!1&&a.stopOnFalse){c=!1;break}b=!1,h&&(i?i.length&&j(i.shift()):c?h=[]:k.disable())},k={add:function(){if(h){var d=h.length;!function f(b){m.each(b,function(b,c){var d=m.type(c);"function"===d?a.unique&&k.has(c)||h.push(c):c&&c.length&&"string"!==d&&f(c)})}(arguments),b?e=h.length:c&&(g=d,j(c))}return this},remove:function(){return h&&m.each(arguments,function(a,c){var d;while((d=m.inArray(c,h,d))>-1)h.splice(d,1),b&&(e>=d&&e--,f>=d&&f--)}),this},has:function(a){return a?m.inArray(a,h)>-1:!(!h||!h.length)},empty:function(){return h=[],e=0,this},disable:function(){return h=i=c=void 0,this},disabled:function(){return!h},lock:function(){return i=void 0,c||k.disable(),this},locked:function(){return!i},fireWith:function(a,c){return!h||d&&!i||(c=c||[],c=[a,c.slice?c.slice():c],b?i.push(c):j(c)),this},fire:function(){return k.fireWith(this,arguments),this},fired:function(){return!!d}};return k},m.extend({Deferred:function(a){var b=[["resolve","done",m.Callbacks("once memory"),"resolved"],["reject","fail",m.Callbacks("once memory"),"rejected"],["notify","progress",m.Callbacks("memory")]],c="pending",d={state:function(){return c},always:function(){return e.done(arguments).fail(arguments),this},then:function(){var a=arguments;return m.Deferred(function(c){m.each(b,function(b,f){var g=m.isFunction(a[b])&&a[b];e[f[1]](function(){var a=g&&g.apply(this,arguments);a&&m.isFunction(a.promise)?a.promise().done(c.resolve).fail(c.reject).progress(c.notify):c[f[0]+"With"](this===d?c.promise():this,g?[a]:arguments)})}),a=null}).promise()},promise:function(a){return null!=a?m.extend(a,d):d}},e={};return d.pipe=d.then,m.each(b,function(a,f){var g=f[2],h=f[3];d[f[1]]=g.add,h&&g.add(function(){c=h},b[1^a][2].disable,b[2][2].lock),e[f[0]]=function(){return e[f[0]+"With"](this===e?d:this,arguments),this},e[f[0]+"With"]=g.fireWith}),d.promise(e),a&&a.call(e,e),e},when:function(a){var b=0,c=d.call(arguments),e=c.length,f=1!==e||a&&m.isFunction(a.promise)?e:0,g=1===f?a:m.Deferred(),h=function(a,b,c){return function(e){b[a]=this,c[a]=arguments.length>1?d.call(arguments):e,c===i?g.notifyWith(b,c):--f||g.resolveWith(b,c)}},i,j,k;if(e>1)for(i=new Array(e),j=new Array(e),k=new Array(e);e>b;b++)c[b]&&m.isFunction(c[b].promise)?c[b].promise().done(h(b,k,c)).fail(g.reject).progress(h(b,j,i)):--f;return f||g.resolveWith(k,c),g.promise()}});var H;m.fn.ready=function(a){return m.ready.promise().done(a),this},m.extend({isReady:!1,readyWait:1,holdReady:function(a){a?m.readyWait++:m.ready(!0)},ready:function(a){if(a===!0?!--m.readyWait:!m.isReady){if(!y.body)return setTimeout(m.ready);m.isReady=!0,a!==!0&&--m.readyWait>0||(H.resolveWith(y,[m]),m.fn.triggerHandler&&(m(y).triggerHandler("ready"),m(y).off("ready")))}}});function I(){y.addEventListener?(y.removeEventListener("DOMContentLoaded",J,!1),a.removeEventListener("load",J,!1)):(y.detachEvent("onreadystatechange",J),a.detachEvent("onload",J))}function J(){(y.addEventListener||"load"===event.type||"complete"===y.readyState)&&(I(),m.ready())}m.ready.promise=function(b){if(!H)if(H=m.Deferred(),"complete"===y.readyState)setTimeout(m.ready);else if(y.addEventListener)y.addEventListener("DOMContentLoaded",J,!1),a.addEventListener("load",J,!1);else{y.attachEvent("onreadystatechange",J),a.attachEvent("onload",J);var c=!1;try{c=null==a.frameElement&&y.documentElement}catch(d){}c&&c.doScroll&&!function e(){if(!m.isReady){try{c.doScroll("left")}catch(a){return setTimeout(e,50)}I(),m.ready()}}()}return H.promise(b)};var K="undefined",L;for(L in m(k))break;k.ownLast="0"!==L,k.inlineBlockNeedsLayout=!1,m(function(){var a,b,c,d;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="display:inline;margin:0;border:0;padding:1px;width:1px;zoom:1",k.inlineBlockNeedsLayout=a=3===b.offsetWidth,a&&(c.style.zoom=1)),c.removeChild(d))}),function(){var a=y.createElement("div");if(null==k.deleteExpando){k.deleteExpando=!0;try{delete a.test}catch(b){k.deleteExpando=!1}}a=null}(),m.acceptData=function(a){var b=m.noData[(a.nodeName+" ").toLowerCase()],c=+a.nodeType||1;return 1!==c&&9!==c?!1:!b||b!==!0&&a.getAttribute("classid")===b};var M=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,N=/([A-Z])/g;function O(a,b,c){if(void 0===c&&1===a.nodeType){var d="data-"+b.replace(N,"-$1").toLowerCase();if(c=a.getAttribute(d),"string"==typeof c){try{c="true"===c?!0:"false"===c?!1:"null"===c?null:+c+""===c?+c:M.test(c)?m.parseJSON(c):c}catch(e){}m.data(a,b,c)}else c=void 0}return c}function P(a){var b;for(b in a)if(("data"!==b||!m.isEmptyObject(a[b]))&&"toJSON"!==b)return!1;

return!0}function Q(a,b,d,e){if(m.acceptData(a)){var f,g,h=m.expando,i=a.nodeType,j=i?m.cache:a,k=i?a[h]:a[h]&&h;if(k&&j[k]&&(e||j[k].data)||void 0!==d||"string"!=typeof b)return k||(k=i?a[h]=c.pop()||m.guid++:h),j[k]||(j[k]=i?{}:{toJSON:m.noop}),("object"==typeof b||"function"==typeof b)&&(e?j[k]=m.extend(j[k],b):j[k].data=m.extend(j[k].data,b)),g=j[k],e||(g.data||(g.data={}),g=g.data),void 0!==d&&(g[m.camelCase(b)]=d),"string"==typeof b?(f=g[b],null==f&&(f=g[m.camelCase(b)])):f=g,f}}function R(a,b,c){if(m.acceptData(a)){var d,e,f=a.nodeType,g=f?m.cache:a,h=f?a[m.expando]:m.expando;if(g[h]){if(b&&(d=c?g[h]:g[h].data)){m.isArray(b)?b=b.concat(m.map(b,m.camelCase)):b in d?b=[b]:(b=m.camelCase(b),b=b in d?[b]:b.split(" ")),e=b.length;while(e--)delete d[b[e]];if(c?!P(d):!m.isEmptyObject(d))return}(c||(delete g[h].data,P(g[h])))&&(f?m.cleanData([a],!0):k.deleteExpando||g!=g.window?delete g[h]:g[h]=null)}}}m.extend({cache:{},noData:{"applet ":!0,"embed ":!0,"object ":"clsid:D27CDB6E-AE6D-11cf-96B8-444553540000"},hasData:function(a){return a=a.nodeType?m.cache[a[m.expando]]:a[m.expando],!!a&&!P(a)},data:function(a,b,c){return Q(a,b,c)},removeData:function(a,b){return R(a,b)},_data:function(a,b,c){return Q(a,b,c,!0)},_removeData:function(a,b){return R(a,b,!0)}}),m.fn.extend({data:function(a,b){var c,d,e,f=this[0],g=f&&f.attributes;if(void 0===a){if(this.length&&(e=m.data(f),1===f.nodeType&&!m._data(f,"parsedAttrs"))){c=g.length;while(c--)g[c]&&(d=g[c].name,0===d.indexOf("data-")&&(d=m.camelCase(d.slice(5)),O(f,d,e[d])));m._data(f,"parsedAttrs",!0)}return e}return"object"==typeof a?this.each(function(){m.data(this,a)}):arguments.length>1?this.each(function(){m.data(this,a,b)}):f?O(f,a,m.data(f,a)):void 0},removeData:function(a){return this.each(function(){m.removeData(this,a)})}}),m.extend({queue:function(a,b,c){var d;return a?(b=(b||"fx")+"queue",d=m._data(a,b),c&&(!d||m.isArray(c)?d=m._data(a,b,m.makeArray(c)):d.push(c)),d||[]):void 0},dequeue:function(a,b){b=b||"fx";var c=m.queue(a,b),d=c.length,e=c.shift(),f=m._queueHooks(a,b),g=function(){m.dequeue(a,b)};"inprogress"===e&&(e=c.shift(),d--),e&&("fx"===b&&c.unshift("inprogress"),delete f.stop,e.call(a,g,f)),!d&&f&&f.empty.fire()},_queueHooks:function(a,b){var c=b+"queueHooks";return m._data(a,c)||m._data(a,c,{empty:m.Callbacks("once memory").add(function(){m._removeData(a,b+"queue"),m._removeData(a,c)})})}}),m.fn.extend({queue:function(a,b){var c=2;return"string"!=typeof a&&(b=a,a="fx",c--),arguments.length<c?m.queue(this[0],a):void 0===b?this:this.each(function(){var c=m.queue(this,a,b);m._queueHooks(this,a),"fx"===a&&"inprogress"!==c[0]&&m.dequeue(this,a)})},dequeue:function(a){return this.each(function(){m.dequeue(this,a)})},clearQueue:function(a){return this.queue(a||"fx",[])},promise:function(a,b){var c,d=1,e=m.Deferred(),f=this,g=this.length,h=function(){--d||e.resolveWith(f,[f])};"string"!=typeof a&&(b=a,a=void 0),a=a||"fx";while(g--)c=m._data(f[g],a+"queueHooks"),c&&c.empty&&(d++,c.empty.add(h));return h(),e.promise(b)}});var S=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,T=["Top","Right","Bottom","Left"],U=function(a,b){return a=b||a,"none"===m.css(a,"display")||!m.contains(a.ownerDocument,a)},V=m.access=function(a,b,c,d,e,f,g){var h=0,i=a.length,j=null==c;if("object"===m.type(c)){e=!0;for(h in c)m.access(a,b,h,c[h],!0,f,g)}else if(void 0!==d&&(e=!0,m.isFunction(d)||(g=!0),j&&(g?(b.call(a,d),b=null):(j=b,b=function(a,b,c){return j.call(m(a),c)})),b))for(;i>h;h++)b(a[h],c,g?d:d.call(a[h],h,b(a[h],c)));return e?a:j?b.call(a):i?b(a[0],c):f},W=/^(?:checkbox|radio)$/i;!function(){var a=y.createElement("input"),b=y.createElement("div"),c=y.createDocumentFragment();if(b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",k.leadingWhitespace=3===b.firstChild.nodeType,k.tbody=!b.getElementsByTagName("tbody").length,k.htmlSerialize=!!b.getElementsByTagName("link").length,k.html5Clone="<:nav></:nav>"!==y.createElement("nav").cloneNode(!0).outerHTML,a.type="checkbox",a.checked=!0,c.appendChild(a),k.appendChecked=a.checked,b.innerHTML="<textarea>x</textarea>",k.noCloneChecked=!!b.cloneNode(!0).lastChild.defaultValue,c.appendChild(b),b.innerHTML="<input type='radio' checked='checked' name='t'/>",k.checkClone=b.cloneNode(!0).cloneNode(!0).lastChild.checked,k.noCloneEvent=!0,b.attachEvent&&(b.attachEvent("onclick",function(){k.noCloneEvent=!1}),b.cloneNode(!0).click()),null==k.deleteExpando){k.deleteExpando=!0;try{delete b.test}catch(d){k.deleteExpando=!1}}}(),function(){var b,c,d=y.createElement("div");for(b in{submit:!0,change:!0,focusin:!0})c="on"+b,(k[b+"Bubbles"]=c in a)||(d.setAttribute(c,"t"),k[b+"Bubbles"]=d.attributes[c].expando===!1);d=null}();var X=/^(?:input|select|textarea)$/i,Y=/^key/,Z=/^(?:mouse|pointer|contextmenu)|click/,$=/^(?:focusinfocus|focusoutblur)$/,_=/^([^.]*)(?:\.(.+)|)$/;function aa(){return!0}function ba(){return!1}function ca(){try{return y.activeElement}catch(a){}}m.event={global:{},add:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m._data(a);if(r){c.handler&&(i=c,c=i.handler,e=i.selector),c.guid||(c.guid=m.guid++),(g=r.events)||(g=r.events={}),(k=r.handle)||(k=r.handle=function(a){return typeof m===K||a&&m.event.triggered===a.type?void 0:m.event.dispatch.apply(k.elem,arguments)},k.elem=a),b=(b||"").match(E)||[""],h=b.length;while(h--)f=_.exec(b[h])||[],o=q=f[1],p=(f[2]||"").split(".").sort(),o&&(j=m.event.special[o]||{},o=(e?j.delegateType:j.bindType)||o,j=m.event.special[o]||{},l=m.extend({type:o,origType:q,data:d,handler:c,guid:c.guid,selector:e,needsContext:e&&m.expr.match.needsContext.test(e),namespace:p.join(".")},i),(n=g[o])||(n=g[o]=[],n.delegateCount=0,j.setup&&j.setup.call(a,d,p,k)!==!1||(a.addEventListener?a.addEventListener(o,k,!1):a.attachEvent&&a.attachEvent("on"+o,k))),j.add&&(j.add.call(a,l),l.handler.guid||(l.handler.guid=c.guid)),e?n.splice(n.delegateCount++,0,l):n.push(l),m.event.global[o]=!0);a=null}},remove:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m.hasData(a)&&m._data(a);if(r&&(k=r.events)){b=(b||"").match(E)||[""],j=b.length;while(j--)if(h=_.exec(b[j])||[],o=q=h[1],p=(h[2]||"").split(".").sort(),o){l=m.event.special[o]||{},o=(d?l.delegateType:l.bindType)||o,n=k[o]||[],h=h[2]&&new RegExp("(^|\\.)"+p.join("\\.(?:.*\\.|)")+"(\\.|$)"),i=f=n.length;while(f--)g=n[f],!e&&q!==g.origType||c&&c.guid!==g.guid||h&&!h.test(g.namespace)||d&&d!==g.selector&&("**"!==d||!g.selector)||(n.splice(f,1),g.selector&&n.delegateCount--,l.remove&&l.remove.call(a,g));i&&!n.length&&(l.teardown&&l.teardown.call(a,p,r.handle)!==!1||m.removeEvent(a,o,r.handle),delete k[o])}else for(o in k)m.event.remove(a,o+b[j],c,d,!0);m.isEmptyObject(k)&&(delete r.handle,m._removeData(a,"events"))}},trigger:function(b,c,d,e){var f,g,h,i,k,l,n,o=[d||y],p=j.call(b,"type")?b.type:b,q=j.call(b,"namespace")?b.namespace.split("."):[];if(h=l=d=d||y,3!==d.nodeType&&8!==d.nodeType&&!$.test(p+m.event.triggered)&&(p.indexOf(".")>=0&&(q=p.split("."),p=q.shift(),q.sort()),g=p.indexOf(":")<0&&"on"+p,b=b[m.expando]?b:new m.Event(p,"object"==typeof b&&b),b.isTrigger=e?2:3,b.namespace=q.join("."),b.namespace_re=b.namespace?new RegExp("(^|\\.)"+q.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,b.result=void 0,b.target||(b.target=d),c=null==c?[b]:m.makeArray(c,[b]),k=m.event.special[p]||{},e||!k.trigger||k.trigger.apply(d,c)!==!1)){if(!e&&!k.noBubble&&!m.isWindow(d)){for(i=k.delegateType||p,$.test(i+p)||(h=h.parentNode);h;h=h.parentNode)o.push(h),l=h;l===(d.ownerDocument||y)&&o.push(l.defaultView||l.parentWindow||a)}n=0;while((h=o[n++])&&!b.isPropagationStopped())b.type=n>1?i:k.bindType||p,f=(m._data(h,"events")||{})[b.type]&&m._data(h,"handle"),f&&f.apply(h,c),f=g&&h[g],f&&f.apply&&m.acceptData(h)&&(b.result=f.apply(h,c),b.result===!1&&b.preventDefault());if(b.type=p,!e&&!b.isDefaultPrevented()&&(!k._default||k._default.apply(o.pop(),c)===!1)&&m.acceptData(d)&&g&&d[p]&&!m.isWindow(d)){l=d[g],l&&(d[g]=null),m.event.triggered=p;try{d[p]()}catch(r){}m.event.triggered=void 0,l&&(d[g]=l)}return b.result}},dispatch:function(a){a=m.event.fix(a);var b,c,e,f,g,h=[],i=d.call(arguments),j=(m._data(this,"events")||{})[a.type]||[],k=m.event.special[a.type]||{};if(i[0]=a,a.delegateTarget=this,!k.preDispatch||k.preDispatch.call(this,a)!==!1){h=m.event.handlers.call(this,a,j),b=0;while((f=h[b++])&&!a.isPropagationStopped()){a.currentTarget=f.elem,g=0;while((e=f.handlers[g++])&&!a.isImmediatePropagationStopped())(!a.namespace_re||a.namespace_re.test(e.namespace))&&(a.handleObj=e,a.data=e.data,c=((m.event.special[e.origType]||{}).handle||e.handler).apply(f.elem,i),void 0!==c&&(a.result=c)===!1&&(a.preventDefault(),a.stopPropagation()))}return k.postDispatch&&k.postDispatch.call(this,a),a.result}},handlers:function(a,b){var c,d,e,f,g=[],h=b.delegateCount,i=a.target;if(h&&i.nodeType&&(!a.button||"click"!==a.type))for(;i!=this;i=i.parentNode||this)if(1===i.nodeType&&(i.disabled!==!0||"click"!==a.type)){for(e=[],f=0;h>f;f++)d=b[f],c=d.selector+" ",void 0===e[c]&&(e[c]=d.needsContext?m(c,this).index(i)>=0:m.find(c,this,null,[i]).length),e[c]&&e.push(d);e.length&&g.push({elem:i,handlers:e})}return h<b.length&&g.push({elem:this,handlers:b.slice(h)}),g},fix:function(a){if(a[m.expando])return a;var b,c,d,e=a.type,f=a,g=this.fixHooks[e];g||(this.fixHooks[e]=g=Z.test(e)?this.mouseHooks:Y.test(e)?this.keyHooks:{}),d=g.props?this.props.concat(g.props):this.props,a=new m.Event(f),b=d.length;while(b--)c=d[b],a[c]=f[c];return a.target||(a.target=f.srcElement||y),3===a.target.nodeType&&(a.target=a.target.parentNode),a.metaKey=!!a.metaKey,g.filter?g.filter(a,f):a},props:"altKey bubbles cancelable ctrlKey currentTarget eventPhase metaKey relatedTarget shiftKey target timeStamp view which".split(" "),fixHooks:{},keyHooks:{props:"char charCode key keyCode".split(" "),filter:function(a,b){return null==a.which&&(a.which=null!=b.charCode?b.charCode:b.keyCode),a}},mouseHooks:{props:"button buttons clientX clientY fromElement offsetX offsetY pageX pageY screenX screenY toElement".split(" "),filter:function(a,b){var c,d,e,f=b.button,g=b.fromElement;return null==a.pageX&&null!=b.clientX&&(d=a.target.ownerDocument||y,e=d.documentElement,c=d.body,a.pageX=b.clientX+(e&&e.scrollLeft||c&&c.scrollLeft||0)-(e&&e.clientLeft||c&&c.clientLeft||0),a.pageY=b.clientY+(e&&e.scrollTop||c&&c.scrollTop||0)-(e&&e.clientTop||c&&c.clientTop||0)),!a.relatedTarget&&g&&(a.relatedTarget=g===a.target?b.toElement:g),a.which||void 0===f||(a.which=1&f?1:2&f?3:4&f?2:0),a}},special:{load:{noBubble:!0},focus:{trigger:function(){if(this!==ca()&&this.focus)try{return this.focus(),!1}catch(a){}},delegateType:"focusin"},blur:{trigger:function(){return this===ca()&&this.blur?(this.blur(),!1):void 0},delegateType:"focusout"},click:{trigger:function(){return m.nodeName(this,"input")&&"checkbox"===this.type&&this.click?(this.click(),!1):void 0},_default:function(a){return m.nodeName(a.target,"a")}},beforeunload:{postDispatch:function(a){void 0!==a.result&&a.originalEvent&&(a.originalEvent.returnValue=a.result)}}},simulate:function(a,b,c,d){var e=m.extend(new m.Event,c,{type:a,isSimulated:!0,originalEvent:{}});d?m.event.trigger(e,null,b):m.event.dispatch.call(b,e),e.isDefaultPrevented()&&c.preventDefault()}},m.removeEvent=y.removeEventListener?function(a,b,c){a.removeEventListener&&a.removeEventListener(b,c,!1)}:function(a,b,c){var d="on"+b;a.detachEvent&&(typeof a[d]===K&&(a[d]=null),a.detachEvent(d,c))},m.Event=function(a,b){return this instanceof m.Event?(a&&a.type?(this.originalEvent=a,this.type=a.type,this.isDefaultPrevented=a.defaultPrevented||void 0===a.defaultPrevented&&a.returnValue===!1?aa:ba):this.type=a,b&&m.extend(this,b),this.timeStamp=a&&a.timeStamp||m.now(),void(this[m.expando]=!0)):new m.Event(a,b)},m.Event.prototype={isDefaultPrevented:ba,isPropagationStopped:ba,isImmediatePropagationStopped:ba,preventDefault:function(){var a=this.originalEvent;this.isDefaultPrevented=aa,a&&(a.preventDefault?a.preventDefault():a.returnValue=!1)},stopPropagation:function(){var a=this.originalEvent;this.isPropagationStopped=aa,a&&(a.stopPropagation&&a.stopPropagation(),a.cancelBubble=!0)},stopImmediatePropagation:function(){var a=this.originalEvent;this.isImmediatePropagationStopped=aa,a&&a.stopImmediatePropagation&&a.stopImmediatePropagation(),this.stopPropagation()}},m.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(a,b){m.event.special[a]={delegateType:b,bindType:b,handle:function(a){var c,d=this,e=a.relatedTarget,f=a.handleObj;return(!e||e!==d&&!m.contains(d,e))&&(a.type=f.origType,c=f.handler.apply(this,arguments),a.type=b),c}}}),k.submitBubbles||(m.event.special.submit={setup:function(){return m.nodeName(this,"form")?!1:void m.event.add(this,"click._submit keypress._submit",function(a){var b=a.target,c=m.nodeName(b,"input")||m.nodeName(b,"button")?b.form:void 0;c&&!m._data(c,"submitBubbles")&&(m.event.add(c,"submit._submit",function(a){a._submit_bubble=!0}),m._data(c,"submitBubbles",!0))})},postDispatch:function(a){a._submit_bubble&&(delete a._submit_bubble,this.parentNode&&!a.isTrigger&&m.event.simulate("submit",this.parentNode,a,!0))},teardown:function(){return m.nodeName(this,"form")?!1:void m.event.remove(this,"._submit")}}),k.changeBubbles||(m.event.special.change={setup:function(){return X.test(this.nodeName)?(("checkbox"===this.type||"radio"===this.type)&&(m.event.add(this,"propertychange._change",function(a){"checked"===a.originalEvent.propertyName&&(this._just_changed=!0)}),m.event.add(this,"click._change",function(a){this._just_changed&&!a.isTrigger&&(this._just_changed=!1),m.event.simulate("change",this,a,!0)})),!1):void m.event.add(this,"beforeactivate._change",function(a){var b=a.target;X.test(b.nodeName)&&!m._data(b,"changeBubbles")&&(m.event.add(b,"change._change",function(a){!this.parentNode||a.isSimulated||a.isTrigger||m.event.simulate("change",this.parentNode,a,!0)}),m._data(b,"changeBubbles",!0))})},handle:function(a){var b=a.target;return this!==b||a.isSimulated||a.isTrigger||"radio"!==b.type&&"checkbox"!==b.type?a.handleObj.handler.apply(this,arguments):void 0},teardown:function(){return m.event.remove(this,"._change"),!X.test(this.nodeName)}}),k.focusinBubbles||m.each({focus:"focusin",blur:"focusout"},function(a,b){var c=function(a){m.event.simulate(b,a.target,m.event.fix(a),!0)};m.event.special[b]={setup:function(){var d=this.ownerDocument||this,e=m._data(d,b);e||d.addEventListener(a,c,!0),m._data(d,b,(e||0)+1)},teardown:function(){var d=this.ownerDocument||this,e=m._data(d,b)-1;e?m._data(d,b,e):(d.removeEventListener(a,c,!0),m._removeData(d,b))}}}),m.fn.extend({on:function(a,b,c,d,e){var f,g;if("object"==typeof a){"string"!=typeof b&&(c=c||b,b=void 0);for(f in a)this.on(f,b,c,a[f],e);return this}if(null==c&&null==d?(d=b,c=b=void 0):null==d&&("string"==typeof b?(d=c,c=void 0):(d=c,c=b,b=void 0)),d===!1)d=ba;else if(!d)return this;return 1===e&&(g=d,d=function(a){return m().off(a),g.apply(this,arguments)},d.guid=g.guid||(g.guid=m.guid++)),this.each(function(){m.event.add(this,a,d,c,b)})},one:function(a,b,c,d){return this.on(a,b,c,d,1)},off:function(a,b,c){var d,e;if(a&&a.preventDefault&&a.handleObj)return d=a.handleObj,m(a.delegateTarget).off(d.namespace?d.origType+"."+d.namespace:d.origType,d.selector,d.handler),this;if("object"==typeof a){for(e in a)this.off(e,b,a[e]);return this}return(b===!1||"function"==typeof b)&&(c=b,b=void 0),c===!1&&(c=ba),this.each(function(){m.event.remove(this,a,c,b)})},trigger:function(a,b){return this.each(function(){m.event.trigger(a,b,this)})},triggerHandler:function(a,b){var c=this[0];return c?m.event.trigger(a,b,c,!0):void 0}});function da(a){var b=ea.split("|"),c=a.createDocumentFragment();if(c.createElement)while(b.length)c.createElement(b.pop());return c}var ea="abbr|article|aside|audio|bdi|canvas|data|datalist|details|figcaption|figure|footer|header|hgroup|mark|meter|nav|output|progress|section|summary|time|video",fa=/ jQuery\d+="(?:null|\d+)"/g,ga=new RegExp("<(?:"+ea+")[\\s/>]","i"),ha=/^\s+/,ia=/<(?!area|br|col|embed|hr|img|input|link|meta|param)(([\w:]+)[^>]*)\/>/gi,ja=/<([\w:]+)/,ka=/<tbody/i,la=/<|&#?\w+;/,ma=/<(?:script|style|link)/i,na=/checked\s*(?:[^=]|=\s*.checked.)/i,oa=/^$|\/(?:java|ecma)script/i,pa=/^true\/(.*)/,qa=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g,ra={option:[1,"<select multiple='multiple'>","</select>"],legend:[1,"<fieldset>","</fieldset>"],area:[1,"<map>","</map>"],param:[1,"<object>","</object>"],thead:[1,"<table>","</table>"],tr:[2,"<table><tbody>","</tbody></table>"],col:[2,"<table><tbody></tbody><colgroup>","</colgroup></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:k.htmlSerialize?[0,"",""]:[1,"X<div>","</div>"]},sa=da(y),ta=sa.appendChild(y.createElement("div"));ra.optgroup=ra.option,ra.tbody=ra.tfoot=ra.colgroup=ra.caption=ra.thead,ra.th=ra.td;function ua(a,b){var c,d,e=0,f=typeof a.getElementsByTagName!==K?a.getElementsByTagName(b||"*"):typeof a.querySelectorAll!==K?a.querySelectorAll(b||"*"):void 0;if(!f)for(f=[],c=a.childNodes||a;null!=(d=c[e]);e++)!b||m.nodeName(d,b)?f.push(d):m.merge(f,ua(d,b));return void 0===b||b&&m.nodeName(a,b)?m.merge([a],f):f}function va(a){W.test(a.type)&&(a.defaultChecked=a.checked)}function wa(a,b){return m.nodeName(a,"table")&&m.nodeName(11!==b.nodeType?b:b.firstChild,"tr")?a.getElementsByTagName("tbody")[0]||a.appendChild(a.ownerDocument.createElement("tbody")):a}function xa(a){return a.type=(null!==m.find.attr(a,"type"))+"/"+a.type,a}function ya(a){var b=pa.exec(a.type);return b?a.type=b[1]:a.removeAttribute("type"),a}function za(a,b){for(var c,d=0;null!=(c=a[d]);d++)m._data(c,"globalEval",!b||m._data(b[d],"globalEval"))}function Aa(a,b){if(1===b.nodeType&&m.hasData(a)){var c,d,e,f=m._data(a),g=m._data(b,f),h=f.events;if(h){delete g.handle,g.events={};for(c in h)for(d=0,e=h[c].length;e>d;d++)m.event.add(b,c,h[c][d])}g.data&&(g.data=m.extend({},g.data))}}function Ba(a,b){var c,d,e;if(1===b.nodeType){if(c=b.nodeName.toLowerCase(),!k.noCloneEvent&&b[m.expando]){e=m._data(b);for(d in e.events)m.removeEvent(b,d,e.handle);b.removeAttribute(m.expando)}"script"===c&&b.text!==a.text?(xa(b).text=a.text,ya(b)):"object"===c?(b.parentNode&&(b.outerHTML=a.outerHTML),k.html5Clone&&a.innerHTML&&!m.trim(b.innerHTML)&&(b.innerHTML=a.innerHTML)):"input"===c&&W.test(a.type)?(b.defaultChecked=b.checked=a.checked,b.value!==a.value&&(b.value=a.value)):"option"===c?b.defaultSelected=b.selected=a.defaultSelected:("input"===c||"textarea"===c)&&(b.defaultValue=a.defaultValue)}}m.extend({clone:function(a,b,c){var d,e,f,g,h,i=m.contains(a.ownerDocument,a);if(k.html5Clone||m.isXMLDoc(a)||!ga.test("<"+a.nodeName+">")?f=a.cloneNode(!0):(ta.innerHTML=a.outerHTML,ta.removeChild(f=ta.firstChild)),!(k.noCloneEvent&&k.noCloneChecked||1!==a.nodeType&&11!==a.nodeType||m.isXMLDoc(a)))for(d=ua(f),h=ua(a),g=0;null!=(e=h[g]);++g)d[g]&&Ba(e,d[g]);if(b)if(c)for(h=h||ua(a),d=d||ua(f),g=0;null!=(e=h[g]);g++)Aa(e,d[g]);else Aa(a,f);return d=ua(f,"script"),d.length>0&&za(d,!i&&ua(a,"script")),d=h=e=null,f},buildFragment:function(a,b,c,d){for(var e,f,g,h,i,j,l,n=a.length,o=da(b),p=[],q=0;n>q;q++)if(f=a[q],f||0===f)if("object"===m.type(f))m.merge(p,f.nodeType?[f]:f);else if(la.test(f)){h=h||o.appendChild(b.createElement("div")),i=(ja.exec(f)||["",""])[1].toLowerCase(),l=ra[i]||ra._default,h.innerHTML=l[1]+f.replace(ia,"<$1></$2>")+l[2],e=l[0];while(e--)h=h.lastChild;if(!k.leadingWhitespace&&ha.test(f)&&p.push(b.createTextNode(ha.exec(f)[0])),!k.tbody){f="table"!==i||ka.test(f)?"<table>"!==l[1]||ka.test(f)?0:h:h.firstChild,e=f&&f.childNodes.length;while(e--)m.nodeName(j=f.childNodes[e],"tbody")&&!j.childNodes.length&&f.removeChild(j)}m.merge(p,h.childNodes),h.textContent="";while(h.firstChild)h.removeChild(h.firstChild);h=o.lastChild}else p.push(b.createTextNode(f));h&&o.removeChild(h),k.appendChecked||m.grep(ua(p,"input"),va),q=0;while(f=p[q++])if((!d||-1===m.inArray(f,d))&&(g=m.contains(f.ownerDocument,f),h=ua(o.appendChild(f),"script"),g&&za(h),c)){e=0;while(f=h[e++])oa.test(f.type||"")&&c.push(f)}return h=null,o},cleanData:function(a,b){for(var d,e,f,g,h=0,i=m.expando,j=m.cache,l=k.deleteExpando,n=m.event.special;null!=(d=a[h]);h++)if((b||m.acceptData(d))&&(f=d[i],g=f&&j[f])){if(g.events)for(e in g.events)n[e]?m.event.remove(d,e):m.removeEvent(d,e,g.handle);j[f]&&(delete j[f],l?delete d[i]:typeof d.removeAttribute!==K?d.removeAttribute(i):d[i]=null,c.push(f))}}}),m.fn.extend({text:function(a){return V(this,function(a){return void 0===a?m.text(this):this.empty().append((this[0]&&this[0].ownerDocument||y).createTextNode(a))},null,a,arguments.length)},append:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.appendChild(a)}})},prepend:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.insertBefore(a,b.firstChild)}})},before:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this)})},after:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this.nextSibling)})},remove:function(a,b){for(var c,d=a?m.filter(a,this):this,e=0;null!=(c=d[e]);e++)b||1!==c.nodeType||m.cleanData(ua(c)),c.parentNode&&(b&&m.contains(c.ownerDocument,c)&&za(ua(c,"script")),c.parentNode.removeChild(c));return this},empty:function(){for(var a,b=0;null!=(a=this[b]);b++){1===a.nodeType&&m.cleanData(ua(a,!1));while(a.firstChild)a.removeChild(a.firstChild);a.options&&m.nodeName(a,"select")&&(a.options.length=0)}return this},clone:function(a,b){return a=null==a?!1:a,b=null==b?a:b,this.map(function(){return m.clone(this,a,b)})},html:function(a){return V(this,function(a){var b=this[0]||{},c=0,d=this.length;if(void 0===a)return 1===b.nodeType?b.innerHTML.replace(fa,""):void 0;if(!("string"!=typeof a||ma.test(a)||!k.htmlSerialize&&ga.test(a)||!k.leadingWhitespace&&ha.test(a)||ra[(ja.exec(a)||["",""])[1].toLowerCase()])){a=a.replace(ia,"<$1></$2>");try{for(;d>c;c++)b=this[c]||{},1===b.nodeType&&(m.cleanData(ua(b,!1)),b.innerHTML=a);b=0}catch(e){}}b&&this.empty().append(a)},null,a,arguments.length)},replaceWith:function(){var a=arguments[0];return this.domManip(arguments,function(b){a=this.parentNode,m.cleanData(ua(this)),a&&a.replaceChild(b,this)}),a&&(a.length||a.nodeType)?this:this.remove()},detach:function(a){return this.remove(a,!0)},domManip:function(a,b){a=e.apply([],a);var c,d,f,g,h,i,j=0,l=this.length,n=this,o=l-1,p=a[0],q=m.isFunction(p);if(q||l>1&&"string"==typeof p&&!k.checkClone&&na.test(p))return this.each(function(c){var d=n.eq(c);q&&(a[0]=p.call(this,c,d.html())),d.domManip(a,b)});if(l&&(i=m.buildFragment(a,this[0].ownerDocument,!1,this),c=i.firstChild,1===i.childNodes.length&&(i=c),c)){for(g=m.map(ua(i,"script"),xa),f=g.length;l>j;j++)d=i,j!==o&&(d=m.clone(d,!0,!0),f&&m.merge(g,ua(d,"script"))),b.call(this[j],d,j);if(f)for(h=g[g.length-1].ownerDocument,m.map(g,ya),j=0;f>j;j++)d=g[j],oa.test(d.type||"")&&!m._data(d,"globalEval")&&m.contains(h,d)&&(d.src?m._evalUrl&&m._evalUrl(d.src):m.globalEval((d.text||d.textContent||d.innerHTML||"").replace(qa,"")));i=c=null}return this}}),m.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(a,b){m.fn[a]=function(a){for(var c,d=0,e=[],g=m(a),h=g.length-1;h>=d;d++)c=d===h?this:this.clone(!0),m(g[d])[b](c),f.apply(e,c.get());return this.pushStack(e)}});var Ca,Da={};function Ea(b,c){var d,e=m(c.createElement(b)).appendTo(c.body),f=a.getDefaultComputedStyle&&(d=a.getDefaultComputedStyle(e[0]))?d.display:m.css(e[0],"display");return e.detach(),f}function Fa(a){var b=y,c=Da[a];return c||(c=Ea(a,b),"none"!==c&&c||(Ca=(Ca||m("<iframe frameborder='0' width='0' height='0'/>")).appendTo(b.documentElement),b=(Ca[0].contentWindow||Ca[0].contentDocument).document,b.write(),b.close(),c=Ea(a,b),Ca.detach()),Da[a]=c),c}!function(){var a;k.shrinkWrapBlocks=function(){if(null!=a)return a;a=!1;var b,c,d;return c=y.getElementsByTagName("body")[0],c&&c.style?(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:1px;width:1px;zoom:1",b.appendChild(y.createElement("div")).style.width="5px",a=3!==b.offsetWidth),c.removeChild(d),a):void 0}}();var Ga=/^margin/,Ha=new RegExp("^("+S+")(?!px)[a-z%]+$","i"),Ia,Ja,Ka=/^(top|right|bottom|left)$/;a.getComputedStyle?(Ia=function(b){return b.ownerDocument.defaultView.opener?b.ownerDocument.defaultView.getComputedStyle(b,null):a.getComputedStyle(b,null)},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c.getPropertyValue(b)||c[b]:void 0,c&&(""!==g||m.contains(a.ownerDocument,a)||(g=m.style(a,b)),Ha.test(g)&&Ga.test(b)&&(d=h.width,e=h.minWidth,f=h.maxWidth,h.minWidth=h.maxWidth=h.width=g,g=c.width,h.width=d,h.minWidth=e,h.maxWidth=f)),void 0===g?g:g+""}):y.documentElement.currentStyle&&(Ia=function(a){return a.currentStyle},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c[b]:void 0,null==g&&h&&h[b]&&(g=h[b]),Ha.test(g)&&!Ka.test(b)&&(d=h.left,e=a.runtimeStyle,f=e&&e.left,f&&(e.left=a.currentStyle.left),h.left="fontSize"===b?"1em":g,g=h.pixelLeft+"px",h.left=d,f&&(e.left=f)),void 0===g?g:g+""||"auto"});function La(a,b){return{get:function(){var c=a();if(null!=c)return c?void delete this.get:(this.get=b).apply(this,arguments)}}}!function(){var b,c,d,e,f,g,h;if(b=y.createElement("div"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=d&&d.style){c.cssText="float:left;opacity:.5",k.opacity="0.5"===c.opacity,k.cssFloat=!!c.cssFloat,b.style.backgroundClip="content-box",b.cloneNode(!0).style.backgroundClip="",k.clearCloneStyle="content-box"===b.style.backgroundClip,k.boxSizing=""===c.boxSizing||""===c.MozBoxSizing||""===c.WebkitBoxSizing,m.extend(k,{reliableHiddenOffsets:function(){return null==g&&i(),g},boxSizingReliable:function(){return null==f&&i(),f},pixelPosition:function(){return null==e&&i(),e},reliableMarginRight:function(){return null==h&&i(),h}});function i(){var b,c,d,i;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),b.style.cssText="-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;display:block;margin-top:1%;top:1%;border:1px;padding:1px;width:4px;position:absolute",e=f=!1,h=!0,a.getComputedStyle&&(e="1%"!==(a.getComputedStyle(b,null)||{}).top,f="4px"===(a.getComputedStyle(b,null)||{width:"4px"}).width,i=b.appendChild(y.createElement("div")),i.style.cssText=b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:0",i.style.marginRight=i.style.width="0",b.style.width="1px",h=!parseFloat((a.getComputedStyle(i,null)||{}).marginRight),b.removeChild(i)),b.innerHTML="<table><tr><td></td><td>t</td></tr></table>",i=b.getElementsByTagName("td"),i[0].style.cssText="margin:0;border:0;padding:0;display:none",g=0===i[0].offsetHeight,g&&(i[0].style.display="",i[1].style.display="none",g=0===i[0].offsetHeight),c.removeChild(d))}}}(),m.swap=function(a,b,c,d){var e,f,g={};for(f in b)g[f]=a.style[f],a.style[f]=b[f];e=c.apply(a,d||[]);for(f in b)a.style[f]=g[f];return e};var Ma=/alpha\([^)]*\)/i,Na=/opacity\s*=\s*([^)]*)/,Oa=/^(none|table(?!-c[ea]).+)/,Pa=new RegExp("^("+S+")(.*)$","i"),Qa=new RegExp("^([+-])=("+S+")","i"),Ra={position:"absolute",visibility:"hidden",display:"block"},Sa={letterSpacing:"0",fontWeight:"400"},Ta=["Webkit","O","Moz","ms"];function Ua(a,b){if(b in a)return b;var c=b.charAt(0).toUpperCase()+b.slice(1),d=b,e=Ta.length;while(e--)if(b=Ta[e]+c,b in a)return b;return d}function Va(a,b){for(var c,d,e,f=[],g=0,h=a.length;h>g;g++)d=a[g],d.style&&(f[g]=m._data(d,"olddisplay"),c=d.style.display,b?(f[g]||"none"!==c||(d.style.display=""),""===d.style.display&&U(d)&&(f[g]=m._data(d,"olddisplay",Fa(d.nodeName)))):(e=U(d),(c&&"none"!==c||!e)&&m._data(d,"olddisplay",e?c:m.css(d,"display"))));for(g=0;h>g;g++)d=a[g],d.style&&(b&&"none"!==d.style.display&&""!==d.style.display||(d.style.display=b?f[g]||"":"none"));return a}function Wa(a,b,c){var d=Pa.exec(b);return d?Math.max(0,d[1]-(c||0))+(d[2]||"px"):b}function Xa(a,b,c,d,e){for(var f=c===(d?"border":"content")?4:"width"===b?1:0,g=0;4>f;f+=2)"margin"===c&&(g+=m.css(a,c+T[f],!0,e)),d?("content"===c&&(g-=m.css(a,"padding"+T[f],!0,e)),"margin"!==c&&(g-=m.css(a,"border"+T[f]+"Width",!0,e))):(g+=m.css(a,"padding"+T[f],!0,e),"padding"!==c&&(g+=m.css(a,"border"+T[f]+"Width",!0,e)));return g}function Ya(a,b,c){var d=!0,e="width"===b?a.offsetWidth:a.offsetHeight,f=Ia(a),g=k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,f);if(0>=e||null==e){if(e=Ja(a,b,f),(0>e||null==e)&&(e=a.style[b]),Ha.test(e))return e;d=g&&(k.boxSizingReliable()||e===a.style[b]),e=parseFloat(e)||0}return e+Xa(a,b,c||(g?"border":"content"),d,f)+"px"}m.extend({cssHooks:{opacity:{get:function(a,b){if(b){var c=Ja(a,"opacity");return""===c?"1":c}}}},cssNumber:{columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{"float":k.cssFloat?"cssFloat":"styleFloat"},style:function(a,b,c,d){if(a&&3!==a.nodeType&&8!==a.nodeType&&a.style){var e,f,g,h=m.camelCase(b),i=a.style;if(b=m.cssProps[h]||(m.cssProps[h]=Ua(i,h)),g=m.cssHooks[b]||m.cssHooks[h],void 0===c)return g&&"get"in g&&void 0!==(e=g.get(a,!1,d))?e:i[b];if(f=typeof c,"string"===f&&(e=Qa.exec(c))&&(c=(e[1]+1)*e[2]+parseFloat(m.css(a,b)),f="number"),null!=c&&c===c&&("number"!==f||m.cssNumber[h]||(c+="px"),k.clearCloneStyle||""!==c||0!==b.indexOf("background")||(i[b]="inherit"),!(g&&"set"in g&&void 0===(c=g.set(a,c,d)))))try{i[b]=c}catch(j){}}},css:function(a,b,c,d){var e,f,g,h=m.camelCase(b);return b=m.cssProps[h]||(m.cssProps[h]=Ua(a.style,h)),g=m.cssHooks[b]||m.cssHooks[h],g&&"get"in g&&(f=g.get(a,!0,c)),void 0===f&&(f=Ja(a,b,d)),"normal"===f&&b in Sa&&(f=Sa[b]),""===c||c?(e=parseFloat(f),c===!0||m.isNumeric(e)?e||0:f):f}}),m.each(["height","width"],function(a,b){m.cssHooks[b]={get:function(a,c,d){return c?Oa.test(m.css(a,"display"))&&0===a.offsetWidth?m.swap(a,Ra,function(){return Ya(a,b,d)}):Ya(a,b,d):void 0},set:function(a,c,d){var e=d&&Ia(a);return Wa(a,c,d?Xa(a,b,d,k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,e),e):0)}}}),k.opacity||(m.cssHooks.opacity={get:function(a,b){return Na.test((b&&a.currentStyle?a.currentStyle.filter:a.style.filter)||"")?.01*parseFloat(RegExp.$1)+"":b?"1":""},set:function(a,b){var c=a.style,d=a.currentStyle,e=m.isNumeric(b)?"alpha(opacity="+100*b+")":"",f=d&&d.filter||c.filter||"";c.zoom=1,(b>=1||""===b)&&""===m.trim(f.replace(Ma,""))&&c.removeAttribute&&(c.removeAttribute("filter"),""===b||d&&!d.filter)||(c.filter=Ma.test(f)?f.replace(Ma,e):f+" "+e)}}),m.cssHooks.marginRight=La(k.reliableMarginRight,function(a,b){return b?m.swap(a,{display:"inline-block"},Ja,[a,"marginRight"]):void 0}),m.each({margin:"",padding:"",border:"Width"},function(a,b){m.cssHooks[a+b]={expand:function(c){for(var d=0,e={},f="string"==typeof c?c.split(" "):[c];4>d;d++)e[a+T[d]+b]=f[d]||f[d-2]||f[0];return e}},Ga.test(a)||(m.cssHooks[a+b].set=Wa)}),m.fn.extend({css:function(a,b){return V(this,function(a,b,c){var d,e,f={},g=0;if(m.isArray(b)){for(d=Ia(a),e=b.length;e>g;g++)f[b[g]]=m.css(a,b[g],!1,d);return f}return void 0!==c?m.style(a,b,c):m.css(a,b)},a,b,arguments.length>1)},show:function(){return Va(this,!0)},hide:function(){return Va(this)},toggle:function(a){return"boolean"==typeof a?a?this.show():this.hide():this.each(function(){U(this)?m(this).show():m(this).hide()})}});function Za(a,b,c,d,e){
return new Za.prototype.init(a,b,c,d,e)}m.Tween=Za,Za.prototype={constructor:Za,init:function(a,b,c,d,e,f){this.elem=a,this.prop=c,this.easing=e||"swing",this.options=b,this.start=this.now=this.cur(),this.end=d,this.unit=f||(m.cssNumber[c]?"":"px")},cur:function(){var a=Za.propHooks[this.prop];return a&&a.get?a.get(this):Za.propHooks._default.get(this)},run:function(a){var b,c=Za.propHooks[this.prop];return this.options.duration?this.pos=b=m.easing[this.easing](a,this.options.duration*a,0,1,this.options.duration):this.pos=b=a,this.now=(this.end-this.start)*b+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),c&&c.set?c.set(this):Za.propHooks._default.set(this),this}},Za.prototype.init.prototype=Za.prototype,Za.propHooks={_default:{get:function(a){var b;return null==a.elem[a.prop]||a.elem.style&&null!=a.elem.style[a.prop]?(b=m.css(a.elem,a.prop,""),b&&"auto"!==b?b:0):a.elem[a.prop]},set:function(a){m.fx.step[a.prop]?m.fx.step[a.prop](a):a.elem.style&&(null!=a.elem.style[m.cssProps[a.prop]]||m.cssHooks[a.prop])?m.style(a.elem,a.prop,a.now+a.unit):a.elem[a.prop]=a.now}}},Za.propHooks.scrollTop=Za.propHooks.scrollLeft={set:function(a){a.elem.nodeType&&a.elem.parentNode&&(a.elem[a.prop]=a.now)}},m.easing={linear:function(a){return a},swing:function(a){return.5-Math.cos(a*Math.PI)/2}},m.fx=Za.prototype.init,m.fx.step={};var $a,_a,ab=/^(?:toggle|show|hide)$/,bb=new RegExp("^(?:([+-])=|)("+S+")([a-z%]*)$","i"),cb=/queueHooks$/,db=[ib],eb={"*":[function(a,b){var c=this.createTween(a,b),d=c.cur(),e=bb.exec(b),f=e&&e[3]||(m.cssNumber[a]?"":"px"),g=(m.cssNumber[a]||"px"!==f&&+d)&&bb.exec(m.css(c.elem,a)),h=1,i=20;if(g&&g[3]!==f){f=f||g[3],e=e||[],g=+d||1;do h=h||".5",g/=h,m.style(c.elem,a,g+f);while(h!==(h=c.cur()/d)&&1!==h&&--i)}return e&&(g=c.start=+g||+d||0,c.unit=f,c.end=e[1]?g+(e[1]+1)*e[2]:+e[2]),c}]};function fb(){return setTimeout(function(){$a=void 0}),$a=m.now()}function gb(a,b){var c,d={height:a},e=0;for(b=b?1:0;4>e;e+=2-b)c=T[e],d["margin"+c]=d["padding"+c]=a;return b&&(d.opacity=d.width=a),d}function hb(a,b,c){for(var d,e=(eb[b]||[]).concat(eb["*"]),f=0,g=e.length;g>f;f++)if(d=e[f].call(c,b,a))return d}function ib(a,b,c){var d,e,f,g,h,i,j,l,n=this,o={},p=a.style,q=a.nodeType&&U(a),r=m._data(a,"fxshow");c.queue||(h=m._queueHooks(a,"fx"),null==h.unqueued&&(h.unqueued=0,i=h.empty.fire,h.empty.fire=function(){h.unqueued||i()}),h.unqueued++,n.always(function(){n.always(function(){h.unqueued--,m.queue(a,"fx").length||h.empty.fire()})})),1===a.nodeType&&("height"in b||"width"in b)&&(c.overflow=[p.overflow,p.overflowX,p.overflowY],j=m.css(a,"display"),l="none"===j?m._data(a,"olddisplay")||Fa(a.nodeName):j,"inline"===l&&"none"===m.css(a,"float")&&(k.inlineBlockNeedsLayout&&"inline"!==Fa(a.nodeName)?p.zoom=1:p.display="inline-block")),c.overflow&&(p.overflow="hidden",k.shrinkWrapBlocks()||n.always(function(){p.overflow=c.overflow[0],p.overflowX=c.overflow[1],p.overflowY=c.overflow[2]}));for(d in b)if(e=b[d],ab.exec(e)){if(delete b[d],f=f||"toggle"===e,e===(q?"hide":"show")){if("show"!==e||!r||void 0===r[d])continue;q=!0}o[d]=r&&r[d]||m.style(a,d)}else j=void 0;if(m.isEmptyObject(o))"inline"===("none"===j?Fa(a.nodeName):j)&&(p.display=j);else{r?"hidden"in r&&(q=r.hidden):r=m._data(a,"fxshow",{}),f&&(r.hidden=!q),q?m(a).show():n.done(function(){m(a).hide()}),n.done(function(){var b;m._removeData(a,"fxshow");for(b in o)m.style(a,b,o[b])});for(d in o)g=hb(q?r[d]:0,d,n),d in r||(r[d]=g.start,q&&(g.end=g.start,g.start="width"===d||"height"===d?1:0))}}function jb(a,b){var c,d,e,f,g;for(c in a)if(d=m.camelCase(c),e=b[d],f=a[c],m.isArray(f)&&(e=f[1],f=a[c]=f[0]),c!==d&&(a[d]=f,delete a[c]),g=m.cssHooks[d],g&&"expand"in g){f=g.expand(f),delete a[d];for(c in f)c in a||(a[c]=f[c],b[c]=e)}else b[d]=e}function kb(a,b,c){var d,e,f=0,g=db.length,h=m.Deferred().always(function(){delete i.elem}),i=function(){if(e)return!1;for(var b=$a||fb(),c=Math.max(0,j.startTime+j.duration-b),d=c/j.duration||0,f=1-d,g=0,i=j.tweens.length;i>g;g++)j.tweens[g].run(f);return h.notifyWith(a,[j,f,c]),1>f&&i?c:(h.resolveWith(a,[j]),!1)},j=h.promise({elem:a,props:m.extend({},b),opts:m.extend(!0,{specialEasing:{}},c),originalProperties:b,originalOptions:c,startTime:$a||fb(),duration:c.duration,tweens:[],createTween:function(b,c){var d=m.Tween(a,j.opts,b,c,j.opts.specialEasing[b]||j.opts.easing);return j.tweens.push(d),d},stop:function(b){var c=0,d=b?j.tweens.length:0;if(e)return this;for(e=!0;d>c;c++)j.tweens[c].run(1);return b?h.resolveWith(a,[j,b]):h.rejectWith(a,[j,b]),this}}),k=j.props;for(jb(k,j.opts.specialEasing);g>f;f++)if(d=db[f].call(j,a,k,j.opts))return d;return m.map(k,hb,j),m.isFunction(j.opts.start)&&j.opts.start.call(a,j),m.fx.timer(m.extend(i,{elem:a,anim:j,queue:j.opts.queue})),j.progress(j.opts.progress).done(j.opts.done,j.opts.complete).fail(j.opts.fail).always(j.opts.always)}m.Animation=m.extend(kb,{tweener:function(a,b){m.isFunction(a)?(b=a,a=["*"]):a=a.split(" ");for(var c,d=0,e=a.length;e>d;d++)c=a[d],eb[c]=eb[c]||[],eb[c].unshift(b)},prefilter:function(a,b){b?db.unshift(a):db.push(a)}}),m.speed=function(a,b,c){var d=a&&"object"==typeof a?m.extend({},a):{complete:c||!c&&b||m.isFunction(a)&&a,duration:a,easing:c&&b||b&&!m.isFunction(b)&&b};return d.duration=m.fx.off?0:"number"==typeof d.duration?d.duration:d.duration in m.fx.speeds?m.fx.speeds[d.duration]:m.fx.speeds._default,(null==d.queue||d.queue===!0)&&(d.queue="fx"),d.old=d.complete,d.complete=function(){m.isFunction(d.old)&&d.old.call(this),d.queue&&m.dequeue(this,d.queue)},d},m.fn.extend({fadeTo:function(a,b,c,d){return this.filter(U).css("opacity",0).show().end().animate({opacity:b},a,c,d)},animate:function(a,b,c,d){var e=m.isEmptyObject(a),f=m.speed(b,c,d),g=function(){var b=kb(this,m.extend({},a),f);(e||m._data(this,"finish"))&&b.stop(!0)};return g.finish=g,e||f.queue===!1?this.each(g):this.queue(f.queue,g)},stop:function(a,b,c){var d=function(a){var b=a.stop;delete a.stop,b(c)};return"string"!=typeof a&&(c=b,b=a,a=void 0),b&&a!==!1&&this.queue(a||"fx",[]),this.each(function(){var b=!0,e=null!=a&&a+"queueHooks",f=m.timers,g=m._data(this);if(e)g[e]&&g[e].stop&&d(g[e]);else for(e in g)g[e]&&g[e].stop&&cb.test(e)&&d(g[e]);for(e=f.length;e--;)f[e].elem!==this||null!=a&&f[e].queue!==a||(f[e].anim.stop(c),b=!1,f.splice(e,1));(b||!c)&&m.dequeue(this,a)})},finish:function(a){return a!==!1&&(a=a||"fx"),this.each(function(){var b,c=m._data(this),d=c[a+"queue"],e=c[a+"queueHooks"],f=m.timers,g=d?d.length:0;for(c.finish=!0,m.queue(this,a,[]),e&&e.stop&&e.stop.call(this,!0),b=f.length;b--;)f[b].elem===this&&f[b].queue===a&&(f[b].anim.stop(!0),f.splice(b,1));for(b=0;g>b;b++)d[b]&&d[b].finish&&d[b].finish.call(this);delete c.finish})}}),m.each(["toggle","show","hide"],function(a,b){var c=m.fn[b];m.fn[b]=function(a,d,e){return null==a||"boolean"==typeof a?c.apply(this,arguments):this.animate(gb(b,!0),a,d,e)}}),m.each({slideDown:gb("show"),slideUp:gb("hide"),slideToggle:gb("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(a,b){m.fn[a]=function(a,c,d){return this.animate(b,a,c,d)}}),m.timers=[],m.fx.tick=function(){var a,b=m.timers,c=0;for($a=m.now();c<b.length;c++)a=b[c],a()||b[c]!==a||b.splice(c--,1);b.length||m.fx.stop(),$a=void 0},m.fx.timer=function(a){m.timers.push(a),a()?m.fx.start():m.timers.pop()},m.fx.interval=13,m.fx.start=function(){_a||(_a=setInterval(m.fx.tick,m.fx.interval))},m.fx.stop=function(){clearInterval(_a),_a=null},m.fx.speeds={slow:600,fast:200,_default:400},m.fn.delay=function(a,b){return a=m.fx?m.fx.speeds[a]||a:a,b=b||"fx",this.queue(b,function(b,c){var d=setTimeout(b,a);c.stop=function(){clearTimeout(d)}})},function(){var a,b,c,d,e;b=y.createElement("div"),b.setAttribute("className","t"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=y.createElement("select"),e=c.appendChild(y.createElement("option")),a=b.getElementsByTagName("input")[0],d.style.cssText="top:1px",k.getSetAttribute="t"!==b.className,k.style=/top/.test(d.getAttribute("style")),k.hrefNormalized="/a"===d.getAttribute("href"),k.checkOn=!!a.value,k.optSelected=e.selected,k.enctype=!!y.createElement("form").enctype,c.disabled=!0,k.optDisabled=!e.disabled,a=y.createElement("input"),a.setAttribute("value",""),k.input=""===a.getAttribute("value"),a.value="t",a.setAttribute("type","radio"),k.radioValue="t"===a.value}();var lb=/\r/g;m.fn.extend({val:function(a){var b,c,d,e=this[0];{if(arguments.length)return d=m.isFunction(a),this.each(function(c){var e;1===this.nodeType&&(e=d?a.call(this,c,m(this).val()):a,null==e?e="":"number"==typeof e?e+="":m.isArray(e)&&(e=m.map(e,function(a){return null==a?"":a+""})),b=m.valHooks[this.type]||m.valHooks[this.nodeName.toLowerCase()],b&&"set"in b&&void 0!==b.set(this,e,"value")||(this.value=e))});if(e)return b=m.valHooks[e.type]||m.valHooks[e.nodeName.toLowerCase()],b&&"get"in b&&void 0!==(c=b.get(e,"value"))?c:(c=e.value,"string"==typeof c?c.replace(lb,""):null==c?"":c)}}}),m.extend({valHooks:{option:{get:function(a){var b=m.find.attr(a,"value");return null!=b?b:m.trim(m.text(a))}},select:{get:function(a){for(var b,c,d=a.options,e=a.selectedIndex,f="select-one"===a.type||0>e,g=f?null:[],h=f?e+1:d.length,i=0>e?h:f?e:0;h>i;i++)if(c=d[i],!(!c.selected&&i!==e||(k.optDisabled?c.disabled:null!==c.getAttribute("disabled"))||c.parentNode.disabled&&m.nodeName(c.parentNode,"optgroup"))){if(b=m(c).val(),f)return b;g.push(b)}return g},set:function(a,b){var c,d,e=a.options,f=m.makeArray(b),g=e.length;while(g--)if(d=e[g],m.inArray(m.valHooks.option.get(d),f)>=0)try{d.selected=c=!0}catch(h){d.scrollHeight}else d.selected=!1;return c||(a.selectedIndex=-1),e}}}}),m.each(["radio","checkbox"],function(){m.valHooks[this]={set:function(a,b){return m.isArray(b)?a.checked=m.inArray(m(a).val(),b)>=0:void 0}},k.checkOn||(m.valHooks[this].get=function(a){return null===a.getAttribute("value")?"on":a.value})});var mb,nb,ob=m.expr.attrHandle,pb=/^(?:checked|selected)$/i,qb=k.getSetAttribute,rb=k.input;m.fn.extend({attr:function(a,b){return V(this,m.attr,a,b,arguments.length>1)},removeAttr:function(a){return this.each(function(){m.removeAttr(this,a)})}}),m.extend({attr:function(a,b,c){var d,e,f=a.nodeType;if(a&&3!==f&&8!==f&&2!==f)return typeof a.getAttribute===K?m.prop(a,b,c):(1===f&&m.isXMLDoc(a)||(b=b.toLowerCase(),d=m.attrHooks[b]||(m.expr.match.bool.test(b)?nb:mb)),void 0===c?d&&"get"in d&&null!==(e=d.get(a,b))?e:(e=m.find.attr(a,b),null==e?void 0:e):null!==c?d&&"set"in d&&void 0!==(e=d.set(a,c,b))?e:(a.setAttribute(b,c+""),c):void m.removeAttr(a,b))},removeAttr:function(a,b){var c,d,e=0,f=b&&b.match(E);if(f&&1===a.nodeType)while(c=f[e++])d=m.propFix[c]||c,m.expr.match.bool.test(c)?rb&&qb||!pb.test(c)?a[d]=!1:a[m.camelCase("default-"+c)]=a[d]=!1:m.attr(a,c,""),a.removeAttribute(qb?c:d)},attrHooks:{type:{set:function(a,b){if(!k.radioValue&&"radio"===b&&m.nodeName(a,"input")){var c=a.value;return a.setAttribute("type",b),c&&(a.value=c),b}}}}}),nb={set:function(a,b,c){return b===!1?m.removeAttr(a,c):rb&&qb||!pb.test(c)?a.setAttribute(!qb&&m.propFix[c]||c,c):a[m.camelCase("default-"+c)]=a[c]=!0,c}},m.each(m.expr.match.bool.source.match(/\w+/g),function(a,b){var c=ob[b]||m.find.attr;ob[b]=rb&&qb||!pb.test(b)?function(a,b,d){var e,f;return d||(f=ob[b],ob[b]=e,e=null!=c(a,b,d)?b.toLowerCase():null,ob[b]=f),e}:function(a,b,c){return c?void 0:a[m.camelCase("default-"+b)]?b.toLowerCase():null}}),rb&&qb||(m.attrHooks.value={set:function(a,b,c){return m.nodeName(a,"input")?void(a.defaultValue=b):mb&&mb.set(a,b,c)}}),qb||(mb={set:function(a,b,c){var d=a.getAttributeNode(c);return d||a.setAttributeNode(d=a.ownerDocument.createAttribute(c)),d.value=b+="","value"===c||b===a.getAttribute(c)?b:void 0}},ob.id=ob.name=ob.coords=function(a,b,c){var d;return c?void 0:(d=a.getAttributeNode(b))&&""!==d.value?d.value:null},m.valHooks.button={get:function(a,b){var c=a.getAttributeNode(b);return c&&c.specified?c.value:void 0},set:mb.set},m.attrHooks.contenteditable={set:function(a,b,c){mb.set(a,""===b?!1:b,c)}},m.each(["width","height"],function(a,b){m.attrHooks[b]={set:function(a,c){return""===c?(a.setAttribute(b,"auto"),c):void 0}}})),k.style||(m.attrHooks.style={get:function(a){return a.style.cssText||void 0},set:function(a,b){return a.style.cssText=b+""}});var sb=/^(?:input|select|textarea|button|object)$/i,tb=/^(?:a|area)$/i;m.fn.extend({prop:function(a,b){return V(this,m.prop,a,b,arguments.length>1)},removeProp:function(a){return a=m.propFix[a]||a,this.each(function(){try{this[a]=void 0,delete this[a]}catch(b){}})}}),m.extend({propFix:{"for":"htmlFor","class":"className"},prop:function(a,b,c){var d,e,f,g=a.nodeType;if(a&&3!==g&&8!==g&&2!==g)return f=1!==g||!m.isXMLDoc(a),f&&(b=m.propFix[b]||b,e=m.propHooks[b]),void 0!==c?e&&"set"in e&&void 0!==(d=e.set(a,c,b))?d:a[b]=c:e&&"get"in e&&null!==(d=e.get(a,b))?d:a[b]},propHooks:{tabIndex:{get:function(a){var b=m.find.attr(a,"tabindex");return b?parseInt(b,10):sb.test(a.nodeName)||tb.test(a.nodeName)&&a.href?0:-1}}}}),k.hrefNormalized||m.each(["href","src"],function(a,b){m.propHooks[b]={get:function(a){return a.getAttribute(b,4)}}}),k.optSelected||(m.propHooks.selected={get:function(a){var b=a.parentNode;return b&&(b.selectedIndex,b.parentNode&&b.parentNode.selectedIndex),null}}),m.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){m.propFix[this.toLowerCase()]=this}),k.enctype||(m.propFix.enctype="encoding");var ub=/[\t\r\n\f]/g;m.fn.extend({addClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j="string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).addClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):" ")){f=0;while(e=b[f++])d.indexOf(" "+e+" ")<0&&(d+=e+" ");g=m.trim(d),c.className!==g&&(c.className=g)}return this},removeClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j=0===arguments.length||"string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).removeClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):"")){f=0;while(e=b[f++])while(d.indexOf(" "+e+" ")>=0)d=d.replace(" "+e+" "," ");g=a?m.trim(d):"",c.className!==g&&(c.className=g)}return this},toggleClass:function(a,b){var c=typeof a;return"boolean"==typeof b&&"string"===c?b?this.addClass(a):this.removeClass(a):this.each(m.isFunction(a)?function(c){m(this).toggleClass(a.call(this,c,this.className,b),b)}:function(){if("string"===c){var b,d=0,e=m(this),f=a.match(E)||[];while(b=f[d++])e.hasClass(b)?e.removeClass(b):e.addClass(b)}else(c===K||"boolean"===c)&&(this.className&&m._data(this,"__className__",this.className),this.className=this.className||a===!1?"":m._data(this,"__className__")||"")})},hasClass:function(a){for(var b=" "+a+" ",c=0,d=this.length;d>c;c++)if(1===this[c].nodeType&&(" "+this[c].className+" ").replace(ub," ").indexOf(b)>=0)return!0;return!1}}),m.each("blur focus focusin focusout load resize scroll unload click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup error contextmenu".split(" "),function(a,b){m.fn[b]=function(a,c){return arguments.length>0?this.on(b,null,a,c):this.trigger(b)}}),m.fn.extend({hover:function(a,b){return this.mouseenter(a).mouseleave(b||a)},bind:function(a,b,c){return this.on(a,null,b,c)},unbind:function(a,b){return this.off(a,null,b)},delegate:function(a,b,c,d){return this.on(b,a,c,d)},undelegate:function(a,b,c){return 1===arguments.length?this.off(a,"**"):this.off(b,a||"**",c)}});var vb=m.now(),wb=/\?/,xb=/(,)|(\[|{)|(}|])|"(?:[^"\\\r\n]|\\["\\\/bfnrt]|\\u[\da-fA-F]{4})*"\s*:?|true|false|null|-?(?!0\d)\d+(?:\.\d+|)(?:[eE][+-]?\d+|)/g;m.parseJSON=function(b){if(a.JSON&&a.JSON.parse)return a.JSON.parse(b+"");var c,d=null,e=m.trim(b+"");return e&&!m.trim(e.replace(xb,function(a,b,e,f){return c&&b&&(d=0),0===d?a:(c=e||b,d+=!f-!e,"")}))?Function("return "+e)():m.error("Invalid JSON: "+b)},m.parseXML=function(b){var c,d;if(!b||"string"!=typeof b)return null;try{a.DOMParser?(d=new DOMParser,c=d.parseFromString(b,"text/xml")):(c=new ActiveXObject("Microsoft.XMLDOM"),c.async="false",c.loadXML(b))}catch(e){c=void 0}return c&&c.documentElement&&!c.getElementsByTagName("parsererror").length||m.error("Invalid XML: "+b),c};var yb,zb,Ab=/#.*$/,Bb=/([?&])_=[^&]*/,Cb=/^(.*?):[ \t]*([^\r\n]*)\r?$/gm,Db=/^(?:about|app|app-storage|.+-extension|file|res|widget):$/,Eb=/^(?:GET|HEAD)$/,Fb=/^\/\//,Gb=/^([\w.+-]+:)(?:\/\/(?:[^\/?#]*@|)([^\/?#:]*)(?::(\d+)|)|)/,Hb={},Ib={},Jb="*/".concat("*");try{zb=location.href}catch(Kb){zb=y.createElement("a"),zb.href="",zb=zb.href}yb=Gb.exec(zb.toLowerCase())||[];function Lb(a){return function(b,c){"string"!=typeof b&&(c=b,b="*");var d,e=0,f=b.toLowerCase().match(E)||[];if(m.isFunction(c))while(d=f[e++])"+"===d.charAt(0)?(d=d.slice(1)||"*",(a[d]=a[d]||[]).unshift(c)):(a[d]=a[d]||[]).push(c)}}function Mb(a,b,c,d){var e={},f=a===Ib;function g(h){var i;return e[h]=!0,m.each(a[h]||[],function(a,h){var j=h(b,c,d);return"string"!=typeof j||f||e[j]?f?!(i=j):void 0:(b.dataTypes.unshift(j),g(j),!1)}),i}return g(b.dataTypes[0])||!e["*"]&&g("*")}function Nb(a,b){var c,d,e=m.ajaxSettings.flatOptions||{};for(d in b)void 0!==b[d]&&((e[d]?a:c||(c={}))[d]=b[d]);return c&&m.extend(!0,a,c),a}function Ob(a,b,c){var d,e,f,g,h=a.contents,i=a.dataTypes;while("*"===i[0])i.shift(),void 0===e&&(e=a.mimeType||b.getResponseHeader("Content-Type"));if(e)for(g in h)if(h[g]&&h[g].test(e)){i.unshift(g);break}if(i[0]in c)f=i[0];else{for(g in c){if(!i[0]||a.converters[g+" "+i[0]]){f=g;break}d||(d=g)}f=f||d}return f?(f!==i[0]&&i.unshift(f),c[f]):void 0}function Pb(a,b,c,d){var e,f,g,h,i,j={},k=a.dataTypes.slice();if(k[1])for(g in a.converters)j[g.toLowerCase()]=a.converters[g];f=k.shift();while(f)if(a.responseFields[f]&&(c[a.responseFields[f]]=b),!i&&d&&a.dataFilter&&(b=a.dataFilter(b,a.dataType)),i=f,f=k.shift())if("*"===f)f=i;else if("*"!==i&&i!==f){if(g=j[i+" "+f]||j["* "+f],!g)for(e in j)if(h=e.split(" "),h[1]===f&&(g=j[i+" "+h[0]]||j["* "+h[0]])){g===!0?g=j[e]:j[e]!==!0&&(f=h[0],k.unshift(h[1]));break}if(g!==!0)if(g&&a["throws"])b=g(b);else try{b=g(b)}catch(l){return{state:"parsererror",error:g?l:"No conversion from "+i+" to "+f}}}return{state:"success",data:b}}m.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:zb,type:"GET",isLocal:Db.test(yb[1]),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Jb,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/xml/,html:/html/,json:/json/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":m.parseJSON,"text xml":m.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(a,b){return b?Nb(Nb(a,m.ajaxSettings),b):Nb(m.ajaxSettings,a)},ajaxPrefilter:Lb(Hb),ajaxTransport:Lb(Ib),ajax:function(a,b){"object"==typeof a&&(b=a,a=void 0),b=b||{};var c,d,e,f,g,h,i,j,k=m.ajaxSetup({},b),l=k.context||k,n=k.context&&(l.nodeType||l.jquery)?m(l):m.event,o=m.Deferred(),p=m.Callbacks("once memory"),q=k.statusCode||{},r={},s={},t=0,u="canceled",v={readyState:0,getResponseHeader:function(a){var b;if(2===t){if(!j){j={};while(b=Cb.exec(f))j[b[1].toLowerCase()]=b[2]}b=j[a.toLowerCase()]}return null==b?null:b},getAllResponseHeaders:function(){return 2===t?f:null},setRequestHeader:function(a,b){var c=a.toLowerCase();return t||(a=s[c]=s[c]||a,r[a]=b),this},overrideMimeType:function(a){return t||(k.mimeType=a),this},statusCode:function(a){var b;if(a)if(2>t)for(b in a)q[b]=[q[b],a[b]];else v.always(a[v.status]);return this},abort:function(a){var b=a||u;return i&&i.abort(b),x(0,b),this}};if(o.promise(v).complete=p.add,v.success=v.done,v.error=v.fail,k.url=((a||k.url||zb)+"").replace(Ab,"").replace(Fb,yb[1]+"//"),k.type=b.method||b.type||k.method||k.type,k.dataTypes=m.trim(k.dataType||"*").toLowerCase().match(E)||[""],null==k.crossDomain&&(c=Gb.exec(k.url.toLowerCase()),k.crossDomain=!(!c||c[1]===yb[1]&&c[2]===yb[2]&&(c[3]||("http:"===c[1]?"80":"443"))===(yb[3]||("http:"===yb[1]?"80":"443")))),k.data&&k.processData&&"string"!=typeof k.data&&(k.data=m.param(k.data,k.traditional)),Mb(Hb,k,b,v),2===t)return v;h=m.event&&k.global,h&&0===m.active++&&m.event.trigger("ajaxStart"),k.type=k.type.toUpperCase(),k.hasContent=!Eb.test(k.type),e=k.url,k.hasContent||(k.data&&(e=k.url+=(wb.test(e)?"&":"?")+k.data,delete k.data),k.cache===!1&&(k.url=Bb.test(e)?e.replace(Bb,"$1_="+vb++):e+(wb.test(e)?"&":"?")+"_="+vb++)),k.ifModified&&(m.lastModified[e]&&v.setRequestHeader("If-Modified-Since",m.lastModified[e]),m.etag[e]&&v.setRequestHeader("If-None-Match",m.etag[e])),(k.data&&k.hasContent&&k.contentType!==!1||b.contentType)&&v.setRequestHeader("Content-Type",k.contentType),v.setRequestHeader("Accept",k.dataTypes[0]&&k.accepts[k.dataTypes[0]]?k.accepts[k.dataTypes[0]]+("*"!==k.dataTypes[0]?", "+Jb+"; q=0.01":""):k.accepts["*"]);for(d in k.headers)v.setRequestHeader(d,k.headers[d]);if(k.beforeSend&&(k.beforeSend.call(l,v,k)===!1||2===t))return v.abort();u="abort";for(d in{success:1,error:1,complete:1})v[d](k[d]);if(i=Mb(Ib,k,b,v)){v.readyState=1,h&&n.trigger("ajaxSend",[v,k]),k.async&&k.timeout>0&&(g=setTimeout(function(){v.abort("timeout")},k.timeout));try{t=1,i.send(r,x)}catch(w){if(!(2>t))throw w;x(-1,w)}}else x(-1,"No Transport");function x(a,b,c,d){var j,r,s,u,w,x=b;2!==t&&(t=2,g&&clearTimeout(g),i=void 0,f=d||"",v.readyState=a>0?4:0,j=a>=200&&300>a||304===a,c&&(u=Ob(k,v,c)),u=Pb(k,u,v,j),j?(k.ifModified&&(w=v.getResponseHeader("Last-Modified"),w&&(m.lastModified[e]=w),w=v.getResponseHeader("etag"),w&&(m.etag[e]=w)),204===a||"HEAD"===k.type?x="nocontent":304===a?x="notmodified":(x=u.state,r=u.data,s=u.error,j=!s)):(s=x,(a||!x)&&(x="error",0>a&&(a=0))),v.status=a,v.statusText=(b||x)+"",j?o.resolveWith(l,[r,x,v]):o.rejectWith(l,[v,x,s]),v.statusCode(q),q=void 0,h&&n.trigger(j?"ajaxSuccess":"ajaxError",[v,k,j?r:s]),p.fireWith(l,[v,x]),h&&(n.trigger("ajaxComplete",[v,k]),--m.active||m.event.trigger("ajaxStop")))}return v},getJSON:function(a,b,c){return m.get(a,b,c,"json")},getScript:function(a,b){return m.get(a,void 0,b,"script")}}),m.each(["get","post"],function(a,b){m[b]=function(a,c,d,e){return m.isFunction(c)&&(e=e||d,d=c,c=void 0),m.ajax({url:a,type:b,dataType:e,data:c,success:d})}}),m._evalUrl=function(a){return m.ajax({url:a,type:"GET",dataType:"script",async:!1,global:!1,"throws":!0})},m.fn.extend({wrapAll:function(a){if(m.isFunction(a))return this.each(function(b){m(this).wrapAll(a.call(this,b))});if(this[0]){var b=m(a,this[0].ownerDocument).eq(0).clone(!0);this[0].parentNode&&b.insertBefore(this[0]),b.map(function(){var a=this;while(a.firstChild&&1===a.firstChild.nodeType)a=a.firstChild;return a}).append(this)}return this},wrapInner:function(a){return this.each(m.isFunction(a)?function(b){m(this).wrapInner(a.call(this,b))}:function(){var b=m(this),c=b.contents();c.length?c.wrapAll(a):b.append(a)})},wrap:function(a){var b=m.isFunction(a);return this.each(function(c){m(this).wrapAll(b?a.call(this,c):a)})},unwrap:function(){return this.parent().each(function(){m.nodeName(this,"body")||m(this).replaceWith(this.childNodes)}).end()}}),m.expr.filters.hidden=function(a){return a.offsetWidth<=0&&a.offsetHeight<=0||!k.reliableHiddenOffsets()&&"none"===(a.style&&a.style.display||m.css(a,"display"))},m.expr.filters.visible=function(a){return!m.expr.filters.hidden(a)};var Qb=/%20/g,Rb=/\[\]$/,Sb=/\r?\n/g,Tb=/^(?:submit|button|image|reset|file)$/i,Ub=/^(?:input|select|textarea|keygen)/i;function Vb(a,b,c,d){var e;if(m.isArray(b))m.each(b,function(b,e){c||Rb.test(a)?d(a,e):Vb(a+"["+("object"==typeof e?b:"")+"]",e,c,d)});else if(c||"object"!==m.type(b))d(a,b);else for(e in b)Vb(a+"["+e+"]",b[e],c,d)}m.param=function(a,b){var c,d=[],e=function(a,b){b=m.isFunction(b)?b():null==b?"":b,d[d.length]=encodeURIComponent(a)+"="+encodeURIComponent(b)};if(void 0===b&&(b=m.ajaxSettings&&m.ajaxSettings.traditional),m.isArray(a)||a.jquery&&!m.isPlainObject(a))m.each(a,function(){e(this.name,this.value)});else for(c in a)Vb(c,a[c],b,e);return d.join("&").replace(Qb,"+")},m.fn.extend({serialize:function(){return m.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var a=m.prop(this,"elements");return a?m.makeArray(a):this}).filter(function(){var a=this.type;return this.name&&!m(this).is(":disabled")&&Ub.test(this.nodeName)&&!Tb.test(a)&&(this.checked||!W.test(a))}).map(function(a,b){var c=m(this).val();return null==c?null:m.isArray(c)?m.map(c,function(a){return{name:b.name,value:a.replace(Sb,"\r\n")}}):{name:b.name,value:c.replace(Sb,"\r\n")}}).get()}}),m.ajaxSettings.xhr=void 0!==a.ActiveXObject?function(){return!this.isLocal&&/^(get|post|head|put|delete|options)$/i.test(this.type)&&Zb()||$b()}:Zb;var Wb=0,Xb={},Yb=m.ajaxSettings.xhr();a.attachEvent&&a.attachEvent("onunload",function(){for(var a in Xb)Xb[a](void 0,!0)}),k.cors=!!Yb&&"withCredentials"in Yb,Yb=k.ajax=!!Yb,Yb&&m.ajaxTransport(function(a){if(!a.crossDomain||k.cors){var b;return{send:function(c,d){var e,f=a.xhr(),g=++Wb;if(f.open(a.type,a.url,a.async,a.username,a.password),a.xhrFields)for(e in a.xhrFields)f[e]=a.xhrFields[e];a.mimeType&&f.overrideMimeType&&f.overrideMimeType(a.mimeType),a.crossDomain||c["X-Requested-With"]||(c["X-Requested-With"]="XMLHttpRequest");for(e in c)void 0!==c[e]&&f.setRequestHeader(e,c[e]+"");f.send(a.hasContent&&a.data||null),b=function(c,e){var h,i,j;if(b&&(e||4===f.readyState))if(delete Xb[g],b=void 0,f.onreadystatechange=m.noop,e)4!==f.readyState&&f.abort();else{j={},h=f.status,"string"==typeof f.responseText&&(j.text=f.responseText);try{i=f.statusText}catch(k){i=""}h||!a.isLocal||a.crossDomain?1223===h&&(h=204):h=j.text?200:404}j&&d(h,i,j,f.getAllResponseHeaders())},a.async?4===f.readyState?setTimeout(b):f.onreadystatechange=Xb[g]=b:b()},abort:function(){b&&b(void 0,!0)}}}});function Zb(){try{return new a.XMLHttpRequest}catch(b){}}function $b(){try{return new a.ActiveXObject("Microsoft.XMLHTTP")}catch(b){}}m.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/(?:java|ecma)script/},converters:{"text script":function(a){return m.globalEval(a),a}}}),m.ajaxPrefilter("script",function(a){void 0===a.cache&&(a.cache=!1),a.crossDomain&&(a.type="GET",a.global=!1)}),m.ajaxTransport("script",function(a){if(a.crossDomain){var b,c=y.head||m("head")[0]||y.documentElement;return{send:function(d,e){b=y.createElement("script"),b.async=!0,a.scriptCharset&&(b.charset=a.scriptCharset),b.src=a.url,b.onload=b.onreadystatechange=function(a,c){(c||!b.readyState||/loaded|complete/.test(b.readyState))&&(b.onload=b.onreadystatechange=null,b.parentNode&&b.parentNode.removeChild(b),b=null,c||e(200,"success"))},c.insertBefore(b,c.firstChild)},abort:function(){b&&b.onload(void 0,!0)}}}});var _b=[],ac=/(=)\?(?=&|$)|\?\?/;m.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var a=_b.pop()||m.expando+"_"+vb++;return this[a]=!0,a}}),m.ajaxPrefilter("json jsonp",function(b,c,d){var e,f,g,h=b.jsonp!==!1&&(ac.test(b.url)?"url":"string"==typeof b.data&&!(b.contentType||"").indexOf("application/x-www-form-urlencoded")&&ac.test(b.data)&&"data");return h||"jsonp"===b.dataTypes[0]?(e=b.jsonpCallback=m.isFunction(b.jsonpCallback)?b.jsonpCallback():b.jsonpCallback,h?b[h]=b[h].replace(ac,"$1"+e):b.jsonp!==!1&&(b.url+=(wb.test(b.url)?"&":"?")+b.jsonp+"="+e),b.converters["script json"]=function(){return g||m.error(e+" was not called"),g[0]},b.dataTypes[0]="json",f=a[e],a[e]=function(){g=arguments},d.always(function(){a[e]=f,b[e]&&(b.jsonpCallback=c.jsonpCallback,_b.push(e)),g&&m.isFunction(f)&&f(g[0]),g=f=void 0}),"script"):void 0}),m.parseHTML=function(a,b,c){if(!a||"string"!=typeof a)return null;"boolean"==typeof b&&(c=b,b=!1),b=b||y;var d=u.exec(a),e=!c&&[];return d?[b.createElement(d[1])]:(d=m.buildFragment([a],b,e),e&&e.length&&m(e).remove(),m.merge([],d.childNodes))};var bc=m.fn.load;m.fn.load=function(a,b,c){if("string"!=typeof a&&bc)return bc.apply(this,arguments);var d,e,f,g=this,h=a.indexOf(" ");return h>=0&&(d=m.trim(a.slice(h,a.length)),a=a.slice(0,h)),m.isFunction(b)?(c=b,b=void 0):b&&"object"==typeof b&&(f="POST"),g.length>0&&m.ajax({url:a,type:f,dataType:"html",data:b}).done(function(a){e=arguments,g.html(d?m("<div>").append(m.parseHTML(a)).find(d):a)}).complete(c&&function(a,b){g.each(c,e||[a.responseText,b,a])}),this},m.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(a,b){m.fn[b]=function(a){return this.on(b,a)}}),m.expr.filters.animated=function(a){return m.grep(m.timers,function(b){return a===b.elem}).length};var cc=a.document.documentElement;function dc(a){return m.isWindow(a)?a:9===a.nodeType?a.defaultView||a.parentWindow:!1}m.offset={setOffset:function(a,b,c){var d,e,f,g,h,i,j,k=m.css(a,"position"),l=m(a),n={};"static"===k&&(a.style.position="relative"),h=l.offset(),f=m.css(a,"top"),i=m.css(a,"left"),j=("absolute"===k||"fixed"===k)&&m.inArray("auto",[f,i])>-1,j?(d=l.position(),g=d.top,e=d.left):(g=parseFloat(f)||0,e=parseFloat(i)||0),m.isFunction(b)&&(b=b.call(a,c,h)),null!=b.top&&(n.top=b.top-h.top+g),null!=b.left&&(n.left=b.left-h.left+e),"using"in b?b.using.call(a,n):l.css(n)}},m.fn.extend({offset:function(a){if(arguments.length)return void 0===a?this:this.each(function(b){m.offset.setOffset(this,a,b)});var b,c,d={top:0,left:0},e=this[0],f=e&&e.ownerDocument;if(f)return b=f.documentElement,m.contains(b,e)?(typeof e.getBoundingClientRect!==K&&(d=e.getBoundingClientRect()),c=dc(f),{top:d.top+(c.pageYOffset||b.scrollTop)-(b.clientTop||0),left:d.left+(c.pageXOffset||b.scrollLeft)-(b.clientLeft||0)}):d},position:function(){if(this[0]){var a,b,c={top:0,left:0},d=this[0];return"fixed"===m.css(d,"position")?b=d.getBoundingClientRect():(a=this.offsetParent(),b=this.offset(),m.nodeName(a[0],"html")||(c=a.offset()),c.top+=m.css(a[0],"borderTopWidth",!0),c.left+=m.css(a[0],"borderLeftWidth",!0)),{top:b.top-c.top-m.css(d,"marginTop",!0),left:b.left-c.left-m.css(d,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var a=this.offsetParent||cc;while(a&&!m.nodeName(a,"html")&&"static"===m.css(a,"position"))a=a.offsetParent;return a||cc})}}),m.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(a,b){var c=/Y/.test(b);m.fn[a]=function(d){return V(this,function(a,d,e){var f=dc(a);return void 0===e?f?b in f?f[b]:f.document.documentElement[d]:a[d]:void(f?f.scrollTo(c?m(f).scrollLeft():e,c?e:m(f).scrollTop()):a[d]=e)},a,d,arguments.length,null)}}),m.each(["top","left"],function(a,b){m.cssHooks[b]=La(k.pixelPosition,function(a,c){return c?(c=Ja(a,b),Ha.test(c)?m(a).position()[b]+"px":c):void 0})}),m.each({Height:"height",Width:"width"},function(a,b){m.each({padding:"inner"+a,content:b,"":"outer"+a},function(c,d){m.fn[d]=function(d,e){var f=arguments.length&&(c||"boolean"!=typeof d),g=c||(d===!0||e===!0?"margin":"border");return V(this,function(b,c,d){var e;return m.isWindow(b)?b.document.documentElement["client"+a]:9===b.nodeType?(e=b.documentElement,Math.max(b.body["scroll"+a],e["scroll"+a],b.body["offset"+a],e["offset"+a],e["client"+a])):void 0===d?m.css(b,c,g):m.style(b,c,d,g)},b,f?d:void 0,f,null)}})}),m.fn.size=function(){return this.length},m.fn.andSelf=m.fn.addBack,"function"==typeof define&&define.amd&&define("jquery",[],function(){return m});var ec=a.jQuery,fc=a.$;return m.noConflict=function(b){return a.$===m&&(a.$=fc),b&&a.jQuery===m&&(a.jQuery=ec),m},typeof b===K&&(a.jQuery=a.$=m),m});
</script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<style type="text/css">html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}audio,canvas,progress,video{display:inline-block;vertical-align:baseline}audio:not([controls]){display:none;height:0}[hidden],template{display:none}a{background-color:transparent}a:active,a:hover{outline:0}abbr[title]{border-bottom:1px dotted}b,strong{font-weight:700}dfn{font-style:italic}h1{margin:.67em 0;font-size:2em}mark{color:#000;background:#ff0}small{font-size:80%}sub,sup{position:relative;font-size:75%;line-height:0;vertical-align:baseline}sup{top:-.5em}sub{bottom:-.25em}img{border:0}svg:not(:root){overflow:hidden}figure{margin:1em 40px}hr{height:0;-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}pre{overflow:auto}code,kbd,pre,samp{font-family:monospace,monospace;font-size:1em}button,input,optgroup,select,textarea{margin:0;font:inherit;color:inherit}button{overflow:visible}button,select{text-transform:none}button,html input[type=button],input[type=reset],input[type=submit]{-webkit-appearance:button;cursor:pointer}button[disabled],html input[disabled]{cursor:default}button::-moz-focus-inner,input::-moz-focus-inner{padding:0;border:0}input{line-height:normal}input[type=checkbox],input[type=radio]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;padding:0}input[type=number]::-webkit-inner-spin-button,input[type=number]::-webkit-outer-spin-button{height:auto}input[type=search]{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;-webkit-appearance:textfield}input[type=search]::-webkit-search-cancel-button,input[type=search]::-webkit-search-decoration{-webkit-appearance:none}fieldset{padding:.35em .625em .75em;margin:0 2px;border:1px solid silver}legend{padding:0;border:0}textarea{overflow:auto}optgroup{font-weight:700}table{border-spacing:0;border-collapse:collapse}td,th{padding:0}@media print{*,:after,:before{color:#000!important;text-shadow:none!important;background:0 0!important;-webkit-box-shadow:none!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}abbr[title]:after{content:" (" attr(title) ")"}a[href^="javascript:"]:after,a[href^="#"]:after{content:""}blockquote,pre{border:1px solid #999;page-break-inside:avoid}thead{display:table-header-group}img,tr{page-break-inside:avoid}img{max-width:100%!important}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}.navbar{display:none}.btn>.caret,.dropup>.btn>.caret{border-top-color:#000!important}.label{border:1px solid #000}.table{border-collapse:collapse!important}.table td,.table th{background-color:#fff!important}.table-bordered td,.table-bordered th{border:1px solid #ddd!important}}@font-face{font-family:'Glyphicons Halflings';src:url(data:application/vnd.ms-fontobject;base64,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);src:url(data:application/vnd.ms-fontobject;base64,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) format('embedded-opentype'),url(data:application/font-woff;base64,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) format('woff'),url(data:application/x-font-truetype;base64,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) format('truetype'),url(data:image/svg+xml;base64,<?xml version="1.0" standalone="no"?>
<!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd" >
<svg xmlns="http://www.w3.org/2000/svg">
<metadata></metadata>
<defs>
<font id="glyphicons_halflingsregular" horiz-adv-x="1200" >
<font-face units-per-em="1200" ascent="960" descent="-240" />
<missing-glyph horiz-adv-x="500" />
<glyph horiz-adv-x="0" />
<glyph horiz-adv-x="400" />
<glyph unicode=" " />
<glyph unicode="*" d="M600 1100q15 0 34 -1.5t30 -3.5l11 -1q10 -2 17.5 -10.5t7.5 -18.5v-224l158 158q7 7 18 8t19 -6l106 -106q7 -8 6 -19t-8 -18l-158 -158h224q10 0 18.5 -7.5t10.5 -17.5q6 -41 6 -75q0 -15 -1.5 -34t-3.5 -30l-1 -11q-2 -10 -10.5 -17.5t-18.5 -7.5h-224l158 -158 q7 -7 8 -18t-6 -19l-106 -106q-8 -7 -19 -6t-18 8l-158 158v-224q0 -10 -7.5 -18.5t-17.5 -10.5q-41 -6 -75 -6q-15 0 -34 1.5t-30 3.5l-11 1q-10 2 -17.5 10.5t-7.5 18.5v224l-158 -158q-7 -7 -18 -8t-19 6l-106 106q-7 8 -6 19t8 18l158 158h-224q-10 0 -18.5 7.5 t-10.5 17.5q-6 41 -6 75q0 15 1.5 34t3.5 30l1 11q2 10 10.5 17.5t18.5 7.5h224l-158 158q-7 7 -8 18t6 19l106 106q8 7 19 6t18 -8l158 -158v224q0 10 7.5 18.5t17.5 10.5q41 6 75 6z" />
<glyph unicode="+" d="M450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-350h350q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-350v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v350h-350q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5 h350v350q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xa0;" />
<glyph unicode="&#xa5;" d="M825 1100h250q10 0 12.5 -5t-5.5 -13l-364 -364q-6 -6 -11 -18h268q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-100h275q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-174q0 -11 -7.5 -18.5t-18.5 -7.5h-148q-11 0 -18.5 7.5t-7.5 18.5v174 h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h125v100h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h118q-5 12 -11 18l-364 364q-8 8 -5.5 13t12.5 5h250q25 0 43 -18l164 -164q8 -8 18 -8t18 8l164 164q18 18 43 18z" />
<glyph unicode="&#x2000;" horiz-adv-x="650" />
<glyph unicode="&#x2001;" horiz-adv-x="1300" />
<glyph unicode="&#x2002;" horiz-adv-x="650" />
<glyph unicode="&#x2003;" horiz-adv-x="1300" />
<glyph unicode="&#x2004;" horiz-adv-x="433" />
<glyph unicode="&#x2005;" horiz-adv-x="325" />
<glyph unicode="&#x2006;" horiz-adv-x="216" />
<glyph unicode="&#x2007;" horiz-adv-x="216" />
<glyph unicode="&#x2008;" horiz-adv-x="162" />
<glyph unicode="&#x2009;" horiz-adv-x="260" />
<glyph unicode="&#x200a;" horiz-adv-x="72" />
<glyph unicode="&#x202f;" horiz-adv-x="260" />
<glyph unicode="&#x205f;" horiz-adv-x="325" />
<glyph unicode="&#x20ac;" d="M744 1198q242 0 354 -189q60 -104 66 -209h-181q0 45 -17.5 82.5t-43.5 61.5t-58 40.5t-60.5 24t-51.5 7.5q-19 0 -40.5 -5.5t-49.5 -20.5t-53 -38t-49 -62.5t-39 -89.5h379l-100 -100h-300q-6 -50 -6 -100h406l-100 -100h-300q9 -74 33 -132t52.5 -91t61.5 -54.5t59 -29 t47 -7.5q22 0 50.5 7.5t60.5 24.5t58 41t43.5 61t17.5 80h174q-30 -171 -128 -278q-107 -117 -274 -117q-206 0 -324 158q-36 48 -69 133t-45 204h-217l100 100h112q1 47 6 100h-218l100 100h134q20 87 51 153.5t62 103.5q117 141 297 141z" />
<glyph unicode="&#x20bd;" d="M428 1200h350q67 0 120 -13t86 -31t57 -49.5t35 -56.5t17 -64.5t6.5 -60.5t0.5 -57v-16.5v-16.5q0 -36 -0.5 -57t-6.5 -61t-17 -65t-35 -57t-57 -50.5t-86 -31.5t-120 -13h-178l-2 -100h288q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-138v-175q0 -11 -5.5 -18 t-15.5 -7h-149q-10 0 -17.5 7.5t-7.5 17.5v175h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v100h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v475q0 10 7.5 17.5t17.5 7.5zM600 1000v-300h203q64 0 86.5 33t22.5 119q0 84 -22.5 116t-86.5 32h-203z" />
<glyph unicode="&#x2212;" d="M250 700h800q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#x231b;" d="M1000 1200v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-50v-100q0 -91 -49.5 -165.5t-130.5 -109.5q81 -35 130.5 -109.5t49.5 -165.5v-150h50q21 0 35.5 -14.5t14.5 -35.5v-150h-800v150q0 21 14.5 35.5t35.5 14.5h50v150q0 91 49.5 165.5t130.5 109.5q-81 35 -130.5 109.5 t-49.5 165.5v100h-50q-21 0 -35.5 14.5t-14.5 35.5v150h800zM400 1000v-100q0 -60 32.5 -109.5t87.5 -73.5q28 -12 44 -37t16 -55t-16 -55t-44 -37q-55 -24 -87.5 -73.5t-32.5 -109.5v-150h400v150q0 60 -32.5 109.5t-87.5 73.5q-28 12 -44 37t-16 55t16 55t44 37 q55 24 87.5 73.5t32.5 109.5v100h-400z" />
<glyph unicode="&#x25fc;" horiz-adv-x="500" d="M0 0z" />
<glyph unicode="&#x2601;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -206.5q0 -121 -85 -207.5t-205 -86.5h-750q-79 0 -135.5 57t-56.5 137q0 69 42.5 122.5t108.5 67.5q-2 12 -2 37q0 153 108 260.5t260 107.5z" />
<glyph unicode="&#x26fa;" d="M774 1193.5q16 -9.5 20.5 -27t-5.5 -33.5l-136 -187l467 -746h30q20 0 35 -18.5t15 -39.5v-42h-1200v42q0 21 15 39.5t35 18.5h30l468 746l-135 183q-10 16 -5.5 34t20.5 28t34 5.5t28 -20.5l111 -148l112 150q9 16 27 20.5t34 -5zM600 200h377l-182 112l-195 534v-646z " />
<glyph unicode="&#x2709;" d="M25 1100h1150q10 0 12.5 -5t-5.5 -13l-564 -567q-8 -8 -18 -8t-18 8l-564 567q-8 8 -5.5 13t12.5 5zM18 882l264 -264q8 -8 8 -18t-8 -18l-264 -264q-8 -8 -13 -5.5t-5 12.5v550q0 10 5 12.5t13 -5.5zM918 618l264 264q8 8 13 5.5t5 -12.5v-550q0 -10 -5 -12.5t-13 5.5 l-264 264q-8 8 -8 18t8 18zM818 482l364 -364q8 -8 5.5 -13t-12.5 -5h-1150q-10 0 -12.5 5t5.5 13l364 364q8 8 18 8t18 -8l164 -164q8 -8 18 -8t18 8l164 164q8 8 18 8t18 -8z" />
<glyph unicode="&#x270f;" d="M1011 1210q19 0 33 -13l153 -153q13 -14 13 -33t-13 -33l-99 -92l-214 214l95 96q13 14 32 14zM1013 800l-615 -614l-214 214l614 614zM317 96l-333 -112l110 335z" />
<glyph unicode="&#xe001;" d="M700 650v-550h250q21 0 35.5 -14.5t14.5 -35.5v-50h-800v50q0 21 14.5 35.5t35.5 14.5h250v550l-500 550h1200z" />
<glyph unicode="&#xe002;" d="M368 1017l645 163q39 15 63 0t24 -49v-831q0 -55 -41.5 -95.5t-111.5 -63.5q-79 -25 -147 -4.5t-86 75t25.5 111.5t122.5 82q72 24 138 8v521l-600 -155v-606q0 -42 -44 -90t-109 -69q-79 -26 -147 -5.5t-86 75.5t25.5 111.5t122.5 82.5q72 24 138 7v639q0 38 14.5 59 t53.5 34z" />
<glyph unicode="&#xe003;" d="M500 1191q100 0 191 -39t156.5 -104.5t104.5 -156.5t39 -191l-1 -2l1 -5q0 -141 -78 -262l275 -274q23 -26 22.5 -44.5t-22.5 -42.5l-59 -58q-26 -20 -46.5 -20t-39.5 20l-275 274q-119 -77 -261 -77l-5 1l-2 -1q-100 0 -191 39t-156.5 104.5t-104.5 156.5t-39 191 t39 191t104.5 156.5t156.5 104.5t191 39zM500 1022q-88 0 -162 -43t-117 -117t-43 -162t43 -162t117 -117t162 -43t162 43t117 117t43 162t-43 162t-117 117t-162 43z" />
<glyph unicode="&#xe005;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104z" />
<glyph unicode="&#xe006;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429z" />
<glyph unicode="&#xe007;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429zM477 700h-240l197 -142l-74 -226 l193 139l195 -140l-74 229l192 140h-234l-78 211z" />
<glyph unicode="&#xe008;" d="M600 1200q124 0 212 -88t88 -212v-250q0 -46 -31 -98t-69 -52v-75q0 -10 6 -21.5t15 -17.5l358 -230q9 -5 15 -16.5t6 -21.5v-93q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v93q0 10 6 21.5t15 16.5l358 230q9 6 15 17.5t6 21.5v75q-38 0 -69 52 t-31 98v250q0 124 88 212t212 88z" />
<glyph unicode="&#xe009;" d="M25 1100h1150q10 0 17.5 -7.5t7.5 -17.5v-1050q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v1050q0 10 7.5 17.5t17.5 7.5zM100 1000v-100h100v100h-100zM875 1000h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5t17.5 -7.5h550 q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM1000 1000v-100h100v100h-100zM100 800v-100h100v100h-100zM1000 800v-100h100v100h-100zM100 600v-100h100v100h-100zM1000 600v-100h100v100h-100zM875 500h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5 t17.5 -7.5h550q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM100 400v-100h100v100h-100zM1000 400v-100h100v100h-100zM100 200v-100h100v100h-100zM1000 200v-100h100v100h-100z" />
<glyph unicode="&#xe010;" d="M50 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM50 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe011;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM850 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 700h200q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h200 q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5 t35.5 14.5z" />
<glyph unicode="&#xe012;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h700q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe013;" d="M465 477l571 571q8 8 18 8t17 -8l177 -177q8 -7 8 -17t-8 -18l-783 -784q-7 -8 -17.5 -8t-17.5 8l-384 384q-8 8 -8 18t8 17l177 177q7 8 17 8t18 -8l171 -171q7 -7 18 -7t18 7z" />
<glyph unicode="&#xe014;" d="M904 1083l178 -179q8 -8 8 -18.5t-8 -17.5l-267 -268l267 -268q8 -7 8 -17.5t-8 -18.5l-178 -178q-8 -8 -18.5 -8t-17.5 8l-268 267l-268 -267q-7 -8 -17.5 -8t-18.5 8l-178 178q-8 8 -8 18.5t8 17.5l267 268l-267 268q-8 7 -8 17.5t8 18.5l178 178q8 8 18.5 8t17.5 -8 l268 -267l268 268q7 7 17.5 7t18.5 -7z" />
<glyph unicode="&#xe015;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM425 900h150q10 0 17.5 -7.5t7.5 -17.5v-75h75q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5 t-17.5 -7.5h-75v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-75q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v75q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe016;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM325 800h350q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-350q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe017;" d="M550 1200h100q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM800 975v166q167 -62 272 -209.5t105 -331.5q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5 t-184.5 123t-123 184.5t-45.5 224q0 184 105 331.5t272 209.5v-166q-103 -55 -165 -155t-62 -220q0 -116 57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5q0 120 -62 220t-165 155z" />
<glyph unicode="&#xe018;" d="M1025 1200h150q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM725 800h150q10 0 17.5 -7.5t7.5 -17.5v-750q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v750 q0 10 7.5 17.5t17.5 7.5zM425 500h150q10 0 17.5 -7.5t7.5 -17.5v-450q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v450q0 10 7.5 17.5t17.5 7.5zM125 300h150q10 0 17.5 -7.5t7.5 -17.5v-250q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5 v250q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe019;" d="M600 1174q33 0 74 -5l38 -152l5 -1q49 -14 94 -39l5 -2l134 80q61 -48 104 -105l-80 -134l3 -5q25 -44 39 -93l1 -6l152 -38q5 -43 5 -73q0 -34 -5 -74l-152 -38l-1 -6q-15 -49 -39 -93l-3 -5l80 -134q-48 -61 -104 -105l-134 81l-5 -3q-44 -25 -94 -39l-5 -2l-38 -151 q-43 -5 -74 -5q-33 0 -74 5l-38 151l-5 2q-49 14 -94 39l-5 3l-134 -81q-60 48 -104 105l80 134l-3 5q-25 45 -38 93l-2 6l-151 38q-6 42 -6 74q0 33 6 73l151 38l2 6q13 48 38 93l3 5l-80 134q47 61 105 105l133 -80l5 2q45 25 94 39l5 1l38 152q43 5 74 5zM600 815 q-89 0 -152 -63t-63 -151.5t63 -151.5t152 -63t152 63t63 151.5t-63 151.5t-152 63z" />
<glyph unicode="&#xe020;" d="M500 1300h300q41 0 70.5 -29.5t29.5 -70.5v-100h275q10 0 17.5 -7.5t7.5 -17.5v-75h-1100v75q0 10 7.5 17.5t17.5 7.5h275v100q0 41 29.5 70.5t70.5 29.5zM500 1200v-100h300v100h-300zM1100 900v-800q0 -41 -29.5 -70.5t-70.5 -29.5h-700q-41 0 -70.5 29.5t-29.5 70.5 v800h900zM300 800v-700h100v700h-100zM500 800v-700h100v700h-100zM700 800v-700h100v700h-100zM900 800v-700h100v700h-100z" />
<glyph unicode="&#xe021;" d="M18 618l620 608q8 7 18.5 7t17.5 -7l608 -608q8 -8 5.5 -13t-12.5 -5h-175v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v375h-300v-375q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v575h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe022;" d="M600 1200v-400q0 -41 29.5 -70.5t70.5 -29.5h300v-650q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5h450zM1000 800h-250q-21 0 -35.5 14.5t-14.5 35.5v250z" />
<glyph unicode="&#xe023;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h50q10 0 17.5 -7.5t7.5 -17.5v-275h175q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe024;" d="M1300 0h-538l-41 400h-242l-41 -400h-538l431 1200h209l-21 -300h162l-20 300h208zM515 800l-27 -300h224l-27 300h-170z" />
<glyph unicode="&#xe025;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-450h191q20 0 25.5 -11.5t-7.5 -27.5l-327 -400q-13 -16 -32 -16t-32 16l-327 400q-13 16 -7.5 27.5t25.5 11.5h191v450q0 21 14.5 35.5t35.5 14.5zM1125 400h50q10 0 17.5 -7.5t7.5 -17.5v-350q0 -10 -7.5 -17.5t-17.5 -7.5 h-1050q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h50q10 0 17.5 -7.5t7.5 -17.5v-175h900v175q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe026;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -275q-13 -16 -32 -16t-32 16l-223 275q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z " />
<glyph unicode="&#xe027;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM632 914l223 -275q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5l223 275q13 16 32 16 t32 -16z" />
<glyph unicode="&#xe028;" d="M225 1200h750q10 0 19.5 -7t12.5 -17l186 -652q7 -24 7 -49v-425q0 -12 -4 -27t-9 -17q-12 -6 -37 -6h-1100q-12 0 -27 4t-17 8q-6 13 -6 38l1 425q0 25 7 49l185 652q3 10 12.5 17t19.5 7zM878 1000h-556q-10 0 -19 -7t-11 -18l-87 -450q-2 -11 4 -18t16 -7h150 q10 0 19.5 -7t11.5 -17l38 -152q2 -10 11.5 -17t19.5 -7h250q10 0 19.5 7t11.5 17l38 152q2 10 11.5 17t19.5 7h150q10 0 16 7t4 18l-87 450q-2 11 -11 18t-19 7z" />
<glyph unicode="&#xe029;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM540 820l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe030;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-362q0 -10 -7.5 -17.5t-17.5 -7.5h-362q-11 0 -13 5.5t5 12.5l133 133q-109 76 -238 76q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5h150q0 -117 -45.5 -224 t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117z" />
<glyph unicode="&#xe031;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-361q0 -11 -7.5 -18.5t-18.5 -7.5h-361q-11 0 -13 5.5t5 12.5l134 134q-110 75 -239 75q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5h-150q0 117 45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117zM1027 600h150 q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5q-192 0 -348 118l-134 -134q-7 -8 -12.5 -5.5t-5.5 12.5v360q0 11 7.5 18.5t18.5 7.5h360q10 0 12.5 -5.5t-5.5 -12.5l-133 -133q110 -76 240 -76q116 0 214.5 57t155.5 155.5t57 214.5z" />
<glyph unicode="&#xe032;" d="M125 1200h1050q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-1050q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM1075 1000h-850q-10 0 -17.5 -7.5t-7.5 -17.5v-850q0 -10 7.5 -17.5t17.5 -7.5h850q10 0 17.5 7.5t7.5 17.5v850 q0 10 -7.5 17.5t-17.5 7.5zM325 900h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 900h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 700h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 700h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 500h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 500h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 300h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 300h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe033;" d="M900 800v200q0 83 -58.5 141.5t-141.5 58.5h-300q-82 0 -141 -59t-59 -141v-200h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h900q41 0 70.5 29.5t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5h-100zM400 800v150q0 21 15 35.5t35 14.5h200 q20 0 35 -14.5t15 -35.5v-150h-300z" />
<glyph unicode="&#xe034;" d="M125 1100h50q10 0 17.5 -7.5t7.5 -17.5v-1075h-100v1075q0 10 7.5 17.5t17.5 7.5zM1075 1052q4 0 9 -2q16 -6 16 -23v-421q0 -6 -3 -12q-33 -59 -66.5 -99t-65.5 -58t-56.5 -24.5t-52.5 -6.5q-26 0 -57.5 6.5t-52.5 13.5t-60 21q-41 15 -63 22.5t-57.5 15t-65.5 7.5 q-85 0 -160 -57q-7 -5 -15 -5q-6 0 -11 3q-14 7 -14 22v438q22 55 82 98.5t119 46.5q23 2 43 0.5t43 -7t32.5 -8.5t38 -13t32.5 -11q41 -14 63.5 -21t57 -14t63.5 -7q103 0 183 87q7 8 18 8z" />
<glyph unicode="&#xe035;" d="M600 1175q116 0 227 -49.5t192.5 -131t131 -192.5t49.5 -227v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v300q0 127 -70.5 231.5t-184.5 161.5t-245 57t-245 -57t-184.5 -161.5t-70.5 -231.5v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50 q-10 0 -17.5 7.5t-7.5 17.5v300q0 116 49.5 227t131 192.5t192.5 131t227 49.5zM220 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460q0 8 6 14t14 6zM820 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460 q0 8 6 14t14 6z" />
<glyph unicode="&#xe036;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM900 668l120 120q7 7 17 7t17 -7l34 -34q7 -7 7 -17t-7 -17l-120 -120l120 -120q7 -7 7 -17 t-7 -17l-34 -34q-7 -7 -17 -7t-17 7l-120 119l-120 -119q-7 -7 -17 -7t-17 7l-34 34q-7 7 -7 17t7 17l119 120l-119 120q-7 7 -7 17t7 17l34 34q7 8 17 8t17 -8z" />
<glyph unicode="&#xe037;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6 l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238q-6 8 -4.5 18t9.5 17l29 22q7 5 15 5z" />
<glyph unicode="&#xe038;" d="M967 1004h3q11 -1 17 -10q135 -179 135 -396q0 -105 -34 -206.5t-98 -185.5q-7 -9 -17 -10h-3q-9 0 -16 6l-42 34q-8 6 -9 16t5 18q111 150 111 328q0 90 -29.5 176t-84.5 157q-6 9 -5 19t10 16l42 33q7 5 15 5zM321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5 t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238 q-6 8 -4.5 18.5t9.5 16.5l29 22q7 5 15 5z" />
<glyph unicode="&#xe039;" d="M500 900h100v-100h-100v-100h-400v-100h-100v600h500v-300zM1200 700h-200v-100h200v-200h-300v300h-200v300h-100v200h600v-500zM100 1100v-300h300v300h-300zM800 1100v-300h300v300h-300zM300 900h-100v100h100v-100zM1000 900h-100v100h100v-100zM300 500h200v-500 h-500v500h200v100h100v-100zM800 300h200v-100h-100v-100h-200v100h-100v100h100v200h-200v100h300v-300zM100 400v-300h300v300h-300zM300 200h-100v100h100v-100zM1200 200h-100v100h100v-100zM700 0h-100v100h100v-100zM1200 0h-300v100h300v-100z" />
<glyph unicode="&#xe040;" d="M100 200h-100v1000h100v-1000zM300 200h-100v1000h100v-1000zM700 200h-200v1000h200v-1000zM900 200h-100v1000h100v-1000zM1200 200h-200v1000h200v-1000zM400 0h-300v100h300v-100zM600 0h-100v91h100v-91zM800 0h-100v91h100v-91zM1100 0h-200v91h200v-91z" />
<glyph unicode="&#xe041;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe042;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM800 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-56 56l424 426l-700 700h150zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5 t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe043;" d="M300 1200h825q75 0 75 -75v-900q0 -25 -18 -43l-64 -64q-8 -8 -13 -5.5t-5 12.5v950q0 10 -7.5 17.5t-17.5 7.5h-700q-25 0 -43 -18l-64 -64q-8 -8 -5.5 -13t12.5 -5h700q10 0 17.5 -7.5t7.5 -17.5v-950q0 -10 -7.5 -17.5t-17.5 -7.5h-850q-10 0 -17.5 7.5t-7.5 17.5v975 q0 25 18 43l139 139q18 18 43 18z" />
<glyph unicode="&#xe044;" d="M250 1200h800q21 0 35.5 -14.5t14.5 -35.5v-1150l-450 444l-450 -445v1151q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe045;" d="M822 1200h-444q-11 0 -19 -7.5t-9 -17.5l-78 -301q-7 -24 7 -45l57 -108q6 -9 17.5 -15t21.5 -6h450q10 0 21.5 6t17.5 15l62 108q14 21 7 45l-83 301q-1 10 -9 17.5t-19 7.5zM1175 800h-150q-10 0 -21 -6.5t-15 -15.5l-78 -156q-4 -9 -15 -15.5t-21 -6.5h-550 q-10 0 -21 6.5t-15 15.5l-78 156q-4 9 -15 15.5t-21 6.5h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-650q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h750q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5 t7.5 17.5v650q0 10 -7.5 17.5t-17.5 7.5zM850 200h-500q-10 0 -19.5 -7t-11.5 -17l-38 -152q-2 -10 3.5 -17t15.5 -7h600q10 0 15.5 7t3.5 17l-38 152q-2 10 -11.5 17t-19.5 7z" />
<glyph unicode="&#xe046;" d="M500 1100h200q56 0 102.5 -20.5t72.5 -50t44 -59t25 -50.5l6 -20h150q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5h150q2 8 6.5 21.5t24 48t45 61t72 48t102.5 21.5zM900 800v-100 h100v100h-100zM600 730q-95 0 -162.5 -67.5t-67.5 -162.5t67.5 -162.5t162.5 -67.5t162.5 67.5t67.5 162.5t-67.5 162.5t-162.5 67.5zM600 603q43 0 73 -30t30 -73t-30 -73t-73 -30t-73 30t-30 73t30 73t73 30z" />
<glyph unicode="&#xe047;" d="M681 1199l385 -998q20 -50 60 -92q18 -19 36.5 -29.5t27.5 -11.5l10 -2v-66h-417v66q53 0 75 43.5t5 88.5l-82 222h-391q-58 -145 -92 -234q-11 -34 -6.5 -57t25.5 -37t46 -20t55 -6v-66h-365v66q56 24 84 52q12 12 25 30.5t20 31.5l7 13l399 1006h93zM416 521h340 l-162 457z" />
<glyph unicode="&#xe048;" d="M753 641q5 -1 14.5 -4.5t36 -15.5t50.5 -26.5t53.5 -40t50.5 -54.5t35.5 -70t14.5 -87q0 -67 -27.5 -125.5t-71.5 -97.5t-98.5 -66.5t-108.5 -40.5t-102 -13h-500v89q41 7 70.5 32.5t29.5 65.5v827q0 24 -0.5 34t-3.5 24t-8.5 19.5t-17 13.5t-28 12.5t-42.5 11.5v71 l471 -1q57 0 115.5 -20.5t108 -57t80.5 -94t31 -124.5q0 -51 -15.5 -96.5t-38 -74.5t-45 -50.5t-38.5 -30.5zM400 700h139q78 0 130.5 48.5t52.5 122.5q0 41 -8.5 70.5t-29.5 55.5t-62.5 39.5t-103.5 13.5h-118v-350zM400 200h216q80 0 121 50.5t41 130.5q0 90 -62.5 154.5 t-156.5 64.5h-159v-400z" />
<glyph unicode="&#xe049;" d="M877 1200l2 -57q-83 -19 -116 -45.5t-40 -66.5l-132 -839q-9 -49 13 -69t96 -26v-97h-500v97q186 16 200 98l173 832q3 17 3 30t-1.5 22.5t-9 17.5t-13.5 12.5t-21.5 10t-26 8.5t-33.5 10q-13 3 -19 5v57h425z" />
<glyph unicode="&#xe050;" d="M1300 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM175 1000h-75v-800h75l-125 -167l-125 167h75v800h-75l125 167z" />
<glyph unicode="&#xe051;" d="M1100 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-650q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v650h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM1167 50l-167 -125v75h-800v-75l-167 125l167 125v-75h800v75z" />
<glyph unicode="&#xe052;" d="M50 1100h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe053;" d="M250 1100h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM250 500h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe054;" d="M500 950v100q0 21 14.5 35.5t35.5 14.5h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5zM100 650v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000 q-21 0 -35.5 14.5t-14.5 35.5zM300 350v100q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5zM0 50v100q0 21 14.5 35.5t35.5 14.5h1100q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5z" />
<glyph unicode="&#xe055;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe056;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 1100h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 800h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 500h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 500h800q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 200h800 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe057;" d="M400 0h-100v1100h100v-1100zM550 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM267 550l-167 -125v75h-200v100h200v75zM550 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe058;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM900 0h-100v1100h100v-1100zM50 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM1100 600h200v-100h-200v-75l-167 125l167 125v-75zM50 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe059;" d="M75 1000h750q31 0 53 -22t22 -53v-650q0 -31 -22 -53t-53 -22h-750q-31 0 -53 22t-22 53v650q0 31 22 53t53 22zM1200 300l-300 300l300 300v-600z" />
<glyph unicode="&#xe060;" d="M44 1100h1112q18 0 31 -13t13 -31v-1012q0 -18 -13 -31t-31 -13h-1112q-18 0 -31 13t-13 31v1012q0 18 13 31t31 13zM100 1000v-737l247 182l298 -131l-74 156l293 318l236 -288v500h-1000zM342 884q56 0 95 -39t39 -94.5t-39 -95t-95 -39.5t-95 39.5t-39 95t39 94.5 t95 39z" />
<glyph unicode="&#xe062;" d="M648 1169q117 0 216 -60t156.5 -161t57.5 -218q0 -115 -70 -258q-69 -109 -158 -225.5t-143 -179.5l-54 -62q-9 8 -25.5 24.5t-63.5 67.5t-91 103t-98.5 128t-95.5 148q-60 132 -60 249q0 88 34 169.5t91.5 142t137 96.5t166.5 36zM652.5 974q-91.5 0 -156.5 -65 t-65 -157t65 -156.5t156.5 -64.5t156.5 64.5t65 156.5t-65 157t-156.5 65z" />
<glyph unicode="&#xe063;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 173v854q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57z" />
<glyph unicode="&#xe064;" d="M554 1295q21 -72 57.5 -143.5t76 -130t83 -118t82.5 -117t70 -116t49.5 -126t18.5 -136.5q0 -71 -25.5 -135t-68.5 -111t-99 -82t-118.5 -54t-125.5 -23q-84 5 -161.5 34t-139.5 78.5t-99 125t-37 164.5q0 69 18 136.5t49.5 126.5t69.5 116.5t81.5 117.5t83.5 119 t76.5 131t58.5 143zM344 710q-23 -33 -43.5 -70.5t-40.5 -102.5t-17 -123q1 -37 14.5 -69.5t30 -52t41 -37t38.5 -24.5t33 -15q21 -7 32 -1t13 22l6 34q2 10 -2.5 22t-13.5 19q-5 4 -14 12t-29.5 40.5t-32.5 73.5q-26 89 6 271q2 11 -6 11q-8 1 -15 -10z" />
<glyph unicode="&#xe065;" d="M1000 1013l108 115q2 1 5 2t13 2t20.5 -1t25 -9.5t28.5 -21.5q22 -22 27 -43t0 -32l-6 -10l-108 -115zM350 1100h400q50 0 105 -13l-187 -187h-368q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v182l200 200v-332 q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM1009 803l-362 -362l-161 -50l55 170l355 355z" />
<glyph unicode="&#xe066;" d="M350 1100h361q-164 -146 -216 -200h-195q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5l200 153v-103q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M824 1073l339 -301q8 -7 8 -17.5t-8 -17.5l-340 -306q-7 -6 -12.5 -4t-6.5 11v203q-26 1 -54.5 0t-78.5 -7.5t-92 -17.5t-86 -35t-70 -57q10 59 33 108t51.5 81.5t65 58.5t68.5 40.5t67 24.5t56 13.5t40 4.5v210q1 10 6.5 12.5t13.5 -4.5z" />
<glyph unicode="&#xe067;" d="M350 1100h350q60 0 127 -23l-178 -177h-349q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v69l200 200v-219q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M643 639l395 395q7 7 17.5 7t17.5 -7l101 -101q7 -7 7 -17.5t-7 -17.5l-531 -532q-7 -7 -17.5 -7t-17.5 7l-248 248q-7 7 -7 17.5t7 17.5l101 101q7 7 17.5 7t17.5 -7l111 -111q8 -7 18 -7t18 7z" />
<glyph unicode="&#xe068;" d="M318 918l264 264q8 8 18 8t18 -8l260 -264q7 -8 4.5 -13t-12.5 -5h-170v-200h200v173q0 10 5 12t13 -5l264 -260q8 -7 8 -17.5t-8 -17.5l-264 -265q-8 -7 -13 -5t-5 12v173h-200v-200h170q10 0 12.5 -5t-4.5 -13l-260 -264q-8 -8 -18 -8t-18 8l-264 264q-8 8 -5.5 13 t12.5 5h175v200h-200v-173q0 -10 -5 -12t-13 5l-264 265q-8 7 -8 17.5t8 17.5l264 260q8 7 13 5t5 -12v-173h200v200h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe069;" d="M250 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe070;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5 t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe071;" d="M1200 1050v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-492 480q-15 14 -15 35t15 35l492 480q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25z" />
<glyph unicode="&#xe072;" d="M243 1074l814 -498q18 -11 18 -26t-18 -26l-814 -498q-18 -11 -30.5 -4t-12.5 28v1000q0 21 12.5 28t30.5 -4z" />
<glyph unicode="&#xe073;" d="M250 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM650 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe074;" d="M1100 950v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe075;" d="M500 612v438q0 21 10.5 25t25.5 -10l492 -480q15 -14 15 -35t-15 -35l-492 -480q-15 -14 -25.5 -10t-10.5 25v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10z" />
<glyph unicode="&#xe076;" d="M1048 1102l100 1q20 0 35 -14.5t15 -35.5l5 -1000q0 -21 -14.5 -35.5t-35.5 -14.5l-100 -1q-21 0 -35.5 14.5t-14.5 35.5l-2 437l-463 -454q-14 -15 -24.5 -10.5t-10.5 25.5l-2 437l-462 -455q-15 -14 -25.5 -9.5t-10.5 24.5l-5 1000q0 21 10.5 25.5t25.5 -10.5l466 -450 l-2 438q0 20 10.5 24.5t25.5 -9.5l466 -451l-2 438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe077;" d="M850 1100h100q21 0 35.5 -14.5t14.5 -35.5v-1000q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10l464 -453v438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe078;" d="M686 1081l501 -540q15 -15 10.5 -26t-26.5 -11h-1042q-22 0 -26.5 11t10.5 26l501 540q15 15 36 15t36 -15zM150 400h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe079;" d="M885 900l-352 -353l352 -353l-197 -198l-552 552l552 550z" />
<glyph unicode="&#xe080;" d="M1064 547l-551 -551l-198 198l353 353l-353 353l198 198z" />
<glyph unicode="&#xe081;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM650 900h-100q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-150 q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5h150v-150q0 -21 14.5 -35.5t35.5 -14.5h100q21 0 35.5 14.5t14.5 35.5v150h150q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-150v150q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe082;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM850 700h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5 t35.5 -14.5h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe083;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM741.5 913q-12.5 0 -21.5 -9l-120 -120l-120 120q-9 9 -21.5 9 t-21.5 -9l-141 -141q-9 -9 -9 -21.5t9 -21.5l120 -120l-120 -120q-9 -9 -9 -21.5t9 -21.5l141 -141q9 -9 21.5 -9t21.5 9l120 120l120 -120q9 -9 21.5 -9t21.5 9l141 141q9 9 9 21.5t-9 21.5l-120 120l120 120q9 9 9 21.5t-9 21.5l-141 141q-9 9 -21.5 9z" />
<glyph unicode="&#xe084;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM546 623l-84 85q-7 7 -17.5 7t-18.5 -7l-139 -139q-7 -8 -7 -18t7 -18 l242 -241q7 -8 17.5 -8t17.5 8l375 375q7 7 7 17.5t-7 18.5l-139 139q-7 7 -17.5 7t-17.5 -7z" />
<glyph unicode="&#xe085;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM588 941q-29 0 -59 -5.5t-63 -20.5t-58 -38.5t-41.5 -63t-16.5 -89.5 q0 -25 20 -25h131q30 -5 35 11q6 20 20.5 28t45.5 8q20 0 31.5 -10.5t11.5 -28.5q0 -23 -7 -34t-26 -18q-1 0 -13.5 -4t-19.5 -7.5t-20 -10.5t-22 -17t-18.5 -24t-15.5 -35t-8 -46q-1 -8 5.5 -16.5t20.5 -8.5h173q7 0 22 8t35 28t37.5 48t29.5 74t12 100q0 47 -17 83 t-42.5 57t-59.5 34.5t-64 18t-59 4.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe086;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM675 1000h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5 t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5zM675 700h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h75v-200h-75q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h350q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5 t-17.5 7.5h-75v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe087;" d="M525 1200h150q10 0 17.5 -7.5t7.5 -17.5v-194q103 -27 178.5 -102.5t102.5 -178.5h194q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-194q-27 -103 -102.5 -178.5t-178.5 -102.5v-194q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v194 q-103 27 -178.5 102.5t-102.5 178.5h-194q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h194q27 103 102.5 178.5t178.5 102.5v194q0 10 7.5 17.5t17.5 7.5zM700 893v-168q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v168q-68 -23 -119 -74 t-74 -119h168q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-168q23 -68 74 -119t119 -74v168q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-168q68 23 119 74t74 119h-168q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h168 q-23 68 -74 119t-119 74z" />
<glyph unicode="&#xe088;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM759 823l64 -64q7 -7 7 -17.5t-7 -17.5l-124 -124l124 -124q7 -7 7 -17.5t-7 -17.5l-64 -64q-7 -7 -17.5 -7t-17.5 7l-124 124l-124 -124q-7 -7 -17.5 -7t-17.5 7l-64 64 q-7 7 -7 17.5t7 17.5l124 124l-124 124q-7 7 -7 17.5t7 17.5l64 64q7 7 17.5 7t17.5 -7l124 -124l124 124q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe089;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM782 788l106 -106q7 -7 7 -17.5t-7 -17.5l-320 -321q-8 -7 -18 -7t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l197 197q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe090;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5q0 -120 65 -225 l587 587q-105 65 -225 65zM965 819l-584 -584q104 -62 219 -62q116 0 214.5 57t155.5 155.5t57 214.5q0 115 -62 219z" />
<glyph unicode="&#xe091;" d="M39 582l522 427q16 13 27.5 8t11.5 -26v-291h550q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-550v-291q0 -21 -11.5 -26t-27.5 8l-522 427q-16 13 -16 32t16 32z" />
<glyph unicode="&#xe092;" d="M639 1009l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291h-550q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h550v291q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe093;" d="M682 1161l427 -522q13 -16 8 -27.5t-26 -11.5h-291v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v550h-291q-21 0 -26 11.5t8 27.5l427 522q13 16 32 16t32 -16z" />
<glyph unicode="&#xe094;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-550h291q21 0 26 -11.5t-8 -27.5l-427 -522q-13 -16 -32 -16t-32 16l-427 522q-13 16 -8 27.5t26 11.5h291v550q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe095;" d="M639 1109l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291q-94 -2 -182 -20t-170.5 -52t-147 -92.5t-100.5 -135.5q5 105 27 193.5t67.5 167t113 135t167 91.5t225.5 42v262q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe096;" d="M850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5zM350 0h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249 q8 7 18 7t18 -7l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5z" />
<glyph unicode="&#xe097;" d="M1014 1120l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249q8 7 18 7t18 -7zM250 600h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5z" />
<glyph unicode="&#xe101;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM704 900h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5 t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe102;" d="M260 1200q9 0 19 -2t15 -4l5 -2q22 -10 44 -23l196 -118q21 -13 36 -24q29 -21 37 -12q11 13 49 35l196 118q22 13 45 23q17 7 38 7q23 0 47 -16.5t37 -33.5l13 -16q14 -21 18 -45l25 -123l8 -44q1 -9 8.5 -14.5t17.5 -5.5h61q10 0 17.5 -7.5t7.5 -17.5v-50 q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 -7.5t-7.5 -17.5v-175h-400v300h-200v-300h-400v175q0 10 -7.5 17.5t-17.5 7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5h61q11 0 18 3t7 8q0 4 9 52l25 128q5 25 19 45q2 3 5 7t13.5 15t21.5 19.5t26.5 15.5 t29.5 7zM915 1079l-166 -162q-7 -7 -5 -12t12 -5h219q10 0 15 7t2 17l-51 149q-3 10 -11 12t-15 -6zM463 917l-177 157q-8 7 -16 5t-11 -12l-51 -143q-3 -10 2 -17t15 -7h231q11 0 12.5 5t-5.5 12zM500 0h-375q-10 0 -17.5 7.5t-7.5 17.5v375h400v-400zM1100 400v-375 q0 -10 -7.5 -17.5t-17.5 -7.5h-375v400h400z" />
<glyph unicode="&#xe103;" d="M1165 1190q8 3 21 -6.5t13 -17.5q-2 -178 -24.5 -323.5t-55.5 -245.5t-87 -174.5t-102.5 -118.5t-118 -68.5t-118.5 -33t-120 -4.5t-105 9.5t-90 16.5q-61 12 -78 11q-4 1 -12.5 0t-34 -14.5t-52.5 -40.5l-153 -153q-26 -24 -37 -14.5t-11 43.5q0 64 42 102q8 8 50.5 45 t66.5 58q19 17 35 47t13 61q-9 55 -10 102.5t7 111t37 130t78 129.5q39 51 80 88t89.5 63.5t94.5 45t113.5 36t129 31t157.5 37t182 47.5zM1116 1098q-8 9 -22.5 -3t-45.5 -50q-38 -47 -119 -103.5t-142 -89.5l-62 -33q-56 -30 -102 -57t-104 -68t-102.5 -80.5t-85.5 -91 t-64 -104.5q-24 -56 -31 -86t2 -32t31.5 17.5t55.5 59.5q25 30 94 75.5t125.5 77.5t147.5 81q70 37 118.5 69t102 79.5t99 111t86.5 148.5q22 50 24 60t-6 19z" />
<glyph unicode="&#xe104;" d="M653 1231q-39 -67 -54.5 -131t-10.5 -114.5t24.5 -96.5t47.5 -80t63.5 -62.5t68.5 -46.5t65 -30q-4 7 -17.5 35t-18.5 39.5t-17 39.5t-17 43t-13 42t-9.5 44.5t-2 42t4 43t13.5 39t23 38.5q96 -42 165 -107.5t105 -138t52 -156t13 -159t-19 -149.5q-13 -55 -44 -106.5 t-68 -87t-78.5 -64.5t-72.5 -45t-53 -22q-72 -22 -127 -11q-31 6 -13 19q6 3 17 7q13 5 32.5 21t41 44t38.5 63.5t21.5 81.5t-6.5 94.5t-50 107t-104 115.5q10 -104 -0.5 -189t-37 -140.5t-65 -93t-84 -52t-93.5 -11t-95 24.5q-80 36 -131.5 114t-53.5 171q-2 23 0 49.5 t4.5 52.5t13.5 56t27.5 60t46 64.5t69.5 68.5q-8 -53 -5 -102.5t17.5 -90t34 -68.5t44.5 -39t49 -2q31 13 38.5 36t-4.5 55t-29 64.5t-36 75t-26 75.5q-15 85 2 161.5t53.5 128.5t85.5 92.5t93.5 61t81.5 25.5z" />
<glyph unicode="&#xe105;" d="M600 1094q82 0 160.5 -22.5t140 -59t116.5 -82.5t94.5 -95t68 -95t42.5 -82.5t14 -57.5t-14 -57.5t-43 -82.5t-68.5 -95t-94.5 -95t-116.5 -82.5t-140 -59t-159.5 -22.5t-159.5 22.5t-140 59t-116.5 82.5t-94.5 95t-68.5 95t-43 82.5t-14 57.5t14 57.5t42.5 82.5t68 95 t94.5 95t116.5 82.5t140 59t160.5 22.5zM888 829q-15 15 -18 12t5 -22q25 -57 25 -119q0 -124 -88 -212t-212 -88t-212 88t-88 212q0 59 23 114q8 19 4.5 22t-17.5 -12q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q22 -36 47 -71t70 -82t92.5 -81t113 -58.5t133.5 -24.5 t133.5 24t113 58.5t92.5 81.5t70 81.5t47 70.5q11 18 9 42.5t-14 41.5q-90 117 -163 189zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l35 34q14 15 12.5 33.5t-16.5 33.5q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe106;" d="M592 0h-148l31 120q-91 20 -175.5 68.5t-143.5 106.5t-103.5 119t-66.5 110t-22 76q0 21 14 57.5t42.5 82.5t68 95t94.5 95t116.5 82.5t140 59t160.5 22.5q61 0 126 -15l32 121h148zM944 770l47 181q108 -85 176.5 -192t68.5 -159q0 -26 -19.5 -71t-59.5 -102t-93 -112 t-129 -104.5t-158 -75.5l46 173q77 49 136 117t97 131q11 18 9 42.5t-14 41.5q-54 70 -107 130zM310 824q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q18 -30 39 -60t57 -70.5t74 -73t90 -61t105 -41.5l41 154q-107 18 -178.5 101.5t-71.5 193.5q0 59 23 114q8 19 4.5 22 t-17.5 -12zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l12 11l22 86l-3 4q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe107;" d="M-90 100l642 1066q20 31 48 28.5t48 -35.5l642 -1056q21 -32 7.5 -67.5t-50.5 -35.5h-1294q-37 0 -50.5 34t7.5 66zM155 200h345v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h345l-445 723zM496 700h208q20 0 32 -14.5t8 -34.5l-58 -252 q-4 -20 -21.5 -34.5t-37.5 -14.5h-54q-20 0 -37.5 14.5t-21.5 34.5l-58 252q-4 20 8 34.5t32 14.5z" />
<glyph unicode="&#xe108;" d="M650 1200q62 0 106 -44t44 -106v-339l363 -325q15 -14 26 -38.5t11 -44.5v-41q0 -20 -12 -26.5t-29 5.5l-359 249v-263q100 -93 100 -113v-64q0 -21 -13 -29t-32 1l-205 128l-205 -128q-19 -9 -32 -1t-13 29v64q0 20 100 113v263l-359 -249q-17 -12 -29 -5.5t-12 26.5v41 q0 20 11 44.5t26 38.5l363 325v339q0 62 44 106t106 44z" />
<glyph unicode="&#xe109;" d="M850 1200h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-150h-1100v150q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5h100q21 0 35.5 -14.5t14.5 -35.5v-50h500v50q0 21 14.5 35.5t35.5 14.5zM1100 800v-750q0 -21 -14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v750h1100zM100 600v-100h100v100h-100zM300 600v-100h100v100h-100zM500 600v-100h100v100h-100zM700 600v-100h100v100h-100zM900 600v-100h100v100h-100zM100 400v-100h100v100h-100zM300 400v-100h100v100h-100zM500 400 v-100h100v100h-100zM700 400v-100h100v100h-100zM900 400v-100h100v100h-100zM100 200v-100h100v100h-100zM300 200v-100h100v100h-100zM500 200v-100h100v100h-100zM700 200v-100h100v100h-100zM900 200v-100h100v100h-100z" />
<glyph unicode="&#xe110;" d="M1135 1165l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-159l-600 -600h-291q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h209l600 600h241v150q0 21 10.5 25t24.5 -10zM522 819l-141 -141l-122 122h-209q-21 0 -35.5 14.5 t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h291zM1135 565l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-241l-181 181l141 141l122 -122h159v150q0 21 10.5 25t24.5 -10z" />
<glyph unicode="&#xe111;" d="M100 1100h1000q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-596l-304 -300v300h-100q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5z" />
<glyph unicode="&#xe112;" d="M150 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM850 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM1100 800v-300q0 -41 -3 -77.5t-15 -89.5t-32 -96t-58 -89t-89 -77t-129 -51t-174 -20t-174 20 t-129 51t-89 77t-58 89t-32 96t-15 89.5t-3 77.5v300h300v-250v-27v-42.5t1.5 -41t5 -38t10 -35t16.5 -30t25.5 -24.5t35 -19t46.5 -12t60 -4t60 4.5t46.5 12.5t35 19.5t25 25.5t17 30.5t10 35t5 38t2 40.5t-0.5 42v25v250h300z" />
<glyph unicode="&#xe113;" d="M1100 411l-198 -199l-353 353l-353 -353l-197 199l551 551z" />
<glyph unicode="&#xe114;" d="M1101 789l-550 -551l-551 551l198 199l353 -353l353 353z" />
<glyph unicode="&#xe115;" d="M404 1000h746q21 0 35.5 -14.5t14.5 -35.5v-551h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v401h-381zM135 984l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-400h385l215 -200h-750q-21 0 -35.5 14.5 t-14.5 35.5v550h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe116;" d="M56 1200h94q17 0 31 -11t18 -27l38 -162h896q24 0 39 -18.5t10 -42.5l-100 -475q-5 -21 -27 -42.5t-55 -21.5h-633l48 -200h535q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-50q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-300v-50 q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-31q-18 0 -32.5 10t-20.5 19l-5 10l-201 961h-54q-20 0 -35 14.5t-15 35.5t15 35.5t35 14.5z" />
<glyph unicode="&#xe117;" d="M1200 1000v-100h-1200v100h200q0 41 29.5 70.5t70.5 29.5h300q41 0 70.5 -29.5t29.5 -70.5h500zM0 800h1200v-800h-1200v800z" />
<glyph unicode="&#xe118;" d="M200 800l-200 -400v600h200q0 41 29.5 70.5t70.5 29.5h300q42 0 71 -29.5t29 -70.5h500v-200h-1000zM1500 700l-300 -700h-1200l300 700h1200z" />
<glyph unicode="&#xe119;" d="M635 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-601h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v601h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe120;" d="M936 864l249 -229q14 -15 14 -35.5t-14 -35.5l-249 -229q-15 -15 -25.5 -10.5t-10.5 24.5v151h-600v-151q0 -20 -10.5 -24.5t-25.5 10.5l-249 229q-14 15 -14 35.5t14 35.5l249 229q15 15 25.5 10.5t10.5 -25.5v-149h600v149q0 21 10.5 25.5t25.5 -10.5z" />
<glyph unicode="&#xe121;" d="M1169 400l-172 732q-5 23 -23 45.5t-38 22.5h-672q-20 0 -38 -20t-23 -41l-172 -739h1138zM1100 300h-1000q-41 0 -70.5 -29.5t-29.5 -70.5v-100q0 -41 29.5 -70.5t70.5 -29.5h1000q41 0 70.5 29.5t29.5 70.5v100q0 41 -29.5 70.5t-70.5 29.5zM800 100v100h100v-100h-100 zM1000 100v100h100v-100h-100z" />
<glyph unicode="&#xe122;" d="M1150 1100q21 0 35.5 -14.5t14.5 -35.5v-850q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v850q0 21 14.5 35.5t35.5 14.5zM1000 200l-675 200h-38l47 -276q3 -16 -5.5 -20t-29.5 -4h-7h-84q-20 0 -34.5 14t-18.5 35q-55 337 -55 351v250v6q0 16 1 23.5t6.5 14 t17.5 6.5h200l675 250v-850zM0 750v-250q-4 0 -11 0.5t-24 6t-30 15t-24 30t-11 48.5v50q0 26 10.5 46t25 30t29 16t25.5 7z" />
<glyph unicode="&#xe123;" d="M553 1200h94q20 0 29 -10.5t3 -29.5l-18 -37q83 -19 144 -82.5t76 -140.5l63 -327l118 -173h17q19 0 33 -14.5t14 -35t-13 -40.5t-31 -27q-8 -4 -23 -9.5t-65 -19.5t-103 -25t-132.5 -20t-158.5 -9q-57 0 -115 5t-104 12t-88.5 15.5t-73.5 17.5t-54.5 16t-35.5 12l-11 4 q-18 8 -31 28t-13 40.5t14 35t33 14.5h17l118 173l63 327q15 77 76 140t144 83l-18 32q-6 19 3.5 32t28.5 13zM498 110q50 -6 102 -6q53 0 102 6q-12 -49 -39.5 -79.5t-62.5 -30.5t-63 30.5t-39 79.5z" />
<glyph unicode="&#xe124;" d="M800 946l224 78l-78 -224l234 -45l-180 -155l180 -155l-234 -45l78 -224l-224 78l-45 -234l-155 180l-155 -180l-45 234l-224 -78l78 224l-234 45l180 155l-180 155l234 45l-78 224l224 -78l45 234l155 -180l155 180z" />
<glyph unicode="&#xe125;" d="M650 1200h50q40 0 70 -40.5t30 -84.5v-150l-28 -125h328q40 0 70 -40.5t30 -84.5v-100q0 -45 -29 -74l-238 -344q-16 -24 -38 -40.5t-45 -16.5h-250q-7 0 -42 25t-66 50l-31 25h-61q-45 0 -72.5 18t-27.5 57v400q0 36 20 63l145 196l96 198q13 28 37.5 48t51.5 20z M650 1100l-100 -212l-150 -213v-375h100l136 -100h214l250 375v125h-450l50 225v175h-50zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe126;" d="M600 1100h250q23 0 45 -16.5t38 -40.5l238 -344q29 -29 29 -74v-100q0 -44 -30 -84.5t-70 -40.5h-328q28 -118 28 -125v-150q0 -44 -30 -84.5t-70 -40.5h-50q-27 0 -51.5 20t-37.5 48l-96 198l-145 196q-20 27 -20 63v400q0 39 27.5 57t72.5 18h61q124 100 139 100z M50 1000h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM636 1000l-136 -100h-100v-375l150 -213l100 -212h50v175l-50 225h450v125l-250 375h-214z" />
<glyph unicode="&#xe127;" d="M356 873l363 230q31 16 53 -6l110 -112q13 -13 13.5 -32t-11.5 -34l-84 -121h302q84 0 138 -38t54 -110t-55 -111t-139 -39h-106l-131 -339q-6 -21 -19.5 -41t-28.5 -20h-342q-7 0 -90 81t-83 94v525q0 17 14 35.5t28 28.5zM400 792v-503l100 -89h293l131 339 q6 21 19.5 41t28.5 20h203q21 0 30.5 25t0.5 50t-31 25h-456h-7h-6h-5.5t-6 0.5t-5 1.5t-5 2t-4 2.5t-4 4t-2.5 4.5q-12 25 5 47l146 183l-86 83zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe128;" d="M475 1103l366 -230q2 -1 6 -3.5t14 -10.5t18 -16.5t14.5 -20t6.5 -22.5v-525q0 -13 -86 -94t-93 -81h-342q-15 0 -28.5 20t-19.5 41l-131 339h-106q-85 0 -139.5 39t-54.5 111t54 110t138 38h302l-85 121q-11 15 -10.5 34t13.5 32l110 112q22 22 53 6zM370 945l146 -183 q17 -22 5 -47q-2 -2 -3.5 -4.5t-4 -4t-4 -2.5t-5 -2t-5 -1.5t-6 -0.5h-6h-6.5h-6h-475v-100h221q15 0 29 -20t20 -41l130 -339h294l106 89v503l-342 236zM1050 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5 v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe129;" d="M550 1294q72 0 111 -55t39 -139v-106l339 -131q21 -6 41 -19.5t20 -28.5v-342q0 -7 -81 -90t-94 -83h-525q-17 0 -35.5 14t-28.5 28l-9 14l-230 363q-16 31 6 53l112 110q13 13 32 13.5t34 -11.5l121 -84v302q0 84 38 138t110 54zM600 972v203q0 21 -25 30.5t-50 0.5 t-25 -31v-456v-7v-6v-5.5t-0.5 -6t-1.5 -5t-2 -5t-2.5 -4t-4 -4t-4.5 -2.5q-25 -12 -47 5l-183 146l-83 -86l236 -339h503l89 100v293l-339 131q-21 6 -41 19.5t-20 28.5zM450 200h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe130;" d="M350 1100h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5zM600 306v-106q0 -84 -39 -139t-111 -55t-110 54t-38 138v302l-121 -84q-15 -12 -34 -11.5t-32 13.5l-112 110 q-22 22 -6 53l230 363q1 2 3.5 6t10.5 13.5t16.5 17t20 13.5t22.5 6h525q13 0 94 -83t81 -90v-342q0 -15 -20 -28.5t-41 -19.5zM308 900l-236 -339l83 -86l183 146q22 17 47 5q2 -1 4.5 -2.5t4 -4t2.5 -4t2 -5t1.5 -5t0.5 -6v-5.5v-6v-7v-456q0 -22 25 -31t50 0.5t25 30.5 v203q0 15 20 28.5t41 19.5l339 131v293l-89 100h-503z" />
<glyph unicode="&#xe131;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM914 632l-275 223q-16 13 -27.5 8t-11.5 -26v-137h-275 q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h275v-137q0 -21 11.5 -26t27.5 8l275 223q16 13 16 32t-16 32z" />
<glyph unicode="&#xe132;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM561 855l-275 -223q-16 -13 -16 -32t16 -32l275 -223q16 -13 27.5 -8 t11.5 26v137h275q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5h-275v137q0 21 -11.5 26t-27.5 -8z" />
<glyph unicode="&#xe133;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM855 639l-223 275q-13 16 -32 16t-32 -16l-223 -275q-13 -16 -8 -27.5 t26 -11.5h137v-275q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v275h137q21 0 26 11.5t-8 27.5z" />
<glyph unicode="&#xe134;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM675 900h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-275h-137q-21 0 -26 -11.5 t8 -27.5l223 -275q13 -16 32 -16t32 16l223 275q13 16 8 27.5t-26 11.5h-137v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe135;" d="M600 1176q116 0 222.5 -46t184 -123.5t123.5 -184t46 -222.5t-46 -222.5t-123.5 -184t-184 -123.5t-222.5 -46t-222.5 46t-184 123.5t-123.5 184t-46 222.5t46 222.5t123.5 184t184 123.5t222.5 46zM627 1101q-15 -12 -36.5 -20.5t-35.5 -12t-43 -8t-39 -6.5 q-15 -3 -45.5 0t-45.5 -2q-20 -7 -51.5 -26.5t-34.5 -34.5q-3 -11 6.5 -22.5t8.5 -18.5q-3 -34 -27.5 -91t-29.5 -79q-9 -34 5 -93t8 -87q0 -9 17 -44.5t16 -59.5q12 0 23 -5t23.5 -15t19.5 -14q16 -8 33 -15t40.5 -15t34.5 -12q21 -9 52.5 -32t60 -38t57.5 -11 q7 -15 -3 -34t-22.5 -40t-9.5 -38q13 -21 23 -34.5t27.5 -27.5t36.5 -18q0 -7 -3.5 -16t-3.5 -14t5 -17q104 -2 221 112q30 29 46.5 47t34.5 49t21 63q-13 8 -37 8.5t-36 7.5q-15 7 -49.5 15t-51.5 19q-18 0 -41 -0.5t-43 -1.5t-42 -6.5t-38 -16.5q-51 -35 -66 -12 q-4 1 -3.5 25.5t0.5 25.5q-6 13 -26.5 17.5t-24.5 6.5q1 15 -0.5 30.5t-7 28t-18.5 11.5t-31 -21q-23 -25 -42 4q-19 28 -8 58q6 16 22 22q6 -1 26 -1.5t33.5 -4t19.5 -13.5q7 -12 18 -24t21.5 -20.5t20 -15t15.5 -10.5l5 -3q2 12 7.5 30.5t8 34.5t-0.5 32q-3 18 3.5 29 t18 22.5t15.5 24.5q6 14 10.5 35t8 31t15.5 22.5t34 22.5q-6 18 10 36q8 0 24 -1.5t24.5 -1.5t20 4.5t20.5 15.5q-10 23 -31 42.5t-37.5 29.5t-49 27t-43.5 23q0 1 2 8t3 11.5t1.5 10.5t-1 9.5t-4.5 4.5q31 -13 58.5 -14.5t38.5 2.5l12 5q5 28 -9.5 46t-36.5 24t-50 15 t-41 20q-18 -4 -37 0zM613 994q0 -17 8 -42t17 -45t9 -23q-8 1 -39.5 5.5t-52.5 10t-37 16.5q3 11 16 29.5t16 25.5q10 -10 19 -10t14 6t13.5 14.5t16.5 12.5z" />
<glyph unicode="&#xe136;" d="M756 1157q164 92 306 -9l-259 -138l145 -232l251 126q6 -89 -34 -156.5t-117 -110.5q-60 -34 -127 -39.5t-126 16.5l-596 -596q-15 -16 -36.5 -16t-36.5 16l-111 110q-15 15 -15 36.5t15 37.5l600 599q-34 101 5.5 201.5t135.5 154.5z" />
<glyph unicode="&#xe137;" horiz-adv-x="1220" d="M100 1196h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 1096h-200v-100h200v100zM100 796h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 696h-500v-100h500v100zM100 396h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 296h-300v-100h300v100z " />
<glyph unicode="&#xe138;" d="M150 1200h900q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM700 500v-300l-200 -200v500l-350 500h900z" />
<glyph unicode="&#xe139;" d="M500 1200h200q41 0 70.5 -29.5t29.5 -70.5v-100h300q41 0 70.5 -29.5t29.5 -70.5v-400h-500v100h-200v-100h-500v400q0 41 29.5 70.5t70.5 29.5h300v100q0 41 29.5 70.5t70.5 29.5zM500 1100v-100h200v100h-200zM1200 400v-200q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v200h1200z" />
<glyph unicode="&#xe140;" d="M50 1200h300q21 0 25 -10.5t-10 -24.5l-94 -94l199 -199q7 -8 7 -18t-7 -18l-106 -106q-8 -7 -18 -7t-18 7l-199 199l-94 -94q-14 -14 -24.5 -10t-10.5 25v300q0 21 14.5 35.5t35.5 14.5zM850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-199 -199q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l199 199l-94 94q-14 14 -10 24.5t25 10.5zM364 470l106 -106q7 -8 7 -18t-7 -18l-199 -199l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l199 199 q8 7 18 7t18 -7zM1071 271l94 94q14 14 24.5 10t10.5 -25v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -25 10.5t10 24.5l94 94l-199 199q-7 8 -7 18t7 18l106 106q8 7 18 7t18 -7z" />
<glyph unicode="&#xe141;" d="M596 1192q121 0 231.5 -47.5t190 -127t127 -190t47.5 -231.5t-47.5 -231.5t-127 -190.5t-190 -127t-231.5 -47t-231.5 47t-190.5 127t-127 190.5t-47 231.5t47 231.5t127 190t190.5 127t231.5 47.5zM596 1010q-112 0 -207.5 -55.5t-151 -151t-55.5 -207.5t55.5 -207.5 t151 -151t207.5 -55.5t207.5 55.5t151 151t55.5 207.5t-55.5 207.5t-151 151t-207.5 55.5zM454.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38.5 -16.5t-38.5 16.5t-16 39t16 38.5t38.5 16zM754.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38 -16.5q-14 0 -29 10l-55 -145 q17 -23 17 -51q0 -36 -25.5 -61.5t-61.5 -25.5t-61.5 25.5t-25.5 61.5q0 32 20.5 56.5t51.5 29.5l122 126l1 1q-9 14 -9 28q0 23 16 39t38.5 16zM345.5 709q22.5 0 38.5 -16t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16zM854.5 709q22.5 0 38.5 -16 t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16z" />
<glyph unicode="&#xe142;" d="M546 173l469 470q91 91 99 192q7 98 -52 175.5t-154 94.5q-22 4 -47 4q-34 0 -66.5 -10t-56.5 -23t-55.5 -38t-48 -41.5t-48.5 -47.5q-376 -375 -391 -390q-30 -27 -45 -41.5t-37.5 -41t-32 -46.5t-16 -47.5t-1.5 -56.5q9 -62 53.5 -95t99.5 -33q74 0 125 51l548 548 q36 36 20 75q-7 16 -21.5 26t-32.5 10q-26 0 -50 -23q-13 -12 -39 -38l-341 -338q-15 -15 -35.5 -15.5t-34.5 13.5t-14 34.5t14 34.5q327 333 361 367q35 35 67.5 51.5t78.5 16.5q14 0 29 -1q44 -8 74.5 -35.5t43.5 -68.5q14 -47 2 -96.5t-47 -84.5q-12 -11 -32 -32 t-79.5 -81t-114.5 -115t-124.5 -123.5t-123 -119.5t-96.5 -89t-57 -45q-56 -27 -120 -27q-70 0 -129 32t-93 89q-48 78 -35 173t81 163l511 511q71 72 111 96q91 55 198 55q80 0 152 -33q78 -36 129.5 -103t66.5 -154q17 -93 -11 -183.5t-94 -156.5l-482 -476 q-15 -15 -36 -16t-37 14t-17.5 34t14.5 35z" />
<glyph unicode="&#xe143;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104zM896 972q-33 0 -64.5 -19t-56.5 -46t-47.5 -53.5t-43.5 -45.5t-37.5 -19t-36 19t-40 45.5t-43 53.5t-54 46t-65.5 19q-67 0 -122.5 -55.5t-55.5 -132.5q0 -23 13.5 -51t46 -65t57.5 -63t76 -75l22 -22q15 -14 44 -44t50.5 -51t46 -44t41 -35t23 -12 t23.5 12t42.5 36t46 44t52.5 52t44 43q4 4 12 13q43 41 63.5 62t52 55t46 55t26 46t11.5 44q0 79 -53 133.5t-120 54.5z" />
<glyph unicode="&#xe144;" d="M776.5 1214q93.5 0 159.5 -66l141 -141q66 -66 66 -160q0 -42 -28 -95.5t-62 -87.5l-29 -29q-31 53 -77 99l-18 18l95 95l-247 248l-389 -389l212 -212l-105 -106l-19 18l-141 141q-66 66 -66 159t66 159l283 283q65 66 158.5 66zM600 706l105 105q10 -8 19 -17l141 -141 q66 -66 66 -159t-66 -159l-283 -283q-66 -66 -159 -66t-159 66l-141 141q-66 66 -66 159.5t66 159.5l55 55q29 -55 75 -102l18 -17l-95 -95l247 -248l389 389z" />
<glyph unicode="&#xe145;" d="M603 1200q85 0 162 -15t127 -38t79 -48t29 -46v-953q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-41 0 -70.5 29.5t-29.5 70.5v953q0 21 30 46.5t81 48t129 37.5t163 15zM300 1000v-700h600v700h-600zM600 254q-43 0 -73.5 -30.5t-30.5 -73.5t30.5 -73.5t73.5 -30.5t73.5 30.5 t30.5 73.5t-30.5 73.5t-73.5 30.5z" />
<glyph unicode="&#xe146;" d="M902 1185l283 -282q15 -15 15 -36t-14.5 -35.5t-35.5 -14.5t-35 15l-36 35l-279 -267v-300l-212 210l-308 -307l-280 -203l203 280l307 308l-210 212h300l267 279l-35 36q-15 14 -15 35t14.5 35.5t35.5 14.5t35 -15z" />
<glyph unicode="&#xe148;" d="M700 1248v-78q38 -5 72.5 -14.5t75.5 -31.5t71 -53.5t52 -84t24 -118.5h-159q-4 36 -10.5 59t-21 45t-40 35.5t-64.5 20.5v-307l64 -13q34 -7 64 -16.5t70 -32t67.5 -52.5t47.5 -80t20 -112q0 -139 -89 -224t-244 -97v-77h-100v79q-150 16 -237 103q-40 40 -52.5 93.5 t-15.5 139.5h139q5 -77 48.5 -126t117.5 -65v335l-27 8q-46 14 -79 26.5t-72 36t-63 52t-40 72.5t-16 98q0 70 25 126t67.5 92t94.5 57t110 27v77h100zM600 754v274q-29 -4 -50 -11t-42 -21.5t-31.5 -41.5t-10.5 -65q0 -29 7 -50.5t16.5 -34t28.5 -22.5t31.5 -14t37.5 -10 q9 -3 13 -4zM700 547v-310q22 2 42.5 6.5t45 15.5t41.5 27t29 42t12 59.5t-12.5 59.5t-38 44.5t-53 31t-66.5 24.5z" />
<glyph unicode="&#xe149;" d="M561 1197q84 0 160.5 -40t123.5 -109.5t47 -147.5h-153q0 40 -19.5 71.5t-49.5 48.5t-59.5 26t-55.5 9q-37 0 -79 -14.5t-62 -35.5q-41 -44 -41 -101q0 -26 13.5 -63t26.5 -61t37 -66q6 -9 9 -14h241v-100h-197q8 -50 -2.5 -115t-31.5 -95q-45 -62 -99 -112 q34 10 83 17.5t71 7.5q32 1 102 -16t104 -17q83 0 136 30l50 -147q-31 -19 -58 -30.5t-55 -15.5t-42 -4.5t-46 -0.5q-23 0 -76 17t-111 32.5t-96 11.5q-39 -3 -82 -16t-67 -25l-23 -11l-55 145q4 3 16 11t15.5 10.5t13 9t15.5 12t14.5 14t17.5 18.5q48 55 54 126.5 t-30 142.5h-221v100h166q-23 47 -44 104q-7 20 -12 41.5t-6 55.5t6 66.5t29.5 70.5t58.5 71q97 88 263 88z" />
<glyph unicode="&#xe150;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM935 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-900h-200v900h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe151;" d="M1000 700h-100v100h-100v-100h-100v500h300v-500zM400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM801 1100v-200h100v200h-100zM1000 350l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150z " />
<glyph unicode="&#xe152;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 1050l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150zM1000 0h-100v100h-100v-100h-100v500h300v-500zM801 400v-200h100v200h-100z " />
<glyph unicode="&#xe153;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 700h-100v400h-100v100h200v-500zM1100 0h-100v100h-200v400h300v-500zM901 400v-200h100v200h-100z" />
<glyph unicode="&#xe154;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1100 700h-100v100h-200v400h300v-500zM901 1100v-200h100v200h-100zM1000 0h-100v400h-100v100h200v-500z" />
<glyph unicode="&#xe155;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM900 1000h-200v200h200v-200zM1000 700h-300v200h300v-200zM1100 400h-400v200h400v-200zM1200 100h-500v200h500v-200z" />
<glyph unicode="&#xe156;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1200 1000h-500v200h500v-200zM1100 700h-400v200h400v-200zM1000 400h-300v200h300v-200zM900 100h-200v200h200v-200z" />
<glyph unicode="&#xe157;" d="M350 1100h400q162 0 256 -93.5t94 -256.5v-400q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5z" />
<glyph unicode="&#xe158;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-163 0 -256.5 92.5t-93.5 257.5v400q0 163 94 256.5t256 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM440 770l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe159;" d="M350 1100h400q163 0 256.5 -94t93.5 -256v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 163 92.5 256.5t257.5 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM350 700h400q21 0 26.5 -12t-6.5 -28l-190 -253q-12 -17 -30 -17t-30 17l-190 253q-12 16 -6.5 28t26.5 12z" />
<glyph unicode="&#xe160;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -163 -92.5 -256.5t-257.5 -93.5h-400q-163 0 -256.5 94t-93.5 256v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM580 693l190 -253q12 -16 6.5 -28t-26.5 -12h-400q-21 0 -26.5 12t6.5 28l190 253q12 17 30 17t30 -17z" />
<glyph unicode="&#xe161;" d="M550 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h450q41 0 70.5 29.5t29.5 70.5v500q0 41 -29.5 70.5t-70.5 29.5h-450q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM338 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe162;" d="M793 1182l9 -9q8 -10 5 -27q-3 -11 -79 -225.5t-78 -221.5l300 1q24 0 32.5 -17.5t-5.5 -35.5q-1 0 -133.5 -155t-267 -312.5t-138.5 -162.5q-12 -15 -26 -15h-9l-9 8q-9 11 -4 32q2 9 42 123.5t79 224.5l39 110h-302q-23 0 -31 19q-10 21 6 41q75 86 209.5 237.5 t228 257t98.5 111.5q9 16 25 16h9z" />
<glyph unicode="&#xe163;" d="M350 1100h400q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-450q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h450q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400 q0 165 92.5 257.5t257.5 92.5zM938 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe164;" d="M750 1200h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -10.5 -25t-24.5 10l-109 109l-312 -312q-15 -15 -35.5 -15t-35.5 15l-141 141q-15 15 -15 35.5t15 35.5l312 312l-109 109q-14 14 -10 24.5t25 10.5zM456 900h-156q-41 0 -70.5 -29.5t-29.5 -70.5v-500 q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v148l200 200v-298q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5h300z" />
<glyph unicode="&#xe165;" d="M600 1186q119 0 227.5 -46.5t187 -125t125 -187t46.5 -227.5t-46.5 -227.5t-125 -187t-187 -125t-227.5 -46.5t-227.5 46.5t-187 125t-125 187t-46.5 227.5t46.5 227.5t125 187t187 125t227.5 46.5zM600 1022q-115 0 -212 -56.5t-153.5 -153.5t-56.5 -212t56.5 -212 t153.5 -153.5t212 -56.5t212 56.5t153.5 153.5t56.5 212t-56.5 212t-153.5 153.5t-212 56.5zM600 794q80 0 137 -57t57 -137t-57 -137t-137 -57t-137 57t-57 137t57 137t137 57z" />
<glyph unicode="&#xe166;" d="M450 1200h200q21 0 35.5 -14.5t14.5 -35.5v-350h245q20 0 25 -11t-9 -26l-383 -426q-14 -15 -33.5 -15t-32.5 15l-379 426q-13 15 -8.5 26t25.5 11h250v350q0 21 14.5 35.5t35.5 14.5zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe167;" d="M583 1182l378 -435q14 -15 9 -31t-26 -16h-244v-250q0 -20 -17 -35t-39 -15h-200q-20 0 -32 14.5t-12 35.5v250h-250q-20 0 -25.5 16.5t8.5 31.5l383 431q14 16 33.5 17t33.5 -14zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe168;" d="M396 723l369 369q7 7 17.5 7t17.5 -7l139 -139q7 -8 7 -18.5t-7 -17.5l-525 -525q-7 -8 -17.5 -8t-17.5 8l-292 291q-7 8 -7 18t7 18l139 139q8 7 18.5 7t17.5 -7zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50 h-100z" />
<glyph unicode="&#xe169;" d="M135 1023l142 142q14 14 35 14t35 -14l77 -77l-212 -212l-77 76q-14 15 -14 36t14 35zM655 855l210 210q14 14 24.5 10t10.5 -25l-2 -599q-1 -20 -15.5 -35t-35.5 -15l-597 -1q-21 0 -25 10.5t10 24.5l208 208l-154 155l212 212zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5 v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe170;" d="M350 1200l599 -2q20 -1 35 -15.5t15 -35.5l1 -597q0 -21 -10.5 -25t-24.5 10l-208 208l-155 -154l-212 212l155 154l-210 210q-14 14 -10 24.5t25 10.5zM524 512l-76 -77q-15 -14 -36 -14t-35 14l-142 142q-14 14 -14 35t14 35l77 77zM50 300h1000q21 0 35.5 -14.5 t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe171;" d="M1200 103l-483 276l-314 -399v423h-399l1196 796v-1096zM483 424v-230l683 953z" />
<glyph unicode="&#xe172;" d="M1100 1000v-850q0 -21 -14.5 -35.5t-35.5 -14.5h-150v400h-700v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200z" />
<glyph unicode="&#xe173;" d="M1100 1000l-2 -149l-299 -299l-95 95q-9 9 -21.5 9t-21.5 -9l-149 -147h-312v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1132 638l106 -106q7 -7 7 -17.5t-7 -17.5l-420 -421q-8 -7 -18 -7 t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l297 297q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe174;" d="M1100 1000v-269l-103 -103l-134 134q-15 15 -33.5 16.5t-34.5 -12.5l-266 -266h-329v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1202 572l70 -70q15 -15 15 -35.5t-15 -35.5l-131 -131 l131 -131q15 -15 15 -35.5t-15 -35.5l-70 -70q-15 -15 -35.5 -15t-35.5 15l-131 131l-131 -131q-15 -15 -35.5 -15t-35.5 15l-70 70q-15 15 -15 35.5t15 35.5l131 131l-131 131q-15 15 -15 35.5t15 35.5l70 70q15 15 35.5 15t35.5 -15l131 -131l131 131q15 15 35.5 15 t35.5 -15z" />
<glyph unicode="&#xe175;" d="M1100 1000v-300h-350q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-500v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM850 600h100q21 0 35.5 -14.5t14.5 -35.5v-250h150q21 0 25 -10.5t-10 -24.5 l-230 -230q-14 -14 -35 -14t-35 14l-230 230q-14 14 -10 24.5t25 10.5h150v250q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe176;" d="M1100 1000v-400l-165 165q-14 15 -35 15t-35 -15l-263 -265h-402v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM935 565l230 -229q14 -15 10 -25.5t-25 -10.5h-150v-250q0 -20 -14.5 -35 t-35.5 -15h-100q-21 0 -35.5 15t-14.5 35v250h-150q-21 0 -25 10.5t10 25.5l230 229q14 15 35 15t35 -15z" />
<glyph unicode="&#xe177;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-150h-1200v150q0 21 14.5 35.5t35.5 14.5zM1200 800v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v550h1200zM100 500v-200h400v200h-400z" />
<glyph unicode="&#xe178;" d="M935 1165l248 -230q14 -14 14 -35t-14 -35l-248 -230q-14 -14 -24.5 -10t-10.5 25v150h-400v200h400v150q0 21 10.5 25t24.5 -10zM200 800h-50q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v-200zM400 800h-100v200h100v-200zM18 435l247 230 q14 14 24.5 10t10.5 -25v-150h400v-200h-400v-150q0 -21 -10.5 -25t-24.5 10l-247 230q-15 14 -15 35t15 35zM900 300h-100v200h100v-200zM1000 500h51q20 0 34.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-34.5 -14.5h-51v200z" />
<glyph unicode="&#xe179;" d="M862 1073l276 116q25 18 43.5 8t18.5 -41v-1106q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v397q-4 1 -11 5t-24 17.5t-30 29t-24 42t-11 56.5v359q0 31 18.5 65t43.5 52zM550 1200q22 0 34.5 -12.5t14.5 -24.5l1 -13v-450q0 -28 -10.5 -59.5 t-25 -56t-29 -45t-25.5 -31.5l-10 -11v-447q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v447q-4 4 -11 11.5t-24 30.5t-30 46t-24 55t-11 60v450q0 2 0.5 5.5t4 12t8.5 15t14.5 12t22.5 5.5q20 0 32.5 -12.5t14.5 -24.5l3 -13v-350h100v350v5.5t2.5 12 t7 15t15 12t25.5 5.5q23 0 35.5 -12.5t13.5 -24.5l1 -13v-350h100v350q0 2 0.5 5.5t3 12t7 15t15 12t24.5 5.5z" />
<glyph unicode="&#xe180;" d="M1200 1100v-56q-4 0 -11 -0.5t-24 -3t-30 -7.5t-24 -15t-11 -24v-888q0 -22 25 -34.5t50 -13.5l25 -2v-56h-400v56q75 0 87.5 6.5t12.5 43.5v394h-500v-394q0 -37 12.5 -43.5t87.5 -6.5v-56h-400v56q4 0 11 0.5t24 3t30 7.5t24 15t11 24v888q0 22 -25 34.5t-50 13.5 l-25 2v56h400v-56q-75 0 -87.5 -6.5t-12.5 -43.5v-394h500v394q0 37 -12.5 43.5t-87.5 6.5v56h400z" />
<glyph unicode="&#xe181;" d="M675 1000h375q21 0 35.5 -14.5t14.5 -35.5v-150h-105l-295 -98v98l-200 200h-400l100 100h375zM100 900h300q41 0 70.5 -29.5t29.5 -70.5v-500q0 -41 -29.5 -70.5t-70.5 -29.5h-300q-41 0 -70.5 29.5t-29.5 70.5v500q0 41 29.5 70.5t70.5 29.5zM100 800v-200h300v200 h-300zM1100 535l-400 -133v163l400 133v-163zM100 500v-200h300v200h-300zM1100 398v-248q0 -21 -14.5 -35.5t-35.5 -14.5h-375l-100 -100h-375l-100 100h400l200 200h105z" />
<glyph unicode="&#xe182;" d="M17 1007l162 162q17 17 40 14t37 -22l139 -194q14 -20 11 -44.5t-20 -41.5l-119 -118q102 -142 228 -268t267 -227l119 118q17 17 42.5 19t44.5 -12l192 -136q19 -14 22.5 -37.5t-13.5 -40.5l-163 -162q-3 -1 -9.5 -1t-29.5 2t-47.5 6t-62.5 14.5t-77.5 26.5t-90 42.5 t-101.5 60t-111 83t-119 108.5q-74 74 -133.5 150.5t-94.5 138.5t-60 119.5t-34.5 100t-15 74.5t-4.5 48z" />
<glyph unicode="&#xe183;" d="M600 1100q92 0 175 -10.5t141.5 -27t108.5 -36.5t81.5 -40t53.5 -37t31 -27l9 -10v-200q0 -21 -14.5 -33t-34.5 -9l-202 34q-20 3 -34.5 20t-14.5 38v146q-141 24 -300 24t-300 -24v-146q0 -21 -14.5 -38t-34.5 -20l-202 -34q-20 -3 -34.5 9t-14.5 33v200q3 4 9.5 10.5 t31 26t54 37.5t80.5 39.5t109 37.5t141 26.5t175 10.5zM600 795q56 0 97 -9.5t60 -23.5t30 -28t12 -24l1 -10v-50l365 -303q14 -15 24.5 -40t10.5 -45v-212q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v212q0 20 10.5 45t24.5 40l365 303v50 q0 4 1 10.5t12 23t30 29t60 22.5t97 10z" />
<glyph unicode="&#xe184;" d="M1100 700l-200 -200h-600l-200 200v500h200v-200h200v200h200v-200h200v200h200v-500zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5 t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe185;" d="M700 1100h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-1000h300v1000q0 41 -29.5 70.5t-70.5 29.5zM1100 800h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-700h300v700q0 41 -29.5 70.5t-70.5 29.5zM400 0h-300v400q0 41 29.5 70.5t70.5 29.5h100q41 0 70.5 -29.5t29.5 -70.5v-400z " />
<glyph unicode="&#xe186;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe187;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 300h-100v200h-100v-200h-100v500h100v-200h100v200h100v-500zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe188;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-300h200v-100h-300v500h300v-100zM900 700h-200v-300h200v-100h-300v500h300v-100z" />
<glyph unicode="&#xe189;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 400l-300 150l300 150v-300zM900 550l-300 -150v300z" />
<glyph unicode="&#xe190;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM900 300h-700v500h700v-500zM800 700h-130q-38 0 -66.5 -43t-28.5 -108t27 -107t68 -42h130v300zM300 700v-300 h130q41 0 68 42t27 107t-28.5 108t-66.5 43h-130z" />
<glyph unicode="&#xe191;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 300h-100v400h-100v100h200v-500z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe192;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM300 700h200v-400h-300v500h100v-100zM900 300h-100v400h-100v100h200v-500zM300 600v-200h100v200h-100z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe193;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 500l-199 -200h-100v50l199 200v150h-200v100h300v-300zM900 300h-100v400h-100v100h200v-500zM701 300h-100 v100h100v-100z" />
<glyph unicode="&#xe194;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700h-300v-200h300v-100h-300l-100 100v200l100 100h300v-100z" />
<glyph unicode="&#xe195;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700v-100l-50 -50l100 -100v-50h-100l-100 100h-150v-100h-100v400h300zM500 700v-100h200v100h-200z" />
<glyph unicode="&#xe197;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -207t-85 -207t-205 -86.5h-128v250q0 21 -14.5 35.5t-35.5 14.5h-300q-21 0 -35.5 -14.5t-14.5 -35.5v-250h-222q-80 0 -136 57.5t-56 136.5q0 69 43 122.5t108 67.5q-2 19 -2 37q0 100 49 185 t134 134t185 49zM525 500h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -244q-13 -16 -32 -16t-32 16l-223 244q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe198;" d="M502 1089q110 0 201 -59.5t135 -156.5q43 15 89 15q121 0 206 -86.5t86 -206.5q0 -99 -60 -181t-150 -110l-378 360q-13 16 -31.5 16t-31.5 -16l-381 -365h-9q-79 0 -135.5 57.5t-56.5 136.5q0 69 43 122.5t108 67.5q-2 19 -2 38q0 100 49 184.5t133.5 134t184.5 49.5z M632 467l223 -228q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5q199 204 223 228q19 19 31.5 19t32.5 -19z" />
<glyph unicode="&#xe199;" d="M700 100v100h400l-270 300h170l-270 300h170l-300 333l-300 -333h170l-270 -300h170l-270 -300h400v-100h-50q-21 0 -35.5 -14.5t-14.5 -35.5v-50h400v50q0 21 -14.5 35.5t-35.5 14.5h-50z" />
<glyph unicode="&#xe200;" d="M600 1179q94 0 167.5 -56.5t99.5 -145.5q89 -6 150.5 -71.5t61.5 -155.5q0 -61 -29.5 -112.5t-79.5 -82.5q9 -29 9 -55q0 -74 -52.5 -126.5t-126.5 -52.5q-55 0 -100 30v-251q21 0 35.5 -14.5t14.5 -35.5v-50h-300v50q0 21 14.5 35.5t35.5 14.5v251q-45 -30 -100 -30 q-74 0 -126.5 52.5t-52.5 126.5q0 18 4 38q-47 21 -75.5 65t-28.5 97q0 74 52.5 126.5t126.5 52.5q5 0 23 -2q0 2 -1 10t-1 13q0 116 81.5 197.5t197.5 81.5z" />
<glyph unicode="&#xe201;" d="M1010 1010q111 -111 150.5 -260.5t0 -299t-150.5 -260.5q-83 -83 -191.5 -126.5t-218.5 -43.5t-218.5 43.5t-191.5 126.5q-111 111 -150.5 260.5t0 299t150.5 260.5q83 83 191.5 126.5t218.5 43.5t218.5 -43.5t191.5 -126.5zM476 1065q-4 0 -8 -1q-121 -34 -209.5 -122.5 t-122.5 -209.5q-4 -12 2.5 -23t18.5 -14l36 -9q3 -1 7 -1q23 0 29 22q27 96 98 166q70 71 166 98q11 3 17.5 13.5t3.5 22.5l-9 35q-3 13 -14 19q-7 4 -15 4zM512 920q-4 0 -9 -2q-80 -24 -138.5 -82.5t-82.5 -138.5q-4 -13 2 -24t19 -14l34 -9q4 -1 8 -1q22 0 28 21 q18 58 58.5 98.5t97.5 58.5q12 3 18 13.5t3 21.5l-9 35q-3 12 -14 19q-7 4 -15 4zM719.5 719.5q-49.5 49.5 -119.5 49.5t-119.5 -49.5t-49.5 -119.5t49.5 -119.5t119.5 -49.5t119.5 49.5t49.5 119.5t-49.5 119.5zM855 551q-22 0 -28 -21q-18 -58 -58.5 -98.5t-98.5 -57.5 q-11 -4 -17 -14.5t-3 -21.5l9 -35q3 -12 14 -19q7 -4 15 -4q4 0 9 2q80 24 138.5 82.5t82.5 138.5q4 13 -2.5 24t-18.5 14l-34 9q-4 1 -8 1zM1000 515q-23 0 -29 -22q-27 -96 -98 -166q-70 -71 -166 -98q-11 -3 -17.5 -13.5t-3.5 -22.5l9 -35q3 -13 14 -19q7 -4 15 -4 q4 0 8 1q121 34 209.5 122.5t122.5 209.5q4 12 -2.5 23t-18.5 14l-36 9q-3 1 -7 1z" />
<glyph unicode="&#xe202;" d="M700 800h300v-380h-180v200h-340v-200h-380v755q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM700 300h162l-212 -212l-212 212h162v200h100v-200zM520 0h-395q-10 0 -17.5 7.5t-7.5 17.5v395zM1000 220v-195q0 -10 -7.5 -17.5t-17.5 -7.5h-195z" />
<glyph unicode="&#xe203;" d="M700 800h300v-520l-350 350l-550 -550v1095q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM862 200h-162v-200h-100v200h-162l212 212zM480 0h-355q-10 0 -17.5 7.5t-7.5 17.5v55h380v-80zM1000 80v-55q0 -10 -7.5 -17.5t-17.5 -7.5h-155v80h180z" />
<glyph unicode="&#xe204;" d="M1162 800h-162v-200h100l100 -100h-300v300h-162l212 212zM200 800h200q27 0 40 -2t29.5 -10.5t23.5 -30t7 -57.5h300v-100h-600l-200 -350v450h100q0 36 7 57.5t23.5 30t29.5 10.5t40 2zM800 400h240l-240 -400h-800l300 500h500v-100z" />
<glyph unicode="&#xe205;" d="M650 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM1000 850v150q41 0 70.5 -29.5t29.5 -70.5v-800 q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-1 0 -20 4l246 246l-326 326v324q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM412 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe206;" d="M450 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM800 850v150q41 0 70.5 -29.5t29.5 -70.5v-500 h-200v-300h200q0 -36 -7 -57.5t-23.5 -30t-29.5 -10.5t-40 -2h-600q-41 0 -70.5 29.5t-29.5 70.5v800q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM1212 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe209;" d="M658 1197l637 -1104q23 -38 7 -65.5t-60 -27.5h-1276q-44 0 -60 27.5t7 65.5l637 1104q22 39 54 39t54 -39zM704 800h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM500 300v-100h200 v100h-200z" />
<glyph unicode="&#xe210;" d="M425 1100h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM825 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM25 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5zM425 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5 v150q0 10 7.5 17.5t17.5 7.5zM25 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe211;" d="M700 1200h100v-200h-100v-100h350q62 0 86.5 -39.5t-3.5 -94.5l-66 -132q-41 -83 -81 -134h-772q-40 51 -81 134l-66 132q-28 55 -3.5 94.5t86.5 39.5h350v100h-100v200h100v100h200v-100zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100 h-950l138 100h-13q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe212;" d="M600 1300q40 0 68.5 -29.5t28.5 -70.5h-194q0 41 28.5 70.5t68.5 29.5zM443 1100h314q18 -37 18 -75q0 -8 -3 -25h328q41 0 44.5 -16.5t-30.5 -38.5l-175 -145h-678l-178 145q-34 22 -29 38.5t46 16.5h328q-3 17 -3 25q0 38 18 75zM250 700h700q21 0 35.5 -14.5 t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-150v-200l275 -200h-950l275 200v200h-150q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe213;" d="M600 1181q75 0 128 -53t53 -128t-53 -128t-128 -53t-128 53t-53 128t53 128t128 53zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13 l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe214;" d="M600 1300q47 0 92.5 -53.5t71 -123t25.5 -123.5q0 -78 -55.5 -133.5t-133.5 -55.5t-133.5 55.5t-55.5 133.5q0 62 34 143l144 -143l111 111l-163 163q34 26 63 26zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45 zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe215;" d="M600 1200l300 -161v-139h-300q0 -57 18.5 -108t50 -91.5t63 -72t70 -67.5t57.5 -61h-530q-60 83 -90.5 177.5t-30.5 178.5t33 164.5t87.5 139.5t126 96.5t145.5 41.5v-98zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100 h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe216;" d="M600 1300q41 0 70.5 -29.5t29.5 -70.5v-78q46 -26 73 -72t27 -100v-50h-400v50q0 54 27 100t73 72v78q0 41 29.5 70.5t70.5 29.5zM400 800h400q54 0 100 -27t72 -73h-172v-100h200v-100h-200v-100h200v-100h-200v-100h200q0 -83 -58.5 -141.5t-141.5 -58.5h-400 q-83 0 -141.5 58.5t-58.5 141.5v400q0 83 58.5 141.5t141.5 58.5z" />
<glyph unicode="&#xe218;" d="M150 1100h900q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM125 400h950q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-283l224 -224q13 -13 13 -31.5t-13 -32 t-31.5 -13.5t-31.5 13l-88 88h-524l-87 -88q-13 -13 -32 -13t-32 13.5t-13 32t13 31.5l224 224h-289q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM541 300l-100 -100h324l-100 100h-124z" />
<glyph unicode="&#xe219;" d="M200 1100h800q83 0 141.5 -58.5t58.5 -141.5v-200h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100v200q0 83 58.5 141.5t141.5 58.5zM100 600h1000q41 0 70.5 -29.5 t29.5 -70.5v-300h-1200v300q0 41 29.5 70.5t70.5 29.5zM300 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200zM1100 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200z" />
<glyph unicode="&#xe221;" d="M480 1165l682 -683q31 -31 31 -75.5t-31 -75.5l-131 -131h-481l-517 518q-32 31 -32 75.5t32 75.5l295 296q31 31 75.5 31t76.5 -31zM108 794l342 -342l303 304l-341 341zM250 100h800q21 0 35.5 -14.5t14.5 -35.5v-50h-900v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe223;" d="M1057 647l-189 506q-8 19 -27.5 33t-40.5 14h-400q-21 0 -40.5 -14t-27.5 -33l-189 -506q-8 -19 1.5 -33t30.5 -14h625v-150q0 -21 14.5 -35.5t35.5 -14.5t35.5 14.5t14.5 35.5v150h125q21 0 30.5 14t1.5 33zM897 0h-595v50q0 21 14.5 35.5t35.5 14.5h50v50 q0 21 14.5 35.5t35.5 14.5h48v300h200v-300h47q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-50z" />
<glyph unicode="&#xe224;" d="M900 800h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-375v591l-300 300v84q0 10 7.5 17.5t17.5 7.5h375v-400zM1200 900h-200v200zM400 600h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-650q-10 0 -17.5 7.5t-7.5 17.5v950q0 10 7.5 17.5t17.5 7.5h375v-400zM700 700h-200v200z " />
<glyph unicode="&#xe225;" d="M484 1095h195q75 0 146 -32.5t124 -86t89.5 -122.5t48.5 -142q18 -14 35 -20q31 -10 64.5 6.5t43.5 48.5q10 34 -15 71q-19 27 -9 43q5 8 12.5 11t19 -1t23.5 -16q41 -44 39 -105q-3 -63 -46 -106.5t-104 -43.5h-62q-7 -55 -35 -117t-56 -100l-39 -234q-3 -20 -20 -34.5 t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l12 70q-49 -14 -91 -14h-195q-24 0 -65 8l-11 -64q-3 -20 -20 -34.5t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l26 157q-84 74 -128 175l-159 53q-19 7 -33 26t-14 40v50q0 21 14.5 35.5t35.5 14.5h124q11 87 56 166l-111 95 q-16 14 -12.5 23.5t24.5 9.5h203q116 101 250 101zM675 1000h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h250q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe226;" d="M641 900l423 247q19 8 42 2.5t37 -21.5l32 -38q14 -15 12.5 -36t-17.5 -34l-139 -120h-390zM50 1100h106q67 0 103 -17t66 -71l102 -212h823q21 0 35.5 -14.5t14.5 -35.5v-50q0 -21 -14 -40t-33 -26l-737 -132q-23 -4 -40 6t-26 25q-42 67 -100 67h-300q-62 0 -106 44 t-44 106v200q0 62 44 106t106 44zM173 928h-80q-19 0 -28 -14t-9 -35v-56q0 -51 42 -51h134q16 0 21.5 8t5.5 24q0 11 -16 45t-27 51q-18 28 -43 28zM550 727q-32 0 -54.5 -22.5t-22.5 -54.5t22.5 -54.5t54.5 -22.5t54.5 22.5t22.5 54.5t-22.5 54.5t-54.5 22.5zM130 389 l152 130q18 19 34 24t31 -3.5t24.5 -17.5t25.5 -28q28 -35 50.5 -51t48.5 -13l63 5l48 -179q13 -61 -3.5 -97.5t-67.5 -79.5l-80 -69q-47 -40 -109 -35.5t-103 51.5l-130 151q-40 47 -35.5 109.5t51.5 102.5zM380 377l-102 -88q-31 -27 2 -65l37 -43q13 -15 27.5 -19.5 t31.5 6.5l61 53q19 16 14 49q-2 20 -12 56t-17 45q-11 12 -19 14t-23 -8z" />
<glyph unicode="&#xe227;" d="M625 1200h150q10 0 17.5 -7.5t7.5 -17.5v-109q79 -33 131 -87.5t53 -128.5q1 -46 -15 -84.5t-39 -61t-46 -38t-39 -21.5l-17 -6q6 0 15 -1.5t35 -9t50 -17.5t53 -30t50 -45t35.5 -64t14.5 -84q0 -59 -11.5 -105.5t-28.5 -76.5t-44 -51t-49.5 -31.5t-54.5 -16t-49.5 -6.5 t-43.5 -1v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-100v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-175q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v600h-75q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5h175v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h100v75q0 10 7.5 17.5t17.5 7.5zM400 900v-200h263q28 0 48.5 10.5t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-263zM400 500v-200h363q28 0 48.5 10.5 t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-363z" />
<glyph unicode="&#xe230;" d="M212 1198h780q86 0 147 -61t61 -147v-416q0 -51 -18 -142.5t-36 -157.5l-18 -66q-29 -87 -93.5 -146.5t-146.5 -59.5h-572q-82 0 -147 59t-93 147q-8 28 -20 73t-32 143.5t-20 149.5v416q0 86 61 147t147 61zM600 1045q-70 0 -132.5 -11.5t-105.5 -30.5t-78.5 -41.5 t-57 -45t-36 -41t-20.5 -30.5l-6 -12l156 -243h560l156 243q-2 5 -6 12.5t-20 29.5t-36.5 42t-57 44.5t-79 42t-105 29.5t-132.5 12zM762 703h-157l195 261z" />
<glyph unicode="&#xe231;" d="M475 1300h150q103 0 189 -86t86 -189v-500q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe232;" d="M475 1300h96q0 -150 89.5 -239.5t239.5 -89.5v-446q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe233;" d="M1294 767l-638 -283l-378 170l-78 -60v-224l100 -150v-199l-150 148l-150 -149v200l100 150v250q0 4 -0.5 10.5t0 9.5t1 8t3 8t6.5 6l47 40l-147 65l642 283zM1000 380l-350 -166l-350 166v147l350 -165l350 165v-147z" />
<glyph unicode="&#xe234;" d="M250 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM650 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM1050 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe235;" d="M550 1100q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 700q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 300q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe236;" d="M125 1100h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM125 700h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM125 300h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe237;" d="M350 1200h500q162 0 256 -93.5t94 -256.5v-500q0 -165 -93.5 -257.5t-256.5 -92.5h-500q-165 0 -257.5 92.5t-92.5 257.5v500q0 165 92.5 257.5t257.5 92.5zM900 1000h-600q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h600q41 0 70.5 29.5 t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5zM350 900h500q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-500q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 14.5 35.5t35.5 14.5zM400 800v-200h400v200h-400z" />
<glyph unicode="&#xe238;" d="M150 1100h1000q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe239;" d="M650 1187q87 -67 118.5 -156t0 -178t-118.5 -155q-87 66 -118.5 155t0 178t118.5 156zM300 800q124 0 212 -88t88 -212q-124 0 -212 88t-88 212zM1000 800q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM300 500q124 0 212 -88t88 -212q-124 0 -212 88t-88 212z M1000 500q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM700 199v-144q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v142q40 -4 43 -4q17 0 57 6z" />
<glyph unicode="&#xe240;" d="M745 878l69 19q25 6 45 -12l298 -295q11 -11 15 -26.5t-2 -30.5q-5 -14 -18 -23.5t-28 -9.5h-8q1 0 1 -13q0 -29 -2 -56t-8.5 -62t-20 -63t-33 -53t-51 -39t-72.5 -14h-146q-184 0 -184 288q0 24 10 47q-20 4 -62 4t-63 -4q11 -24 11 -47q0 -288 -184 -288h-142 q-48 0 -84.5 21t-56 51t-32 71.5t-16 75t-3.5 68.5q0 13 2 13h-7q-15 0 -27.5 9.5t-18.5 23.5q-6 15 -2 30.5t15 25.5l298 296q20 18 46 11l76 -19q20 -5 30.5 -22.5t5.5 -37.5t-22.5 -31t-37.5 -5l-51 12l-182 -193h891l-182 193l-44 -12q-20 -5 -37.5 6t-22.5 31t6 37.5 t31 22.5z" />
<glyph unicode="&#xe241;" d="M1200 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM500 450h-25q0 15 -4 24.5t-9 14.5t-17 7.5t-20 3t-25 0.5h-100v-425q0 -11 12.5 -17.5t25.5 -7.5h12v-50h-200v50q50 0 50 25v425h-100q-17 0 -25 -0.5t-20 -3t-17 -7.5t-9 -14.5t-4 -24.5h-25v150h500v-150z" />
<glyph unicode="&#xe242;" d="M1000 300v50q-25 0 -55 32q-14 14 -25 31t-16 27l-4 11l-289 747h-69l-300 -754q-18 -35 -39 -56q-9 -9 -24.5 -18.5t-26.5 -14.5l-11 -5v-50h273v50q-49 0 -78.5 21.5t-11.5 67.5l69 176h293l61 -166q13 -34 -3.5 -66.5t-55.5 -32.5v-50h312zM412 691l134 342l121 -342 h-255zM1100 150v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe243;" d="M50 1200h1100q21 0 35.5 -14.5t14.5 -35.5v-1100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5zM611 1118h-70q-13 0 -18 -12l-299 -753q-17 -32 -35 -51q-18 -18 -56 -34q-12 -5 -12 -18v-50q0 -8 5.5 -14t14.5 -6 h273q8 0 14 6t6 14v50q0 8 -6 14t-14 6q-55 0 -71 23q-10 14 0 39l63 163h266l57 -153q11 -31 -6 -55q-12 -17 -36 -17q-8 0 -14 -6t-6 -14v-50q0 -8 6 -14t14 -6h313q8 0 14 6t6 14v50q0 7 -5.5 13t-13.5 7q-17 0 -42 25q-25 27 -40 63h-1l-288 748q-5 12 -19 12zM639 611 h-197l103 264z" />
<glyph unicode="&#xe244;" d="M1200 1100h-1200v100h1200v-100zM50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 1000h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM700 900v-300h300v300h-300z" />
<glyph unicode="&#xe245;" d="M50 1200h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 700h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM700 600v-300h300v300h-300zM1200 0h-1200v100h1200v-100z" />
<glyph unicode="&#xe246;" d="M50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-350h100v150q0 21 14.5 35.5t35.5 14.5h400q21 0 35.5 -14.5t14.5 -35.5v-150h100v-100h-100v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v150h-100v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM700 700v-300h300v300h-300z" />
<glyph unicode="&#xe247;" d="M100 0h-100v1200h100v-1200zM250 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM300 1000v-300h300v300h-300zM250 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe248;" d="M600 1100h150q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-100h450q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h350v100h-150q-21 0 -35.5 14.5 t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h150v100h100v-100zM400 1000v-300h300v300h-300z" />
<glyph unicode="&#xe249;" d="M1200 0h-100v1200h100v-1200zM550 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM600 1000v-300h300v300h-300zM50 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe250;" d="M865 565l-494 -494q-23 -23 -41 -23q-14 0 -22 13.5t-8 38.5v1000q0 25 8 38.5t22 13.5q18 0 41 -23l494 -494q14 -14 14 -35t-14 -35z" />
<glyph unicode="&#xe251;" d="M335 635l494 494q29 29 50 20.5t21 -49.5v-1000q0 -41 -21 -49.5t-50 20.5l-494 494q-14 14 -14 35t14 35z" />
<glyph unicode="&#xe252;" d="M100 900h1000q41 0 49.5 -21t-20.5 -50l-494 -494q-14 -14 -35 -14t-35 14l-494 494q-29 29 -20.5 50t49.5 21z" />
<glyph unicode="&#xe253;" d="M635 865l494 -494q29 -29 20.5 -50t-49.5 -21h-1000q-41 0 -49.5 21t20.5 50l494 494q14 14 35 14t35 -14z" />
<glyph unicode="&#xe254;" d="M700 741v-182l-692 -323v221l413 193l-413 193v221zM1200 0h-800v200h800v-200z" />
<glyph unicode="&#xe255;" d="M1200 900h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300zM0 700h50q0 21 4 37t9.5 26.5t18 17.5t22 11t28.5 5.5t31 2t37 0.5h100v-550q0 -22 -25 -34.5t-50 -13.5l-25 -2v-100h400v100q-4 0 -11 0.5t-24 3t-30 7t-24 15t-11 24.5v550h100q25 0 37 -0.5t31 -2 t28.5 -5.5t22 -11t18 -17.5t9.5 -26.5t4 -37h50v300h-800v-300z" />
<glyph unicode="&#xe256;" d="M800 700h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-100v-550q0 -22 25 -34.5t50 -14.5l25 -1v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v550h-100q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h800v-300zM1100 200h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300z" />
<glyph unicode="&#xe257;" d="M701 1098h160q16 0 21 -11t-7 -23l-464 -464l464 -464q12 -12 7 -23t-21 -11h-160q-13 0 -23 9l-471 471q-7 8 -7 18t7 18l471 471q10 9 23 9z" />
<glyph unicode="&#xe258;" d="M339 1098h160q13 0 23 -9l471 -471q7 -8 7 -18t-7 -18l-471 -471q-10 -9 -23 -9h-160q-16 0 -21 11t7 23l464 464l-464 464q-12 12 -7 23t21 11z" />
<glyph unicode="&#xe259;" d="M1087 882q11 -5 11 -21v-160q0 -13 -9 -23l-471 -471q-8 -7 -18 -7t-18 7l-471 471q-9 10 -9 23v160q0 16 11 21t23 -7l464 -464l464 464q12 12 23 7z" />
<glyph unicode="&#xe260;" d="M618 993l471 -471q9 -10 9 -23v-160q0 -16 -11 -21t-23 7l-464 464l-464 -464q-12 -12 -23 -7t-11 21v160q0 13 9 23l471 471q8 7 18 7t18 -7z" />
<glyph unicode="&#xf8ff;" d="M1000 1200q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM450 1000h100q21 0 40 -14t26 -33l79 -194q5 1 16 3q34 6 54 9.5t60 7t65.5 1t61 -10t56.5 -23t42.5 -42t29 -64t5 -92t-19.5 -121.5q-1 -7 -3 -19.5t-11 -50t-20.5 -73t-32.5 -81.5t-46.5 -83t-64 -70 t-82.5 -50q-13 -5 -42 -5t-65.5 2.5t-47.5 2.5q-14 0 -49.5 -3.5t-63 -3.5t-43.5 7q-57 25 -104.5 78.5t-75 111.5t-46.5 112t-26 90l-7 35q-15 63 -18 115t4.5 88.5t26 64t39.5 43.5t52 25.5t58.5 13t62.5 2t59.5 -4.5t55.5 -8l-147 192q-12 18 -5.5 30t27.5 12z" />
<glyph unicode="&#x1f511;" d="M250 1200h600q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-500l-255 -178q-19 -9 -32 -1t-13 29v650h-150q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM400 1100v-100h300v100h-300z" />
<glyph unicode="&#x1f6aa;" d="M250 1200h750q39 0 69.5 -40.5t30.5 -84.5v-933l-700 -117v950l600 125h-700v-1000h-100v1025q0 23 15.5 49t34.5 26zM500 525v-100l100 20v100z" />
</font>
</defs></svg> ) format('svg')}.glyphicon{position:relative;top:1px;display:inline-block;font-family:'Glyphicons Halflings';font-style:normal;font-weight:400;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.glyphicon-asterisk:before{content:"\2a"}.glyphicon-plus:before{content:"\2b"}.glyphicon-eur:before,.glyphicon-euro:before{content:"\20ac"}.glyphicon-minus:before{content:"\2212"}.glyphicon-cloud:before{content:"\2601"}.glyphicon-envelope:before{content:"\2709"}.glyphicon-pencil:before{content:"\270f"}.glyphicon-glass:before{content:"\e001"}.glyphicon-music:before{content:"\e002"}.glyphicon-search:before{content:"\e003"}.glyphicon-heart:before{content:"\e005"}.glyphicon-star:before{content:"\e006"}.glyphicon-star-empty:before{content:"\e007"}.glyphicon-user:before{content:"\e008"}.glyphicon-film:before{content:"\e009"}.glyphicon-th-large:before{content:"\e010"}.glyphicon-th:before{content:"\e011"}.glyphicon-th-list:before{content:"\e012"}.glyphicon-ok:before{content:"\e013"}.glyphicon-remove:before{content:"\e014"}.glyphicon-zoom-in:before{content:"\e015"}.glyphicon-zoom-out:before{content:"\e016"}.glyphicon-off:before{content:"\e017"}.glyphicon-signal:before{content:"\e018"}.glyphicon-cog:before{content:"\e019"}.glyphicon-trash:before{content:"\e020"}.glyphicon-home:before{content:"\e021"}.glyphicon-file:before{content:"\e022"}.glyphicon-time:before{content:"\e023"}.glyphicon-road:before{content:"\e024"}.glyphicon-download-alt:before{content:"\e025"}.glyphicon-download:before{content:"\e026"}.glyphicon-upload:before{content:"\e027"}.glyphicon-inbox:before{content:"\e028"}.glyphicon-play-circle:before{content:"\e029"}.glyphicon-repeat:before{content:"\e030"}.glyphicon-refresh:before{content:"\e031"}.glyphicon-list-alt:before{content:"\e032"}.glyphicon-lock:before{content:"\e033"}.glyphicon-flag:before{content:"\e034"}.glyphicon-headphones:before{content:"\e035"}.glyphicon-volume-off:before{content:"\e036"}.glyphicon-volume-down:before{content:"\e037"}.glyphicon-volume-up:before{content:"\e038"}.glyphicon-qrcode:before{content:"\e039"}.glyphicon-barcode:before{content:"\e040"}.glyphicon-tag:before{content:"\e041"}.glyphicon-tags:before{content:"\e042"}.glyphicon-book:before{content:"\e043"}.glyphicon-bookmark:before{content:"\e044"}.glyphicon-print:before{content:"\e045"}.glyphicon-camera:before{content:"\e046"}.glyphicon-font:before{content:"\e047"}.glyphicon-bold:before{content:"\e048"}.glyphicon-italic:before{content:"\e049"}.glyphicon-text-height:before{content:"\e050"}.glyphicon-text-width:before{content:"\e051"}.glyphicon-align-left:before{content:"\e052"}.glyphicon-align-center:before{content:"\e053"}.glyphicon-align-right:before{content:"\e054"}.glyphicon-align-justify:before{content:"\e055"}.glyphicon-list:before{content:"\e056"}.glyphicon-indent-left:before{content:"\e057"}.glyphicon-indent-right:before{content:"\e058"}.glyphicon-facetime-video:before{content:"\e059"}.glyphicon-picture:before{content:"\e060"}.glyphicon-map-marker:before{content:"\e062"}.glyphicon-adjust:before{content:"\e063"}.glyphicon-tint:before{content:"\e064"}.glyphicon-edit:before{content:"\e065"}.glyphicon-share:before{content:"\e066"}.glyphicon-check:before{content:"\e067"}.glyphicon-move:before{content:"\e068"}.glyphicon-step-backward:before{content:"\e069"}.glyphicon-fast-backward:before{content:"\e070"}.glyphicon-backward:before{content:"\e071"}.glyphicon-play:before{content:"\e072"}.glyphicon-pause:before{content:"\e073"}.glyphicon-stop:before{content:"\e074"}.glyphicon-forward:before{content:"\e075"}.glyphicon-fast-forward:before{content:"\e076"}.glyphicon-step-forward:before{content:"\e077"}.glyphicon-eject:before{content:"\e078"}.glyphicon-chevron-left:before{content:"\e079"}.glyphicon-chevron-right:before{content:"\e080"}.glyphicon-plus-sign:before{content:"\e081"}.glyphicon-minus-sign:before{content:"\e082"}.glyphicon-remove-sign:before{content:"\e083"}.glyphicon-ok-sign:before{content:"\e084"}.glyphicon-question-sign:before{content:"\e085"}.glyphicon-info-sign:before{content:"\e086"}.glyphicon-screenshot:before{content:"\e087"}.glyphicon-remove-circle:before{content:"\e088"}.glyphicon-ok-circle:before{content:"\e089"}.glyphicon-ban-circle:before{content:"\e090"}.glyphicon-arrow-left:before{content:"\e091"}.glyphicon-arrow-right:before{content:"\e092"}.glyphicon-arrow-up:before{content:"\e093"}.glyphicon-arrow-down:before{content:"\e094"}.glyphicon-share-alt:before{content:"\e095"}.glyphicon-resize-full:before{content:"\e096"}.glyphicon-resize-small:before{content:"\e097"}.glyphicon-exclamation-sign:before{content:"\e101"}.glyphicon-gift:before{content:"\e102"}.glyphicon-leaf:before{content:"\e103"}.glyphicon-fire:before{content:"\e104"}.glyphicon-eye-open:before{content:"\e105"}.glyphicon-eye-close:before{content:"\e106"}.glyphicon-warning-sign:before{content:"\e107"}.glyphicon-plane:before{content:"\e108"}.glyphicon-calendar:before{content:"\e109"}.glyphicon-random:before{content:"\e110"}.glyphicon-comment:before{content:"\e111"}.glyphicon-magnet:before{content:"\e112"}.glyphicon-chevron-up:before{content:"\e113"}.glyphicon-chevron-down:before{content:"\e114"}.glyphicon-retweet:before{content:"\e115"}.glyphicon-shopping-cart:before{content:"\e116"}.glyphicon-folder-close:before{content:"\e117"}.glyphicon-folder-open:before{content:"\e118"}.glyphicon-resize-vertical:before{content:"\e119"}.glyphicon-resize-horizontal:before{content:"\e120"}.glyphicon-hdd:before{content:"\e121"}.glyphicon-bullhorn:before{content:"\e122"}.glyphicon-bell:before{content:"\e123"}.glyphicon-certificate:before{content:"\e124"}.glyphicon-thumbs-up:before{content:"\e125"}.glyphicon-thumbs-down:before{content:"\e126"}.glyphicon-hand-right:before{content:"\e127"}.glyphicon-hand-left:before{content:"\e128"}.glyphicon-hand-up:before{content:"\e129"}.glyphicon-hand-down:before{content:"\e130"}.glyphicon-circle-arrow-right:before{content:"\e131"}.glyphicon-circle-arrow-left:before{content:"\e132"}.glyphicon-circle-arrow-up:before{content:"\e133"}.glyphicon-circle-arrow-down:before{content:"\e134"}.glyphicon-globe:before{content:"\e135"}.glyphicon-wrench:before{content:"\e136"}.glyphicon-tasks:before{content:"\e137"}.glyphicon-filter:before{content:"\e138"}.glyphicon-briefcase:before{content:"\e139"}.glyphicon-fullscreen:before{content:"\e140"}.glyphicon-dashboard:before{content:"\e141"}.glyphicon-paperclip:before{content:"\e142"}.glyphicon-heart-empty:before{content:"\e143"}.glyphicon-link:before{content:"\e144"}.glyphicon-phone:before{content:"\e145"}.glyphicon-pushpin:before{content:"\e146"}.glyphicon-usd:before{content:"\e148"}.glyphicon-gbp:before{content:"\e149"}.glyphicon-sort:before{content:"\e150"}.glyphicon-sort-by-alphabet:before{content:"\e151"}.glyphicon-sort-by-alphabet-alt:before{content:"\e152"}.glyphicon-sort-by-order:before{content:"\e153"}.glyphicon-sort-by-order-alt:before{content:"\e154"}.glyphicon-sort-by-attributes:before{content:"\e155"}.glyphicon-sort-by-attributes-alt:before{content:"\e156"}.glyphicon-unchecked:before{content:"\e157"}.glyphicon-expand:before{content:"\e158"}.glyphicon-collapse-down:before{content:"\e159"}.glyphicon-collapse-up:before{content:"\e160"}.glyphicon-log-in:before{content:"\e161"}.glyphicon-flash:before{content:"\e162"}.glyphicon-log-out:before{content:"\e163"}.glyphicon-new-window:before{content:"\e164"}.glyphicon-record:before{content:"\e165"}.glyphicon-save:before{content:"\e166"}.glyphicon-open:before{content:"\e167"}.glyphicon-saved:before{content:"\e168"}.glyphicon-import:before{content:"\e169"}.glyphicon-export:before{content:"\e170"}.glyphicon-send:before{content:"\e171"}.glyphicon-floppy-disk:before{content:"\e172"}.glyphicon-floppy-saved:before{content:"\e173"}.glyphicon-floppy-remove:before{content:"\e174"}.glyphicon-floppy-save:before{content:"\e175"}.glyphicon-floppy-open:before{content:"\e176"}.glyphicon-credit-card:before{content:"\e177"}.glyphicon-transfer:before{content:"\e178"}.glyphicon-cutlery:before{content:"\e179"}.glyphicon-header:before{content:"\e180"}.glyphicon-compressed:before{content:"\e181"}.glyphicon-earphone:before{content:"\e182"}.glyphicon-phone-alt:before{content:"\e183"}.glyphicon-tower:before{content:"\e184"}.glyphicon-stats:before{content:"\e185"}.glyphicon-sd-video:before{content:"\e186"}.glyphicon-hd-video:before{content:"\e187"}.glyphicon-subtitles:before{content:"\e188"}.glyphicon-sound-stereo:before{content:"\e189"}.glyphicon-sound-dolby:before{content:"\e190"}.glyphicon-sound-5-1:before{content:"\e191"}.glyphicon-sound-6-1:before{content:"\e192"}.glyphicon-sound-7-1:before{content:"\e193"}.glyphicon-copyright-mark:before{content:"\e194"}.glyphicon-registration-mark:before{content:"\e195"}.glyphicon-cloud-download:before{content:"\e197"}.glyphicon-cloud-upload:before{content:"\e198"}.glyphicon-tree-conifer:before{content:"\e199"}.glyphicon-tree-deciduous:before{content:"\e200"}.glyphicon-cd:before{content:"\e201"}.glyphicon-save-file:before{content:"\e202"}.glyphicon-open-file:before{content:"\e203"}.glyphicon-level-up:before{content:"\e204"}.glyphicon-copy:before{content:"\e205"}.glyphicon-paste:before{content:"\e206"}.glyphicon-alert:before{content:"\e209"}.glyphicon-equalizer:before{content:"\e210"}.glyphicon-king:before{content:"\e211"}.glyphicon-queen:before{content:"\e212"}.glyphicon-pawn:before{content:"\e213"}.glyphicon-bishop:before{content:"\e214"}.glyphicon-knight:before{content:"\e215"}.glyphicon-baby-formula:before{content:"\e216"}.glyphicon-tent:before{content:"\26fa"}.glyphicon-blackboard:before{content:"\e218"}.glyphicon-bed:before{content:"\e219"}.glyphicon-apple:before{content:"\f8ff"}.glyphicon-erase:before{content:"\e221"}.glyphicon-hourglass:before{content:"\231b"}.glyphicon-lamp:before{content:"\e223"}.glyphicon-duplicate:before{content:"\e224"}.glyphicon-piggy-bank:before{content:"\e225"}.glyphicon-scissors:before{content:"\e226"}.glyphicon-bitcoin:before{content:"\e227"}.glyphicon-btc:before{content:"\e227"}.glyphicon-xbt:before{content:"\e227"}.glyphicon-yen:before{content:"\00a5"}.glyphicon-jpy:before{content:"\00a5"}.glyphicon-ruble:before{content:"\20bd"}.glyphicon-rub:before{content:"\20bd"}.glyphicon-scale:before{content:"\e230"}.glyphicon-ice-lolly:before{content:"\e231"}.glyphicon-ice-lolly-tasted:before{content:"\e232"}.glyphicon-education:before{content:"\e233"}.glyphicon-option-horizontal:before{content:"\e234"}.glyphicon-option-vertical:before{content:"\e235"}.glyphicon-menu-hamburger:before{content:"\e236"}.glyphicon-modal-window:before{content:"\e237"}.glyphicon-oil:before{content:"\e238"}.glyphicon-grain:before{content:"\e239"}.glyphicon-sunglasses:before{content:"\e240"}.glyphicon-text-size:before{content:"\e241"}.glyphicon-text-color:before{content:"\e242"}.glyphicon-text-background:before{content:"\e243"}.glyphicon-object-align-top:before{content:"\e244"}.glyphicon-object-align-bottom:before{content:"\e245"}.glyphicon-object-align-horizontal:before{content:"\e246"}.glyphicon-object-align-left:before{content:"\e247"}.glyphicon-object-align-vertical:before{content:"\e248"}.glyphicon-object-align-right:before{content:"\e249"}.glyphicon-triangle-right:before{content:"\e250"}.glyphicon-triangle-left:before{content:"\e251"}.glyphicon-triangle-bottom:before{content:"\e252"}.glyphicon-triangle-top:before{content:"\e253"}.glyphicon-console:before{content:"\e254"}.glyphicon-superscript:before{content:"\e255"}.glyphicon-subscript:before{content:"\e256"}.glyphicon-menu-left:before{content:"\e257"}.glyphicon-menu-right:before{content:"\e258"}.glyphicon-menu-down:before{content:"\e259"}.glyphicon-menu-up:before{content:"\e260"}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:rgba(0,0,0,0)}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}button,input,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}figure{margin:0}img{vertical-align:middle}.carousel-inner>.item>a>img,.carousel-inner>.item>img,.img-responsive,.thumbnail a>img,.thumbnail>img{display:block;max-width:100%;height:auto}.img-rounded{border-radius:6px}.img-thumbnail{display:inline-block;max-width:100%;height:auto;padding:4px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:all .2s ease-in-out;-o-transition:all .2s ease-in-out;transition:all .2s ease-in-out}.img-circle{border-radius:50%}hr{margin-top:20px;margin-bottom:20px;border:0;border-top:1px solid #eee}.sr-only{position:absolute;width:1px;height:1px;padding:0;margin:-1px;overflow:hidden;clip:rect(0,0,0,0);border:0}.sr-only-focusable:active,.sr-only-focusable:focus{position:static;width:auto;height:auto;margin:0;overflow:visible;clip:auto}[role=button]{cursor:pointer}.h1,.h2,.h3,.h4,.h5,.h6,h1,h2,h3,h4,h5,h6{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-weight:400;line-height:1;color:#777}.h1,.h2,.h3,h1,h2,h3{margin-top:20px;margin-bottom:10px}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small{font-size:65%}.h4,.h5,.h6,h4,h5,h6{margin-top:10px;margin-bottom:10px}.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-size:75%}.h1,h1{font-size:36px}.h2,h2{font-size:30px}.h3,h3{font-size:24px}.h4,h4{font-size:18px}.h5,h5{font-size:14px}.h6,h6{font-size:12px}p{margin:0 0 10px}.lead{margin-bottom:20px;font-size:16px;font-weight:300;line-height:1.4}@media (min-width:768px){.lead{font-size:21px}}.small,small{font-size:85%}.mark,mark{padding:.2em;background-color:#fcf8e3}.text-left{text-align:left}.text-right{text-align:right}.text-center{text-align:center}.text-justify{text-align:justify}.text-nowrap{white-space:nowrap}.text-lowercase{text-transform:lowercase}.text-uppercase{text-transform:uppercase}.text-capitalize{text-transform:capitalize}.text-muted{color:#777}.text-primary{color:#337ab7}a.text-primary:focus,a.text-primary:hover{color:#286090}.text-success{color:#3c763d}a.text-success:focus,a.text-success:hover{color:#2b542c}.text-info{color:#31708f}a.text-info:focus,a.text-info:hover{color:#245269}.text-warning{color:#8a6d3b}a.text-warning:focus,a.text-warning:hover{color:#66512c}.text-danger{color:#a94442}a.text-danger:focus,a.text-danger:hover{color:#843534}.bg-primary{color:#fff;background-color:#337ab7}a.bg-primary:focus,a.bg-primary:hover{background-color:#286090}.bg-success{background-color:#dff0d8}a.bg-success:focus,a.bg-success:hover{background-color:#c1e2b3}.bg-info{background-color:#d9edf7}a.bg-info:focus,a.bg-info:hover{background-color:#afd9ee}.bg-warning{background-color:#fcf8e3}a.bg-warning:focus,a.bg-warning:hover{background-color:#f7ecb5}.bg-danger{background-color:#f2dede}a.bg-danger:focus,a.bg-danger:hover{background-color:#e4b9b9}.page-header{padding-bottom:9px;margin:40px 0 20px;border-bottom:1px solid #eee}ol,ul{margin-top:0;margin-bottom:10px}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}.list-unstyled{padding-left:0;list-style:none}.list-inline{padding-left:0;margin-left:-5px;list-style:none}.list-inline>li{display:inline-block;padding-right:5px;padding-left:5px}dl{margin-top:0;margin-bottom:20px}dd,dt{line-height:1.42857143}dt{font-weight:700}dd{margin-left:0}@media (min-width:768px){.dl-horizontal dt{float:left;width:160px;overflow:hidden;clear:left;text-align:right;text-overflow:ellipsis;white-space:nowrap}.dl-horizontal dd{margin-left:180px}}abbr[data-original-title],abbr[title]{cursor:help;border-bottom:1px dotted #777}.initialism{font-size:90%;text-transform:uppercase}blockquote{padding:10px 20px;margin:0 0 20px;font-size:17.5px;border-left:5px solid #eee}blockquote ol:last-child,blockquote p:last-child,blockquote ul:last-child{margin-bottom:0}blockquote .small,blockquote footer,blockquote small{display:block;font-size:80%;line-height:1.42857143;color:#777}blockquote .small:before,blockquote footer:before,blockquote small:before{content:'\2014 \00A0'}.blockquote-reverse,blockquote.pull-right{padding-right:15px;padding-left:0;text-align:right;border-right:5px solid #eee;border-left:0}.blockquote-reverse .small:before,.blockquote-reverse footer:before,.blockquote-reverse small:before,blockquote.pull-right .small:before,blockquote.pull-right footer:before,blockquote.pull-right small:before{content:''}.blockquote-reverse .small:after,.blockquote-reverse footer:after,.blockquote-reverse small:after,blockquote.pull-right .small:after,blockquote.pull-right footer:after,blockquote.pull-right small:after{content:'\00A0 \2014'}address{margin-bottom:20px;font-style:normal;line-height:1.42857143}code,kbd,pre,samp{font-family:monospace}code{padding:2px 4px;font-size:90%;color:#c7254e;background-color:#f9f2f4;border-radius:4px}kbd{padding:2px 4px;font-size:90%;color:#fff;background-color:#333;border-radius:3px;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.25);box-shadow:inset 0 -1px 0 rgba(0,0,0,.25)}kbd kbd{padding:0;font-size:100%;font-weight:700;-webkit-box-shadow:none;box-shadow:none}pre{display:block;padding:9.5px;margin:0 0 10px;font-size:13px;line-height:1.42857143;color:#333;word-break:break-all;word-wrap:break-word;background-color:#f5f5f5;border:1px solid #ccc;border-radius:4px}pre code{padding:0;font-size:inherit;color:inherit;white-space:pre-wrap;background-color:transparent;border-radius:0}.pre-scrollable{max-height:340px;overflow-y:scroll}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9,.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9,.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9,.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{position:relative;min-height:1px;padding-right:15px;padding-left:15px}.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{float:left}.col-xs-12{width:100%}.col-xs-11{width:91.66666667%}.col-xs-10{width:83.33333333%}.col-xs-9{width:75%}.col-xs-8{width:66.66666667%}.col-xs-7{width:58.33333333%}.col-xs-6{width:50%}.col-xs-5{width:41.66666667%}.col-xs-4{width:33.33333333%}.col-xs-3{width:25%}.col-xs-2{width:16.66666667%}.col-xs-1{width:8.33333333%}.col-xs-pull-12{right:100%}.col-xs-pull-11{right:91.66666667%}.col-xs-pull-10{right:83.33333333%}.col-xs-pull-9{right:75%}.col-xs-pull-8{right:66.66666667%}.col-xs-pull-7{right:58.33333333%}.col-xs-pull-6{right:50%}.col-xs-pull-5{right:41.66666667%}.col-xs-pull-4{right:33.33333333%}.col-xs-pull-3{right:25%}.col-xs-pull-2{right:16.66666667%}.col-xs-pull-1{right:8.33333333%}.col-xs-pull-0{right:auto}.col-xs-push-12{left:100%}.col-xs-push-11{left:91.66666667%}.col-xs-push-10{left:83.33333333%}.col-xs-push-9{left:75%}.col-xs-push-8{left:66.66666667%}.col-xs-push-7{left:58.33333333%}.col-xs-push-6{left:50%}.col-xs-push-5{left:41.66666667%}.col-xs-push-4{left:33.33333333%}.col-xs-push-3{left:25%}.col-xs-push-2{left:16.66666667%}.col-xs-push-1{left:8.33333333%}.col-xs-push-0{left:auto}.col-xs-offset-12{margin-left:100%}.col-xs-offset-11{margin-left:91.66666667%}.col-xs-offset-10{margin-left:83.33333333%}.col-xs-offset-9{margin-left:75%}.col-xs-offset-8{margin-left:66.66666667%}.col-xs-offset-7{margin-left:58.33333333%}.col-xs-offset-6{margin-left:50%}.col-xs-offset-5{margin-left:41.66666667%}.col-xs-offset-4{margin-left:33.33333333%}.col-xs-offset-3{margin-left:25%}.col-xs-offset-2{margin-left:16.66666667%}.col-xs-offset-1{margin-left:8.33333333%}.col-xs-offset-0{margin-left:0}@media (min-width:768px){.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9{float:left}.col-sm-12{width:100%}.col-sm-11{width:91.66666667%}.col-sm-10{width:83.33333333%}.col-sm-9{width:75%}.col-sm-8{width:66.66666667%}.col-sm-7{width:58.33333333%}.col-sm-6{width:50%}.col-sm-5{width:41.66666667%}.col-sm-4{width:33.33333333%}.col-sm-3{width:25%}.col-sm-2{width:16.66666667%}.col-sm-1{width:8.33333333%}.col-sm-pull-12{right:100%}.col-sm-pull-11{right:91.66666667%}.col-sm-pull-10{right:83.33333333%}.col-sm-pull-9{right:75%}.col-sm-pull-8{right:66.66666667%}.col-sm-pull-7{right:58.33333333%}.col-sm-pull-6{right:50%}.col-sm-pull-5{right:41.66666667%}.col-sm-pull-4{right:33.33333333%}.col-sm-pull-3{right:25%}.col-sm-pull-2{right:16.66666667%}.col-sm-pull-1{right:8.33333333%}.col-sm-pull-0{right:auto}.col-sm-push-12{left:100%}.col-sm-push-11{left:91.66666667%}.col-sm-push-10{left:83.33333333%}.col-sm-push-9{left:75%}.col-sm-push-8{left:66.66666667%}.col-sm-push-7{left:58.33333333%}.col-sm-push-6{left:50%}.col-sm-push-5{left:41.66666667%}.col-sm-push-4{left:33.33333333%}.col-sm-push-3{left:25%}.col-sm-push-2{left:16.66666667%}.col-sm-push-1{left:8.33333333%}.col-sm-push-0{left:auto}.col-sm-offset-12{margin-left:100%}.col-sm-offset-11{margin-left:91.66666667%}.col-sm-offset-10{margin-left:83.33333333%}.col-sm-offset-9{margin-left:75%}.col-sm-offset-8{margin-left:66.66666667%}.col-sm-offset-7{margin-left:58.33333333%}.col-sm-offset-6{margin-left:50%}.col-sm-offset-5{margin-left:41.66666667%}.col-sm-offset-4{margin-left:33.33333333%}.col-sm-offset-3{margin-left:25%}.col-sm-offset-2{margin-left:16.66666667%}.col-sm-offset-1{margin-left:8.33333333%}.col-sm-offset-0{margin-left:0}}@media (min-width:992px){.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9{float:left}.col-md-12{width:100%}.col-md-11{width:91.66666667%}.col-md-10{width:83.33333333%}.col-md-9{width:75%}.col-md-8{width:66.66666667%}.col-md-7{width:58.33333333%}.col-md-6{width:50%}.col-md-5{width:41.66666667%}.col-md-4{width:33.33333333%}.col-md-3{width:25%}.col-md-2{width:16.66666667%}.col-md-1{width:8.33333333%}.col-md-pull-12{right:100%}.col-md-pull-11{right:91.66666667%}.col-md-pull-10{right:83.33333333%}.col-md-pull-9{right:75%}.col-md-pull-8{right:66.66666667%}.col-md-pull-7{right:58.33333333%}.col-md-pull-6{right:50%}.col-md-pull-5{right:41.66666667%}.col-md-pull-4{right:33.33333333%}.col-md-pull-3{right:25%}.col-md-pull-2{right:16.66666667%}.col-md-pull-1{right:8.33333333%}.col-md-pull-0{right:auto}.col-md-push-12{left:100%}.col-md-push-11{left:91.66666667%}.col-md-push-10{left:83.33333333%}.col-md-push-9{left:75%}.col-md-push-8{left:66.66666667%}.col-md-push-7{left:58.33333333%}.col-md-push-6{left:50%}.col-md-push-5{left:41.66666667%}.col-md-push-4{left:33.33333333%}.col-md-push-3{left:25%}.col-md-push-2{left:16.66666667%}.col-md-push-1{left:8.33333333%}.col-md-push-0{left:auto}.col-md-offset-12{margin-left:100%}.col-md-offset-11{margin-left:91.66666667%}.col-md-offset-10{margin-left:83.33333333%}.col-md-offset-9{margin-left:75%}.col-md-offset-8{margin-left:66.66666667%}.col-md-offset-7{margin-left:58.33333333%}.col-md-offset-6{margin-left:50%}.col-md-offset-5{margin-left:41.66666667%}.col-md-offset-4{margin-left:33.33333333%}.col-md-offset-3{margin-left:25%}.col-md-offset-2{margin-left:16.66666667%}.col-md-offset-1{margin-left:8.33333333%}.col-md-offset-0{margin-left:0}}@media (min-width:1200px){.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9{float:left}.col-lg-12{width:100%}.col-lg-11{width:91.66666667%}.col-lg-10{width:83.33333333%}.col-lg-9{width:75%}.col-lg-8{width:66.66666667%}.col-lg-7{width:58.33333333%}.col-lg-6{width:50%}.col-lg-5{width:41.66666667%}.col-lg-4{width:33.33333333%}.col-lg-3{width:25%}.col-lg-2{width:16.66666667%}.col-lg-1{width:8.33333333%}.col-lg-pull-12{right:100%}.col-lg-pull-11{right:91.66666667%}.col-lg-pull-10{right:83.33333333%}.col-lg-pull-9{right:75%}.col-lg-pull-8{right:66.66666667%}.col-lg-pull-7{right:58.33333333%}.col-lg-pull-6{right:50%}.col-lg-pull-5{right:41.66666667%}.col-lg-pull-4{right:33.33333333%}.col-lg-pull-3{right:25%}.col-lg-pull-2{right:16.66666667%}.col-lg-pull-1{right:8.33333333%}.col-lg-pull-0{right:auto}.col-lg-push-12{left:100%}.col-lg-push-11{left:91.66666667%}.col-lg-push-10{left:83.33333333%}.col-lg-push-9{left:75%}.col-lg-push-8{left:66.66666667%}.col-lg-push-7{left:58.33333333%}.col-lg-push-6{left:50%}.col-lg-push-5{left:41.66666667%}.col-lg-push-4{left:33.33333333%}.col-lg-push-3{left:25%}.col-lg-push-2{left:16.66666667%}.col-lg-push-1{left:8.33333333%}.col-lg-push-0{left:auto}.col-lg-offset-12{margin-left:100%}.col-lg-offset-11{margin-left:91.66666667%}.col-lg-offset-10{margin-left:83.33333333%}.col-lg-offset-9{margin-left:75%}.col-lg-offset-8{margin-left:66.66666667%}.col-lg-offset-7{margin-left:58.33333333%}.col-lg-offset-6{margin-left:50%}.col-lg-offset-5{margin-left:41.66666667%}.col-lg-offset-4{margin-left:33.33333333%}.col-lg-offset-3{margin-left:25%}.col-lg-offset-2{margin-left:16.66666667%}.col-lg-offset-1{margin-left:8.33333333%}.col-lg-offset-0{margin-left:0}}table{background-color:transparent}caption{padding-top:8px;padding-bottom:8px;color:#777;text-align:left}th{}.table{width:100%;max-width:100%;margin-bottom:20px}.table>tbody>tr>td,.table>tbody>tr>th,.table>tfoot>tr>td,.table>tfoot>tr>th,.table>thead>tr>td,.table>thead>tr>th{padding:8px;line-height:1.42857143;vertical-align:top;border-top:1px solid #ddd}.table>thead>tr>th{vertical-align:bottom;border-bottom:2px solid #ddd}.table>caption+thead>tr:first-child>td,.table>caption+thead>tr:first-child>th,.table>colgroup+thead>tr:first-child>td,.table>colgroup+thead>tr:first-child>th,.table>thead:first-child>tr:first-child>td,.table>thead:first-child>tr:first-child>th{border-top:0}.table>tbody+tbody{border-top:2px solid #ddd}.table .table{background-color:#fff}.table-condensed>tbody>tr>td,.table-condensed>tbody>tr>th,.table-condensed>tfoot>tr>td,.table-condensed>tfoot>tr>th,.table-condensed>thead>tr>td,.table-condensed>thead>tr>th{padding:5px}.table-bordered{border:1px solid #ddd}.table-bordered>tbody>tr>td,.table-bordered>tbody>tr>th,.table-bordered>tfoot>tr>td,.table-bordered>tfoot>tr>th,.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border:1px solid #ddd}.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border-bottom-width:2px}.table-striped>tbody>tr:nth-of-type(odd){background-color:#f9f9f9}.table-hover>tbody>tr:hover{background-color:#f5f5f5}table col[class*=col-]{position:static;display:table-column;float:none}table td[class*=col-],table th[class*=col-]{position:static;display:table-cell;float:none}.table>tbody>tr.active>td,.table>tbody>tr.active>th,.table>tbody>tr>td.active,.table>tbody>tr>th.active,.table>tfoot>tr.active>td,.table>tfoot>tr.active>th,.table>tfoot>tr>td.active,.table>tfoot>tr>th.active,.table>thead>tr.active>td,.table>thead>tr.active>th,.table>thead>tr>td.active,.table>thead>tr>th.active{background-color:#f5f5f5}.table-hover>tbody>tr.active:hover>td,.table-hover>tbody>tr.active:hover>th,.table-hover>tbody>tr:hover>.active,.table-hover>tbody>tr>td.active:hover,.table-hover>tbody>tr>th.active:hover{background-color:#e8e8e8}.table>tbody>tr.success>td,.table>tbody>tr.success>th,.table>tbody>tr>td.success,.table>tbody>tr>th.success,.table>tfoot>tr.success>td,.table>tfoot>tr.success>th,.table>tfoot>tr>td.success,.table>tfoot>tr>th.success,.table>thead>tr.success>td,.table>thead>tr.success>th,.table>thead>tr>td.success,.table>thead>tr>th.success{background-color:#dff0d8}.table-hover>tbody>tr.success:hover>td,.table-hover>tbody>tr.success:hover>th,.table-hover>tbody>tr:hover>.success,.table-hover>tbody>tr>td.success:hover,.table-hover>tbody>tr>th.success:hover{background-color:#d0e9c6}.table>tbody>tr.info>td,.table>tbody>tr.info>th,.table>tbody>tr>td.info,.table>tbody>tr>th.info,.table>tfoot>tr.info>td,.table>tfoot>tr.info>th,.table>tfoot>tr>td.info,.table>tfoot>tr>th.info,.table>thead>tr.info>td,.table>thead>tr.info>th,.table>thead>tr>td.info,.table>thead>tr>th.info{background-color:#d9edf7}.table-hover>tbody>tr.info:hover>td,.table-hover>tbody>tr.info:hover>th,.table-hover>tbody>tr:hover>.info,.table-hover>tbody>tr>td.info:hover,.table-hover>tbody>tr>th.info:hover{background-color:#c4e3f3}.table>tbody>tr.warning>td,.table>tbody>tr.warning>th,.table>tbody>tr>td.warning,.table>tbody>tr>th.warning,.table>tfoot>tr.warning>td,.table>tfoot>tr.warning>th,.table>tfoot>tr>td.warning,.table>tfoot>tr>th.warning,.table>thead>tr.warning>td,.table>thead>tr.warning>th,.table>thead>tr>td.warning,.table>thead>tr>th.warning{background-color:#fcf8e3}.table-hover>tbody>tr.warning:hover>td,.table-hover>tbody>tr.warning:hover>th,.table-hover>tbody>tr:hover>.warning,.table-hover>tbody>tr>td.warning:hover,.table-hover>tbody>tr>th.warning:hover{background-color:#faf2cc}.table>tbody>tr.danger>td,.table>tbody>tr.danger>th,.table>tbody>tr>td.danger,.table>tbody>tr>th.danger,.table>tfoot>tr.danger>td,.table>tfoot>tr.danger>th,.table>tfoot>tr>td.danger,.table>tfoot>tr>th.danger,.table>thead>tr.danger>td,.table>thead>tr.danger>th,.table>thead>tr>td.danger,.table>thead>tr>th.danger{background-color:#f2dede}.table-hover>tbody>tr.danger:hover>td,.table-hover>tbody>tr.danger:hover>th,.table-hover>tbody>tr:hover>.danger,.table-hover>tbody>tr>td.danger:hover,.table-hover>tbody>tr>th.danger:hover{background-color:#ebcccc}.table-responsive{min-height:.01%;overflow-x:auto}@media screen and (max-width:767px){.table-responsive{width:100%;margin-bottom:15px;overflow-y:hidden;-ms-overflow-style:-ms-autohiding-scrollbar;border:1px solid #ddd}.table-responsive>.table{margin-bottom:0}.table-responsive>.table>tbody>tr>td,.table-responsive>.table>tbody>tr>th,.table-responsive>.table>tfoot>tr>td,.table-responsive>.table>tfoot>tr>th,.table-responsive>.table>thead>tr>td,.table-responsive>.table>thead>tr>th{white-space:nowrap}.table-responsive>.table-bordered{border:0}.table-responsive>.table-bordered>tbody>tr>td:first-child,.table-responsive>.table-bordered>tbody>tr>th:first-child,.table-responsive>.table-bordered>tfoot>tr>td:first-child,.table-responsive>.table-bordered>tfoot>tr>th:first-child,.table-responsive>.table-bordered>thead>tr>td:first-child,.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.table-responsive>.table-bordered>tbody>tr>td:last-child,.table-responsive>.table-bordered>tbody>tr>th:last-child,.table-responsive>.table-bordered>tfoot>tr>td:last-child,.table-responsive>.table-bordered>tfoot>tr>th:last-child,.table-responsive>.table-bordered>thead>tr>td:last-child,.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.table-responsive>.table-bordered>tbody>tr:last-child>td,.table-responsive>.table-bordered>tbody>tr:last-child>th,.table-responsive>.table-bordered>tfoot>tr:last-child>td,.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}}fieldset{min-width:0;padding:0;margin:0;border:0}legend{display:block;width:100%;padding:0;margin-bottom:20px;font-size:21px;line-height:inherit;color:#333;border:0;border-bottom:1px solid #e5e5e5}label{display:inline-block;max-width:100%;margin-bottom:5px;font-weight:700}input[type=search]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}input[type=checkbox],input[type=radio]{margin:4px 0 0;margin-top:1px\9;line-height:normal}input[type=file]{display:block}input[type=range]{display:block;width:100%}select[multiple],select[size]{height:auto}input[type=file]:focus,input[type=checkbox]:focus,input[type=radio]:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}output{display:block;padding-top:7px;font-size:14px;line-height:1.42857143;color:#555}.form-control{display:block;width:100%;height:34px;padding:6px 12px;font-size:14px;line-height:1.42857143;color:#555;background-color:#fff;background-image:none;border:1px solid #ccc;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075);-webkit-transition:border-color ease-in-out .15s,-webkit-box-shadow ease-in-out .15s;-o-transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s;transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s}.form-control:focus{border-color:#66afe9;outline:0;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6);box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6)}.form-control::-moz-placeholder{color:#999;opacity:1}.form-control:-ms-input-placeholder{color:#999}.form-control::-webkit-input-placeholder{color:#999}.form-control[disabled],.form-control[readonly],fieldset[disabled] .form-control{background-color:#eee;opacity:1}.form-control[disabled],fieldset[disabled] .form-control{cursor:not-allowed}textarea.form-control{height:auto}input[type=search]{-webkit-appearance:none}@media screen and (-webkit-min-device-pixel-ratio:0){input[type=date].form-control,input[type=time].form-control,input[type=datetime-local].form-control,input[type=month].form-control{line-height:34px}.input-group-sm input[type=date],.input-group-sm input[type=time],.input-group-sm input[type=datetime-local],.input-group-sm input[type=month],input[type=date].input-sm,input[type=time].input-sm,input[type=datetime-local].input-sm,input[type=month].input-sm{line-height:30px}.input-group-lg input[type=date],.input-group-lg input[type=time],.input-group-lg input[type=datetime-local],.input-group-lg input[type=month],input[type=date].input-lg,input[type=time].input-lg,input[type=datetime-local].input-lg,input[type=month].input-lg{line-height:46px}}.form-group{margin-bottom:15px}.checkbox,.radio{position:relative;display:block;margin-top:10px;margin-bottom:10px}.checkbox label,.radio label{min-height:20px;padding-left:20px;margin-bottom:0;font-weight:400;cursor:pointer}.checkbox input[type=checkbox],.checkbox-inline input[type=checkbox],.radio input[type=radio],.radio-inline input[type=radio]{position:absolute;margin-top:4px\9;margin-left:-20px}.checkbox+.checkbox,.radio+.radio{margin-top:-5px}.checkbox-inline,.radio-inline{position:relative;display:inline-block;padding-left:20px;margin-bottom:0;font-weight:400;vertical-align:middle;cursor:pointer}.checkbox-inline+.checkbox-inline,.radio-inline+.radio-inline{margin-top:0;margin-left:10px}fieldset[disabled] input[type=checkbox],fieldset[disabled] input[type=radio],input[type=checkbox].disabled,input[type=checkbox][disabled],input[type=radio].disabled,input[type=radio][disabled]{cursor:not-allowed}.checkbox-inline.disabled,.radio-inline.disabled,fieldset[disabled] .checkbox-inline,fieldset[disabled] .radio-inline{cursor:not-allowed}.checkbox.disabled label,.radio.disabled label,fieldset[disabled] .checkbox label,fieldset[disabled] .radio label{cursor:not-allowed}.form-control-static{min-height:34px;padding-top:7px;padding-bottom:7px;margin-bottom:0}.form-control-static.input-lg,.form-control-static.input-sm{padding-right:0;padding-left:0}.input-sm{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-sm{height:30px;line-height:30px}select[multiple].input-sm,textarea.input-sm{height:auto}.form-group-sm .form-control{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.form-group-sm select.form-control{height:30px;line-height:30px}.form-group-sm select[multiple].form-control,.form-group-sm textarea.form-control{height:auto}.form-group-sm .form-control-static{height:30px;min-height:32px;padding:6px 10px;font-size:12px;line-height:1.5}.input-lg{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-lg{height:46px;line-height:46px}select[multiple].input-lg,textarea.input-lg{height:auto}.form-group-lg .form-control{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.form-group-lg select.form-control{height:46px;line-height:46px}.form-group-lg select[multiple].form-control,.form-group-lg textarea.form-control{height:auto}.form-group-lg .form-control-static{height:46px;min-height:38px;padding:11px 16px;font-size:18px;line-height:1.3333333}.has-feedback{position:relative}.has-feedback .form-control{padding-right:42.5px}.form-control-feedback{position:absolute;top:0;right:0;z-index:2;display:block;width:34px;height:34px;line-height:34px;text-align:center;pointer-events:none}.form-group-lg .form-control+.form-control-feedback,.input-group-lg+.form-control-feedback,.input-lg+.form-control-feedback{width:46px;height:46px;line-height:46px}.form-group-sm .form-control+.form-control-feedback,.input-group-sm+.form-control-feedback,.input-sm+.form-control-feedback{width:30px;height:30px;line-height:30px}.has-success .checkbox,.has-success .checkbox-inline,.has-success .control-label,.has-success .help-block,.has-success .radio,.has-success .radio-inline,.has-success.checkbox label,.has-success.checkbox-inline label,.has-success.radio label,.has-success.radio-inline label{color:#3c763d}.has-success .form-control{border-color:#3c763d;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-success .form-control:focus{border-color:#2b542c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168}.has-success .input-group-addon{color:#3c763d;background-color:#dff0d8;border-color:#3c763d}.has-success .form-control-feedback{color:#3c763d}.has-warning .checkbox,.has-warning .checkbox-inline,.has-warning .control-label,.has-warning .help-block,.has-warning .radio,.has-warning .radio-inline,.has-warning.checkbox label,.has-warning.checkbox-inline label,.has-warning.radio label,.has-warning.radio-inline label{color:#8a6d3b}.has-warning .form-control{border-color:#8a6d3b;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-warning .form-control:focus{border-color:#66512c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b}.has-warning .input-group-addon{color:#8a6d3b;background-color:#fcf8e3;border-color:#8a6d3b}.has-warning .form-control-feedback{color:#8a6d3b}.has-error .checkbox,.has-error .checkbox-inline,.has-error .control-label,.has-error .help-block,.has-error .radio,.has-error .radio-inline,.has-error.checkbox label,.has-error.checkbox-inline label,.has-error.radio label,.has-error.radio-inline label{color:#a94442}.has-error .form-control{border-color:#a94442;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-error .form-control:focus{border-color:#843534;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483}.has-error .input-group-addon{color:#a94442;background-color:#f2dede;border-color:#a94442}.has-error .form-control-feedback{color:#a94442}.has-feedback label~.form-control-feedback{top:25px}.has-feedback label.sr-only~.form-control-feedback{top:0}.help-block{display:block;margin-top:5px;margin-bottom:10px;color:#737373}@media (min-width:768px){.form-inline .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.form-inline .form-control{display:inline-block;width:auto;vertical-align:middle}.form-inline .form-control-static{display:inline-block}.form-inline .input-group{display:inline-table;vertical-align:middle}.form-inline .input-group .form-control,.form-inline .input-group .input-group-addon,.form-inline .input-group .input-group-btn{width:auto}.form-inline .input-group>.form-control{width:100%}.form-inline .control-label{margin-bottom:0;vertical-align:middle}.form-inline .checkbox,.form-inline .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.form-inline .checkbox label,.form-inline .radio label{padding-left:0}.form-inline .checkbox input[type=checkbox],.form-inline .radio input[type=radio]{position:relative;margin-left:0}.form-inline .has-feedback .form-control-feedback{top:0}}.form-horizontal .checkbox,.form-horizontal .checkbox-inline,.form-horizontal .radio,.form-horizontal .radio-inline{padding-top:7px;margin-top:0;margin-bottom:0}.form-horizontal .checkbox,.form-horizontal .radio{min-height:27px}.form-horizontal .form-group{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.form-horizontal .control-label{padding-top:7px;margin-bottom:0;text-align:right}}.form-horizontal .has-feedback .form-control-feedback{right:15px}@media (min-width:768px){.form-horizontal .form-group-lg .control-label{padding-top:14.33px;font-size:18px}}@media (min-width:768px){.form-horizontal .form-group-sm .control-label{padding-top:6px;font-size:12px}}.btn{display:inline-block;padding:6px 12px;margin-bottom:0;font-size:14px;font-weight:400;line-height:1.42857143;text-align:center;white-space:nowrap;vertical-align:middle;-ms-touch-action:manipulation;touch-action:manipulation;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;background-image:none;border:1px solid transparent;border-radius:4px}.btn.active.focus,.btn.active:focus,.btn.focus,.btn:active.focus,.btn:active:focus,.btn:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}.btn.focus,.btn:focus,.btn:hover{color:#333;text-decoration:none}.btn.active,.btn:active{background-image:none;outline:0;-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn.disabled,.btn[disabled],fieldset[disabled] .btn{cursor:not-allowed;filter:alpha(opacity=65);-webkit-box-shadow:none;box-shadow:none;opacity:.65}a.btn.disabled,fieldset[disabled] a.btn{pointer-events:none}.btn-default{color:#333;background-color:#fff;border-color:#ccc}.btn-default.focus,.btn-default:focus{color:#333;background-color:#e6e6e6;border-color:#8c8c8c}.btn-default:hover{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active.focus,.btn-default.active:focus,.btn-default.active:hover,.btn-default:active.focus,.btn-default:active:focus,.btn-default:active:hover,.open>.dropdown-toggle.btn-default.focus,.open>.dropdown-toggle.btn-default:focus,.open>.dropdown-toggle.btn-default:hover{color:#333;background-color:#d4d4d4;border-color:#8c8c8c}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{background-image:none}.btn-default.disabled,.btn-default.disabled.active,.btn-default.disabled.focus,.btn-default.disabled:active,.btn-default.disabled:focus,.btn-default.disabled:hover,.btn-default[disabled],.btn-default[disabled].active,.btn-default[disabled].focus,.btn-default[disabled]:active,.btn-default[disabled]:focus,.btn-default[disabled]:hover,fieldset[disabled] .btn-default,fieldset[disabled] .btn-default.active,fieldset[disabled] .btn-default.focus,fieldset[disabled] .btn-default:active,fieldset[disabled] .btn-default:focus,fieldset[disabled] .btn-default:hover{background-color:#fff;border-color:#ccc}.btn-default .badge{color:#fff;background-color:#333}.btn-primary{color:#fff;background-color:#337ab7;border-color:#2e6da4}.btn-primary.focus,.btn-primary:focus{color:#fff;background-color:#286090;border-color:#122b40}.btn-primary:hover{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active.focus,.btn-primary.active:focus,.btn-primary.active:hover,.btn-primary:active.focus,.btn-primary:active:focus,.btn-primary:active:hover,.open>.dropdown-toggle.btn-primary.focus,.open>.dropdown-toggle.btn-primary:focus,.open>.dropdown-toggle.btn-primary:hover{color:#fff;background-color:#204d74;border-color:#122b40}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{background-image:none}.btn-primary.disabled,.btn-primary.disabled.active,.btn-primary.disabled.focus,.btn-primary.disabled:active,.btn-primary.disabled:focus,.btn-primary.disabled:hover,.btn-primary[disabled],.btn-primary[disabled].active,.btn-primary[disabled].focus,.btn-primary[disabled]:active,.btn-primary[disabled]:focus,.btn-primary[disabled]:hover,fieldset[disabled] .btn-primary,fieldset[disabled] .btn-primary.active,fieldset[disabled] .btn-primary.focus,fieldset[disabled] .btn-primary:active,fieldset[disabled] .btn-primary:focus,fieldset[disabled] .btn-primary:hover{background-color:#337ab7;border-color:#2e6da4}.btn-primary .badge{color:#337ab7;background-color:#fff}.btn-success{color:#fff;background-color:#5cb85c;border-color:#4cae4c}.btn-success.focus,.btn-success:focus{color:#fff;background-color:#449d44;border-color:#255625}.btn-success:hover{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active.focus,.btn-success.active:focus,.btn-success.active:hover,.btn-success:active.focus,.btn-success:active:focus,.btn-success:active:hover,.open>.dropdown-toggle.btn-success.focus,.open>.dropdown-toggle.btn-success:focus,.open>.dropdown-toggle.btn-success:hover{color:#fff;background-color:#398439;border-color:#255625}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{background-image:none}.btn-success.disabled,.btn-success.disabled.active,.btn-success.disabled.focus,.btn-success.disabled:active,.btn-success.disabled:focus,.btn-success.disabled:hover,.btn-success[disabled],.btn-success[disabled].active,.btn-success[disabled].focus,.btn-success[disabled]:active,.btn-success[disabled]:focus,.btn-success[disabled]:hover,fieldset[disabled] .btn-success,fieldset[disabled] .btn-success.active,fieldset[disabled] .btn-success.focus,fieldset[disabled] .btn-success:active,fieldset[disabled] .btn-success:focus,fieldset[disabled] .btn-success:hover{background-color:#5cb85c;border-color:#4cae4c}.btn-success .badge{color:#5cb85c;background-color:#fff}.btn-info{color:#fff;background-color:#5bc0de;border-color:#46b8da}.btn-info.focus,.btn-info:focus{color:#fff;background-color:#31b0d5;border-color:#1b6d85}.btn-info:hover{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active.focus,.btn-info.active:focus,.btn-info.active:hover,.btn-info:active.focus,.btn-info:active:focus,.btn-info:active:hover,.open>.dropdown-toggle.btn-info.focus,.open>.dropdown-toggle.btn-info:focus,.open>.dropdown-toggle.btn-info:hover{color:#fff;background-color:#269abc;border-color:#1b6d85}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{background-image:none}.btn-info.disabled,.btn-info.disabled.active,.btn-info.disabled.focus,.btn-info.disabled:active,.btn-info.disabled:focus,.btn-info.disabled:hover,.btn-info[disabled],.btn-info[disabled].active,.btn-info[disabled].focus,.btn-info[disabled]:active,.btn-info[disabled]:focus,.btn-info[disabled]:hover,fieldset[disabled] .btn-info,fieldset[disabled] .btn-info.active,fieldset[disabled] .btn-info.focus,fieldset[disabled] .btn-info:active,fieldset[disabled] .btn-info:focus,fieldset[disabled] .btn-info:hover{background-color:#5bc0de;border-color:#46b8da}.btn-info .badge{color:#5bc0de;background-color:#fff}.btn-warning{color:#fff;background-color:#f0ad4e;border-color:#eea236}.btn-warning.focus,.btn-warning:focus{color:#fff;background-color:#ec971f;border-color:#985f0d}.btn-warning:hover{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active.focus,.btn-warning.active:focus,.btn-warning.active:hover,.btn-warning:active.focus,.btn-warning:active:focus,.btn-warning:active:hover,.open>.dropdown-toggle.btn-warning.focus,.open>.dropdown-toggle.btn-warning:focus,.open>.dropdown-toggle.btn-warning:hover{color:#fff;background-color:#d58512;border-color:#985f0d}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{background-image:none}.btn-warning.disabled,.btn-warning.disabled.active,.btn-warning.disabled.focus,.btn-warning.disabled:active,.btn-warning.disabled:focus,.btn-warning.disabled:hover,.btn-warning[disabled],.btn-warning[disabled].active,.btn-warning[disabled].focus,.btn-warning[disabled]:active,.btn-warning[disabled]:focus,.btn-warning[disabled]:hover,fieldset[disabled] .btn-warning,fieldset[disabled] .btn-warning.active,fieldset[disabled] .btn-warning.focus,fieldset[disabled] .btn-warning:active,fieldset[disabled] .btn-warning:focus,fieldset[disabled] .btn-warning:hover{background-color:#f0ad4e;border-color:#eea236}.btn-warning .badge{color:#f0ad4e;background-color:#fff}.btn-danger{color:#fff;background-color:#d9534f;border-color:#d43f3a}.btn-danger.focus,.btn-danger:focus{color:#fff;background-color:#c9302c;border-color:#761c19}.btn-danger:hover{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active.focus,.btn-danger.active:focus,.btn-danger.active:hover,.btn-danger:active.focus,.btn-danger:active:focus,.btn-danger:active:hover,.open>.dropdown-toggle.btn-danger.focus,.open>.dropdown-toggle.btn-danger:focus,.open>.dropdown-toggle.btn-danger:hover{color:#fff;background-color:#ac2925;border-color:#761c19}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{background-image:none}.btn-danger.disabled,.btn-danger.disabled.active,.btn-danger.disabled.focus,.btn-danger.disabled:active,.btn-danger.disabled:focus,.btn-danger.disabled:hover,.btn-danger[disabled],.btn-danger[disabled].active,.btn-danger[disabled].focus,.btn-danger[disabled]:active,.btn-danger[disabled]:focus,.btn-danger[disabled]:hover,fieldset[disabled] .btn-danger,fieldset[disabled] .btn-danger.active,fieldset[disabled] .btn-danger.focus,fieldset[disabled] .btn-danger:active,fieldset[disabled] .btn-danger:focus,fieldset[disabled] .btn-danger:hover{background-color:#d9534f;border-color:#d43f3a}.btn-danger .badge{color:#d9534f;background-color:#fff}.btn-link{font-weight:400;color:#337ab7;border-radius:0}.btn-link,.btn-link.active,.btn-link:active,.btn-link[disabled],fieldset[disabled] .btn-link{background-color:transparent;-webkit-box-shadow:none;box-shadow:none}.btn-link,.btn-link:active,.btn-link:focus,.btn-link:hover{border-color:transparent}.btn-link:focus,.btn-link:hover{color:#23527c;text-decoration:underline;background-color:transparent}.btn-link[disabled]:focus,.btn-link[disabled]:hover,fieldset[disabled] .btn-link:focus,fieldset[disabled] .btn-link:hover{color:#777;text-decoration:none}.btn-group-lg>.btn,.btn-lg{padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.btn-group-sm>.btn,.btn-sm{padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.btn-group-xs>.btn,.btn-xs{padding:1px 5px;font-size:12px;line-height:1.5;border-radius:3px}.btn-block{display:block;width:100%}.btn-block+.btn-block{margin-top:5px}input[type=button].btn-block,input[type=reset].btn-block,input[type=submit].btn-block{width:100%}.fade{opacity:0;-webkit-transition:opacity .15s linear;-o-transition:opacity .15s linear;transition:opacity .15s linear}.fade.in{opacity:1}.collapse{display:none}.collapse.in{display:block}tr.collapse.in{display:table-row}tbody.collapse.in{display:table-row-group}.collapsing{position:relative;height:0;overflow:hidden;-webkit-transition-timing-function:ease;-o-transition-timing-function:ease;transition-timing-function:ease;-webkit-transition-duration:.35s;-o-transition-duration:.35s;transition-duration:.35s;-webkit-transition-property:height,visibility;-o-transition-property:height,visibility;transition-property:height,visibility}.caret{display:inline-block;width:0;height:0;margin-left:2px;vertical-align:middle;border-top:4px dashed;border-top:4px solid\9;border-right:4px solid transparent;border-left:4px solid transparent}.dropdown,.dropup{position:relative}.dropdown-toggle:focus{outline:0}.dropdown-menu{position:absolute;top:100%;left:0;z-index:1000;display:none;float:left;min-width:160px;padding:5px 0;margin:2px 0 0;font-size:14px;text-align:left;list-style:none;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.15);border-radius:4px;-webkit-box-shadow:0 6px 12px rgba(0,0,0,.175);box-shadow:0 6px 12px rgba(0,0,0,.175)}.dropdown-menu.pull-right{right:0;left:auto}.dropdown-menu .divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.dropdown-menu>li>a{display:block;padding:3px 20px;clear:both;font-weight:400;line-height:1.42857143;color:#333;white-space:nowrap}.dropdown-menu>li>a:focus,.dropdown-menu>li>a:hover{color:#262626;text-decoration:none;background-color:#f5f5f5}.dropdown-menu>.active>a,.dropdown-menu>.active>a:focus,.dropdown-menu>.active>a:hover{color:#fff;text-decoration:none;background-color:#337ab7;outline:0}.dropdown-menu>.disabled>a,.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{color:#777}.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{text-decoration:none;cursor:not-allowed;background-color:transparent;background-image:none;filter:progid:DXImageTransform.Microsoft.gradient(enabled=false)}.open>.dropdown-menu{display:block}.open>a{outline:0}.dropdown-menu-right{right:0;left:auto}.dropdown-menu-left{right:auto;left:0}.dropdown-header{display:block;padding:3px 20px;font-size:12px;line-height:1.42857143;color:#777;white-space:nowrap}.dropdown-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:990}.pull-right>.dropdown-menu{right:0;left:auto}.dropup .caret,.navbar-fixed-bottom .dropdown .caret{content:"";border-top:0;border-bottom:4px dashed;border-bottom:4px solid\9}.dropup .dropdown-menu,.navbar-fixed-bottom .dropdown .dropdown-menu{top:auto;bottom:100%;margin-bottom:2px}@media (min-width:768px){.navbar-right .dropdown-menu{right:0;left:auto}.navbar-right .dropdown-menu-left{right:auto;left:0}}.btn-group,.btn-group-vertical{position:relative;display:inline-block;vertical-align:middle}.btn-group-vertical>.btn,.btn-group>.btn{position:relative;float:left}.btn-group-vertical>.btn.active,.btn-group-vertical>.btn:active,.btn-group-vertical>.btn:focus,.btn-group-vertical>.btn:hover,.btn-group>.btn.active,.btn-group>.btn:active,.btn-group>.btn:focus,.btn-group>.btn:hover{z-index:2}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:-1px}.btn-toolbar{margin-left:-5px}.btn-toolbar .btn,.btn-toolbar .btn-group,.btn-toolbar .input-group{float:left}.btn-toolbar>.btn,.btn-toolbar>.btn-group,.btn-toolbar>.input-group{margin-left:5px}.btn-group>.btn:not(:first-child):not(:last-child):not(.dropdown-toggle){border-radius:0}.btn-group>.btn:first-child{margin-left:0}.btn-group>.btn:first-child:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn:last-child:not(:first-child),.btn-group>.dropdown-toggle:not(:first-child){border-top-left-radius:0;border-bottom-left-radius:0}.btn-group>.btn-group{float:left}.btn-group>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-bottom-left-radius:0}.btn-group .dropdown-toggle:active,.btn-group.open .dropdown-toggle{outline:0}.btn-group>.btn+.dropdown-toggle{padding-right:8px;padding-left:8px}.btn-group>.btn-lg+.dropdown-toggle{padding-right:12px;padding-left:12px}.btn-group.open .dropdown-toggle{-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn-group.open .dropdown-toggle.btn-link{-webkit-box-shadow:none;box-shadow:none}.btn .caret{margin-left:0}.btn-lg .caret{border-width:5px 5px 0;border-bottom-width:0}.dropup .btn-lg .caret{border-width:0 5px 5px}.btn-group-vertical>.btn,.btn-group-vertical>.btn-group,.btn-group-vertical>.btn-group>.btn{display:block;float:none;width:100%;max-width:100%}.btn-group-vertical>.btn-group>.btn{float:none}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:-1px;margin-left:0}.btn-group-vertical>.btn:not(:first-child):not(:last-child){border-radius:0}.btn-group-vertical>.btn:first-child:not(:last-child){border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn:last-child:not(:first-child){border-top-left-radius:0;border-top-right-radius:0;border-bottom-left-radius:4px}.btn-group-vertical>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group-vertical>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group-vertical>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-top-right-radius:0}.btn-group-justified{display:table;width:100%;table-layout:fixed;border-collapse:separate}.btn-group-justified>.btn,.btn-group-justified>.btn-group{display:table-cell;float:none;width:1%}.btn-group-justified>.btn-group .btn{width:100%}.btn-group-justified>.btn-group .dropdown-menu{left:auto}[data-toggle=buttons]>.btn input[type=checkbox],[data-toggle=buttons]>.btn input[type=radio],[data-toggle=buttons]>.btn-group>.btn input[type=checkbox],[data-toggle=buttons]>.btn-group>.btn input[type=radio]{position:absolute;clip:rect(0,0,0,0);pointer-events:none}.input-group{position:relative;display:table;border-collapse:separate}.input-group[class*=col-]{float:none;padding-right:0;padding-left:0}.input-group .form-control{position:relative;z-index:2;float:left;width:100%;margin-bottom:0}.input-group-lg>.form-control,.input-group-lg>.input-group-addon,.input-group-lg>.input-group-btn>.btn{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-group-lg>.form-control,select.input-group-lg>.input-group-addon,select.input-group-lg>.input-group-btn>.btn{height:46px;line-height:46px}select[multiple].input-group-lg>.form-control,select[multiple].input-group-lg>.input-group-addon,select[multiple].input-group-lg>.input-group-btn>.btn,textarea.input-group-lg>.form-control,textarea.input-group-lg>.input-group-addon,textarea.input-group-lg>.input-group-btn>.btn{height:auto}.input-group-sm>.form-control,.input-group-sm>.input-group-addon,.input-group-sm>.input-group-btn>.btn{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-group-sm>.form-control,select.input-group-sm>.input-group-addon,select.input-group-sm>.input-group-btn>.btn{height:30px;line-height:30px}select[multiple].input-group-sm>.form-control,select[multiple].input-group-sm>.input-group-addon,select[multiple].input-group-sm>.input-group-btn>.btn,textarea.input-group-sm>.form-control,textarea.input-group-sm>.input-group-addon,textarea.input-group-sm>.input-group-btn>.btn{height:auto}.input-group .form-control,.input-group-addon,.input-group-btn{display:table-cell}.input-group .form-control:not(:first-child):not(:last-child),.input-group-addon:not(:first-child):not(:last-child),.input-group-btn:not(:first-child):not(:last-child){border-radius:0}.input-group-addon,.input-group-btn{width:1%;white-space:nowrap;vertical-align:middle}.input-group-addon{padding:6px 12px;font-size:14px;font-weight:400;line-height:1;color:#555;text-align:center;background-color:#eee;border:1px solid #ccc;border-radius:4px}.input-group-addon.input-sm{padding:5px 10px;font-size:12px;border-radius:3px}.input-group-addon.input-lg{padding:10px 16px;font-size:18px;border-radius:6px}.input-group-addon input[type=checkbox],.input-group-addon input[type=radio]{margin-top:0}.input-group .form-control:first-child,.input-group-addon:first-child,.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group>.btn,.input-group-btn:first-child>.dropdown-toggle,.input-group-btn:last-child>.btn-group:not(:last-child)>.btn,.input-group-btn:last-child>.btn:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.input-group-addon:first-child{border-right:0}.input-group .form-control:last-child,.input-group-addon:last-child,.input-group-btn:first-child>.btn-group:not(:first-child)>.btn,.input-group-btn:first-child>.btn:not(:first-child),.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group>.btn,.input-group-btn:last-child>.dropdown-toggle{border-top-left-radius:0;border-bottom-left-radius:0}.input-group-addon:last-child{border-left:0}.input-group-btn{position:relative;font-size:0;white-space:nowrap}.input-group-btn>.btn{position:relative}.input-group-btn>.btn+.btn{margin-left:-1px}.input-group-btn>.btn:active,.input-group-btn>.btn:focus,.input-group-btn>.btn:hover{z-index:2}.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group{margin-right:-1px}.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group{z-index:2;margin-left:-1px}.nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.nav>li.disabled>a{color:#777}.nav>li.disabled>a:focus,.nav>li.disabled>a:hover{color:#777;text-decoration:none;cursor:not-allowed;background-color:transparent}.nav .open>a,.nav .open>a:focus,.nav .open>a:hover{background-color:#eee;border-color:#337ab7}.nav .nav-divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.nav>li>a>img{max-width:none}.nav-tabs{border-bottom:1px solid #ddd}.nav-tabs>li{float:left;margin-bottom:-1px}.nav-tabs>li>a{margin-right:2px;line-height:1.42857143;border:1px solid transparent;border-radius:4px 4px 0 0}.nav-tabs>li>a:hover{border-color:#eee #eee #ddd}.nav-tabs>li.active>a,.nav-tabs>li.active>a:focus,.nav-tabs>li.active>a:hover{color:#555;cursor:default;background-color:#fff;border:1px solid #ddd;border-bottom-color:transparent}.nav-tabs.nav-justified{width:100%;border-bottom:0}.nav-tabs.nav-justified>li{float:none}.nav-tabs.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-tabs.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-tabs.nav-justified>li{display:table-cell;width:1%}.nav-tabs.nav-justified>li>a{margin-bottom:0}}.nav-tabs.nav-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs.nav-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border-bottom-color:#fff}}.nav-pills>li{float:left}.nav-pills>li>a{border-radius:4px}.nav-pills>li+li{margin-left:2px}.nav-pills>li.active>a,.nav-pills>li.active>a:focus,.nav-pills>li.active>a:hover{color:#fff;background-color:#337ab7}.nav-stacked>li{float:none}.nav-stacked>li+li{margin-top:2px;margin-left:0}.nav-justified{width:100%}.nav-justified>li{float:none}.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-justified>li{display:table-cell;width:1%}.nav-justified>li>a{margin-bottom:0}}.nav-tabs-justified{border-bottom:0}.nav-tabs-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border-bottom-color:#fff}}.tab-content>.tab-pane{display:none}.tab-content>.active{display:block}.nav-tabs .dropdown-menu{margin-top:-1px;border-top-left-radius:0;border-top-right-radius:0}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.in{overflow-y:auto}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;-webkit-box-shadow:none;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}.navbar-collapse.in{overflow-y:visible}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse,.navbar-static-top .navbar-collapse{padding-right:0;padding-left:0}}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:340px}@media (max-device-width:480px) and (orientation:landscape){.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:200px}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:0;margin-left:0}}.navbar-static-top{z-index:1000;border-width:0 0 1px}@media (min-width:768px){.navbar-static-top{border-radius:0}}.navbar-fixed-bottom,.navbar-fixed-top{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-bottom,.navbar-fixed-top{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-fixed-bottom{bottom:0;margin-bottom:0;border-width:1px 0 0}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}.navbar-brand>img{display:block}@media (min-width:768px){.navbar>.container .navbar-brand,.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-toggle{position:relative;float:right;padding:9px 10px;margin-top:8px;margin-right:15px;margin-bottom:8px;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:4px}.navbar-toggle:focus{outline:0}.navbar-toggle .icon-bar{display:block;width:22px;height:2px;border-radius:1px}.navbar-toggle .icon-bar+.icon-bar{margin-top:4px}@media (min-width:768px){.navbar-toggle{display:none}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (max-width:767px){.navbar-nav .open .dropdown-menu{position:static;float:none;width:auto;margin-top:0;background-color:transparent;border:0;-webkit-box-shadow:none;box-shadow:none}.navbar-nav .open .dropdown-menu .dropdown-header,.navbar-nav .open .dropdown-menu>li>a{padding:5px 15px 5px 25px}.navbar-nav .open .dropdown-menu>li>a{line-height:20px}.navbar-nav .open .dropdown-menu>li>a:focus,.navbar-nav .open .dropdown-menu>li>a:hover{background-image:none}}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}}.navbar-form{padding:10px 15px;margin-top:8px;margin-right:-15px;margin-bottom:8px;margin-left:-15px;border-top:1px solid transparent;border-bottom:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-form .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.navbar-form .form-control{display:inline-block;width:auto;vertical-align:middle}.navbar-form .form-control-static{display:inline-block}.navbar-form .input-group{display:inline-table;vertical-align:middle}.navbar-form .input-group .form-control,.navbar-form .input-group .input-group-addon,.navbar-form .input-group .input-group-btn{width:auto}.navbar-form .input-group>.form-control{width:100%}.navbar-form .control-label{margin-bottom:0;vertical-align:middle}.navbar-form .checkbox,.navbar-form .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.navbar-form .checkbox label,.navbar-form .radio label{padding-left:0}.navbar-form .checkbox input[type=checkbox],.navbar-form .radio input[type=radio]{position:relative;margin-left:0}.navbar-form .has-feedback .form-control-feedback{top:0}}@media (max-width:767px){.navbar-form .form-group{margin-bottom:5px}.navbar-form .form-group:last-child{margin-bottom:0}}@media (min-width:768px){.navbar-form{width:auto;padding-top:0;padding-bottom:0;margin-right:0;margin-left:0;border:0;-webkit-box-shadow:none;box-shadow:none}}.navbar-nav>li>.dropdown-menu{margin-top:0;border-top-left-radius:0;border-top-right-radius:0}.navbar-fixed-bottom .navbar-nav>li>.dropdown-menu{margin-bottom:0;border-top-left-radius:4px;border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.navbar-btn{margin-top:8px;margin-bottom:8px}.navbar-btn.btn-sm{margin-top:10px;margin-bottom:10px}.navbar-btn.btn-xs{margin-top:14px;margin-bottom:14px}.navbar-text{margin-top:15px;margin-bottom:15px}@media (min-width:768px){.navbar-text{float:left;margin-right:15px;margin-left:15px}}@media (min-width:768px){.navbar-left{float:left!important}.navbar-right{float:right!important;margin-right:-15px}.navbar-right~.navbar-right{margin-right:0}}.navbar-default{background-color:#f8f8f8;border-color:#e7e7e7}.navbar-default .navbar-brand{color:#777}.navbar-default .navbar-brand:focus,.navbar-default .navbar-brand:hover{color:#5e5e5e;background-color:transparent}.navbar-default .navbar-text{color:#777}.navbar-default .navbar-nav>li>a{color:#777}.navbar-default .navbar-nav>li>a:focus,.navbar-default .navbar-nav>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav>.active>a,.navbar-default .navbar-nav>.active>a:focus,.navbar-default .navbar-nav>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav>.disabled>a,.navbar-default .navbar-nav>.disabled>a:focus,.navbar-default .navbar-nav>.disabled>a:hover{color:#ccc;background-color:transparent}.navbar-default .navbar-toggle{border-color:#ddd}.navbar-default .navbar-toggle:focus,.navbar-default .navbar-toggle:hover{background-color:#ddd}.navbar-default .navbar-toggle .icon-bar{background-color:#888}.navbar-default .navbar-collapse,.navbar-default .navbar-form{border-color:#e7e7e7}.navbar-default .navbar-nav>.open>a,.navbar-default .navbar-nav>.open>a:focus,.navbar-default .navbar-nav>.open>a:hover{color:#555;background-color:#e7e7e7}@media (max-width:767px){.navbar-default .navbar-nav .open .dropdown-menu>li>a{color:#777}.navbar-default .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav .open .dropdown-menu>.active>a,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#ccc;background-color:transparent}}.navbar-default .navbar-link{color:#777}.navbar-default .navbar-link:hover{color:#333}.navbar-default .btn-link{color:#777}.navbar-default .btn-link:focus,.navbar-default .btn-link:hover{color:#333}.navbar-default .btn-link[disabled]:focus,.navbar-default .btn-link[disabled]:hover,fieldset[disabled] .navbar-default .btn-link:focus,fieldset[disabled] .navbar-default .btn-link:hover{color:#ccc}.navbar-inverse{background-color:#222;border-color:#080808}.navbar-inverse .navbar-brand{color:#9d9d9d}.navbar-inverse .navbar-brand:focus,.navbar-inverse .navbar-brand:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-text{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a:focus,.navbar-inverse .navbar-nav>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav>.active>a,.navbar-inverse .navbar-nav>.active>a:focus,.navbar-inverse .navbar-nav>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav>.disabled>a,.navbar-inverse .navbar-nav>.disabled>a:focus,.navbar-inverse .navbar-nav>.disabled>a:hover{color:#444;background-color:transparent}.navbar-inverse .navbar-toggle{border-color:#333}.navbar-inverse .navbar-toggle:focus,.navbar-inverse .navbar-toggle:hover{background-color:#333}.navbar-inverse .navbar-toggle .icon-bar{background-color:#fff}.navbar-inverse .navbar-collapse,.navbar-inverse .navbar-form{border-color:#101010}.navbar-inverse .navbar-nav>.open>a,.navbar-inverse .navbar-nav>.open>a:focus,.navbar-inverse .navbar-nav>.open>a:hover{color:#fff;background-color:#080808}@media (max-width:767px){.navbar-inverse .navbar-nav .open .dropdown-menu>.dropdown-header{border-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu .divider{background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#444;background-color:transparent}}.navbar-inverse .navbar-link{color:#9d9d9d}.navbar-inverse .navbar-link:hover{color:#fff}.navbar-inverse .btn-link{color:#9d9d9d}.navbar-inverse .btn-link:focus,.navbar-inverse .btn-link:hover{color:#fff}.navbar-inverse .btn-link[disabled]:focus,.navbar-inverse .btn-link[disabled]:hover,fieldset[disabled] .navbar-inverse .btn-link:focus,fieldset[disabled] .navbar-inverse .btn-link:hover{color:#444}.breadcrumb{padding:8px 15px;margin-bottom:20px;list-style:none;background-color:#f5f5f5;border-radius:4px}.breadcrumb>li{display:inline-block}.breadcrumb>li+li:before{padding:0 5px;color:#ccc;content:"/\00a0"}.breadcrumb>.active{color:#777}.pagination{display:inline-block;padding-left:0;margin:20px 0;border-radius:4px}.pagination>li{display:inline}.pagination>li>a,.pagination>li>span{position:relative;float:left;padding:6px 12px;margin-left:-1px;line-height:1.42857143;color:#337ab7;text-decoration:none;background-color:#fff;border:1px solid #ddd}.pagination>li:first-child>a,.pagination>li:first-child>span{margin-left:0;border-top-left-radius:4px;border-bottom-left-radius:4px}.pagination>li:last-child>a,.pagination>li:last-child>span{border-top-right-radius:4px;border-bottom-right-radius:4px}.pagination>li>a:focus,.pagination>li>a:hover,.pagination>li>span:focus,.pagination>li>span:hover{z-index:3;color:#23527c;background-color:#eee;border-color:#ddd}.pagination>.active>a,.pagination>.active>a:focus,.pagination>.active>a:hover,.pagination>.active>span,.pagination>.active>span:focus,.pagination>.active>span:hover{z-index:2;color:#fff;cursor:default;background-color:#337ab7;border-color:#337ab7}.pagination>.disabled>a,.pagination>.disabled>a:focus,.pagination>.disabled>a:hover,.pagination>.disabled>span,.pagination>.disabled>span:focus,.pagination>.disabled>span:hover{color:#777;cursor:not-allowed;background-color:#fff;border-color:#ddd}.pagination-lg>li>a,.pagination-lg>li>span{padding:10px 16px;font-size:18px;line-height:1.3333333}.pagination-lg>li:first-child>a,.pagination-lg>li:first-child>span{border-top-left-radius:6px;border-bottom-left-radius:6px}.pagination-lg>li:last-child>a,.pagination-lg>li:last-child>span{border-top-right-radius:6px;border-bottom-right-radius:6px}.pagination-sm>li>a,.pagination-sm>li>span{padding:5px 10px;font-size:12px;line-height:1.5}.pagination-sm>li:first-child>a,.pagination-sm>li:first-child>span{border-top-left-radius:3px;border-bottom-left-radius:3px}.pagination-sm>li:last-child>a,.pagination-sm>li:last-child>span{border-top-right-radius:3px;border-bottom-right-radius:3px}.pager{padding-left:0;margin:20px 0;text-align:center;list-style:none}.pager li{display:inline}.pager li>a,.pager li>span{display:inline-block;padding:5px 14px;background-color:#fff;border:1px solid #ddd;border-radius:15px}.pager li>a:focus,.pager li>a:hover{text-decoration:none;background-color:#eee}.pager .next>a,.pager .next>span{float:right}.pager .previous>a,.pager .previous>span{float:left}.pager .disabled>a,.pager .disabled>a:focus,.pager .disabled>a:hover,.pager .disabled>span{color:#777;cursor:not-allowed;background-color:#fff}.label{display:inline;padding:.2em .6em .3em;font-size:75%;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:baseline;border-radius:.25em}a.label:focus,a.label:hover{color:#fff;text-decoration:none;cursor:pointer}.label:empty{display:none}.btn .label{position:relative;top:-1px}.label-default{background-color:#777}.label-default[href]:focus,.label-default[href]:hover{background-color:#5e5e5e}.label-primary{background-color:#337ab7}.label-primary[href]:focus,.label-primary[href]:hover{background-color:#286090}.label-success{background-color:#5cb85c}.label-success[href]:focus,.label-success[href]:hover{background-color:#449d44}.label-info{background-color:#5bc0de}.label-info[href]:focus,.label-info[href]:hover{background-color:#31b0d5}.label-warning{background-color:#f0ad4e}.label-warning[href]:focus,.label-warning[href]:hover{background-color:#ec971f}.label-danger{background-color:#d9534f}.label-danger[href]:focus,.label-danger[href]:hover{background-color:#c9302c}.badge{display:inline-block;min-width:10px;padding:3px 7px;font-size:12px;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:middle;background-color:#777;border-radius:10px}.badge:empty{display:none}.btn .badge{position:relative;top:-1px}.btn-group-xs>.btn .badge,.btn-xs .badge{top:0;padding:1px 5px}a.badge:focus,a.badge:hover{color:#fff;text-decoration:none;cursor:pointer}.list-group-item.active>.badge,.nav-pills>.active>a>.badge{color:#337ab7;background-color:#fff}.list-group-item>.badge{float:right}.list-group-item>.badge+.badge{margin-right:5px}.nav-pills>li>a>.badge{margin-left:3px}.jumbotron{padding-top:30px;padding-bottom:30px;margin-bottom:30px;color:inherit;background-color:#eee}.jumbotron .h1,.jumbotron h1{color:inherit}.jumbotron p{margin-bottom:15px;font-size:21px;font-weight:200}.jumbotron>hr{border-top-color:#d5d5d5}.container .jumbotron,.container-fluid .jumbotron{border-radius:6px}.jumbotron .container{max-width:100%}@media screen and (min-width:768px){.jumbotron{padding-top:48px;padding-bottom:48px}.container .jumbotron,.container-fluid .jumbotron{padding-right:60px;padding-left:60px}.jumbotron .h1,.jumbotron h1{font-size:63px}}.thumbnail{display:block;padding:4px;margin-bottom:20px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:border .2s ease-in-out;-o-transition:border .2s ease-in-out;transition:border .2s ease-in-out}.thumbnail a>img,.thumbnail>img{margin-right:auto;margin-left:auto}a.thumbnail.active,a.thumbnail:focus,a.thumbnail:hover{border-color:#337ab7}.thumbnail .caption{padding:9px;color:#333}.alert{padding:15px;margin-bottom:20px;border:1px solid transparent;border-radius:4px}.alert h4{margin-top:0;color:inherit}.alert .alert-link{font-weight:700}.alert>p,.alert>ul{margin-bottom:0}.alert>p+p{margin-top:5px}.alert-dismissable,.alert-dismissible{padding-right:35px}.alert-dismissable .close,.alert-dismissible .close{position:relative;top:-2px;right:-21px;color:inherit}.alert-success{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.alert-success hr{border-top-color:#c9e2b3}.alert-success .alert-link{color:#2b542c}.alert-info{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.alert-info hr{border-top-color:#a6e1ec}.alert-info .alert-link{color:#245269}.alert-warning{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.alert-warning hr{border-top-color:#f7e1b5}.alert-warning .alert-link{color:#66512c}.alert-danger{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.alert-danger hr{border-top-color:#e4b9c0}.alert-danger .alert-link{color:#843534}@-webkit-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@-o-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}.progress{height:20px;margin-bottom:20px;overflow:hidden;background-color:#f5f5f5;border-radius:4px;-webkit-box-shadow:inset 0 1px 2px rgba(0,0,0,.1);box-shadow:inset 0 1px 2px rgba(0,0,0,.1)}.progress-bar{float:left;width:0;height:100%;font-size:12px;line-height:20px;color:#fff;text-align:center;background-color:#337ab7;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);-webkit-transition:width .6s ease;-o-transition:width .6s ease;transition:width .6s ease}.progress-bar-striped,.progress-striped .progress-bar{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);-webkit-background-size:40px 40px;background-size:40px 40px}.progress-bar.active,.progress.active .progress-bar{-webkit-animation:progress-bar-stripes 2s linear infinite;-o-animation:progress-bar-stripes 2s linear infinite;animation:progress-bar-stripes 2s linear infinite}.progress-bar-success{background-color:#5cb85c}.progress-striped .progress-bar-success{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-info{background-color:#5bc0de}.progress-striped .progress-bar-info{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-warning{background-color:#f0ad4e}.progress-striped .progress-bar-warning{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-danger{background-color:#d9534f}.progress-striped .progress-bar-danger{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.media{margin-top:15px}.media:first-child{margin-top:0}.media,.media-body{overflow:hidden;zoom:1}.media-body{width:10000px}.media-object{display:block}.media-object.img-thumbnail{max-width:none}.media-right,.media>.pull-right{padding-left:10px}.media-left,.media>.pull-left{padding-right:10px}.media-body,.media-left,.media-right{display:table-cell;vertical-align:top}.media-middle{vertical-align:middle}.media-bottom{vertical-align:bottom}.media-heading{margin-top:0;margin-bottom:5px}.media-list{padding-left:0;list-style:none}.list-group{padding-left:0;margin-bottom:20px}.list-group-item{position:relative;display:block;padding:10px 15px;margin-bottom:-1px;background-color:#fff;border:1px solid #ddd}.list-group-item:first-child{border-top-left-radius:4px;border-top-right-radius:4px}.list-group-item:last-child{margin-bottom:0;border-bottom-right-radius:4px;border-bottom-left-radius:4px}a.list-group-item,button.list-group-item{color:#555}a.list-group-item .list-group-item-heading,button.list-group-item .list-group-item-heading{color:#333}a.list-group-item:focus,a.list-group-item:hover,button.list-group-item:focus,button.list-group-item:hover{color:#555;text-decoration:none;background-color:#f5f5f5}button.list-group-item{width:100%;text-align:left}.list-group-item.disabled,.list-group-item.disabled:focus,.list-group-item.disabled:hover{color:#777;cursor:not-allowed;background-color:#eee}.list-group-item.disabled .list-group-item-heading,.list-group-item.disabled:focus .list-group-item-heading,.list-group-item.disabled:hover .list-group-item-heading{color:inherit}.list-group-item.disabled .list-group-item-text,.list-group-item.disabled:focus .list-group-item-text,.list-group-item.disabled:hover .list-group-item-text{color:#777}.list-group-item.active,.list-group-item.active:focus,.list-group-item.active:hover{z-index:2;color:#fff;background-color:#337ab7;border-color:#337ab7}.list-group-item.active .list-group-item-heading,.list-group-item.active .list-group-item-heading>.small,.list-group-item.active .list-group-item-heading>small,.list-group-item.active:focus .list-group-item-heading,.list-group-item.active:focus .list-group-item-heading>.small,.list-group-item.active:focus .list-group-item-heading>small,.list-group-item.active:hover .list-group-item-heading,.list-group-item.active:hover .list-group-item-heading>.small,.list-group-item.active:hover .list-group-item-heading>small{color:inherit}.list-group-item.active .list-group-item-text,.list-group-item.active:focus .list-group-item-text,.list-group-item.active:hover .list-group-item-text{color:#c7ddef}.list-group-item-success{color:#3c763d;background-color:#dff0d8}a.list-group-item-success,button.list-group-item-success{color:#3c763d}a.list-group-item-success .list-group-item-heading,button.list-group-item-success .list-group-item-heading{color:inherit}a.list-group-item-success:focus,a.list-group-item-success:hover,button.list-group-item-success:focus,button.list-group-item-success:hover{color:#3c763d;background-color:#d0e9c6}a.list-group-item-success.active,a.list-group-item-success.active:focus,a.list-group-item-success.active:hover,button.list-group-item-success.active,button.list-group-item-success.active:focus,button.list-group-item-success.active:hover{color:#fff;background-color:#3c763d;border-color:#3c763d}.list-group-item-info{color:#31708f;background-color:#d9edf7}a.list-group-item-info,button.list-group-item-info{color:#31708f}a.list-group-item-info .list-group-item-heading,button.list-group-item-info .list-group-item-heading{color:inherit}a.list-group-item-info:focus,a.list-group-item-info:hover,button.list-group-item-info:focus,button.list-group-item-info:hover{color:#31708f;background-color:#c4e3f3}a.list-group-item-info.active,a.list-group-item-info.active:focus,a.list-group-item-info.active:hover,button.list-group-item-info.active,button.list-group-item-info.active:focus,button.list-group-item-info.active:hover{color:#fff;background-color:#31708f;border-color:#31708f}.list-group-item-warning{color:#8a6d3b;background-color:#fcf8e3}a.list-group-item-warning,button.list-group-item-warning{color:#8a6d3b}a.list-group-item-warning .list-group-item-heading,button.list-group-item-warning .list-group-item-heading{color:inherit}a.list-group-item-warning:focus,a.list-group-item-warning:hover,button.list-group-item-warning:focus,button.list-group-item-warning:hover{color:#8a6d3b;background-color:#faf2cc}a.list-group-item-warning.active,a.list-group-item-warning.active:focus,a.list-group-item-warning.active:hover,button.list-group-item-warning.active,button.list-group-item-warning.active:focus,button.list-group-item-warning.active:hover{color:#fff;background-color:#8a6d3b;border-color:#8a6d3b}.list-group-item-danger{color:#a94442;background-color:#f2dede}a.list-group-item-danger,button.list-group-item-danger{color:#a94442}a.list-group-item-danger .list-group-item-heading,button.list-group-item-danger .list-group-item-heading{color:inherit}a.list-group-item-danger:focus,a.list-group-item-danger:hover,button.list-group-item-danger:focus,button.list-group-item-danger:hover{color:#a94442;background-color:#ebcccc}a.list-group-item-danger.active,a.list-group-item-danger.active:focus,a.list-group-item-danger.active:hover,button.list-group-item-danger.active,button.list-group-item-danger.active:focus,button.list-group-item-danger.active:hover{color:#fff;background-color:#a94442;border-color:#a94442}.list-group-item-heading{margin-top:0;margin-bottom:5px}.list-group-item-text{margin-bottom:0;line-height:1.3}.panel{margin-bottom:20px;background-color:#fff;border:1px solid transparent;border-radius:4px;-webkit-box-shadow:0 1px 1px rgba(0,0,0,.05);box-shadow:0 1px 1px rgba(0,0,0,.05)}.panel-body{padding:15px}.panel-heading{padding:10px 15px;border-bottom:1px solid transparent;border-top-left-radius:3px;border-top-right-radius:3px}.panel-heading>.dropdown .dropdown-toggle{color:inherit}.panel-title{margin-top:0;margin-bottom:0;font-size:16px;color:inherit}.panel-title>.small,.panel-title>.small>a,.panel-title>a,.panel-title>small,.panel-title>small>a{color:inherit}.panel-footer{padding:10px 15px;background-color:#f5f5f5;border-top:1px solid #ddd;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.list-group,.panel>.panel-collapse>.list-group{margin-bottom:0}.panel>.list-group .list-group-item,.panel>.panel-collapse>.list-group .list-group-item{border-width:1px 0;border-radius:0}.panel>.list-group:first-child .list-group-item:first-child,.panel>.panel-collapse>.list-group:first-child .list-group-item:first-child{border-top:0;border-top-left-radius:3px;border-top-right-radius:3px}.panel>.list-group:last-child .list-group-item:last-child,.panel>.panel-collapse>.list-group:last-child .list-group-item:last-child{border-bottom:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.panel-heading+.panel-collapse>.list-group .list-group-item:first-child{border-top-left-radius:0;border-top-right-radius:0}.panel-heading+.list-group .list-group-item:first-child{border-top-width:0}.list-group+.panel-footer{border-top-width:0}.panel>.panel-collapse>.table,.panel>.table,.panel>.table-responsive>.table{margin-bottom:0}.panel>.panel-collapse>.table caption,.panel>.table caption,.panel>.table-responsive>.table caption{padding-right:15px;padding-left:15px}.panel>.table-responsive:first-child>.table:first-child,.panel>.table:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child,.panel>.table:first-child>thead:first-child>tr:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table:first-child>thead:first-child>tr:first-child th:first-child{border-top-left-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table:first-child>thead:first-child>tr:first-child th:last-child{border-top-right-radius:3px}.panel>.table-responsive:last-child>.table:last-child,.panel>.table:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:first-child{border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:last-child{border-bottom-right-radius:3px}.panel>.panel-body+.table,.panel>.panel-body+.table-responsive,.panel>.table+.panel-body,.panel>.table-responsive+.panel-body{border-top:1px solid #ddd}.panel>.table>tbody:first-child>tr:first-child td,.panel>.table>tbody:first-child>tr:first-child th{border-top:0}.panel>.table-bordered,.panel>.table-responsive>.table-bordered{border:0}.panel>.table-bordered>tbody>tr>td:first-child,.panel>.table-bordered>tbody>tr>th:first-child,.panel>.table-bordered>tfoot>tr>td:first-child,.panel>.table-bordered>tfoot>tr>th:first-child,.panel>.table-bordered>thead>tr>td:first-child,.panel>.table-bordered>thead>tr>th:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:first-child,.panel>.table-responsive>.table-bordered>thead>tr>td:first-child,.panel>.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.panel>.table-bordered>tbody>tr>td:last-child,.panel>.table-bordered>tbody>tr>th:last-child,.panel>.table-bordered>tfoot>tr>td:last-child,.panel>.table-bordered>tfoot>tr>th:last-child,.panel>.table-bordered>thead>tr>td:last-child,.panel>.table-bordered>thead>tr>th:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:last-child,.panel>.table-responsive>.table-bordered>thead>tr>td:last-child,.panel>.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.panel>.table-bordered>tbody>tr:first-child>td,.panel>.table-bordered>tbody>tr:first-child>th,.panel>.table-bordered>thead>tr:first-child>td,.panel>.table-bordered>thead>tr:first-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>th,.panel>.table-responsive>.table-bordered>thead>tr:first-child>td,.panel>.table-responsive>.table-bordered>thead>tr:first-child>th{border-bottom:0}.panel>.table-bordered>tbody>tr:last-child>td,.panel>.table-bordered>tbody>tr:last-child>th,.panel>.table-bordered>tfoot>tr:last-child>td,.panel>.table-bordered>tfoot>tr:last-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>th,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>td,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}.panel>.table-responsive{margin-bottom:0;border:0}.panel-group{margin-bottom:20px}.panel-group .panel{margin-bottom:0;border-radius:4px}.panel-group .panel+.panel{margin-top:5px}.panel-group .panel-heading{border-bottom:0}.panel-group .panel-heading+.panel-collapse>.list-group,.panel-group .panel-heading+.panel-collapse>.panel-body{border-top:1px solid #ddd}.panel-group .panel-footer{border-top:0}.panel-group .panel-footer+.panel-collapse .panel-body{border-bottom:1px solid #ddd}.panel-default{border-color:#ddd}.panel-default>.panel-heading{color:#333;background-color:#f5f5f5;border-color:#ddd}.panel-default>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ddd}.panel-default>.panel-heading .badge{color:#f5f5f5;background-color:#333}.panel-default>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ddd}.panel-primary{border-color:#337ab7}.panel-primary>.panel-heading{color:#fff;background-color:#337ab7;border-color:#337ab7}.panel-primary>.panel-heading+.panel-collapse>.panel-body{border-top-color:#337ab7}.panel-primary>.panel-heading .badge{color:#337ab7;background-color:#fff}.panel-primary>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#337ab7}.panel-success{border-color:#d6e9c6}.panel-success>.panel-heading{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.panel-success>.panel-heading+.panel-collapse>.panel-body{border-top-color:#d6e9c6}.panel-success>.panel-heading .badge{color:#dff0d8;background-color:#3c763d}.panel-success>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#d6e9c6}.panel-info{border-color:#bce8f1}.panel-info>.panel-heading{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.panel-info>.panel-heading+.panel-collapse>.panel-body{border-top-color:#bce8f1}.panel-info>.panel-heading .badge{color:#d9edf7;background-color:#31708f}.panel-info>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#bce8f1}.panel-warning{border-color:#faebcc}.panel-warning>.panel-heading{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.panel-warning>.panel-heading+.panel-collapse>.panel-body{border-top-color:#faebcc}.panel-warning>.panel-heading .badge{color:#fcf8e3;background-color:#8a6d3b}.panel-warning>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#faebcc}.panel-danger{border-color:#ebccd1}.panel-danger>.panel-heading{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.panel-danger>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ebccd1}.panel-danger>.panel-heading .badge{color:#f2dede;background-color:#a94442}.panel-danger>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ebccd1}.embed-responsive{position:relative;display:block;height:0;padding:0;overflow:hidden}.embed-responsive .embed-responsive-item,.embed-responsive embed,.embed-responsive iframe,.embed-responsive object,.embed-responsive video{position:absolute;top:0;bottom:0;left:0;width:100%;height:100%;border:0}.embed-responsive-16by9{padding-bottom:56.25%}.embed-responsive-4by3{padding-bottom:75%}.well{min-height:20px;padding:19px;margin-bottom:20px;background-color:#f5f5f5;border:1px solid #e3e3e3;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.05);box-shadow:inset 0 1px 1px rgba(0,0,0,.05)}.well blockquote{border-color:#ddd;border-color:rgba(0,0,0,.15)}.well-lg{padding:24px;border-radius:6px}.well-sm{padding:9px;border-radius:3px}.close{float:right;font-size:21px;font-weight:700;line-height:1;color:#000;text-shadow:0 1px 0 #fff;filter:alpha(opacity=20);opacity:.2}.close:focus,.close:hover{color:#000;text-decoration:none;cursor:pointer;filter:alpha(opacity=50);opacity:.5}button.close{-webkit-appearance:none;padding:0;cursor:pointer;background:0 0;border:0}.modal-open{overflow:hidden}.modal{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1050;display:none;overflow:hidden;-webkit-overflow-scrolling:touch;outline:0}.modal.fade .modal-dialog{-webkit-transition:-webkit-transform .3s ease-out;-o-transition:-o-transform .3s ease-out;transition:transform .3s ease-out;-webkit-transform:translate(0,-25%);-ms-transform:translate(0,-25%);-o-transform:translate(0,-25%);transform:translate(0,-25%)}.modal.in .modal-dialog{-webkit-transform:translate(0,0);-ms-transform:translate(0,0);-o-transform:translate(0,0);transform:translate(0,0)}.modal-open .modal{overflow-x:hidden;overflow-y:auto}.modal-dialog{position:relative;width:auto;margin:10px}.modal-content{position:relative;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #999;border:1px solid rgba(0,0,0,.2);border-radius:6px;outline:0;-webkit-box-shadow:0 3px 9px rgba(0,0,0,.5);box-shadow:0 3px 9px rgba(0,0,0,.5)}.modal-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1040;background-color:#000}.modal-backdrop.fade{filter:alpha(opacity=0);opacity:0}.modal-backdrop.in{filter:alpha(opacity=50);opacity:.5}.modal-header{min-height:16.43px;padding:15px;border-bottom:1px solid #e5e5e5}.modal-header .close{margin-top:-2px}.modal-title{margin:0;line-height:1.42857143}.modal-body{position:relative;padding:15px}.modal-footer{padding:15px;text-align:right;border-top:1px solid #e5e5e5}.modal-footer .btn+.btn{margin-bottom:0;margin-left:5px}.modal-footer .btn-group .btn+.btn{margin-left:-1px}.modal-footer .btn-block+.btn-block{margin-left:0}.modal-scrollbar-measure{position:absolute;top:-9999px;width:50px;height:50px;overflow:scroll}@media (min-width:768px){.modal-dialog{width:600px;margin:30px auto}.modal-content{-webkit-box-shadow:0 5px 15px rgba(0,0,0,.5);box-shadow:0 5px 15px rgba(0,0,0,.5)}.modal-sm{width:300px}}@media (min-width:992px){.modal-lg{width:900px}}.tooltip{position:absolute;z-index:1070;display:block;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:12px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;filter:alpha(opacity=0);opacity:0;line-break:auto}.tooltip.in{filter:alpha(opacity=90);opacity:.9}.tooltip.top{padding:5px 0;margin-top:-3px}.tooltip.right{padding:0 5px;margin-left:3px}.tooltip.bottom{padding:5px 0;margin-top:3px}.tooltip.left{padding:0 5px;margin-left:-3px}.tooltip-inner{max-width:200px;padding:3px 8px;color:#fff;text-align:center;background-color:#000;border-radius:4px}.tooltip-arrow{position:absolute;width:0;height:0;border-color:transparent;border-style:solid}.tooltip.top .tooltip-arrow{bottom:0;left:50%;margin-left:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-left .tooltip-arrow{right:5px;bottom:0;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-right .tooltip-arrow{bottom:0;left:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.right .tooltip-arrow{top:50%;left:0;margin-top:-5px;border-width:5px 5px 5px 0;border-right-color:#000}.tooltip.left .tooltip-arrow{top:50%;right:0;margin-top:-5px;border-width:5px 0 5px 5px;border-left-color:#000}.tooltip.bottom .tooltip-arrow{top:0;left:50%;margin-left:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-left .tooltip-arrow{top:0;right:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-right .tooltip-arrow{top:0;left:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.popover{position:absolute;top:0;left:0;z-index:1060;display:none;max-width:276px;padding:1px;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.2);border-radius:6px;-webkit-box-shadow:0 5px 10px rgba(0,0,0,.2);box-shadow:0 5px 10px rgba(0,0,0,.2);line-break:auto}.popover.top{margin-top:-10px}.popover.right{margin-left:10px}.popover.bottom{margin-top:10px}.popover.left{margin-left:-10px}.popover-title{padding:8px 14px;margin:0;font-size:14px;background-color:#f7f7f7;border-bottom:1px solid #ebebeb;border-radius:5px 5px 0 0}.popover-content{padding:9px 14px}.popover>.arrow,.popover>.arrow:after{position:absolute;display:block;width:0;height:0;border-color:transparent;border-style:solid}.popover>.arrow{border-width:11px}.popover>.arrow:after{content:"";border-width:10px}.popover.top>.arrow{bottom:-11px;left:50%;margin-left:-11px;border-top-color:#999;border-top-color:rgba(0,0,0,.25);border-bottom-width:0}.popover.top>.arrow:after{bottom:1px;margin-left:-10px;content:" ";border-top-color:#fff;border-bottom-width:0}.popover.right>.arrow{top:50%;left:-11px;margin-top:-11px;border-right-color:#999;border-right-color:rgba(0,0,0,.25);border-left-width:0}.popover.right>.arrow:after{bottom:-10px;left:1px;content:" ";border-right-color:#fff;border-left-width:0}.popover.bottom>.arrow{top:-11px;left:50%;margin-left:-11px;border-top-width:0;border-bottom-color:#999;border-bottom-color:rgba(0,0,0,.25)}.popover.bottom>.arrow:after{top:1px;margin-left:-10px;content:" ";border-top-width:0;border-bottom-color:#fff}.popover.left>.arrow{top:50%;right:-11px;margin-top:-11px;border-right-width:0;border-left-color:#999;border-left-color:rgba(0,0,0,.25)}.popover.left>.arrow:after{right:1px;bottom:-10px;content:" ";border-right-width:0;border-left-color:#fff}.carousel{position:relative}.carousel-inner{position:relative;width:100%;overflow:hidden}.carousel-inner>.item{position:relative;display:none;-webkit-transition:.6s ease-in-out left;-o-transition:.6s ease-in-out left;transition:.6s ease-in-out left}.carousel-inner>.item>a>img,.carousel-inner>.item>img{line-height:1}@media all and (transform-3d),(-webkit-transform-3d){.carousel-inner>.item{-webkit-transition:-webkit-transform .6s ease-in-out;-o-transition:-o-transform .6s ease-in-out;transition:transform .6s ease-in-out;-webkit-backface-visibility:hidden;backface-visibility:hidden;-webkit-perspective:1000px;perspective:1000px}.carousel-inner>.item.active.right,.carousel-inner>.item.next{left:0;-webkit-transform:translate3d(100%,0,0);transform:translate3d(100%,0,0)}.carousel-inner>.item.active.left,.carousel-inner>.item.prev{left:0;-webkit-transform:translate3d(-100%,0,0);transform:translate3d(-100%,0,0)}.carousel-inner>.item.active,.carousel-inner>.item.next.left,.carousel-inner>.item.prev.right{left:0;-webkit-transform:translate3d(0,0,0);transform:translate3d(0,0,0)}}.carousel-inner>.active,.carousel-inner>.next,.carousel-inner>.prev{display:block}.carousel-inner>.active{left:0}.carousel-inner>.next,.carousel-inner>.prev{position:absolute;top:0;width:100%}.carousel-inner>.next{left:100%}.carousel-inner>.prev{left:-100%}.carousel-inner>.next.left,.carousel-inner>.prev.right{left:0}.carousel-inner>.active.left{left:-100%}.carousel-inner>.active.right{left:100%}.carousel-control{position:absolute;top:0;bottom:0;left:0;width:15%;font-size:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6);filter:alpha(opacity=50);opacity:.5}.carousel-control.left{background-image:-webkit-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.5)),to(rgba(0,0,0,.0001)));background-image:linear-gradient(to right,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#80000000', endColorstr='#00000000', GradientType=1);background-repeat:repeat-x}.carousel-control.right{right:0;left:auto;background-image:-webkit-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.0001)),to(rgba(0,0,0,.5)));background-image:linear-gradient(to right,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#00000000', endColorstr='#80000000', GradientType=1);background-repeat:repeat-x}.carousel-control:focus,.carousel-control:hover{color:#fff;text-decoration:none;filter:alpha(opacity=90);outline:0;opacity:.9}.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{position:absolute;top:50%;z-index:5;display:inline-block;margin-top:-10px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{left:50%;margin-left:-10px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{right:50%;margin-right:-10px}.carousel-control .icon-next,.carousel-control .icon-prev{width:20px;height:20px;font-family:serif;line-height:1}.carousel-control .icon-prev:before{content:'\2039'}.carousel-control .icon-next:before{content:'\203a'}.carousel-indicators{position:absolute;bottom:10px;left:50%;z-index:15;width:60%;padding-left:0;margin-left:-30%;text-align:center;list-style:none}.carousel-indicators li{display:inline-block;width:10px;height:10px;margin:1px;text-indent:-999px;cursor:pointer;background-color:#000\9;background-color:rgba(0,0,0,0);border:1px solid #fff;border-radius:10px}.carousel-indicators .active{width:12px;height:12px;margin:0;background-color:#fff}.carousel-caption{position:absolute;right:15%;bottom:20px;left:15%;z-index:10;padding-top:20px;padding-bottom:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6)}.carousel-caption .btn{text-shadow:none}@media screen and (min-width:768px){.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{width:30px;height:30px;margin-top:-15px;font-size:30px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{margin-left:-15px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{margin-right:-15px}.carousel-caption{right:20%;left:20%;padding-bottom:30px}.carousel-indicators{bottom:20px}}.btn-group-vertical>.btn-group:after,.btn-group-vertical>.btn-group:before,.btn-toolbar:after,.btn-toolbar:before,.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.dl-horizontal dd:after,.dl-horizontal dd:before,.form-horizontal .form-group:after,.form-horizontal .form-group:before,.modal-footer:after,.modal-footer:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.pager:after,.pager:before,.panel-body:after,.panel-body:before,.row:after,.row:before{display:table;content:" "}.btn-group-vertical>.btn-group:after,.btn-toolbar:after,.clearfix:after,.container-fluid:after,.container:after,.dl-horizontal dd:after,.form-horizontal .form-group:after,.modal-footer:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.pager:after,.panel-body:after,.row:after{clear:both}.center-block{display:block;margin-right:auto;margin-left:auto}.pull-right{float:right!important}.pull-left{float:left!important}.hide{display:none!important}.show{display:block!important}.invisible{visibility:hidden}.text-hide{font:0/0 a;color:transparent;text-shadow:none;background-color:transparent;border:0}.hidden{display:none!important}.affix{position:fixed}@-ms-viewport{width:device-width}.visible-lg,.visible-md,.visible-sm,.visible-xs{display:none!important}.visible-lg-block,.visible-lg-inline,.visible-lg-inline-block,.visible-md-block,.visible-md-inline,.visible-md-inline-block,.visible-sm-block,.visible-sm-inline,.visible-sm-inline-block,.visible-xs-block,.visible-xs-inline,.visible-xs-inline-block{display:none!important}@media (max-width:767px){.visible-xs{display:block!important}table.visible-xs{display:table!important}tr.visible-xs{display:table-row!important}td.visible-xs,th.visible-xs{display:table-cell!important}}@media (max-width:767px){.visible-xs-block{display:block!important}}@media (max-width:767px){.visible-xs-inline{display:inline!important}}@media (max-width:767px){.visible-xs-inline-block{display:inline-block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm{display:block!important}table.visible-sm{display:table!important}tr.visible-sm{display:table-row!important}td.visible-sm,th.visible-sm{display:table-cell!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-block{display:block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline{display:inline!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline-block{display:inline-block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md{display:block!important}table.visible-md{display:table!important}tr.visible-md{display:table-row!important}td.visible-md,th.visible-md{display:table-cell!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-block{display:block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline{display:inline!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline-block{display:inline-block!important}}@media (min-width:1200px){.visible-lg{display:block!important}table.visible-lg{display:table!important}tr.visible-lg{display:table-row!important}td.visible-lg,th.visible-lg{display:table-cell!important}}@media (min-width:1200px){.visible-lg-block{display:block!important}}@media (min-width:1200px){.visible-lg-inline{display:inline!important}}@media (min-width:1200px){.visible-lg-inline-block{display:inline-block!important}}@media (max-width:767px){.hidden-xs{display:none!important}}@media (min-width:768px) and (max-width:991px){.hidden-sm{display:none!important}}@media (min-width:992px) and (max-width:1199px){.hidden-md{display:none!important}}@media (min-width:1200px){.hidden-lg{display:none!important}}.visible-print{display:none!important}@media print{.visible-print{display:block!important}table.visible-print{display:table!important}tr.visible-print{display:table-row!important}td.visible-print,th.visible-print{display:table-cell!important}}.visible-print-block{display:none!important}@media print{.visible-print-block{display:block!important}}.visible-print-inline{display:none!important}@media print{.visible-print-inline{display:inline!important}}.visible-print-inline-block{display:none!important}@media print{.visible-print-inline-block{display:inline-block!important}}@media print{.hidden-print{display:none!important}}
</style>
<script>/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);</script>
<script>/**
* @preserve HTML5 Shiv 3.7.2 | @afarkas @jdalton @jon_neal @rem | MIT/GPL2 Licensed
*/
// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a,b){function c(a,b){var c=a.createElement("p"),d=a.getElementsByTagName("head")[0]||a.documentElement;return c.innerHTML="x<style>"+b+"</style>",d.insertBefore(c.lastChild,d.firstChild)}function d(){var a=t.elements;return"string"==typeof a?a.split(" "):a}function e(a,b){var c=t.elements;"string"!=typeof c&&(c=c.join(" ")),"string"!=typeof a&&(a=a.join(" ")),t.elements=c+" "+a,j(b)}function f(a){var b=s[a[q]];return b||(b={},r++,a[q]=r,s[r]=b),b}function g(a,c,d){if(c||(c=b),l)return c.createElement(a);d||(d=f(c));var e;return e=d.cache[a]?d.cache[a].cloneNode():p.test(a)?(d.cache[a]=d.createElem(a)).cloneNode():d.createElem(a),!e.canHaveChildren||o.test(a)||e.tagUrn?e:d.frag.appendChild(e)}function h(a,c){if(a||(a=b),l)return a.createDocumentFragment();c=c||f(a);for(var e=c.frag.cloneNode(),g=0,h=d(),i=h.length;i>g;g++)e.createElement(h[g]);return e}function i(a,b){b.cache||(b.cache={},b.createElem=a.createElement,b.createFrag=a.createDocumentFragment,b.frag=b.createFrag()),a.createElement=function(c){return t.shivMethods?g(c,a,b):b.createElem(c)},a.createDocumentFragment=Function("h,f","return function(){var n=f.cloneNode(),c=n.createElement;h.shivMethods&&("+d().join().replace(/[\w\-:]+/g,function(a){return b.createElem(a),b.frag.createElement(a),'c("'+a+'")'})+");return n}")(t,b.frag)}function j(a){a||(a=b);var d=f(a);return!t.shivCSS||k||d.hasCSS||(d.hasCSS=!!c(a,"article,aside,dialog,figcaption,figure,footer,header,hgroup,main,nav,section{display:block}mark{background:#FF0;color:#000}template{display:none}")),l||i(a,d),a}var k,l,m="3.7.2",n=a.html5||{},o=/^<|^(?:button|map|select|textarea|object|iframe|option|optgroup)$/i,p=/^(?:a|b|code|div|fieldset|h1|h2|h3|h4|h5|h6|i|label|li|ol|p|q|span|strong|style|table|tbody|td|th|tr|ul)$/i,q="_html5shiv",r=0,s={};!function(){try{var a=b.createElement("a");a.innerHTML="<xyz></xyz>",k="hidden"in a,l=1==a.childNodes.length||function(){b.createElement("a");var a=b.createDocumentFragment();return"undefined"==typeof a.cloneNode||"undefined"==typeof a.createDocumentFragment||"undefined"==typeof a.createElement}()}catch(c){k=!0,l=!0}}();var t={elements:n.elements||"abbr article aside audio bdi canvas data datalist details dialog figcaption figure footer header hgroup main mark meter nav output picture progress section summary template time video",version:m,shivCSS:n.shivCSS!==!1,supportsUnknownElements:l,shivMethods:n.shivMethods!==!1,type:"default",shivDocument:j,createElement:g,createDocumentFragment:h,addElements:e};a.html5=t,j(b)}(this,document);
};
</script>
<script>/*! Respond.js v1.4.2: min/max-width media query polyfill * Copyright 2013 Scott Jehl
 * Licensed under https://github.com/scottjehl/Respond/blob/master/LICENSE-MIT
 *  */

// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a){"use strict";a.matchMedia=a.matchMedia||function(a){var b,c=a.documentElement,d=c.firstElementChild||c.firstChild,e=a.createElement("body"),f=a.createElement("div");return f.id="mq-test-1",f.style.cssText="position:absolute;top:-100em",e.style.background="none",e.appendChild(f),function(a){return f.innerHTML='&shy;<style media="'+a+'"> #mq-test-1 { width: 42px; }</style>',c.insertBefore(e,d),b=42===f.offsetWidth,c.removeChild(e),{matches:b,media:a}}}(a.document)}(this),function(a){"use strict";function b(){u(!0)}var c={};a.respond=c,c.update=function(){};var d=[],e=function(){var b=!1;try{b=new a.XMLHttpRequest}catch(c){b=new a.ActiveXObject("Microsoft.XMLHTTP")}return function(){return b}}(),f=function(a,b){var c=e();c&&(c.open("GET",a,!0),c.onreadystatechange=function(){4!==c.readyState||200!==c.status&&304!==c.status||b(c.responseText)},4!==c.readyState&&c.send(null))};if(c.ajax=f,c.queue=d,c.regex={media:/@media[^\{]+\{([^\{\}]*\{[^\}\{]*\})+/gi,keyframes:/@(?:\-(?:o|moz|webkit)\-)?keyframes[^\{]+\{(?:[^\{\}]*\{[^\}\{]*\})+[^\}]*\}/gi,urls:/(url\()['"]?([^\/\)'"][^:\)'"]+)['"]?(\))/g,findStyles:/@media *([^\{]+)\{([\S\s]+?)$/,only:/(only\s+)?([a-zA-Z]+)\s?/,minw:/\([\s]*min\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/,maxw:/\([\s]*max\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/},c.mediaQueriesSupported=a.matchMedia&&null!==a.matchMedia("only all")&&a.matchMedia("only all").matches,!c.mediaQueriesSupported){var g,h,i,j=a.document,k=j.documentElement,l=[],m=[],n=[],o={},p=30,q=j.getElementsByTagName("head")[0]||k,r=j.getElementsByTagName("base")[0],s=q.getElementsByTagName("link"),t=function(){var a,b=j.createElement("div"),c=j.body,d=k.style.fontSize,e=c&&c.style.fontSize,f=!1;return b.style.cssText="position:absolute;font-size:1em;width:1em",c||(c=f=j.createElement("body"),c.style.background="none"),k.style.fontSize="100%",c.style.fontSize="100%",c.appendChild(b),f&&k.insertBefore(c,k.firstChild),a=b.offsetWidth,f?k.removeChild(c):c.removeChild(b),k.style.fontSize=d,e&&(c.style.fontSize=e),a=i=parseFloat(a)},u=function(b){var c="clientWidth",d=k[c],e="CSS1Compat"===j.compatMode&&d||j.body[c]||d,f={},o=s[s.length-1],r=(new Date).getTime();if(b&&g&&p>r-g)return a.clearTimeout(h),h=a.setTimeout(u,p),void 0;g=r;for(var v in l)if(l.hasOwnProperty(v)){var w=l[v],x=w.minw,y=w.maxw,z=null===x,A=null===y,B="em";x&&(x=parseFloat(x)*(x.indexOf(B)>-1?i||t():1)),y&&(y=parseFloat(y)*(y.indexOf(B)>-1?i||t():1)),w.hasquery&&(z&&A||!(z||e>=x)||!(A||y>=e))||(f[w.media]||(f[w.media]=[]),f[w.media].push(m[w.rules]))}for(var C in n)n.hasOwnProperty(C)&&n[C]&&n[C].parentNode===q&&q.removeChild(n[C]);n.length=0;for(var D in f)if(f.hasOwnProperty(D)){var E=j.createElement("style"),F=f[D].join("\n");E.type="text/css",E.media=D,q.insertBefore(E,o.nextSibling),E.styleSheet?E.styleSheet.cssText=F:E.appendChild(j.createTextNode(F)),n.push(E)}},v=function(a,b,d){var e=a.replace(c.regex.keyframes,"").match(c.regex.media),f=e&&e.length||0;b=b.substring(0,b.lastIndexOf("/"));var g=function(a){return a.replace(c.regex.urls,"$1"+b+"$2$3")},h=!f&&d;b.length&&(b+="/"),h&&(f=1);for(var i=0;f>i;i++){var j,k,n,o;h?(j=d,m.push(g(a))):(j=e[i].match(c.regex.findStyles)&&RegExp.$1,m.push(RegExp.$2&&g(RegExp.$2))),n=j.split(","),o=n.length;for(var p=0;o>p;p++)k=n[p],l.push({media:k.split("(")[0].match(c.regex.only)&&RegExp.$2||"all",rules:m.length-1,hasquery:k.indexOf("(")>-1,minw:k.match(c.regex.minw)&&parseFloat(RegExp.$1)+(RegExp.$2||""),maxw:k.match(c.regex.maxw)&&parseFloat(RegExp.$1)+(RegExp.$2||"")})}u()},w=function(){if(d.length){var b=d.shift();f(b.href,function(c){v(c,b.href,b.media),o[b.href]=!0,a.setTimeout(function(){w()},0)})}},x=function(){for(var b=0;b<s.length;b++){var c=s[b],e=c.href,f=c.media,g=c.rel&&"stylesheet"===c.rel.toLowerCase();e&&g&&!o[e]&&(c.styleSheet&&c.styleSheet.rawCssText?(v(c.styleSheet.rawCssText,e,f),o[e]=!0):(!/^([a-zA-Z:]*\/\/)/.test(e)&&!r||e.replace(RegExp.$1,"").split("/")[0]===a.location.host)&&("//"===e.substring(0,2)&&(e=a.location.protocol+e),d.push({href:e,media:f})))}w()};x(),c.update=x,c.getEmValue=t,a.addEventListener?a.addEventListener("resize",b,!1):a.attachEvent&&a.attachEvent("onresize",b)}}(this);
};
</script>
<script>

/**
 * jQuery Plugin: Sticky Tabs
 *
 * @author Aidan Lister <aidan@php.net>
 * adapted by Ruben Arslan to activate parent tabs too
 * http://www.aidanlister.com/2014/03/persisting-the-tab-state-in-bootstrap/
 */
(function($) {
  "use strict";
  $.fn.rmarkdownStickyTabs = function() {
    var context = this;
    // Show the tab corresponding with the hash in the URL, or the first tab
    var showStuffFromHash = function() {
      var hash = window.location.hash;
      var selector = hash ? 'a[href="' + hash + '"]' : 'li.active > a';
      var $selector = $(selector, context);
      if($selector.data('toggle') === "tab") {
        $selector.tab('show');
        // walk up the ancestors of this element, show any hidden tabs
        $selector.parents('.section.tabset').each(function(i, elm) {
          var link = $('a[href="#' + $(elm).attr('id') + '"]');
          if(link.data('toggle') === "tab") {
            link.tab("show");
          }
        });
      }
    };


    // Set the correct tab when the page loads
    showStuffFromHash(context);

    // Set the correct tab when a user uses their back/forward button
    $(window).on('hashchange', function() {
      showStuffFromHash(context);
    });

    // Change the URL when tabs are clicked
    $('a', context).on('click', function(e) {
      history.pushState(null, null, this.href);
      showStuffFromHash(context);
    });

    return this;
  };
}(jQuery));

window.buildTabsets = function(tocID) {

  // build a tabset from a section div with the .tabset class
  function buildTabset(tabset) {

    // check for fade and pills options
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // remove any table of contents entries associated with
      // this ID (since we'll be removing the heading element)
      $("div#" + tocID + " li a[href='#" + id + "']").parent().remove();

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it, grab it's text, then remove it
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();
      heading.remove();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children('li')[activeTab]).addClass('active');
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    if (tabset.hasClass("tabset-sticky"))
      tabset.rmarkdownStickyTabs();
  }

  // convert section divs with the .tabset class to tabsets
  var tabsets = $("div.section.tabset");
  tabsets.each(function(i) {
    buildTabset($(tabsets[i]));
  });
};

</script>
<style type="text/css">.hljs-literal {
color: #990073;
}
.hljs-number {
color: #099;
}
.hljs-comment {
color: #998;
font-style: italic;
}
.hljs-keyword {
color: #900;
font-weight: bold;
}
.hljs-string {
color: #d14;
}
</style>
<script src="data:application/javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>

<style type="text/css">code{white-space: pre;}</style>
<style type="text/css">
  pre:not([class]) {
    background-color: white;
  }
</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>



<style type="text/css">
h1 {
  font-size: 34px;
}
h1.title {
  font-size: 38px;
}
h2 {
  font-size: 30px;
}
h3 {
  font-size: 24px;
}
h4 {
  font-size: 18px;
}
h5 {
  font-size: 16px;
}
h6 {
  font-size: 12px;
}
.table th:not([align]) {
  text-align: left;
}
</style>




<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
code {
  color: inherit;
  background-color: rgba(0, 0, 0, 0.04);
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
</style>



<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  background: white;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="fluid-row" id="header">



<h1 class="title toc-ignore">PM566-Assignment3</h1>
<h4 class="author">Yina Liu</h4>
<h4 class="date">10/13/2020</h4>

</div>


<div id="apis" class="section level2">
<h2>APIs</h2>
<ol style="list-style-type: decimal">
<li>Using the NCBI API, look for papers that show up under the term “sars-cov-2 trial vaccine.” Look for the data in the pubmed database, and then retrieve the details of the paper as shown in lab 7. How many papers were you able to find?</li>
</ol>
<pre class="r"><code># Downloading the website
website &lt;- xml2::read_html(&quot;https://pubmed.ncbi.nlm.nih.gov/?term=sars-cov-2+trial+vaccine&quot;)
# Finding the counts
counts &lt;- xml2::xml_find_first(website, &quot;/html/body/main/div[9]/div[2]/div[2]/div[1]/span&quot;)
# Turning it into text
counts &lt;- as.character(counts)
# Extracting the data using regex
stringr::str_extract(counts, &quot;[0-9,]+&quot;)</code></pre>
<pre><code>## [1] &quot;560&quot;</code></pre>
<p>560 papers were retrieved with the term “sars-cov-2 trial vaccine”, which corresponds with the search on the PubMed database.</p>
<ol start="2" style="list-style-type: decimal">
<li>Using the list of pubmed ids you retrieved, download each papers’ details using the query parameter rettype = abstract. If you get more than 250 ids, just keep the first 250.</li>
</ol>
<pre class="r"><code>library(httr)
query_ids &lt;- GET(
  url   = &quot;https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi&quot;,
  query = list(
    db = &quot;pubmed&quot;,
               term = &quot;sars-cov-2 trial vaccine&quot;,
               retmax = 250)
)
# Extracting the content of the response of GET
ids &lt;- httr::content(query_ids)

# Turn the result into a character vector
ids &lt;- as.character(ids)
cat(ids)
# Find all the ids 
ids &lt;- stringr::str_extract_all(ids, &quot;&lt;Id&gt;[0-9]+&lt;/Id&gt;&quot;)[[1]]
# Remove all the leading and trailing &lt;Id&gt; &lt;/Id&gt;. Make use of &quot;|&quot;
ids &lt;- stringr::str_remove_all(ids, &quot;&lt;Id&gt;|&lt;/Id&gt;&quot;)

publications &lt;- GET(
  url   = &quot;https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi&quot;,
  query = list(
    db = &quot;pubmed&quot;,
    id = paste(ids, collapse=&quot;,&quot;),
      retmax = 250,
    rettype = &quot;abstract&quot;
    )
)
# Turning the output into character vector
publications &lt;- httr::content(publications)
publications_txt &lt;- as.character(publications)</code></pre>
<ol start="3" style="list-style-type: decimal">
<li>As we did in lab 7. Create a dataset containing the following: Pubmed ID number, Title of the paper, Name of the journal where it was published, Publication date, and Abstract of the paper (if any).</li>
</ol>
<pre class="r"><code>pub_char_list &lt;- xml2::xml_children(publications)
#Splits the xml file
pub_char_list &lt;- sapply(pub_char_list, as.character)

# get titles
titles &lt;- str_extract(pub_char_list, &quot;&lt;ArticleTitle&gt;(\\n|.)+&lt;/ArticleTitle&gt;&quot;)
titles &lt;- str_remove_all(titles, &quot;&lt;/?[[:alnum:]]+&gt;&quot;)
titles &lt;- str_replace_all(titles, &quot;\\s+&quot;, &quot; &quot;)
table(is.na(titles))

# get journals
journals &lt;- str_extract(pub_char_list, &quot;&lt;MedlineTA&gt;(\\n|.)+&lt;/MedlineTA&gt;&quot;)
table(is.na(journals))

# get publication date
dates3 &lt;- str_extract(pub_char_list, &quot;&lt;PubDate&gt;(\\n|.)+&lt;/PubDate&gt;&quot;)
dates3 &lt;- str_remove_all(dates3, &quot;&lt;/?[[:alpha:]]+&gt;&quot;)
dates4 &lt;- str_remove_all(dates3, &quot;\n&quot;)
dates &lt;- str_remove_all(dates4, &quot;&lt;/?[[:punct:]]+&gt;&quot;)
table(is.na(dates))

# get abstracts
abstracts &lt;- str_extract(pub_char_list, &quot;&lt;Abstract&gt;(\\n|.)+&lt;/Abstract&gt;&quot;)
abstracts &lt;- str_remove_all(abstracts, &quot;&lt;/?[[:alnum:]]+&gt;&quot;)
abstracts &lt;- str_replace_all(abstracts, &quot;\\s+&quot;, &quot; &quot;)
table(is.na(abstracts))</code></pre>
<pre class="r"><code># Table of Articles
database &lt;- data.frame(
  PubMedID = ids,
  Title = titles,
  Journal=journals,
  PublicationDate=dates,
  Abstract = abstracts
)
knitr::kable(database)</code></pre>
<table>
<colgroup>
<col width="0%"></col>
<col width="3%"></col>
<col width="0%"></col>
<col width="0%"></col>
<col width="95%"></col>
</colgroup>
<thead>
<tr class="header">
<th align="left">PubMedID</th>
<th align="left">Title</th>
<th align="left">Journal</th>
<th align="left">PublicationDate</th>
<th align="left">Abstract</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">33043110</td>
<td align="left">EXPLORING SURFACE GLYCOPROTEIN TO DESIGN MULTI-EPITOPE VACCINE AGAINST COVID-19.</td>
<td align="left"><MedlineTA>Inform Med Unlocked</MedlineTA></td>
<td align="left">2020 Oct 04</td>
<td align="left">Stimulation and generation of T and B cell mediated long-term immune response is essential for the curbing of a deadly virus such as SAR-CoV-2. Immunoinformatics approach in vaccine design takes advantage of antigenic and non-allergenic epitopes present on the spike glycoprotein of SARS-CoV-2 to elicit immune responses. T cells and B cells epitopes were predicted, and the selected residues were subjected to allergenicity, antigenicity and toxicity screening which were linked by appropriate linkers to form a multi-epitope subunit vaccine. The physiochemical properties of the vaccine construct was analyzed and the molecular weight, molecular formula, theoretical isoelectric point value, half-life, solubility score, instability index, aliphatic index and GRAVY were predicted. The vaccine structure was constructed, refined, validated, and disulfide engineered to get the best model. Molecular binding simulation and molecular dynamics simulation were carried out to predict the stability and binding affinity of the vaccine construct with TLRs. Codon acclimatization and in silico cloning were performed to confirm the vaccine expression and potency. Results obtained indicated that this novel vaccine candidate is non-toxic, capable of initiating the immunogenic response and will not induce an allergic reaction. The highest binding energy was observed in TLR 4 (-1398.1) and the least is TLR 2 (-1479. 6). The steady rise in Th (helper) cell population with memory development was noticed and IFN-g was provoked after simulation. At this point, the vaccine candidate awaits animal trial to validate its efficacy and safety for use in the prevention of the novel COVID-19 infections. © 2020 The Author(s).</td>
</tr>
<tr class="even">
<td align="left">33042591</td>
<td align="left">Impact of COVID-19 on clinical trials and clinical research: A systematic review.</td>
<td align="left"><MedlineTA>Nepal J Epidemiol</MedlineTA></td>
<td align="left">2020 Sep</td>
<td align="left">Background: The World Health Organization has reported more than 31,186,000 confirmed cases of coronavirus disease-19 (COVID-19), including 962,343 deaths, worldwide as on September 21, 2020. The current COVID-19 pandemic is affecting clinical research activities in most parts of the world. The focus on developing a vaccine for SARS-CoV-2 and the treatment of COVID-19 is, in fact, disrupting many upcoming and/or ongoing clinical trials on other diseases around the globe. On March 18, 2020, the United States Food and Drug Administration (FDA) issued an updated guideline for the conduct of clinical trials during the current health emergency situation. The potential challenges, such as social distancing and quarantines, result in study participants’ inaccessibility and trial personnel for in-person scheduled study visits and/or follow-up. Due to the sudden onset and wide-spread impact of COVID-19, its influence on the management of clinical trials and research necessitates urgent attention. Therefore, our systematic review of the literature aims to assess the impact of the COVID-19 pandemic on the conduction of clinical trials and research. The search for the relevant articles for review included the keywords “COVID-19” AND “clinical trial” in PubMed, MEDLINE, Embase, Google scholar and Google electronic databases. Key findings include: delaying subject enrollment and operational gaps in most ongoing clinical trials, which in turn has a negative impact on trial programmes and data integrity. Globally, most sites conducting clinical trials other than COVID-19 are experiencing a delay in timelines and a complete halt of operations in lieu of this pandemic, thus affecting clinical research outcomes. © 2020 CEA&amp; INEA.</td>
</tr>
<tr class="odd">
<td align="left">33038433</td>
<td align="left">COVID-19: discovery, diagnostics and drug development.</td>
<td align="left"><MedlineTA>J Hepatol</MedlineTA></td>
<td align="left">2020 Oct 07</td>
<td align="left">An epidemic of acute respiratory syndrome (Covid-19) started in humans in Wuhan in 2019, and became a pandemic. Groups from China Identified and sequenced the virus responsible for COVID-19, named SARS-CoV-2, and determined that it was a novel coronavirus (CoV) that shared high sequence identity with bat- and pangolin-derived SARS-like CoVs, suggesting a zoonotic origin. SARS-CoV-2 is a member of Coronaviridae, a family of enveloped, positive-sense, single-stranded RNA viruses that infect a broad range of vertebrates. The rapid release of the sequence of the virus has allowed the development of diagnostic tools (e.g., RT-PCR). Additionally, serological tests can allow identification of persons who have been infected. In humans, CoVs tend to cause mild to moderate upper respiratory tract infections. The fatality rate is around 1-3% for infected persons. An acute respiratory distress syndrome (ARDS) likely due to an uncontrolled immune activation (“cytokine storm”) occurs in patients with severe disease and poor prognosis. Risk factors for mortality include: advanced age, obesity, diabetes, hypertension and other comorbidities. Drug repurposing has been used to rapidly identify potential treatment for COVID-19, which could move quickly to phase-3. Better knowledge of the virus, its enzymes, will be mandatory to develop more potent and specific direct-acting antiviral agents (DAA). In the long term, a vaccine to prevent infection would be crucial; however even if successful it might not be available before 2021-22. To date, with the exception of intravenous Remdesivir and dexamethasone, which have modest effects in moderate to severe COVID-19, no strong clinical evidence supports the efficacy and safety of any other drugs against SARS-CoV-2. The aim of this review is to provide insights on the discovery of SARS-CoV-2, its virology, the diagnostic tools, and the ongoing drug discovery effort. Copyright © 2020 European Association for the Study of the Liver. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">33022293</td>
<td align="left">Clinical trial protocols of repurposed prophylaxis for COVID-19: a review.</td>
<td align="left"><MedlineTA>Med Mal Infect</MedlineTA></td>
<td align="left">2020 Oct 03</td>
<td align="left">Efficient therapeutic strategies are needed to counter the COVID-19 pandemic, caused by the SARS-CoV-2 virus. In a context where specific vaccines are not yet available, the containment of the pandemic would be facilitated with efficient prophylaxis. We screened several clinical trials repositories and platforms in search of the prophylactic strategies being investigated against COVID-19 in July 2020. Up to July 5, 2020, only one clinical trial result was published, although we found 112 clinical trial protocols targeting medical workers (n=70, 63%), patients relatives (n=20, 18%) or individuals at risk of severe COVID-19 (n=14, 13%). (Hydroxy)chloroquine was the most frequently evaluated treatment (n=69, 62%), before BCG vaccine (n=12, 11%), this followed by numerous antivirals and immune enhancers. Ninety-eight (88%) clinical trials were randomized with a median of planned inclusions of 530 (IQR 258-1299). Both pre- and post-exposure prophylaxes are investigated. Copyright © 2020 Elsevier Masson SAS. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">33013255</td>
<td align="left">Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease.</td>
<td align="left"><MedlineTA>Int J Pept Res Ther</MedlineTA></td>
<td align="left">2020 Sep 28</td>
<td align="left">At the end of December 2019, a new strain of coronavirus was identified in the Wuhan city of Hubei province in China. Within a shorter period of time, an unprecedented outbreak of this strain was witnessed over the entire Wuhan city. This novel coronavirus strain was later officially renamed as COVID-19 (Coronavirus disease 2019) by the World Health Organization. The mode of transmission was human-to-human contact and hence resulted in a rapid surge across the globe where more than 24 million people have been infected with COVID-19. In the current scenario, finding potent drug candidates for the treatment of COVID-19 has emerged as the most challenging task for clinicians and researchers worldwide. Identification of new drugs and vaccine development may take from a few months to years based on the clinical trial processes. To overcome the several limitations involved in identifying and bringing out potent drug candidates for treating COVID-19, in the present study attempts were made to screen the FDA approved drugs using High Throughput Virtual Screening (HTVS). The COVID-19 main protease (COVID-19 Mpro) was chosen as the drug target for which the FDA approved drugs were initially screened with HTVS. The drug candidates that exhibited favorable docking score, energy, and emodel calculations were further taken for performing Induced Fit Docking (IFD) using Schrodinger’s GLIDE. From the flexible docking results, the following four FDA approved drugs Sincalide, Pentagastrin, Ritonavir, and Phytonadione were identified. In particular, Sincalide and Pentagastrin can be considered potential key players for the treatment of COVID-19 disease. © Springer Nature B.V. 2020.</td>
</tr>
<tr class="even">
<td align="left">33012348</td>
<td align="left">SARS-CoV-2 Vaccine Development: Current Status.</td>
<td align="left"><MedlineTA>Mayo Clin Proc</MedlineTA></td>
<td align="left">2020 10</td>
<td align="left">In the midst of the severe acute respiratory syndrome coronavirus 2 pandemic and its attendant morbidity and mortality, safe and efficacious vaccines are needed that induce protective and long-lived immune responses. More than 120 vaccine candidates worldwide are in various preclinical and phase 1 to 3 clinical trials that include inactivated, live-attenuated, viral-vectored replicating and nonreplicating, protein- and peptide-based, and nucleic acid approaches. Vaccines will be necessary both for individual protection and for the safe development of population-level herd immunity. Public-private partnership collaborative efforts, such as the Accelerating COVID-19 Therapeutic Interventions and Vaccines mechanism, are key to rapidly identifying safe and effective vaccine candidates as quickly and efficiently as possible. In this article, we review the major vaccine approaches being taken and issues that must be resolved in the quest for vaccines to prevent coronavirus disease 2019. For this study, we scanned the PubMed database from 1963 to 2020 for all publications using the following search terms in various combinations: SARS, MERS, COVID-19, SARS-CoV-2, vaccine, clinical trial, coronavirus, pandemic, and vaccine development. We also did a Web search for these same terms. In addition, we examined the World Health Organization, Centers for Disease Control and Prevention, and other public health authority websites. We excluded abstracts and all articles that were not written in English. Copyright © 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32998488</td>
<td align="left">Status of COVID-19 vaccine development.</td>
<td align="left"><MedlineTA>Tidsskr Nor Laegeforen</MedlineTA></td>
<td align="left">2020 09 29</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32998157</td>
<td align="left">COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 Sep 30</td>
<td align="left">An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase 1/2 coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein1. Here we present antibody and T-cell responses after BNT162b1 vaccination from a second, non-randomized open-label phase 1/2 trial in healthy adults, 18-55 years of age. Two doses of 1 to 50 µg of BNT162b1 elicited robust CD4+ and CD8+ T-cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those in a COVID-19 human convalescent sample (HCS) panel. Day 43 SARS-CoV-2 serum neutralising geometric mean titers were 0.7-fold (1 µg) to 3.5-fold (50 µg) those of the HCS panel. Immune sera broadly neutralised pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (TH1) skewed T cell immune responses with RBD-specific CD8+ and CD4+ T-cell expansion. Interferon (IFN)γ was produced by a high fraction of RBD-specific CD8+ and CD4+ T cells. The robust RBD-specific antibody, T-cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest multiple beneficial mechanisms with potential to protect against COVID-19.</td>
</tr>
<tr class="odd">
<td align="left">32997699</td>
<td align="left">Analysis of COVID-19 clinical trials: A data-driven, ontology-based, and natural language processing approach.</td>
<td align="left"><MedlineTA>PLoS One</MedlineTA></td>
<td align="left">2020</td>
<td align="left">With the novel COVID-19 pandemic disrupting and threatening the lives of millions, researchers and clinicians have been recently conducting clinical trials at an unprecedented rate to learn more about the virus and potential drugs/treatments/vaccines to treat its infection. As a result of the influx of clinical trials, researchers, clinicians, and the lay public, now more than ever, face a significant challenge in keeping up-to-date with the rapid rate of discoveries and advances. To remedy this problem, this research mined the ClinicalTrials.gov corpus to extract COVID-19 related clinical trials, produce unique reports to summarize findings and make the meta-data available via Application Programming Interfaces (APIs). Unique reports were created for each drug/intervention, Medical Subject Heading (MeSH) term, and Human Phenotype Ontology (HPO) term. These reports, which have been run over multiple time points, along with APIs to access meta-data, are freely available at <a href="http://covidresearchtrials.com" class="uri">http://covidresearchtrials.com</a>. The pipeline, reports, association of COVID-19 clinical trials with MeSH and HPO terms, insights, public repository, APIs, and correlations produced are all novel in this work. The freely available, novel resources present up-to-date relevant biological information and insights in a robust, accessible manner, illustrating their invaluable potential to aid researchers overcome COVID-19 and save hundreds of thousands of lives.</td>
</tr>
<tr class="even">
<td align="left">32994572</td>
<td align="left">COVID vaccine confidence requires radical transparency.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 10</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32991794</td>
<td align="left">Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.</td>
<td align="left"><MedlineTA>N Engl J Med</MedlineTA></td>
<td align="left">2020 Sep 29</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age. <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein (S-2P) in healthy adults. The trial was expanded to include 40 older adults, who were stratified according to age (56 to 70 years or ≥71 years). All the participants were assigned sequentially to receive two doses of either 25 μg or 100 μg of vaccine administered 28 days apart. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Solicited adverse events were predominantly mild or moderate in severity and most frequently included fatigue, chills, headache, myalgia, and pain at the injection site. Such adverse events were dose-dependent and were more common after the second immunization. Binding-antibody responses increased rapidly after the first immunization. By day 57, among the participants who received the 25-μg dose, the anti-S-2P geometric mean titer (GMT) was 323,945 among those between the ages of 56 and 70 years and 1,128,391 among those who were 71 years of age or older; among the participants who received the 100-μg dose, the GMT in the two age subgroups was 1,183,066 and 3,638,522, respectively. After the second immunization, serum neutralizing activity was detected in all the participants by multiple methods. Binding- and neutralizing-antibody responses appeared to be similar to those previously reported among vaccine recipients between the ages of 18 and 55 years and were above the median of a panel of controls who had donated convalescent serum. The vaccine elicited a strong CD4 cytokine response involving type 1 helper T cells. <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 Study ClinicalTrials.gov number, NCT04283461.). Copyright © 2020 Massachusetts Medical Society.</td>
</tr>
<tr class="even">
<td align="left">32988688</td>
<td align="left">Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic.</td>
<td align="left"><MedlineTA>Vaccine</MedlineTA></td>
<td align="left">2020 10 21</td>
<td align="left"><AbstractText Label="INTRODUCTION">The world is facing the COVID-19 pandemic. The development of a vaccine is challenging. We aimed to determine the proportion of people who intend to get vaccinated against COVID-19 in France or to participate in a vaccine clinical trial. <AbstractText Label="METHODS">We conducted an anonymous on-line survey from the 26th of March to the 20th of April 2020. Primary endpoints were the intention to get vaccinated against COVID-19 if a vaccine was available or participate in a vaccine clinical trial. <AbstractText Label="RESULTS">Three thousand two hundred and fifty nine individuals answered the survey; women accounted for 67.4% of the respondents. According to their statements, 2.512 participants (77.6%, 95% CI 76.2-79%) will certainly or probably agree to get vaccinated against COVID-19. Older age, male gender, fear about COVID-19, being a healthcare worker and individual perceived risk were associated with COVID-19 vaccine acceptance. Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance. One thousand and five hundred and fifty respondents (47.6% 95% CI 45.9-49.3%) will certainly or probably agree to participate in a COVID-19 vaccine clinical trial. Older age, male gender, being a healthcare worker and individual perceived risk were associated with potential acceptance to participate in a COVID-19 vaccine clinical trial. Vaccine hesitancy was associated with refusal for participation in a COVID-19 vaccine clinical trial. <AbstractText Label="CONCLUSIONS">Nearly 75% and 48% of the survey respondents were respectively likely to accept vaccination or participation in a clinical trial against COVID-19. Vaccine hesitancy will be the major barrier to COVID-19 vaccine uptake. Copyright © 2020 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32985963</td>
<td align="left">Coronavirus Disease 2019 Vaccine Development: An Overview.</td>
<td align="left"><MedlineTA>Viral Immunol</MedlineTA></td>
<td align="left">2020 Sep 23</td>
<td align="left">To this day, the coronavirus disease 2019 (COVID-19) pandemic has not shown signs of abating. Moreover, the virus responsible for the pandemic, severe acute respiratory syndrome coronavirus 2, has evolved into three different variants. This phenomenon highlights an even greater need to develop drugs and vaccines to control the rate of infection and spread of the disease. As of July 7, 2020, at least 160 vaccine candidates, 21 of which have entered the clinical trial phase, have been developed. This article describes the latest advances in development, reliable platforms, strategies used, and challenges that remain in developing COVID-19 vaccines.</td>
</tr>
<tr class="even">
<td align="left">32978611</td>
<td align="left">COVID-vaccine results are on the way - and scientists’ concerns are growing.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 10</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32974268</td>
<td align="left">Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs.</td>
<td align="left"><MedlineTA>Front Public Health</MedlineTA></td>
<td align="left">2020</td>
<td align="left">SARS-CoV-2 rapidly spread from China until it was defined a pandemic by WHO in March 2020. Related scientific papers have rapidly extended information regarding the diagnosis, treatment and epidemiology of COVID-19 infection. To date, no vaccine or definitive treatment is available to defeat the virus and therapies are mainly based on existing drugs used to treat other conditions. Existing therapies used in several clinical trials work by affecting the biology of COVID-19 and/or counteracting the harmful host excessive immune response. Here, we have reviewed 526 ongoing clinical trials for COVID-19 to provide a perspective on the first 6 months of global efforts to identify an effective therapy. The drugs most actively tested in various centers include hydroxychloroquine, ritonavir, azithromycin, tocilizumab, lopinavir chloroquine and ivermectin. Our analysis shows that most clinical trials focus on a small number of candidate drugs (namely hydroxychloroquine and chloroquine representing 25% of total clinical trials) while underestimating the potential of other promising drugs. A global coordination in clinical trial management could avoid duplications and increase the effectiveness of the response to the global challenge. Copyright © 2020 Idda, Soru and Floris.</td>
</tr>
<tr class="even">
<td align="left">32973779</td>
<td align="left">The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.</td>
<td align="left"><MedlineTA>Front Immunol</MedlineTA></td>
<td align="left">2020</td>
<td align="left">Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome infecting animals and humans. Coronaviruses have been described more than 70 years ago and contain many species. Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) are lethal species caused by human coronaviruses (HCoVs). Currently, a novel strain of HCoVs, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19). SARS-CoV-2 was first identified in December 2019 in Wuhan, the capital city of the Hubei province of China, and has since spread worldwide causing an outbreak in more than 200 countries. The SARS-CoV-2 outbreak was declared a pandemic on March 11th, 2020 and a public health emergency of international concern (PHEIC) in late January 2020 by the World Health Organization (WHO). SARS-CoV-2 infects the respiratory tract causing flu-like symptoms and, in some, may cause severe illness like pneumonia and multi-organ failure leading to death. Today, Covid-19 cases almost reaching 9 million, with more than 450 thousand deaths. There is an urgent demand for developing a vaccine since no effective therapies or vaccines have been approved to this day to prevent or minimize the spread of the infection. In this review, we summarized the furthest vaccines in the clinical pipeline. Copyright © 2020 Alturki, Alturki, Connors, Cusimano, Kutzler, Izmirly and Haddad.</td>
</tr>
<tr class="odd">
<td align="left">32969973</td>
<td align="left">Coronavirus disease-19 vaccine development utilizing promising technology.</td>
<td align="left"><MedlineTA>Curr Opin HIV AIDS</MedlineTA></td>
<td align="left">2020 11</td>
<td align="left"><AbstractText Label="PURPOSE OF REVIEW">Coronavirus disease-19 (COVID-19) is a highly transmittable and pathogenic pneumonia-causing disease, which is caused by severe acute respiratory syndrome coronavirus-2, resulting in millions of deaths globally. Severe acute respiratory syndrome coronavirus-2 may coexist with human populations for a long time. Therefore, high-effective COVID-19 vaccines are an urgent need. <AbstractText Label="RECENT FINDINGS">Vaccines help in the development of long-lasting humoral or cellular immunity, or both, by exposing individuals to antigens that induce an immunological response and memory prior to infections with live pathogens. New vaccine technologies, such as viral vectors and nucleic acid-based vaccines, which represent highly versatile technologies, may allow for faster vaccine manufacture and scale up production. <AbstractText Label="SUMMARY">We summarized the recent progress made in relation to COVID-19 vaccine development using several promising technologies, with particular emphasis on advancements that are currently at the clinical trial stage.</td>
</tr>
<tr class="even">
<td align="left">32969369</td>
<td align="left">Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19.</td>
<td align="left"><MedlineTA>J Nepal Health Res Counc</MedlineTA></td>
<td align="left">2020 Sep 07</td>
<td align="left">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), a respiratory illness. COVID-19 has now become a global public health crisis causing alarming numbers of morbidity and mortality. Ever since the COVID-19 pandemic started scientists, researchers, universities, companies, and institutions all around the world have been endeavoring to discover a potential treatment for COVID-19. Numerous studies and clinical trials on vaccines and drugs for the prevention and treatment of COVID-19 are underway across the world. However, the uncertainty around the efficacy and safety of various treatment regimens have become one of the biggest challenges in the battle against the SARS-CoV-2. This paper is a narrative review of articles regarding the various treatments and vaccines being tested for the SARS-CoV-2, available in the PubMed database along with Google Scholar. There are ongoing clinical trials on potential drugs such as remdesivir, favipiravir, lopinavir/ritonavir, chloroquine, and hydroxychloroquine, corticosteroids tocilizumab, azithromycin, anakinra, etc. and other therapeutic modalities like convalescent plasma therapy. Likewise, vaccines against SARS-CoV-2 are being developed and tested, including mRNA, non-replicating viral vector, DNA, protein subunit candidate vaccines, etc. Although some early-stage clinical trials and studies on these drugs and vaccines have shown positive results, definitive and conclusive results are yet to be obtained. Keywords: COVID-19; antiviral drugs; COVID-19 treatment; COVID-19 vaccine; SARS-CoV-2.</td>
</tr>
<tr class="odd">
<td align="left">32967006</td>
<td align="left">SARS-CoV-2 vaccines in development.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 Sep 23</td>
<td align="left">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are currently more than 180 vaccines at various stages of development. Data from phase I and phase II trials are already available for several vaccine candidates, and many have moved into phase III trials. The data available so far suggest that effective and safe vaccines might become available within months, rather than years.</td>
</tr>
<tr class="even">
<td align="left">32963672</td>
<td align="left">Expedited COVID-19 vaccine trials: a rat-race with challenges and ethical issues.</td>
<td align="left"><MedlineTA>Pan Afr Med J</MedlineTA></td>
<td align="left">2020</td>
<td align="left">The intense global efforts are directed towards development of vaccines to halt the COVID-19 virus pandemic. There are 160 candidate vaccines under clinical trials across the world using different molecular targets and techniques. This race for the vaccine has several challenges and ethical issues like compressed timelines, generation and proper management of resources and finances, risks to the participating volunteers due to curtailed research trial processes, geopolitical contentions, misinformation through social media and parallel race with drugs. We feel that the fundamental principles of ethics: autonomy, beneficence, non-maleficence and justice should not be violated in this hastened vaccine development process. We recommend constitute a Consortium on a global platform to formulate, provide and monitor a comprehensive ethical umbrella to the process of vaccine development. Copyright: Prathamesh Haridas Kamble et al.</td>
</tr>
<tr class="odd">
<td align="left">32958009</td>
<td align="left">The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019.</td>
<td align="left"><MedlineTA>J Transl Med</MedlineTA></td>
<td align="left">2020 09 21</td>
<td align="left">More than seven months into the coronavirus disease -19 (COVID-19) pandemic, infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 21.2 million cases and resulted in over 760,000 deaths worldwide so far. As a result, COVID-19 has changed all our lives as we battle to curtail the spread of the infection in the absence of specific therapies against coronaviruses and in anticipation of a proven safe and efficacious vaccine. Common with previous outbreaks of coronavirus infections, SARS and Middle East respiratory syndrome, COVID-19 can lead to acute respiratory distress syndrome (ARDS) that arises due to an imbalanced immune response. While several repurposed antiviral and host-response drugs are under examination as potential treatments, other novel therapeutics are also being explored to alleviate the effects on critically ill patients. The use of mesenchymal stromal cells (MSCs) for COVID-19 has become an attractive avenue down which almost 70 different clinical trial teams have ventured. Successfully trialled for the treatment of other conditions such as multiple sclerosis, osteoarthritis and graft versus host disease, MSCs possess both regenerative and immunomodulatory properties, the latter of which can be harnessed to reduce the severity and longevity of ARDS in patients under intensive care due to SARS-CoV-2 infection.</td>
</tr>
<tr class="even">
<td align="left">32943115</td>
<td align="left">Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.</td>
<td align="left"><MedlineTA>Trials</MedlineTA></td>
<td align="left">2020 Sep 17</td>
<td align="left"><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The Bacille Calmette-Guérin (BCG) vaccine against tuberculosis is associated with non- specific protective effects against other infections, and significant reductions in all-cause morbidity and mortality have been reported. We aim to test whether BCG vaccination may reduce susceptibility to and/or the severity of COVID-19 and other infectious diseases in health care workers (HCW) and thus prevent work absenteeism.The primary objective is to reduce absenteeism due to illness among HCW during the COVID-19 pandemic. The secondary objectives are to reduce the number of HCW that are infected with SARS-CoV-2, and to reduce the number of hospital admissions among HCW during the COVID-19 pandemic. <AbstractText Label="HYPOTHESIS" NlmCategory="OBJECTIVE">BCG vaccination of HCW will reduce absenteeism by 20% over a period of 6 months. <AbstractText Label="TRIAL DESIGN" NlmCategory="METHODS">Placebo-controlled, single-blinded, randomised controlled trial, recruiting study participants at several geographic locations. The BCG vaccine is used in this study on a different indication than the one it has been approved for by the Danish Medicines Agency, therefore this is classified as a phase III study. <AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">The trial will recruit 1,500 HCW at Danish hospitals.To be eligible for participation, a subject must meet the following criteria: Adult (≥18 years); Hospital personnel working at a participating hospital for more than 22 hours per week.A potential subject who meets any of the following criteria will be excluded from participation in this study: Known allergy to components of the BCG vaccine or serious adverse events to prior BCG administration Known prior active or latent infection with Mycobacterium tuberculosis (M. tuberculosis) or other mycobacterial species Previous confirmed COVID-19 Fever (&gt;38 C) within the past 24 hours Suspicion of active viral or bacterial infection Pregnancy Breastfeeding Vaccination with other live attenuated vaccine within the last 4 weeks Severely immunocompromised subjects. This exclusion category comprises: a) subjects with known infection by the human immunodeficiency virus (HIV-1) b) subjects with solid organ transplantation c) subjects with bone marrow transplantation d) subjects under chemotherapy e) subjects with primary immunodeficiency f) subjects under treatment with any anti-cytokine therapy within the last year g) subjects under treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months h) Active solid or non-solid malignancy or lymphoma within the prior two years Direct involvement in the design or the execution of the BCG-DENMARK-COVID trial Intervention and comparator: Participants will be randomised to BCG vaccine (BCG-Denmark, AJ Vaccines, Copenhagen, Denmark) or placebo (saline). An adult dose of 0.1 ml of resuspended BCG vaccine (intervention) or 0.1 ml of sterile 0.9% NaCl solution (control) is administered intradermally in the upper deltoid area of the right arm. All participants will receive one injection at inclusion, and no further treatment of study participants will take place. <AbstractText Label="MAIN OUTCOMES" NlmCategory="RESULTS">Main study endpoint: Days of unplanned absenteeism due to illness within 180 days of randomisation.Secondary study endpoints: The cumulative incidence of documented COVID-19 and the cumulative incidence of hospital admission for any reason within 180 days of randomisation.Randomisation: Randomisation will be done centrally using the REDCap tool with stratification by hospital, sex and age groups (+/- 45 years of age) in random blocks of 4 and 6. The allocation ratio is 1:1.Blinding (masking): Participants will be blinded to treatment. The participant will be asked to leave the room while the allocated treatment is prepared. Once ready for injection, vaccine and placebo will look similar, and the participant will not be able to tell the difference.The physicians administering the treatment are not blinded.Numbers to be randomised (sample size): Sample size: N=1,500. The 1,500 participants will be randomised 1:1 to BCG or placebo with 750 participants in each group.Trial Status: Current protocol version 5.1, from July 6, 2020.Recruitment of study participants started on May 18, 2020 and we anticipate having finished recruiting by the end of December 2020. <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">The trial was registered with EudraCT on April 16, 2020, EudraCT number: 2020-001888-90, and with ClinicalTrials.gov on May 1, 2020, registration number NCT04373291.Full protocol: The full protocol is attached as an additional file, accessible from the Trialswebsite (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.</td>
</tr>
<tr class="odd">
<td align="left">32934758</td>
<td align="left">Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes.</td>
<td align="left"><MedlineTA>Can Respir J</MedlineTA></td>
<td align="left">2020</td>
<td align="left"><AbstractText Label="Background">The threat of contagious infectious diseases is constantly evolving as demographic explosion, travel globalization, and changes in human lifestyle increase the risk of spreading pathogens, leading to accelerated changes in disease landscape. Of particular interest is the aftermath of superimposing viral epidemics (especially SARS-CoV-2) over long-standing diseases, such as tuberculosis (TB), which remains a significant disease for public health worldwide and especially in emerging economies. <AbstractText Label="Methods and Results">The PubMed electronic database was systematically searched for relevant articles linking TB, influenza, and SARS-CoV viruses and subsequently assessed eligibility according to inclusion criteria. Using a data mining approach, we also queried the COVID-19 Open Research Dataset (CORD-19). We aimed to answer the following questions: What can be learned from other coronavirus outbreaks (focusing on TB patients)? Is coinfection (TB and SARS-CoV-2) more severe? Is there a vaccine for SARS-CoV-2? How does the TB vaccine affect COVID-19? How does one diagnosis affect the other? Discussions. Few essential elements about TB and SARS-CoV coinfections were discussed. First, lessons from past outbreaks (other coronaviruses) and influenza pandemic/seasonal outbreaks have taught the importance of infection control to avoid the severe impact on TB patients. Second, although challenging due to data scarcity, investigating the pathological pathways linking TB and SARS-CoV-2 leads to the idea that their coexistence might yield a more severe clinical evolution. Finally, we addressed the issues of vaccination and diagnostic reliability in the context of coinfection. <AbstractText Label="Conclusions">Because viral respiratory infections and TB impede the host’s immune responses, it can be assumed that their lethal synergism may contribute to more severe clinical evolution. Despite the rapidly growing number of cases, the data needed to predict the impact of the COVID-19 pandemic on patients with latent TB and TB sequelae still lies ahead. The trial is registered with NCT04327206, NCT01829490, and NCT04121494. Copyright © 2020 Radu Crisan-Dabija et al.</td>
</tr>
<tr class="even">
<td align="left">32934375</td>
<td align="left">Researchers highlight ‘questionable’ data in Russian coronavirus vaccine trial results.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 09</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32933536</td>
<td align="left">Pathophysiology and treatment strategies for COVID-19.</td>
<td align="left"><MedlineTA>J Transl Med</MedlineTA></td>
<td align="left">2020 09 15</td>
<td align="left">The outbreak of Coronavirus disease of 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has posed a serious health threat. The increasing number of COVID-19 cases around the world is overwhelming hospitals and pushing the global death toll to over 746,000, which has pushed the sprint to find new treatment options. In this article, we reviewed the SARS-CoV-2 pathophysiology, transmission, and potential treatment strategies.</td>
</tr>
<tr class="even">
<td align="left">32929259</td>
<td align="left">Scientists relieved as coronavirus vaccine trial restarts - but question lack of transparency.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 09</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32918548</td>
<td align="left">Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2.</td>
<td align="left"><MedlineTA>J Pediatric Infect Dis Soc</MedlineTA></td>
<td align="left">2020 Sep 12</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although Coronavirus Disease 2019 (COVID-19) is a mild infection in most children, a small proportion develop severe or critical illness. Data evaluating agents with potential antiviral activity continue to expand, such that updated guidance is needed regarding use of these agents in children. <AbstractText Label="METHODS" NlmCategory="METHODS">A panel of pediatric infectious diseases physicians and pharmacists from 20 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of the best available evidence and expert opinion. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Given the typically mild course of COVID-19 in children, supportive care alone is suggested for most cases. For children with severe illness, defined as a supplemental oxygen requirement without need for non-invasive or invasive mechanical ventilation or extra-corporeal membrane oxygenation (ECMO), remdesivir is suggested, preferably as part of a clinical trial if available. Remdesivir should also be considered for critically ill children requiring invasive or non-invasive mechanical ventilation or ECMO. A duration of 5 days is appropriate for most patients. The panel recommends against the use of hydroxychloroquine or lopinavir-ritonavir (or other protease inhibitors) for COVID-19 in children. <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For children with severe or critical disease, this guidance offers an approach for decision-making regarding use of remdesivir. © The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="even">
<td align="left">32918053</td>
<td align="left">China’s coronavirus vaccine shows military’s growing role in medical research.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 09</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32908297</td>
<td align="left">The underdog coronavirus vaccines that the world will need if front runners stumble.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 09</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32908295</td>
<td align="left">A leading coronavirus vaccine trial is on hold: scientists react.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 Sep 09</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32907286</td>
<td align="left">[Exploration and application of a novel attempt to recruit participants in clinical trials of vaccines under the emergency].</td>
<td align="left"><MedlineTA>Zhonghua Yu Fang Yi Xue Za Zhi</MedlineTA></td>
<td align="left">2020 Sep 06</td>
<td align="left">Objective: To evaluate and share the novel method for recruiting participants in clinical trials of vaccines in emergency situations. Methods: To publish recruitment notice in local areas of Wuhan through websites and medium, and guide interested persons to log in to the“Clinical Trials of SARS-CoV-2 Vaccine Reservation and Health Declaration System”to appoint and register their health information. The “Health Declaration System” provides each volunteer evaluation and risk levels to preliminarily exclude those who do not meet the inclusion criteria. Researchers review the qualified volunteers by telephone, organize them to go to the vaccination site, and finally conduct a strict medical screening to determine the final subjects. Results: A total of 4 819 people and 5 132 people registered in the Phase Ⅰ and Phase Ⅱ recruitment system respectively, with men 2 912 (60.43%) and 2 887 (56.25%) more than women 1 907 (39.57%) and 2 245 (43.75%), mostly in the 20-39 age group, with 3 211 (66.63%) and 3 966 (77.28%). All 13 districts in Wuhan have interested residents to participate clinical research.The initial qualified rate of the Phase Ⅱ recruitment system was higher than that of Phase Ⅰ, with men 2 047 (70.28%) and 2 135(73.95%), higher than women 1 083 (56.80%) and 1 472 (65.57%); 440 and 689 people were reviewed by telephone in Phase Ⅰ and Phase Ⅱ respectively, and the number of verified volunteers was about 440 (35.00%) and 689 (67.20%); Of the 201 603 people who arrived at the vaccination site, 12 and 26 of them were positive for the SARS-CoV-2 antibody with an antibody positive rate of 6.00% and 4.31% respectively. Conclusion: The novel method for recruiting subjects in this clinical study is efficient and reliable, and the recruitment situation of Phase Ⅰ had set a good example for Phase Ⅱ but the medium-and long-term compliance of subjects and the separation of willingness and behaviors still need to be further studied.</td>
</tr>
<tr class="even">
<td align="left">32905186</td>
<td align="left">A brief outline of respiratory viral disease outbreaks: 1889-till date on the public health perspectives.</td>
<td align="left"><MedlineTA>Virusdisease</MedlineTA></td>
<td align="left">2020 Sep 02</td>
<td align="left">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently causing the respiratory illness termed as the coronavirus disease 2019 or the COVID-19 pandemic. Indeed, the significant increase in deaths in the current days due to influenza around the world started in 1889 is a continued public health threat because of its intermittent style of pandemic outbreaks. An array of research on the influenza viruses has been conducted especially pointing on (1) the development of the anti-viral drugs and the design of probable vaccines on trial basis, (2) the biochemical and genetic aspects underlying the viral pathogenicity, (3) the viral epidemiology, and on (4) the protective immunity against the influenza viruses. Current review briefly discussed the epidemic/ pandemic history of influenza and correlated with the current epidemiology, the possible preventive measures that may be taken by the public health professionals as well as to increase the protective awareness among the general people. The viral reassortments during the initiation of pandemics have also been focused based on the previous literatures. © Indian Virological Society 2020.</td>
</tr>
<tr class="odd">
<td align="left">32905011</td>
<td align="left">SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies.</td>
<td align="left"><MedlineTA>Asian J Pharm Sci</MedlineTA></td>
<td align="left">2020 Sep 01</td>
<td align="left">The development of a massively producible vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, is essential for stopping the current coronavirus disease (COVID-19) pandemic. A vaccine must stimulate effective antibody and T cell responses in vivo to induce long-term protection. Scientific researchers have been developing vaccine candidates for the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) since the outbreaks of these diseases. The prevalence of new biotechnologies such as genetic engineering has shed light on the generation of vaccines against novel viruses. In this review, we present the status of the development of coronavirus vaccines, focusing particularly on the biomimetic nanoparticle technology platform, which is likely to have a major role in future developments of personalized medicine. © 2020 Published by Elsevier B.V. on behalf of Shenyang Pharmaceutical University.</td>
</tr>
<tr class="even">
<td align="left">32903199</td>
<td align="left">Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study.</td>
<td align="left"><MedlineTA>JMIR Res Protoc</MedlineTA></td>
<td align="left">2020 Oct 02</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The COVID-19 pandemic is expected to cause significant morbidity and mortality. The development of an effective vaccine will take several months to become available, and its affordability is unpredictable. Transfusion of convalescent plasma (CP) may provide passive immunity. Based on initial data from China, a group of hematologists, infectious disease specialists, and intensivists drafted this protocol in March 2020. <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study is to test the feasibility, safety, and efficacy of CP in treating patients with COVID-19 across Saudi Arabia. <AbstractText Label="METHODS" NlmCategory="METHODS">Eligible patients with COVID-19 will be recruited for CP infusion according to the inclusion criteria. As COVID-19 has proven to be a moving target as far as its management is concerned, we will use current definitions according to the Ministry of Health (MOH) guidelines for diagnosis, treatment, and recovery. All CP recipients will receive supportive management including all available recommended therapies according to the available MOH guidelines. Eligible CP donors will be patients with COVID-19 who have fully recovered from their disease according to MOH recovery criteria as detailed in the inclusion criteria. CP donors have to qualify as blood donors according to MOH regulations except for the history of COVID-19 in the recent past. We will also test the CP donors for the presence of SARS-CoV-2 antibodies by a rapid test, and aliquots will be archived for future antibody titration. Due to the perceived benefit of CP, randomization was not considered. However, we will compare the outcome of the cohort treated with CP with those who did not receive CP due to a lack of consent or lack of availability. In this national collaborative study, there is a likelihood of not finding exactly matched control group patients. Hence, we plan to perform a propensity score matching of the CP recipients with the comparator group patients for the major characteristics. We plan to collect demographic, clinical, and laboratory characteristics of both groups and compare the outcomes. A total sample size of 575 patients, 115 CP recipients and 460 matched controls (1:4 ratio), will be sufficient to detect a clinically important hospital stay and 30-day mortality difference between the two groups with 80% power and a 5% level of significance. <AbstractText Label="RESULTS" NlmCategory="RESULTS">At present, patient recruitment is still ongoing, and the interim analysis of the first 40 patients will be shared soon. <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this paper, we present a protocol for a national collaborative multicenter phase II study in Saudi Arabia for assessing the feasibility, safety, and potential efficacy of CP in treating patients with severe COVID-19. We plan to publish an interim report of the first 40 CP recipients and their matched comparators soon. <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT04347681; <a href="https://clinicaltrials.gov/ct2/show/NCT04347681" class="uri">https://clinicaltrials.gov/ct2/show/NCT04347681</a>. <AbstractText Label="INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)" NlmCategory="UNASSIGNED">PRR1-10.2196/23543. ©Mohammed Albalawi, Syed Ziauddin Ahmed Zaidi, Nawal AlShehry, Ahmed AlAskar, Abdul Rehman Zia Zaidi, Rania Nagib Mohammed Abdallah, Abdul Salam, Ahmed AlSagheir, Nour AlMozain, Ghada Elgohary, Khalid Batarfi, Alia Alfaraedi, Osamah Khojah, Rehab Al-Ansari, Mona Alfaraj, Afra Dayel, Ahmed Al Bahrani, Arwa Nabhan Abdelhameed, Hind Alhumaidan, Jawaher M Al-Otaibi, Ghazala Radwi, Abdulrahman Raizah, Hind Shatry, Sara Alsaleh, Hazzaa AlZahrani, Hani Al-Hashmi. Originally published in JMIR Research Protocols (<a href="http://www.researchprotocols.org" class="uri">http://www.researchprotocols.org</a>), 02.10.2020.</td>
</tr>
<tr class="odd">
<td align="left">32901559</td>
<td align="left">In search of a vaccine against COVID-19: implications for nursing practice.</td>
<td align="left"><MedlineTA>Br J Nurs</MedlineTA></td>
<td align="left">2020 Sep 10</td>
<td align="left">This article discusses the background to the current COVID-19 pandemic. The specific features of the causative pathogen (SARS-CoV-2) are outlined, together with a ‘whistlestop’ revision of immunological principles. The article goes on to discuss the principles and mechanisms of immunisation and the stages of vaccine development. The current situation in relation to the race to develop a vaccine against COVID-19 is incorporated and the immunological principles being adapted by the top contenders are outlined. These include new approaches based on genetic sequencing. Finally, the importance of understanding theoretical principles and the potential practical implications for nurses who will be at the coalface, reassuring patients and delivering vaccines, is addressed.</td>
</tr>
<tr class="even">
<td align="left">32898468</td>
<td align="left">Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy.</td>
<td align="left"><MedlineTA>Open Biol</MedlineTA></td>
<td align="left">2020 09</td>
<td align="left">The world is passing through a very difficult phase due to the coronavirus disease 2019 (COVID-19) pandemic, which has disrupted almost all spheres of life. Globally, according to the latest World Health Organization report (10 August 2020), COVID-19 has affected nearly 20 million lives, causing 728 013 deaths. Due to the lack of specific therapeutic drugs and vaccines, the outbreak of disease has spawned a corpus of contagious infection all over the world, day by day, without control. As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a very rapid infection rate, it is essential to develop a novel ameliorative and curative strategy as quickly as possible. Convalescent plasma (CP) therapy is a type of adaptive immunity that has already been found to be effective in confronting several infectious diseases from the last two decades. For example, CP therapy was used in the treatment of viral-induced diseases like SARS-CoV epidemics, Middle East respiratory syndrome coronavirus (MERS-CoV) pandemics, Ebola epidemics and H1N1 pandemic. In this review, we have mainly focused on the therapeutic role of CP therapy and its neutralizing effect to fight against the COVID-19 outbreak.</td>
</tr>
<tr class="odd">
<td align="left">32896291</td>
<td align="left">Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.</td>
<td align="left"><MedlineTA>Lancet</MedlineTA></td>
<td align="left">2020 09 26</td>
<td align="left"><AbstractText Label="BACKGROUND">We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S). We aimed to assess the safety and immunogenicity of two formulations (frozen and lyophilised) of this vaccine. <AbstractText Label="METHODS">We did two open, non-randomised phase 1/2 studies at two hospitals in Russia. We enrolled healthy adult volunteers (men and women) aged 18-60 years to both studies. In phase 1 of each study, we administered intramuscularly on day 0 either one dose of rAd26-S or one dose of rAd5-S and assessed the safety of the two components for 28 days. In phase 2 of the study, which began no earlier than 5 days after phase 1 vaccination, we administered intramuscularly a prime-boost vaccination, with rAd26-S given on day 0 and rAd5-S on day 21. Primary outcome measures were antigen-specific humoral immunity (SARS-CoV-2-specific antibodies measured by ELISA on days 0, 14, 21, 28, and 42) and safety (number of participants with adverse events monitored throughout the study). Secondary outcome measures were antigen-specific cellular immunity (T-cell responses and interferon-γ concentration) and change in neutralising antibodies (detected with a SARS-CoV-2 neutralisation assay). These trials are registered with ClinicalTrials.gov, NCT04436471 and NCT04437875. <AbstractText Label="FINDINGS">Between June 18 and Aug 3, 2020, we enrolled 76 participants to the two studies (38 in each study). In each study, nine volunteers received rAd26-S in phase 1, nine received rAd5-S in phase 1, and 20 received rAd26-S and rAd5-S in phase 2. Both vaccine formulations were safe and well tolerated. The most common adverse events were pain at injection site (44 [58%]), hyperthermia (38 [50%]), headache (32 [42%]), asthenia (21 [28%]), and muscle and joint pain (18 [24%]). Most adverse events were mild and no serious adverse events were detected. All participants produced antibodies to SARS-CoV-2 glycoprotein. At day 42, receptor binding domain-specific IgG titres were 14 703 with the frozen formulation and 11 143 with the lyophilised formulation, and neutralising antibodies were 49·25 with the frozen formulation and 45·95 with the lyophilised formulation, with a seroconversion rate of 100%. Cell-mediated responses were detected in all participants at day 28, with median cell proliferation of 2·5% CD4+ and 1·3% CD8+ with the frozen formulation, and a median cell proliferation of 1·3% CD4+ and 1·1% CD8+ with the lyophilised formulation. <AbstractText Label="INTERPRETATION">The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants. Further investigation is needed of the effectiveness of this vaccine for prevention of COVID-19. <AbstractText Label="FUNDING">Ministry of Health of the Russian Federation. Copyright © 2020 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32887954</td>
<td align="left">Immunological considerations for COVID-19 vaccine strategies.</td>
<td align="left"><MedlineTA>Nat Rev Immunol</MedlineTA></td>
<td align="left">2020 10</td>
<td align="left">The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most formidable challenge to humanity in a century. It is widely believed that prepandemic normalcy will never return until a safe and effective vaccine strategy becomes available and a global vaccination programme is implemented successfully. Here, we discuss the immunological principles that need to be taken into consideration in the development of COVID-19 vaccine strategies. On the basis of these principles, we examine the current COVID-19 vaccine candidates, their strengths and potential shortfalls, and make inferences about their chances of success. Finally, we discuss the scientific and practical challenges that will be faced in the process of developing a successful vaccine and the ways in which COVID-19 vaccine strategies may evolve over the next few years.</td>
</tr>
<tr class="odd">
<td align="left">32877576</td>
<td align="left">Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.</td>
<td align="left"><MedlineTA>N Engl J Med</MedlineTA></td>
<td align="left">2020 Sep 02</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant. <AbstractText Label="METHODS" NlmCategory="METHODS">We initiated a randomized, placebo-controlled, phase 1-2 trial to evaluate the safety and immunogenicity of the rSARS-CoV-2 vaccine (in 5-μg and 25-μg doses, with or without Matrix-M1 adjuvant, and with observers unaware of trial-group assignments) in 131 healthy adults. In phase 1, vaccination comprised two intramuscular injections, 21 days apart. The primary outcomes were reactogenicity; laboratory values (serum chemistry and hematology), according to Food and Drug Administration toxicity scoring, to assess safety; and IgG anti-spike protein response (in enzyme-linked immunosorbent assay [ELISA] units). Secondary outcomes included unsolicited adverse events, wild-type virus neutralization (microneutralization assay), and T-cell responses (cytokine staining). IgG and microneutralization assay results were compared with 32 (IgG) and 29 (neutralization) convalescent serum samples from patients with Covid-19, most of whom were symptomatic. We performed a primary analysis at day 35. <AbstractText Label="RESULTS" NlmCategory="RESULTS">After randomization, 83 participants were assigned to receive the vaccine with adjuvant and 25 without adjuvant, and 23 participants were assigned to receive placebo. No serious adverse events were noted. Reactogenicity was absent or mild in the majority of participants, more common with adjuvant, and of short duration (mean, ≤2 days). One participant had mild fever that lasted 1 day. Unsolicited adverse events were mild in most participants; there were no severe adverse events. The addition of adjuvant resulted in enhanced immune responses, was antigen dose-sparing, and induced a T helper 1 (Th1) response. The two-dose 5-μg adjuvanted regimen induced geometric mean anti-spike IgG (63,160 ELISA units) and neutralization (3906) responses that exceeded geometric mean responses in convalescent serum from mostly symptomatic Covid-19 patients (8344 and 983, respectively). <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum. The Matrix-M1 adjuvant induced CD4+ T-cell responses that were biased toward a Th1 phenotype. (Funded by the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04368988). Copyright © 2020 Massachusetts Medical Society.</td>
</tr>
<tr class="even">
<td align="left">32862824</td>
<td align="left">COVID-19: Small-Molecule Clinical Trials Landscape.</td>
<td align="left"><MedlineTA>Curr Top Med Chem</MedlineTA></td>
<td align="left">2020</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32857836</td>
<td align="left">Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers.</td>
<td align="left"><MedlineTA>Clin Infect Dis</MedlineTA></td>
<td align="left">2020 Aug 28</td>
<td align="left">WHO convened an Advisory Group (AG) to consider the feasibility, potential value and limitations of establishing a closely-monitored challenge model of experimental SARS-CoV-2 infection and COVID-19 in healthy adult volunteers. The AG included experts in design, establishment and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (SARS-CoV-2’s potential to cause severe/fatal illness, its high transmissibility, and lack of a “rescue treatment” to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.</td>
</tr>
<tr class="even">
<td align="left">32854391</td>
<td align="left">Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2.</td>
<td align="left"><MedlineTA>Vaccines (Basel)</MedlineTA></td>
<td align="left">2020 Aug 25</td>
<td align="left">Coronavirus disease 2019 (COVID-19) is the biggest health challenge of the 21st century, affecting millions of people globally. The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has ignited an unprecedented effort from the scientific community in the development of new vaccines on different platforms due to the absence of a broad and effective treatment for COVID-19 or prevention strategy for SARS-CoV-2 dissemination. Based on 50 current studies selected from the main clinical trial databases, this systematic review summarizes the global race for vaccine development against COVID-19. For each study, the main intervention characteristics, the design used, and the local or global center partnerships created are highlighted. Most vaccine developments have taken place in Asia, using a viral vector method. Two purified inactivated SARS-CoV-2 vaccine candidates, an mRNA-based vaccine mRNA1273, and the chimpanzee adenoviral vaccine ChAdOx1 are currently in phase III clinical trials in the respective countries Brazil, the United Arab Emirates, the USA, and the United Kingdom. These vaccines are being developed based on a quickly formed network of collaboration.</td>
</tr>
<tr class="odd">
<td align="left">32850922</td>
<td align="left">Treatment Options for COVID-19: A Review.</td>
<td align="left"><MedlineTA>Front Med (Lausanne)</MedlineTA></td>
<td align="left">2020</td>
<td align="left">Background: The recent COVID-19 pandemic sweeping the globe has caused great concern worldwide. Due to the limited evidence available on the dynamics of the virus and effective treatment options available, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a huge impact in terms of morbidity and mortality. The economic impact is still to be assessed. Aims: The purpose of this article is to review the evidence for the multiple treatment options available, to consider the future of this global pandemic, and to identify some potential options that could revolutionize the treatment of COVID-19. Moreover, this article underscores the sheer importance of repurposing some of the available antiviral and antimicrobial agents that have long been in use so as to have an effective and expeditious response to this widespread pandemic and the need to conduct a multicenter global randomized controlled trial to find an effective single antiviral agent or a cocktail of available antimicrobial agents. Method: We thoroughly searched and reviewed various case reports, retrospective analyses, and in vitro studies published in PubMed, EMBASE, and Google Scholar regarding the treatment options used for SARS-CoV, MERS-CoV, and SARS-CoV-2 since its outbreak in an attempt to highlight treatments with the most promising results. Conclusion: We are currently facing one of the worst pandemics in history. Although SARS-CoV-2 is associated with a lower mortality rate than are SARS-CoV and MERS-CoV, its higher infectivity is making it a far more serious threat. Unfortunately, no vaccine against SARS-CoV-2 or effective drug regimen for COVID-19 currently exists. Drug repurposing of available antiviral agents may provide a respite; moreover, a cocktail of antiviral agents may be helpful in treating this disease. Here, we have highlighted a few available antimicrobial agents that could be very effective in treating COVID-19; indeed, a number of trials are underway to detect and confirm the efficacy of these agents. Copyright © 2020 Ali, Hanif, Haider, Ahmed, Sundas, Hirani, Khan, Anis and Karim.</td>
</tr>
<tr class="even">
<td align="left">32850116</td>
<td align="left">Development of vaccines for SARS-CoV-2.</td>
<td align="left"><MedlineTA>F1000Res</MedlineTA></td>
<td align="left">2020</td>
<td align="left">COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches. Copyright: © 2020 Ng WH et al.</td>
</tr>
<tr class="odd">
<td align="left">32846196</td>
<td align="left">Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.</td>
<td align="left"><MedlineTA>Virus Res</MedlineTA></td>
<td align="left">2020 10 15</td>
<td align="left">The recent outbreak of the betacoronavirus SARS-CoV-2 has become a significant concern to public health care worldwide. As of August 19, 2020, more than 22,140,472 people are infected, and over 781,135 people have died due to this deadly virus. In the USA alone, over 5,482,602 people are currently infected, and more than 171,823 people have died. SARS-CoV-2 has shown a higher infectivity rate and a more extended incubation period as compared to previous coronaviruses. SARS-CoV-2 binds much more strongly than SARS-CoV to the same host receptor, angiotensin-converting enzyme 2 (ACE2). Previously, several methods to develop a vaccine against SARS-CoV or MERS-CoV have been tried with limited success. Since SARS-CoV-2 uses the spike (S) protein for entry to the host cell, it is one of the most preferred targets for making vaccines or therapeutics against SARS-CoV-2. In this review, we have summarised the characteristics of the S protein, as well as the different approaches being used for the development of vaccines and/or therapeutics based on the S protein. Copyright © 2020. Published by Elsevier B.V.</td>
</tr>
<tr class="even">
<td align="left">32845317</td>
<td align="left">Large Simple Double-Blind Randomized Trials for the Rapid Assessment of the Effectiveness of COVID-19 Vaccines.</td>
<td align="left"><MedlineTA>J Infect Dis</MedlineTA></td>
<td align="left">2020 10 01</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32841042</td>
<td align="left">The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy.</td>
<td align="left"><MedlineTA>Cell Transplant</MedlineTA></td>
<td align="left">2020 Jan-Dec</td>
<td align="left">Coronavirus disease 2019 or COVID-19 is highly infectious, which can lead to acute and chronic debilitating symptoms, as well as mortality. The advent of safe and effective vaccines or antiviral drugs remains distant in the future. Practical public health measures, such as social distancing, hand washing, and wearing a face mask, are the current recommended guidelines by the Centers for Disease Control and Prevention for limiting the spread of the virus. Weakened immune system and aberrant inflammation represent a major pathological symptom of COVID-19 patients. Based on the unique immunomodulatory properties of both convalescent plasma and stem cells, we discuss here their potential use for treating COVID-19.</td>
</tr>
<tr class="even">
<td align="left">32839784</td>
<td align="left">RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study.</td>
<td align="left"><MedlineTA>medRxiv</MedlineTA></td>
<td align="left">2020 Aug 20</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (COVID-19), have spread to millions of people globally. Multiple vaccine candidates are under development, but no vaccine is currently available. <AbstractText Label="METHODS" NlmCategory="METHODS">Healthy adults 18-55 and 65-85 years of age were randomized in an ongoing, placebo-controlled, observer-blinded dose-escalation study to receive 2 doses at 21-day intervals of placebo or either of 2 lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidates: BNT162b1, which encodes a secreted trimerized SARS-CoV-2 receptor-binding domain, or BNT162b2, which encodes a prefusion stabilized membrane-anchored SARS-CoV-2 full-length spike. In each of 13 groups of 15 participants, 12 received vaccine and 3 received placebo. Groups were distinguished by vaccine candidate, age of participant, and vaccine dose level. Interim safety and immunogenicity data of BNT162b1 in younger adults have been reported previously from US and German trials. We now present additional safety and immunogenicity data from the US Phase 1 trial that supported selection of the vaccine candidate advanced to a pivotal Phase 2/3 safety and efficacy evaluation. <AbstractText Label="RESULTS" NlmCategory="RESULTS">In both younger and older adults, the 2 vaccine candidates elicited similar dose-dependent SARS-CoV-2-neutralizing geometric mean titers (GMTs), comparable to or higher than the GMT of a panel of SARS-CoV-2 convalescent sera. BNT162b2 was associated with less systemic reactogenicity, particularly in older adults. <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results support selection of the BNT162b2 vaccine candidate for Phase 2/3 large-scale safety and efficacy evaluation, currently underway.</td>
</tr>
<tr class="odd">
<td align="left">32839593</td>
<td align="left">The unequal scramble for coronavirus vaccines - by the numbers.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 08</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32839191</td>
<td align="left">Russian SARS-CoV-2 vaccine.</td>
<td align="left"><MedlineTA>BMJ</MedlineTA></td>
<td align="left">2020 08 24</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32839164</td>
<td align="left">Covid-19: Should doctors recommend treatments and vaccines when full data are not publicly available?</td>
<td align="left"><MedlineTA>BMJ</MedlineTA></td>
<td align="left">2020 08 24</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32838299</td>
<td align="left">Addressing COVID-19 Drug Development with Artificial Intelligence.</td>
<td align="left"><MedlineTA>Adv Intell Syst</MedlineTA></td>
<td align="left">2020 Apr 27</td>
<td align="left">The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that led to the COVID-19 (Coronavirus Disease 2019) pandemic, has resulted in substantial overburdening of healthcare systems as well as an economic crisis on a global scale. This has in turn resulted in widespread efforts to identify suitable therapies to address this aggressive pathogen. Therapeutic antibody and vaccine development are being actively explored, and a phase I clinical trial of mRNA-1273 which is developed in collaboration between the National Institute of Allergy and Infectious Diseases and Moderna, Inc. is currently underway. Timelines for the broad deployment of a vaccine and antibody therapies have been estimated to be 12-18 months or longer. These are promising approaches that may lead to sustained efficacy in treating COVID-19. However, its emergence has also led to a large number of clinical trials evaluating drug combinations composed of repurposed therapies. As study results of these combinations continue to be evaluated, there is a need to move beyond traditional drug screening and repurposing by harnessing artificial intelligence (AI) to optimize combination therapy design. This may lead to the rapid identification of regimens that mediate unexpected and markedly enhanced treatment outcomes. © 2020 The Authors. Published by WILEY‐VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</td>
</tr>
<tr class="odd">
<td align="left">32838206</td>
<td align="left">A narrative review of emerging therapeutics for COVID-19.</td>
<td align="left"><MedlineTA>Mayo Clin Proc Innov Qual Outcomes</MedlineTA></td>
<td align="left">2020 Jul 20</td>
<td align="left">The novel coronavirus SARS-CoV-2, causal agent of COVID-19, quickly spread around the world resulting in the most aggressive pandemic experienced in over 100 years. Research into targeted therapies and vaccines has been initiated on an unprecedented scale and speed but will take months and even years to come to fruition. Meanwhile, the efficacy of emerging therapeutics for use in treating COVID-19 is feverishly being investigated to identify the best available treatment options for dealing with the current wave of disease. This review provides frontline clinicians with a pragmatic summary of the current state of the rapidly evolving evidence supporting emerging candidate therapeutics for COVID-19. Two main categories of pharmaceutical therapeutics are showing promise-those with antiviral activity directly addressing infection and those that counteract the inflammatory cytokine storm induced by severe disease. Preliminary results suggest that other approaches such as convalescent plasma therapy and lung radiation therapy may have some efficacy. The current clinical evidence for potential treatments is preliminary - often small retrospective series or early results from randomized trials - and the science is evolving rapidly. Long-term results from large, well-designed randomized trials will provide definitive evidence of therapeutic effectiveness and are likely months away. The trial landscape for promising therapies is described. .</td>
</tr>
<tr class="even">
<td align="left">32837854</td>
<td align="left">Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update.</td>
<td align="left"><MedlineTA>Curr Pharmacol Rep</MedlineTA></td>
<td align="left">2020 Jul 18</td>
<td align="left">The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for causing coronavirus disease 2019 (COVID-19), marked the third time in the twenty-first century when a new, highly pathogenic human coronavirus outbreak has led to an epidemic. The COVID-19 epidemic has emerged in late December 2019 in Wuhan city of China and spread rapidly to other parts of the world. This quick spread of SARS-CoV-2 infection to many states across the globe affecting many people has led WHO to declare it a pandemic on March 12, 2020. As of July 4, 2020, more than 523,011 people lost their lives worldwide because of this deadly SARS-CoV-2. The current situation becomes more frightening as no FDA-approved drugs or vaccines are available to treat or prevent SARS-CoV-2 infection. The current therapeutic options for COVID-19 are limited only to supportive measures and non-specific interventions. So, the need of the hour is to search for SARS-CoV-2-specific antiviral treatments and to develop vaccines for SARS-CoV-2. Also, it is equally important to maintain our immunity, and natural products and Ayurvedic medicines are indispensable in this regard. In this review, we discuss recent updates regarding various therapeutic approaches to combat COVID-19 pandemic and enlist the major pipeline drugs and traditional medicines that are under trial for COVID-19. Also, possible mechanisms involved in viral pathogenesis are discussed, which further allow us to understand various drug targets and helps in discovering novel therapeutic approaches for COVID-19. Altogether, the information provided in this review will work as an intellectual groundwork and provides an insight into the ongoing development of various therapeutic agents. © Springer Nature Switzerland AG 2020.</td>
</tr>
<tr class="odd">
<td align="left">32837100</td>
<td align="left">An Ayurvedic Perspective along with in Silico Study of the Drugs for the Management of Sars-Cov-2.</td>
<td align="left"><MedlineTA>J Ayurveda Integr Med</MedlineTA></td>
<td align="left">2020 Jul 21</td>
<td align="left"><AbstractText Label="Background" NlmCategory="UNASSIGNED">Covid-19 is the disease caused by SARS-CoV2, it was identified in Wuhan, China, in 2019. It then extended across the globe and was termed as a pandemic in 2020. Though research work on its vaccine and drugs are carried out across the globe, it is even necessary to look over it through alternative sciences. <AbstractText Label="Objective" NlmCategory="UNASSIGNED">The objective of this study is to look over the disease through Ayurvedic perspective, analyse possible pathologies, select appropriate drugs and to study in-silico screening on these selected drugs.Materials &amp; Methods: Available symptoms of Covid 19 were thoroughly studied and reviewed through Ayurveda classics, internet, preprints, etc. to understand the nature of the disease with the Ayurvedic perspective.The molecular Docking and Grid were generated through Pyrx Software with Autodock. The Lipinski Rule of Five data generated from Swiss ADME software and Target prediction of selected phytoconstituents were done by Swiss target prediction. <AbstractText Label="Results" NlmCategory="UNASSIGNED">and Discussion: In Ayurveda, Covid19 can be considered as Janapadaudhwans, Vaat-Kaphaj Sannipatik Jwara, Aupsargika Vyadhi, and Dhatupaka Awastha. In the molecular docking study, the binding energy and inhibition of 6 Gingesulphonic acid from Zingiber Officinalis (Sunthi) is greater than hydroxychloroquine and quinine. Most of the selected phytoconstituents follow the Lipinski rule of five. Target prediction of selected phytoconstituents was done on target of SARS-COV-2, humoral immunity, and antiviral activity. Every selected phytoconstituents works on minimum one of the targets. <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Thus, from the above results obtained from reviewing Ayurveda classics and after the virtual screening of selected drugs we can conclude that Nagaraadi Kashaya(Sunthi, Puskarmoola, Kantakari, Guduchi) may have appreciable results in combating SARS-COV-2. Thus, Nagaraadi Kashayam, a classical formulation can be a trial candidate for conducting further clinical trial. © 2020 The Authors.</td>
</tr>
<tr class="even">
<td align="left">32837030</td>
<td align="left">Novel Stem Cells and Nucleic Acid-Based Vaccine Trials Against Viral Outbreak: A Systematic Evaluation During COVID-2019 Pandemic.</td>
<td align="left"><MedlineTA>Indian J Clin Biochem</MedlineTA></td>
<td align="left">2020 Jul 10</td>
<td align="left">The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outbreak, the cause of coronavirus disease (COVID-19), has influenced health globally. So far, there are no established management options and prophylaxis for those who have been exposed to SARS-CoV-2, and those who develop COVID-19. Documented scientific evidences in similar viral outbreaks in past suggested few therapy regimens. These rather have not shown promising results in management of current pandemic. So, in the current review, we are exploring novel treatment strategies and therapies that are being explored and are in clinical and preclinical stages of research. To explore more about the same, we directed our search towards stem cell based, DNA based, or RNA based vaccines against COVID-19 under development by various universities, institutes or pharmaceutical companies. The current scientific literature and database search were performed by exploring various Trials registry (NIH: <a href="https://clinicaltrials.gov/" class="uri">https://clinicaltrials.gov/</a> and <a href="https://www.coronavirus.gov" class="uri">https://www.coronavirus.gov</a>) and Chinese clinical trial registry <a href="http://www.chictr.org.cn/" class="uri">http://www.chictr.org.cn/</a>) and for preclinical trials various University, Institutions, Pharmaceutical companies websites and news bulletins along with google search were checked routinely from 3rd March 2020 to 16 May 2020. The term “Stem Cell therapy and COVID-19”, “Mesenchymal stem cell and corona 2019 virus”, “DNA Vaccines and COVID-19, RNA Vaccines and COVID-19” and “Cell-based therapy with SARS-CoV-2, University/Institutions and COVID-19 research” were used. The vaccine trials (Stem Cells/DNA/RNA) which were cancelled were not included in this review. Similarly, few others like repurposing of drugs, Nano Vaccines, other miscellaneous trials of Herbs, Music therapy etc., were also excluded. In the present review, we have included the various novel therapies like stem cell therapy, DNA or RNA vaccines which are under development and if proven successful may have a lasting impact on the health industry. © Association of Clinical Biochemists of India 2020.</td>
</tr>
<tr class="odd">
<td align="left">32821086</td>
<td align="left">A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.</td>
<td align="left"><MedlineTA>Drug Des Devel Ther</MedlineTA></td>
<td align="left">2020</td>
<td align="left">The novel coronavirus 2019 (2019-nCoV), formally named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel human infectious coronavirus. The disease caused by SARS-CoV-2 is named COVID-19. Development and manufacturing of specific therapeutics and vaccines to treat COVID-19 are time-consuming processes. At this time, using available conventional therapeutics along with other treatment options may be useful to fight COVID-19. In different clinical trials, efficacy of remdesivir (GS-5734) against Ebola virus has been demonstrated. Moreover, remdesivir may be an effective therapy in vitro and in animal models infected by SARS and MERS coronaviruses. Hence, the drug may be theoretically effective against SARS-CoV-2. Remdesivir is a phosphoramidate prodrug of an adenosine C-nucleoside. By entrance into respiratory epithelial cells in human, the prodrug is metabolized to a nucleoside triphosphate as the active form. The nucleoside analog inhibits the viral RNA-dependent RNA polymerase (RdRp) by competing with the usual counterpart adenosine triphosphate (ATP). The nucleoside analog is incorporated into the generating RNA strand and causes a delayed stop in the viral replication process. Knowledge about the potential efficacy of remdesivir against coronaviruses has been restricted to in vitro studies and animal models. However, information related to COVID-19 is rapidly growing. Several clinical trials are ongoing for the management of COVID-19 using remdesivir. In this study, characteristics of remdesivir and its usage for treatment of COVID-19 are reviewed based on an electronic search using PubMed and Google Scholar. © 2020 Hashemian et al.</td>
</tr>
<tr class="even">
<td align="left">32820746</td>
<td align="left">Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season.</td>
<td align="left"><MedlineTA>MMWR Recomm Rep</MedlineTA></td>
<td align="left">2020 08 21</td>
<td align="left">This report updates the 2019-20 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2019;68[No. RR-3]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Most influenza vaccines available for the 2020-21 season will be quadrivalent, with the exception of MF59-adjuvanted IIV, which is expected to be available in both quadrivalent and trivalent formulations.Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 23, 2019; February 26, 2020; and June 24, 2020. Primary updates to this report include the following two items. First, the composition of 2020-21 U.S. influenza vaccines includes updates to the influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B/Victoria lineage components. Second, recent licensures of two new influenza vaccines, Fluzone High-Dose Quadrivalent and Fluad Quadrivalent, are discussed. Both new vaccines are licensed for persons aged ≥65 years. Additional changes include updated discussion of contraindications and precautions to influenza vaccination and the accompanying Table, updated discussion concerning use of LAIV4 in the setting of influenza antiviral medication use, and updated recommendations concerning vaccination of persons with egg allergy who receive either cell culture-based IIV4 (ccIIV4) or RIV4.The 2020-21 influenza season will coincide with the continued or recurrent circulation of SARS-CoV-2 (the novel coronavirus associated with coronavirus disease 2019 [COVID-19]). Influenza vaccination of persons aged ≥6 months to reduce prevalence of illness caused by influenza will reduce symptoms that might be confused with those of COVID-19. Prevention of and reduction in the severity of influenza illness and reduction of outpatient illnesses, hospitalizations, and intensive care unit admissions through influenza vaccination also could alleviate stress on the U.S. health care system. Guidance for vaccine planning during the pandemic is available at <a href="https://www.cdc.gov/vaccines/pandemic-guidance/index.html.This" class="uri">https://www.cdc.gov/vaccines/pandemic-guidance/index.html.This</a> report focuses on recommendations for the use of vaccines for the prevention and control of seasonal influenza during the 2020-21 season in the United States. A brief summary of the recommendations and a link to the most recent Background Document containing additional information are available at <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html" class="uri">https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html</a>. These recommendations apply to U.S.-licensed influenza vaccines used within Food and Drug Administration (FDA)-licensed indications. Updates and other information are available from CDC’s influenza website (<a href="https://www.cdc.gov/flu" class="uri">https://www.cdc.gov/flu</a>). Vaccination and health care providers should check this site periodically for additional information.</td>
</tr>
<tr class="odd">
<td align="left">32813843</td>
<td align="left">Study of ongoing registered clinical trials on COVID-19: a narrative review.</td>
<td align="left"><MedlineTA>Sao Paulo Med J</MedlineTA></td>
<td align="left">2020 Aug 14</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The dangerous SARS-CoV-2 virus first emerged in China in December 2019 and has rapidly spread worldwide. Currently, it has affected more than 2,850,000 people. No vaccine or drug is available yet, and therefore researchers and scientists are striving to identify potential drugs or vaccines for combating this virus. We were unable to find any review of the literature or analysis on ongoing registered clinical trials that reported diagnostic tests, therapeutics, vaccines and devices for COVID-19 along with estimated enrollment, participants’ ages, study type, start and completion date, status, treatment/intervention and country. <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review ongoing trials relating to COVID-19. <AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search for clinical trials was conducted in the ClinicalTrials.gov database up to April 12, 2020. A total of 339 trials relating to COVID-19 were analyzed and key information on each trial was recorded. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Most of the trials were being conducted in the United States and completion of most of them was expected by May 2020. They were mostly on drugs and treatment, while a minority were on diagnostic tests. The analysis showed that hydroxychloroquine was investigated in most of the trials. The trials identified were categorized into five classes: a) diagnostic tests; b) therapeutics; c) biologics and vaccines; d) devices and products; and e) others. <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The trials identified have potential against COVID-19 that can be applied in treatment processes after the necessary investigations and experiments. Additionally, the items identified were organized in a proper way, which can assist in current research activities.</td>
</tr>
<tr class="even">
<td align="left">32808972</td>
<td align="left">Ethical Considerations for COVID-19 Vaccine Trials in Correctional Facilities.</td>
<td align="left"><MedlineTA>JAMA</MedlineTA></td>
<td align="left">2020 Sep 15</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32802896</td>
<td align="left">The Application of Single-Cell RNA Sequencing in Vaccinology.</td>
<td align="left"><MedlineTA>J Immunol Res</MedlineTA></td>
<td align="left">2020</td>
<td align="left">Single-cell RNA sequencing allows highly detailed profiling of cellular immune responses from limited-volume samples, advancing prospects of a new era of systems immunology. The power of single-cell RNA sequencing offers various opportunities to decipher the immune response to infectious diseases and vaccines. Here, we describe the potential uses of single-cell RNA sequencing methods in prophylactic vaccine development, concentrating on infectious diseases including COVID-19. Using examples from several diseases, we review how single-cell RNA sequencing has been used to evaluate the immunological response to different vaccine platforms and regimens. By highlighting published and unpublished single-cell RNA sequencing studies relevant to vaccinology, we discuss some general considerations how the field could be enriched with the widespread adoption of this technology. Copyright © 2020 Andrés Noé et al.</td>
</tr>
<tr class="even">
<td align="left">32800805</td>
<td align="left">COVID-19 Vaccine: A comprehensive status report.</td>
<td align="left"><MedlineTA>Virus Res</MedlineTA></td>
<td align="left">2020 10 15</td>
<td align="left">The current COVID-19 pandemic has urged the scientific community internationally to find answers in terms of therapeutics and vaccines to control SARS-CoV-2. Published investigations mostly on SARS-CoV and to some extent on MERS has taught lessons on vaccination strategies to this novel coronavirus. This is attributed to the fact that SARS-CoV-2 uses the same receptor as SARS-CoV on the host cell i.e. human Angiotensin Converting Enzyme 2 (hACE2) and is approximately 79% similar genetically to SARS-CoV. Though the efforts on COVID-19 vaccines started very early, initially in China, as soon as the outbreak of novel coronavirus erupted and then world-over as the disease was declared a pandemic by WHO. But we will not be having an effective COVID-19 vaccine before September, 2020 as per very optimistic estimates. This is because a successful COVID-19 vaccine will require a cautious validation of efficacy and adverse reactivity as the target vaccinee population include high-risk individuals over the age of 60, particularly those with chronic co-morbid conditions, frontline healthcare workers and those involved in essentials industries. Various platforms for vaccine development are available namely: virus vectored vaccines, protein subunit vaccines, genetic vaccines, and monoclonal antibodies for passive immunization which are under evaluations for SARS-CoV-2, with each having discrete benefits and hindrances. The COVID-19 pandemic which probably is the most devastating one in the last 100 years after Spanish flu mandates the speedy evaluation of the multiple approaches for competence to elicit protective immunity and safety to curtail unwanted immune-potentiation which plays an important role in the pathogenesis of this virus. This review is aimed at providing an overview of the efforts dedicated to an effective vaccine for this novel coronavirus which has crippled the world in terms of economy, human health and life. Copyright © 2020 Elsevier B.V. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32789505</td>
<td align="left">Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.</td>
<td align="left"><MedlineTA>JAMA</MedlineTA></td>
<td align="left">2020 Aug 13</td>
<td align="left"><AbstractText Label="Importance" NlmCategory="UNASSIGNED">A vaccine against coronavirus disease 2019 (COVID-19) is urgently needed. <AbstractText Label="Objective" NlmCategory="UNASSIGNED">To evaluate the safety and immunogenicity of an investigational inactivated whole-virus COVID-19 vaccine in China. <AbstractText Label="Interventions" NlmCategory="UNASSIGNED">In the phase 1 trial, 96 participants were assigned to 1 of the 3 dose groups (2.5, 5, and 10 μg/dose) and an aluminum hydroxide (alum) adjuvant-only group (n = 24 in each group), and received 3 intramuscular injections at days 0, 28, and 56. In the phase 2 trial, 224 adults were randomized to 5 μg/dose in 2 schedule groups (injections on days 0 and 14 [n = 84] vs alum only [n = 28], and days 0 and 21 [n = 84] vs alum only [n = 28]). <AbstractText Label="Design, Setting, and Participants" NlmCategory="UNASSIGNED">Interim analysis of ongoing randomized, double-blind, placebo-controlled, phase 1 and 2 clinical trials to assess an inactivated COVID-19 vaccine. The trials were conducted in Henan Province, China, among 96 (phase 1) and 224 (phase 2) healthy adults aged between 18 and 59 years. Study enrollment began on April 12, 2020. The interim analysis was conducted on June 16, 2020, and updated on July 27, 2020. <AbstractText Label="Main Outcomes and Measures" NlmCategory="UNASSIGNED">The primary safety outcome was the combined adverse reactions 7 days after each injection, and the primary immunogenicity outcome was neutralizing antibody response 14 days after the whole-course vaccination, which was measured by a 50% plaque reduction neutralization test against live severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <AbstractText Label="Results" NlmCategory="UNASSIGNED">Among 320 patients who were randomized (mean age, 42.8 years; 200 women [62.5%]), all completed the trial up to 28 days after the whole-course vaccination. The 7-day adverse reactions occurred in 3 (12.5%), 5 (20.8%), 4 (16.7%), and 6 (25.0%) patients in the alum only, low-dose, medium-dose, and high-dose groups, respectively, in the phase 1 trial; and in 5 (6.0%) and 4 (14.3%) patients who received injections on days 0 and 14 for vaccine and alum only, and 16 (19.0%) and 5 (17.9%) patients who received injections on days 0 and 21 for vaccine and alum only, respectively, in the phase 2 trial. The most common adverse reaction was injection site pain, followed by fever, which were mild and self-limiting; no serious adverse reactions were noted. The geometric mean titers of neutralizing antibodies in the low-, medium-, and high-dose groups at day 14 after 3 injections were 316 (95% CI, 218-457), 206 (95% CI, 123-343), and 297 (95% CI, 208-424), respectively, in the phase 1 trial, and were 121 (95% CI, 95-154) and 247 (95% CI, 176-345) at day 14 after 2 injections in participants receiving vaccine on days 0 and 14 and on days 0 and 21, respectively, in the phase 2 trial. There were no detectable antibody responses in all alum-only groups. <AbstractText Label="Conclusions and Relevance" NlmCategory="UNASSIGNED">In this interim report of the phase 1 and phase 2 trials of an inactivated COVID-19 vaccine, patients had a low rate of adverse reactions and demonstrated immunogenicity; the study is ongoing. Efficacy and longer-term adverse event assessment will require phase 3 trials. <AbstractText Label="Trial Registration" NlmCategory="UNASSIGNED">Chinese Clinical Trial Registry Identifier: ChiCTR2000031809.</td>
</tr>
<tr class="even">
<td align="left">32789501</td>
<td align="left">Researchers Strive to Recruit Hard-Hit Minorities Into COVID-19 Vaccine Trials.</td>
<td align="left"><MedlineTA>JAMA</MedlineTA></td>
<td align="left">2020 09 01</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32784685</td>
<td align="left">Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?</td>
<td align="left"><MedlineTA>Viruses</MedlineTA></td>
<td align="left">2020 08 07</td>
<td align="left">Seven years after the Middle East respiratory syndrome (MERS) outbreak, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) made its first appearance in a food market in Wuhan, China, drawing an entirely new course to our lives. As the virus belongs to the same genus of MERS and SARS, researchers have been trying to draw lessons from previous outbreaks to find a potential cure. Although there were five Phase I human vaccine trials against SARS and MERS, the lack of data in humans provided us with limited benchmarks that could help us design a new vaccine for Coronavirus disease 2019 (COVID-19). In this review, we showcase the similarities in structures of virus components between SARS-CoV, MERS-CoV, and SARS-CoV-2 in areas relevant to vaccine design. Using the ClinicalTrials.gov and World Health Organization (WHO) databases, we shed light on the 16 current approved clinical trials worldwide in search for a COVID-19 vaccine. The different vaccine platforms being tested are Bacillus Calmette-Guérin (BCG) vaccines, DNA and RNA-based vaccines, inactivated vaccines, protein subunits, and viral vectors. By thoroughly analyzing different trials and platforms, we also discuss the advantages and disadvantages of using each type of vaccine and how they can contribute to the design of an adequate vaccine for COVID-19. Studying past efforts invested in conducting vaccine trials for MERS and SARS will provide vital insights regarding the best approach to designing an effective vaccine against COVID-19.</td>
</tr>
<tr class="even">
<td align="left">32782402</td>
<td align="left">Antibody therapies could be a bridge to a coronavirus vaccine - but will the world benefit?</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 08</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32782400</td>
<td align="left">Russia’s fast-track coronavirus vaccine draws outrage over safety.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 08</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32778829</td>
<td align="left">After 62 years of regulating immunity, dexamethasone meets COVID-19.</td>
<td align="left"><MedlineTA>Nat Rev Immunol</MedlineTA></td>
<td align="left">2020 10</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32778225</td>
<td align="left">Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.</td>
<td align="left"><MedlineTA>Cell</MedlineTA></td>
<td align="left">2020 08 06</td>
<td align="left">The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial. Copyright © 2020 Elsevier Inc. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32770854</td>
<td align="left">Clinical trial to test the efficacy of melatonin in COVID-19.</td>
<td align="left"><MedlineTA>J Pineal Res</MedlineTA></td>
<td align="left">2020 Oct</td>
<td align="left">The pharmacological properties of melatonin are well known. However, there is noticeable the lack of clinical trials that confirm the efficacy, security, absence of side effects in the short and long term, and the effective doses of melatonin. This point is especially important in diseases with high morbidity and mortality including COVID-19. There is not treatment for COVID-19, and several anti-inflammatory and antiviral molecules are being tested, and different vaccines are in preparation. Although the SARS-CoV-2 pandemic is apparently improving, it is expected new resurges next fall. Thus, looking for an effective treatment of COVID-19 is mandatory. Melatonin has significant anti-inflammatory, antioxidant, and mitochondrial protective effects, and its efficacy has been demonstrated in multiple experimental models of disease and in a clinical trial in sepsis. Because COVID-19 courses with a severe septic response, multiple reviews proposing melatonin as a treatment for COVID-19 have been published. Nevertheless, there is a lack of experimental and clinical data on the use of melatonin on SARS-CoV-2 infection. Accordingly, we designed a clinical trial with an injectable formulation of melatonin for intravenous perfusion in ICU patients suffering from COVID-19 that has been just approved by the Spanish Agency of Medicines and Medical Devices (AEMPS). The trial will allow by the first time understand the doses and efficacy of melatonin against COVID-19. © 2020 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</td>
</tr>
<tr class="odd">
<td align="left">32769322</td>
<td align="left">COVID-19: An up-to-date review - from morphology to pathogenesis.</td>
<td align="left"><MedlineTA>Indian J Pathol Microbiol</MedlineTA></td>
<td align="left">2020 Jul-Sep</td>
<td align="left">The entire world is under a devastating pandemic caused by COVID-19 with a high mortality rate. Knowledge of the viral structure, factors that help in its progression and spread, pathological findings, diagnostic methods and, treatment modalities helps in understanding the viral disease and also in treating the patients in a better way besides preventing the community spread of this deadly infection. The causative agent is a single- stranded RNA virus. The clinical spectrum varies in symptomatic and asymptomatic patients, who later become potential silent carriers, thus unknowingly spreading the virus. The virus constantly undergoes recombination, with reports of cross-species infections. Studies have indicated a strong immunological basis of COVID-19 infection. Not only does it weaken the immune system causing multi-organ involvement but also helps in its progression and spread to others.Multiple organs especially lungs, heart, kidney, gastrointestinal and hepatic system, brain and skin are affected varying in their severity. Similarly, persons with associated co-morbidities are likely to be affected more in terms of the number as well as in the severity. Real- time reverse transcription polymerase chain reaction confirms the presence of COVID-19 infection. Serological diagnosis helps in diagnosing an ongoing outbreak or retrospective infection. Furthermore, it also identifies individuals who have been infected or have recovered from the disease especially the asymptomatic. This helps in the development of an effective vaccine indicating the status of herd immunity in the community. Different treatment modalities are being tried and under trial. This review article thus highlights the global epidemiological status, characteristic of the virus, symptomatology of the patients, role of diagnostic tests available, organs affected including their morphological changes and the latest line of treatment of COVID-19.</td>
</tr>
<tr class="even">
<td align="left">32756480</td>
<td align="left">COVID-19: The Immune Responses and Clinical Therapy Candidates.</td>
<td align="left"><MedlineTA>Int J Mol Sci</MedlineTA></td>
<td align="left">2020 Aug 03</td>
<td align="left">The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US Food and Drug Administration (FDA) approved for emergency use in adults and children hospitalized with severe suspected or laboratory-confirmed COVID-19. Herein we summarize the general features of SARS-CoV-2’s molecular and immune pathogenesis and discuss available pharmacological strategies, based on our present understanding of SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) infections. Finally, we outline clinical trials currently in progress to investigate the efficacy of potential therapies for COVID-19.</td>
</tr>
<tr class="odd">
<td align="left">32746653</td>
<td align="left">Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges.</td>
<td align="left"><MedlineTA>Expert Rev Clin Pharmacol</MedlineTA></td>
<td align="left">2020 Aug 13</td>
<td align="left"><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The coronavirus disease 2019 (COVID-19) pandemic has spread globally since it outbroke in December 2019. The urgent pandemic presents an unprecedented challenge to develop and identify effective medication therapy strategies to combat the COVID-19. <AbstractText Label="AREAS COVERED" NlmCategory="UNASSIGNED">Here, we summarized and evaluated the current treatment drugs and regimens, and put forward the treatment recommendations, including using the potential repurposed or experimental drugs against COVID-19, e.g. chloroquine (CQ), hydroxychloroquine (HCQ), lopinavir/ritonavir (LPV/r), remdesivir (RDV), and favipiravir (FPV). We also analyzed the specific drugs and vaccines against SARS-CoV-2 ongoing development and formulated the comprehensive treatment regimens based on condition of patients, diseases and drugs as well as concomitant medications. <AbstractText Label="EXPERT OPINION" NlmCategory="UNASSIGNED">No drugs and vaccines have been proven to be particularly effective against SARS-CoV-2 up to now. The recommended comprehensive medication therapy strategies have already displayed favorable effect in the fight against COVID-19. Research should be focused on the development of anti-SARS-CoV-2 drugs and vaccines based on high-quality clinical trial evidence, treatment guidelines and expert consensus.</td>
</tr>
<tr class="even">
<td align="left">32742241</td>
<td align="left">Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.</td>
<td align="left"><MedlineTA>SSRN</MedlineTA></td>
<td align="left">2020 Jul 21</td>
<td align="left">Biotin-labeled molecular probes, comprising specific regions of the SARS-CoV-2 spike, would be helpful in the isolation and characterization of antibodies targeting this recently emerged pathogen. To develop such probes, we designed constructs incorporating an N-terminal purification tag, a site-specific protease-cleavage site, the probe region of interest, and a C-terminal sequence targeted by biotin ligase. Probe regions included full-length spike ectodomain as well as various subregions, and we also designed mutants to eliminate recognition of the ACE2 receptor. Yields of biotin-labeled probes from transient transfection ranged from ~0.5 mg/L for the complete ectodomain to &amp;gt;5 mg/L for several subregions. Probes were characterized for antigenicity and ACE2 recognition, and the structure of the spike ectodomain probe was determined by cryo-electron microscopy. We also characterized antibody-binding specificities and cell-sorting capabilities of the biotinylated probes. Altogether, structure-based design coupled to efficient purification and biotinylation processes can thus enable streamlined development of SARS-CoV-2 spike-ectodomain probes. Funding: Support for this work was provided by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID). Support for this work was also provided by COVID-19 Fast Grants, the Jack Ma Foundation, the Self Graduate Fellowship Program, and NIH grants DP5OD023118, R21AI143407, and R21AI144408. Some of this work was performed at the Columbia University Cryo-EM Center at the Zuckerman Institute, and some at the Simons Electron Microscopy Center (SEMC) and National Center for Cryo-EM Access and Training (NCCAT) located at the New York Structural Biology Center, supported by grants from the Simons Foundation (SF349247), NYSTAR, and the NIH National Institute of General Medical Sciences (GM103310). Conflict of Interest: The authors declare that they have no conflict of interest. Ethical Approval: Peripheral blood mononuclear cells (PBMCs) for B cell sorting were obtained from a convalescent SARS-CoV-2 patient (collected 75 days post symptom onset under an IRB approved clinical trial protocol, VRC 200 - ClinicalTrials.gov Identifier: NCT00067054) and a healthy control donor from the NIH blood bank pre-SARS-CoV-2 pandemic.</td>
</tr>
<tr class="odd">
<td align="left">32742146</td>
<td align="left">Impact of COVID-19 on Clinical Research and Inclusion of Diverse Populations.</td>
<td align="left"><MedlineTA>Ethn Dis</MedlineTA></td>
<td align="left">Summer 2020</td>
<td align="left">The randomized clinical trial (RCT) has long been recognized as the ‘gold standard’ for developing evidence for clinical treatments and vaccines; however, the successful implementation and translation of these findings is predicated upon external validity. The generalization of RCT findings are jeopardized by the lack of participation of at-risk groups such as African Americans, with long-recognized disproportional representation. Distinct factors that deter participation in RCTs include distrust, access, recruitment strategies, perceptions of research, and socioeconomic factors. While strategies have been implemented to improve external validity with greater participation among all segments of the population in RCTs, the coronavirus disease 2019 (COVID-19) pandemic may exacerbate disparities in RCT participation with the potential impact of delaying treatment development and vaccine interventions that are applicable and generalizable. Thus, it is essential to include diverse populations in such strategies and RCTs. This Perspective aims to direct attention to the additional harm from the pandemic as well as a refocus on the unresolved lack of inclusion of diverse populations in conducting RCTs. Copyright © 2020, Ethnicity &amp; Disease, Inc.</td>
</tr>
<tr class="even">
<td align="left">32739342</td>
<td align="left">COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials.</td>
<td align="left"><MedlineTA>Biochem Pharmacol</MedlineTA></td>
<td align="left">2020 Jul 30</td>
<td align="left">COVID-19, the greatest public health emergency of the 21st century, has affected 215 countries and territories around the world resulting in 15,151,738 confirmed cases and 621,121 deaths. The outbreak has continued at breakneck pace despite stringent public health measures, ravaging the global economy and causing profound human casualties. Vaccination is currently the best bet for the prevention of COVID-19. Still, in its absence, there has been considerable interest in repurposing existing therapeutic agents to reduce the severity of the illness and ease the burden on the already strained healthcare systems. This review outlines the current evidence regarding proposed treatments- experimental or repurposed, for COVID-19, and gives an insight into the clinical trial landscape for drugs as well as vaccines. Copyright © 2020. Published by Elsevier Inc.</td>
</tr>
<tr class="odd">
<td align="left">32737453</td>
<td align="left">China’s coronavirus vaccines are leaping ahead - but face challenges as virus wanes.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 08</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32734670</td>
<td align="left">Characteristics of Clinical Trials relating to COVID-19 registered at ClinicalTrials.gov.</td>
<td align="left"><MedlineTA>J Clin Pharm Ther</MedlineTA></td>
<td align="left">2020 Jul 30</td>
<td align="left"><AbstractText Label="WHAT IS KNOWN AND OBJECTIVE" NlmCategory="OBJECTIVE">Since the beginning of the COVID-19 outbreak in China in December 2019, the epidemic has continued to spread globally. Despite continuous reports of clinical trials being launched, no studies have yet systematically summarized and analysed their characteristics. Our objective is to do this by reviewing trials registered at ClinicalTrials.gov. <AbstractText Label="METHODS" NlmCategory="METHODS">We searched the ClinicalTrials.gov database and retrieved all clinical trials on COVID-19 registered up to and including 3 April 2020. We summarized the characteristics of the trials, presenting the results of all trials, all intervention trials and drug intervention (including vaccines and traditional Chinese medicine) trials. <AbstractText Label="RESULTS AND DISCUSSION" NlmCategory="CONCLUSIONS">We identified 306 COVID-19-related clinical trials. Seven of the studies had been withdrawn, leaving 299 active trials. Of the trials, 28.8% were planned to be conducted in Asia, 26.8% in Europe and 18.7% in North America. Most (73.0%) proposed trials expected to recruit fewer than 500 people, and only 22.1% of the studies included children (aged &lt;18 years). About two-thirds (67.2%) of the studies were funded by the own resources of medical or research institutions. Of intervention trials, 73.9% used random allocation, and 73.4% used parallel assignment. Only 36.7% of the intervention trials used blinding. In terms of drug trials, 147 trials were drug intervention studies, covering 80 conventional drugs and seven traditional Chinese medicine drugs. Antiviral drugs and antimalarial drugs were the most commonly studied drugs with 52 and 45 trials registered, respectively. Five registered clinical trials were on vaccines. <AbstractText Label="WHAT IS NEW AND CONCLUSION" NlmCategory="CONCLUSIONS">A large number of COVID-19-related trials have been registered within the first 4 months since the first infection was reported. These involve a large number of different drugs, the most common being antiviral drugs and antimalarial drugs. More attention should be paid to adequate blinding in future trials. © 2020 John Wiley &amp; Sons Ltd.</td>
</tr>
<tr class="odd">
<td align="left">32731192</td>
<td align="left">COVID-19: Understanding the science of antibody testing and lessons from the HIV epidemic.</td>
<td align="left"><MedlineTA>Diagn Microbiol Infect Dis</MedlineTA></td>
<td align="left">2020 Sep</td>
<td align="left">Potential pitfalls in the development, deployment and interpretation of antibody tests for COVID-19 are discussed. Lessons learned from the experience with the introduction of antibody tests for HIV are highlighted.Each test will need to be separately vetted for performance and clinical implementation based upon rigorous clinical trial data. The issues we highlight will also be similarly important for vaccine and therapeutic drug efficacy trials. Copyright © 2020 Elsevier Inc. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32726230</td>
<td align="left">Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.</td>
<td align="left"><MedlineTA>West J Emerg Med</MedlineTA></td>
<td align="left">2020 May 20</td>
<td align="left">In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic. To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 million cases and over 99,000 deaths. Given that there is neither a vaccine nor proven treatment for COVID-19, there is currently an urgent need for effective pharmacotherapy. To address the need for an effective treatment of SARS-CoV-2 during the worldwide pandemic, this systematic review of intravenous (IV) remdesivir was performed. Remdesivir, an anti-viral prodrug originally developed to treat Ebola virus disease, has shown broad spectrum activity against the Coronavirus family. A recent case report reported improvement of clinical symptoms with remdesivir in a patient with COVID-19. After conducting a systematic search of 18 clinical trial registries and three large scientific databases, we identified 86 potentially eligible items. Following removal of duplicates (n = 21), eligible studies were reviewed independently by two authors. After the first round of screening, inter-rater agreement was 98.5% (κ = 0.925). After the second round of full-text screening, inter-rater agreement was 100%. A total of seven ongoing and recruiting clinical trials of remdesivir (100-200 milligrams, intravenous [IV]) were included. We identified the following primary outcomes: patients discharged (n = 2); time to clinical status improvement (n = 2); improved O2 saturation (n = 2); body temperature normalization (n = 2); and clinical status (n = 1). Secondary outcomes in all identified studies included documentation of adverse events. Phase 3 trials are expected to be completed between April 2020-2023. Therefore, despite supportive data from in vitro and in vivo studies, the clinical effectiveness of IV remdesivir for treatment of COVID-19 and potential side effects remain incompletely defined in the human population.</td>
</tr>
<tr class="odd">
<td align="left">32725080</td>
<td align="left">Past, present, and future of COVID-19: a review.</td>
<td align="left"><MedlineTA>Braz J Med Biol Res</MedlineTA></td>
<td align="left">2020</td>
<td align="left">SARS-CoV-2 has recently emerged, becoming a global threat, affecting directly all human beings owing to its morbidity and mortality and indirectly, due to the enormous economic and psychological impact produced by social isolation, the most effective measure so far, but unsustainable for a long period. The scientific effort to understand and control SARS-CoV-2 transmission and clinical impact has been huge, and important achievements are highlighted in this review. Diagnosis is central and is the first step in recognizing and fighting any infectious agent. Instrumental to that is the quality of the data, relying on serological and molecular surveys in addition to trustworthy clinical records. However, the fast spread of a virus adapted for human-to-human respiratory transmission raised a demand for millions of molecular tests that are simply not available. Several candidate drugs are under evaluation in clinical trials. Those with an already recognized safety profile are more auspicious, since, if proven effective, can cut several steps of production and phase 2 and 3 trials. More than one hundred vaccine prototypes are in different stages of development, however, safety and efficacy evaluations cannot be obviated, implicating, most optimistically, in at least months for us to have an effective immunization, the definite measure to allow a safe return to the pre-pandemic lifestyle. Science has never been more necessary and present in daily life. Relying on the best of human wit is the only way out to this pandemic, saving as many lives as possible.</td>
</tr>
<tr class="even">
<td align="left">32723801</td>
<td align="left">Drug Discovery Strategies for SARS-CoV-2.</td>
<td align="left"><MedlineTA>J Pharmacol Exp Ther</MedlineTA></td>
<td align="left">2020 10</td>
<td align="left">Coronavirus disease 2019 (COVID-19) is a novel disease caused by the severe acute respiratory syndrome coronavirus (SARS-CoV)-2 virus that was first detected in December of 2019 in Wuhan, China, and has rapidly spread worldwide. The search for a suitable vaccine as well as effective therapeutics for the treatment of COVID-19 is underway. Drug repurposing screens provide a useful and effective solution for identifying potential therapeutics against SARS-CoV-2. For example, the experimental drug remdesivir, originally developed for Ebola virus infections, has been approved by the US Food and Drug Administration as an emergency use treatment of COVID-19. However, the efficacy and toxicity of this drug need further improvements. In this review, we discuss recent findings on the pathology of coronaviruses and the drug targets for the treatment of COVID-19. Both SARS-CoV-2-specific inhibitors and broad-spectrum anticoronavirus drugs against SARS-CoV, Middle East respiratory syndrome coronavirus, and SARS-CoV-2 will be valuable additions to the anti-SARS-CoV-2 armament. A multitarget treatment approach with synergistic drug combinations containing different mechanisms of action may be a practical therapeutic strategy for the treatment of severe COVID-19. SIGNIFICANCE STATEMENT: Understanding the biology and pathology of RNA viruses is critical to accomplish the challenging task of developing vaccines and therapeutics against SARS-CoV-2. This review highlights the anti-SARS-CoV-2 drug targets and therapeutic development strategies for COVID-19 treatment. U.S. Government work not protected by U.S. copyright.</td>
</tr>
<tr class="odd">
<td align="left">32719684</td>
<td align="left">COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.</td>
<td align="left"><MedlineTA>Front Immunol</MedlineTA></td>
<td align="left">2020</td>
<td align="left">To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. Our literature and clinical trial survey showed that the whole virus, as well as the spike (S) protein, nucleocapsid (N) protein, and membrane (M) protein, have been tested for vaccine development against SARS and MERS. However, these vaccine candidates might lack the induction of complete protection and have safety concerns. We then applied the Vaxign and the newly developed machine learning-based Vaxign-ML reverse vaccinology tools to predict COVID-19 vaccine candidates. Our Vaxign analysis found that the SARS-CoV-2 N protein sequence is conserved with SARS-CoV and MERS-CoV but not from the other four human coronaviruses causing mild symptoms. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10), were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity. Besides the commonly used S protein, the nsp3 protein has not been tested in any coronavirus vaccine studies and was selected for further investigation. The nsp3 was found to be more conserved among SARS-CoV-2, SARS-CoV, and MERS-CoV than among 15 coronaviruses infecting human and other animals. The protein was also predicted to contain promiscuous MHC-I and MHC-II T-cell epitopes, and the predicted linear B-cell epitopes were found to be localized on the surface of the protein. Our predicted vaccine targets have the potential for effective and safe COVID-19 vaccine development. We also propose that an “Sp/Nsp cocktail vaccine” containing a structural protein(s) (Sp) and a non-structural protein(s) (Nsp) would stimulate effective complementary immune responses. Copyright © 2020 Ong, Wong, Huffman and He.</td>
</tr>
<tr class="even">
<td align="left">32719619</td>
<td align="left">While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?</td>
<td align="left"><MedlineTA>Front Physiol</MedlineTA></td>
<td align="left">2020</td>
<td align="left">At the time of reception of this article (April 2, 2020), efforts to develop a specific vaccine against SARS-Cov-2, the causative agent of the coronavirus disease 2019 (COVID-19), had just begun trial phase 1, but full validation of this and other current developments is likely to take many more months to reach completion. The ongoing pandemic constitutes a major health burden of world proportions that is also having a devastating impact on whole economies worldwide, the knock-on effects of which could be catastrophic especially in poorer countries. Alternative measures to ameliorate the impact and hamper or minimally slow down disease progression are urgently called for. This review discusses past and currently evolving data on the etiological agent of the current pandemic, SARS-CoV-2, and its host cell receptors with a view to disclosing alternative drugs for palliative or therapeutic approaches. Firstly, SARS-CoV-2 exhibits marked tropism for cells that harbor the membrane-bound metalloprotease angiotensin-converting enzyme 2 (ACE2) at their plasmalemma, predominantly in cells lining the oral cavity, upper respiratory tract, and bronchoalveolar cells, making these epithelial mucosae the most likely viral receptor cell targets and entry routes. Secondly, the crystal structures of several coronavirus spike proteins in complex with their cell host target receptors, and of SARS-Cov-2 in complex with an inhibitor, are now available at atomic resolution through X-ray diffraction and cryo-electron microscopy studies. Thirdly, viral entry of other viruses has been successfully blocked by inhibiting viral endogenous proteases or clathrin/dynamin-dependent endocytosis, the same internalization pathway followed by ACE2 and some viruses. Fourthly, the target cell-surface receptor molecules and SARS-CoV-2 possess other putative sites for drugs potentially modulating receptor activity or virus processing. A multi-pronged pharmacological approach attacking more than one flank of the viral-receptor interactions is worth considering as a front-line strategy. Copyright © 2020 Barrantes.</td>
</tr>
<tr class="odd">
<td align="left">32718020</td>
<td align="left">Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.</td>
<td align="left"><MedlineTA>Int J Mol Sci</MedlineTA></td>
<td align="left">2020 Jul 23</td>
<td align="left">The ongoing pandemic of coronavirus disease-2019 (COVID-19) is being caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The disease continues to present significant challenges to the health care systems around the world. This is primarily because of the lack of vaccines to protect against the infection and the lack of highly effective therapeutics to prevent and/or treat the illness. Nevertheless, researchers have swiftly responded to the pandemic by advancing old and new potential therapeutics into clinical trials. In this review, we summarize potential anti-COVID-19 therapeutics that block the early stage of the viral life cycle. The review presents the structures, mechanisms, and reported results of clinical trials of potential therapeutics that have been listed in clinicaltrials.gov. Given the fact that some of these therapeutics are multi-acting molecules, other relevant mechanisms will also be described. The reviewed therapeutics include small molecules and macromolecules of sulfated polysaccharides, polypeptides, and monoclonal antibodies. The potential therapeutics target viral and/or host proteins or processes that facilitate the early stage of the viral infection. Frequent targets are the viral spike protein, the host angiotensin converting enzyme 2, the host transmembrane protease serine 2, and clathrin-mediated endocytosis process. Overall, the review aims at presenting update-to-date details, so as to enhance awareness of potential therapeutics, and thus, to catalyze their appropriate use in combating the pandemic.</td>
</tr>
<tr class="even">
<td align="left">32710003</td>
<td align="left">Coronavirus vaccines leap through safety trials - but which will work is anybody’s guess.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 07</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32702822</td>
<td align="left">Efficacy of integrative Traditional Chinese and Western medicine for the treatment of patients infected with 2019 novel coronavirus (COVID-19): A protocol for systematic review and meta analysis.</td>
<td align="left"><MedlineTA>Medicine (Baltimore)</MedlineTA></td>
<td align="left">2020 Jul 17</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">No specific anti-virus drugs or vaccines have been available for the treatment of COVID-19. Integrative traditional Chinese and western medicine has been proposed as a therapeutic option with substantial applications in China. This protocol is proposed for a systematic review and meta-analysis that aims to evaluate the efficacy of integrative traditional Chinese and western medicine treatment on patients with COVID-19. <AbstractText Label="METHODS" NlmCategory="METHODS">Ten databases including PubMed, EMBASE, Cochrane Library, CIHAHL, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang database, China Biomedical Literature Database (CBM) and Chinese Biomedical Literature Service System (SinoMed) will be searched. All published randomized controlled trials, clinical controlled trials, case-control, and case series that meet the pre-specified eligibility criteria will be included. Primary outcome measures include mortality, clinical recovery rate, duration of fever, progression rate from mild or moderate to severe, improvement of symptoms, biomarkers of laboratory examination and changes in computed tomography. Secondary outcomes include dosage of hormonotherapy, incidence and severity of adverse events and quality of life. Study selection, data extraction and assessment of bias risk will be conducted by 2 reviewers independently. RevMan software (V.5.3.5) will be used to perform data synthesis. Subgroup and sensitivity analysis will be performed when necessary. The strength of evidence will be assessed by the GRADE system. <AbstractText Label="RESULTS" NlmCategory="RESULTS">This study will provide a well-reported and high-quality synthesis on the efficacy of integrative traditional Chinese and western medicine treatment on patients with COVID-19. <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This systematic review protocol will be helpful for providing evidence of whether integrative traditional Chinese and western medicine treatment is an effective therapeutic approach for patients with COVID-19. <AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="UNASSIGNED">Ethical approval is unnecessary as no individual patient or privacy data is collected. The results of this study will be disseminated in a peer-reviewed scientific journal and/or conference presentation. <AbstractText Label="SYSTEMATIC REVIEW REGISTRATION" NlmCategory="UNASSIGNED">PROSPERO CRD42020167205.</td>
</tr>
<tr class="even">
<td align="left">32702299</td>
<td align="left">Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.</td>
<td align="left"><MedlineTA>Lancet</MedlineTA></td>
<td align="left">2020 08 15</td>
<td align="left"><AbstractText Label="BACKGROUND">This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study. <AbstractText Label="METHODS">This randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China. Healthy adults aged 18 years or older, who were HIV-negative and previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-free, were eligible to participate and were randomly assigned to receive the vaccine at a dose of 1 × 1011 viral particles per mL or 5 × 1010 viral particles per mL, or placebo. Investigators allocated participants at a ratio of 2:1:1 to receive a single injection intramuscularly in the arm. The randomisation list (block size 4) was generated by an independent statistician. Participants, investigators, and staff undertaking laboratory analyses were masked to group allocation. The primary endpoints for immunogenicity were the geometric mean titres (GMTs) of specific ELISA antibody responses to the receptor binding domain (RBD) and neutralising antibody responses at day 28. The primary endpoint for safety evaluation was the incidence of adverse reactions within 14 days. All recruited participants who received at least one dose were included in the primary and safety analyses. This study is registered with ClinicalTrials.gov, NCT04341389. <AbstractText Label="FINDINGS">603 volunteers were recruited and screened for eligibility between April 11 and 16, 2020. 508 eligible participants (50% male; mean age 39·7 years, SD 12·5) consented to participate in the trial and were randomly assigned to receive the vaccine (1 × 1011 viral particles n=253; 5 × 1010 viral particles n=129) or placebo (n=126). In the 1 × 1011 and 5 × 1010 viral particles dose groups, the RBD-specific ELISA antibodies peaked at 656·5 (95% CI 575·2-749·2) and 571·0 (467·6-697·3), with seroconversion rates at 96% (95% CI 93-98) and 97% (92-99), respectively, at day 28. Both doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2, with GMTs of 19·5 (95% CI 16·8-22·7) and 18·3 (14·4-23·3) in participants receiving 1 × 1011 and 5 × 1010 viral particles, respectively. Specific interferon γ enzyme-linked immunospot assay responses post vaccination were observed in 227 (90%, 95% CI 85-93) of 253 and 113 (88%, 81-92) of 129 participants in the 1 × 1011 and 5 × 1010 viral particles dose groups, respectively. Solicited adverse reactions were reported by 183 (72%) of 253 and 96 (74%) of 129 participants in the 1 × 1011 and 5 × 1010 viral particles dose groups, respectively. Severe adverse reactions were reported by 24 (9%) participants in the 1 × 1011 viral particles dose group and one (1%) participant in the 5 × 1010 viral particles dose group. No serious adverse reactions were documented. <AbstractText Label="INTERPRETATION">The Ad5-vectored COVID-19 vaccine at 5 × 1010 viral particles is safe, and induced significant immune responses in the majority of recipients after a single immunisation. <AbstractText Label="FUNDING">National Key R&amp;D Programme of China, National Science and Technology Major Project, and CanSino Biologics. Copyright © 2020 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32702298</td>
<td align="left">Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.</td>
<td align="left"><MedlineTA>Lancet</MedlineTA></td>
<td align="left">2020 08 15</td>
<td align="left"><AbstractText Label="BACKGROUND">The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2. <AbstractText Label="METHODS">We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. Healthy adults aged 18-55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose of 5 × 1010 viral particles or MenACWY as a single intramuscular injection. A protocol amendment in two of the five sites allowed prophylactic paracetamol to be administered before vaccination. Ten participants assigned to a non-randomised, unblinded ChAdOx1 nCoV-19 prime-boost group received a two-dose schedule, with the booster vaccine administered 28 days after the first dose. Humoral responses at baseline and following vaccination were assessed using a standardised total IgG ELISA against trimeric SARS-CoV-2 spike protein, a muliplexed immunoassay, three live SARS-CoV-2 neutralisation assays (a 50% plaque reduction neutralisation assay [PRNT50]; a microneutralisation assay [MNA50, MNA80, and MNA90]; and Marburg VN), and a pseudovirus neutralisation assay. Cellular responses were assessed using an ex-vivo interferon-γ enzyme-linked immunospot assay. The co-primary outcomes are to assess efficacy, as measured by cases of symptomatic virologically confirmed COVID-19, and safety, as measured by the occurrence of serious adverse events. Analyses were done by group allocation in participants who received the vaccine. Safety was assessed over 28 days after vaccination. Here, we report the preliminary findings on safety, reactogenicity, and cellular and humoral immune responses. The study is ongoing, and was registered at ISRCTN, 15281137, and ClinicalTrials.gov, NCT04324606. <AbstractText Label="FINDINGS">Between April 23 and May 21, 2020, 1077 participants were enrolled and assigned to receive either ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534), ten of whom were enrolled in the non-randomised ChAdOx1 nCoV-19 prime-boost group. Local and systemic reactions were more common in the ChAdOx1 nCoV-19 group and many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, chills, muscle ache, headache, and malaise (all p&lt;0·05). There were no serious adverse events related to ChAdOx1 nCoV-19. In the ChAdOx1 nCoV-19 group, spike-specific T-cell responses peaked on day 14 (median 856 spot-forming cells per million peripheral blood mononuclear cells, IQR 493-1802; n=43). Anti-spike IgG responses rose by day 28 (median 157 ELISA units [EU], 96-317; n=127), and were boosted following a second dose (639 EU, 360-792; n=10). Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose when measured in MNA80 and in 35 (100%) participants when measured in PRNT50. After a booster dose, all participants had neutralising activity (nine of nine in MNA80 at day 42 and ten of ten in Marburg VN on day 56). Neutralising antibody responses correlated strongly with antibody levels measured by ELISA (R2=0·67 by Marburg VN; p&lt;0·001). <AbstractText Label="INTERPRETATION">ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses. These results, together with the induction of both humoral and cellular immune responses, support large-scale evaluation of this candidate vaccine in an ongoing phase 3 programme. <AbstractText Label="FUNDING">UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland’s NIHR Clinical Research Network, and the German Center for Infection Research (DZIF), Partner site Gießen-Marburg-Langen. Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32699167</td>
<td align="left">Artificial intelligence mobile health platform for early detection of COVID-19 in quarantine subjects using a wearable biosensor: protocol for a randomised controlled trial.</td>
<td align="left"><MedlineTA>BMJ Open</MedlineTA></td>
<td align="left">2020 07 22</td>
<td align="left"><AbstractText Label="INTRODUCTION">There is an outbreak of COVID-19 worldwide. As there is no effective therapy or vaccine yet, rigorous implementation of traditional public health measures such as isolation and quarantine remains the most effective tool to control the outbreak. When an asymptomatic individual with COVID-19 exposure is being quarantined, it is necessary to perform temperature and symptom surveillance. As such surveillance is intermittent in nature and highly dependent on self-discipline, it has limited effectiveness. Advances in biosensor technologies made it possible to continuously monitor physiological parameters using wearable biosensors with a variety of form factors. <AbstractText Label="OBJECTIVE">To explore the potential of using wearable biosensors to continuously monitor multidimensional physiological parameters for early detection of COVID-19 clinical progression. <AbstractText Label="METHOD">This randomised controlled open-labelled trial will involve 200-1000 asymptomatic subjects with close COVID-19 contact under mandatory quarantine at designated facilities in Hong Kong. Subjects will be randomised to receive a remote monitoring strategy (intervention group) or standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine period. In addition to fever and symptom surveillance in the control group, subjects in the intervention group will wear wearable biosensors on their arms to continuously monitor skin temperature, respiratory rate, blood pressure, pulse rate, blood oxygen saturation and daily activities. These physiological parameters will be transferred in real time to a smartphone application called Biovitals Sentinel. These data will then be processed using a cloud-based multivariate physiology analytics engine called Biovitals to detect subtle physiological changes. The results will be displayed on a web-based dashboard for clinicians’ review. The primary outcome is the time to diagnosis of COVID-19. <AbstractText Label="ETHICS AND DISSEMINATION">Ethical approval has been obtained from institutional review boards at the study sites. Results will be published in peer-reviewed journals. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="odd">
<td align="left">32696862</td>
<td align="left">Use of remdesivir for patients with Covid-19: a review article.</td>
<td align="left"><MedlineTA>Rev Assoc Med Bras (1992)</MedlineTA></td>
<td align="left">2020 Jun</td>
<td align="left">The etiological agent of COVID-19, which causes severe respiratory diseases such as pneumonia and pulmonary insufficiency, has been confirmed as a new coronavirus, now known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is currently no authorized medication for the treatment of COVID-19. No vaccines have been authorized. Thus, this study aimed at conducting a review of the use of Remdesivir in patients with COVID-19. The following electronic databases were used MEDLINE, SCIELO, LILACS, and PUBMED. On May 1, Remdesivir received emergency use authorization from the Food and Drug Administration. Remdesivir is currently the most promising molecule in the treatment of COVID-19, taking into account its broad antiviral spectrum (considering the genetic sequences of the virus, it is expected to maintain activity against SARS-CoV-2). There is in vitro and in vivo information available for coronaviruses, as well as an extensive clinical safety database (from a clinical trial of the Ebola virus and in the context of the Monitored Emergency Use of Unregistered and Investigational Interventions - MEURI). Further studies are relevant as available data on the efficacy and safety of Remdesivir against SARS-nCoV-2 are limited.</td>
</tr>
<tr class="even">
<td align="left">32694847</td>
<td align="left">Coronavirus vaccines get a biotech boost.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 07</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32694043</td>
<td align="left">Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.</td>
<td align="left"><MedlineTA>Transfus Apher Sci</MedlineTA></td>
<td align="left">2020 Jul 15</td>
<td align="left">Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients’ need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy. Copyright © 2020 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32671831</td>
<td align="left">COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.</td>
<td align="left"><MedlineTA>Clin Exp Immunol</MedlineTA></td>
<td align="left">2020 Jul 16</td>
<td align="left">Although most autoimmune diseases are considered to be CD4 T cell- or antibody-mediated, many respond to CD20-depleting antibodies that have limited influence on CD4 and plasma cells. This includes rituximab, oblinutuzumab and ofatumumab that are used in cancer, rheumatoid arthritis and off-label in a large number of other autoimmunities and ocrelizumab in multiple sclerosis. Recently, the COVID-19 pandemic created concerns about immunosuppression in autoimmunity, leading to cessation or a delay in immunotherapy treatments. However, based on the known and emerging biology of autoimmunity and COVID-19, it was hypothesised that while B cell depletion should not necessarily expose people to severe SARS-CoV-2-related issues, it may inhibit protective immunity following infection and vaccination. As such, drug-induced B cell subset inhibition, that controls at least some autoimmunities, would not influence innate and CD8 T cell responses, which are central to SARS-CoV-2 elimination, nor the hypercoagulation and innate inflammation causing severe morbidity. This is supported clinically, as the majority of SARS-CoV-2-infected, CD20-depleted people with autoimmunity have recovered. However, protective neutralizing antibody and vaccination responses are predicted to be blunted until naive B cells repopulate, based on B cell repopulation kinetics and vaccination responses, from published rituximab and unpublished ocrelizumab (NCT00676715, NCT02545868) trial data, shown here. This suggests that it may be possible to undertake dose interruption to maintain inflammatory disease control, while allowing effective vaccination against SARS-CoV-29, if and when an effective vaccine is available. © 2020 The Authors. Clinical &amp; Experimental Immunology published by John Wiley &amp; Sons Ltd on behalf of British Society for Immunology.</td>
</tr>
<tr class="odd">
<td align="left">32669462</td>
<td align="left">Human Infection Challenge Studies: a Test for the Social Value Criterion of Research Ethics.</td>
<td align="left"><MedlineTA>mSphere</MedlineTA></td>
<td align="left">2020 07 15</td>
<td align="left">Human infection challenge studies involving the intentional infection of research participants with a disease-causing agent have recently been suggested as a means to speed up the search for a vaccine for the ongoing coronavirus disease 2019 (COVID-19) outbreak. Calls for challenge studies, however, rely on the expected social value of these studies. This value represents more than the simple possibility that a successful study will lead to the rapid development and dissemination of vaccines but also some expectation that this will actually occur. I show how this expectation may not be realistic in the current political moment and offer potential ways to make sure that any challenge trials that arise actually achieve their goals. Copyright © 2020 Evans.</td>
</tr>
<tr class="even">
<td align="left">32667492</td>
<td align="left">Trained innate immunity, COVID-19 therapeutic dilemma, and fake science.</td>
<td align="left"><MedlineTA>Clinics (Sao Paulo)</MedlineTA></td>
<td align="left">2020</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32664543</td>
<td align="left">Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation.</td>
<td align="left"><MedlineTA>Int J Mol Sci</MedlineTA></td>
<td align="left">2020 Jul 11</td>
<td align="left">Recently, the world has been dealing with a devastating global pandemic coronavirus infection, with more than 12 million infected worldwide and over 300,000 deaths as of May 15th 2020, related to a novel coronavirus (2019-nCoV), characterized by a spherical morphology and identified through next-generation sequencing. Although the respiratory tract is the primary portal of entry of SARS-CoV-2, gastrointestinal involvement associated with nausea, vomiting and diarrhoea may also occur. No drug or vaccine has been approved due to the absence of evidence deriving from rigorous clinical trials. Increasing interest has been highlighted on the possible preventative role and adjunct treatment of lactoferrin, glycoprotein of human secretions part of a non-specific defensive system, known to play a crucial role against microbial and viral infections and exerting anti-inflammatory effects on different mucosal surfaces and able to regulate iron metabolism. In this review, analysing lactoferrin properties, we propose designing a clinical trial to evaluate and verify its effect using a dual combination treatment with local, solubilized intranasal spray formulation and oral administration. Lactoferrin could counteract the coronavirus infection and inflammation, acting either as natural barrier of both respiratory and intestinal mucosa or reverting the iron disorders related to the viral colonization.</td>
</tr>
<tr class="even">
<td align="left">32663912</td>
<td align="left">An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.</td>
<td align="left"><MedlineTA>N Engl J Med</MedlineTA></td>
<td align="left">2020 Jul 14</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 μg, or 250 μg. There were 15 participants in each dose group. <AbstractText Label="RESULTS" NlmCategory="RESULTS">After the first vaccination, antibody responses were higher with higher dose (day 29 enzyme-linked immunosorbent assay anti-S-2P antibody geometric mean titer [GMT], 40,227 in the 25-μg group, 109,209 in the 100-μg group, and 213,526 in the 250-μg group). After the second vaccination, the titers increased (day 57 GMT, 299,751, 782,719, and 1,192,154, respectively). After the second vaccination, serum-neutralizing activity was detected by two methods in all participants evaluated, with values generally similar to those in the upper half of the distribution of a panel of control convalescent serum specimens. Solicited adverse events that occurred in more than half the participants included fatigue, chills, headache, myalgia, and pain at the injection site. Systemic adverse events were more common after the second vaccination, particularly with the highest dose, and three participants (21%) in the 250-μg dose group reported one or more severe adverse events. <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 ClinicalTrials.gov number, NCT04283461). Copyright © 2020 Massachusetts Medical Society.</td>
</tr>
<tr class="odd">
<td align="left">32661140</td>
<td align="left">The SARS-CoV-2 N Protein Is a Good Component in a Vaccine.</td>
<td align="left"><MedlineTA>J Virol</MedlineTA></td>
<td align="left">2020 08 31</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32661074</td>
<td align="left">Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.</td>
<td align="left"><MedlineTA>J Med Ethics</MedlineTA></td>
<td align="left">2020 Jul 13</td>
<td align="left">To counter the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), some have proposed accelerating SARS-CoV-2 vaccine development through controlled human infection (or ‘challenge’) trials. These trials would involve the deliberate exposure of relatively few young, healthy volunteers to SARS-CoV-2. We defend this proposal against the charge that there is still too much uncertainty surrounding the risks of COVID-19 to responsibly run such a trial. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="odd">
<td align="left">32658877</td>
<td align="left">[The naked king in the pandemic: about the production and communication of scientific knowledge at the time of SARS-CoV-2.]</td>
<td align="left"><MedlineTA>Recenti Prog Med</MedlineTA></td>
<td align="left">2020 Jul-Aug</td>
<td align="left">The SARS-CoV-2 pandemic has lifted the veil about how medical knowledge is produced and disseminated. Action Bias, together with economic, academic and media-related interests, has concurred to generate and spread low-value and even unreliable information about some hypothetical therapeutic interventions for CoViD-19. Not only this “infodemic” has weakened people’s ability to make informed health choices, but it also has influenced the process of new evidence generation through the violation of the equipoise principle. The CoViD-19 infodemic has further highlighted the need for reliable health information and for people to enter the process of understanding and promoting valuable research. Through a randomized controlled trial, the Informed Health Choices project has shown that it is not impossible neither quixotic to better orient people about health choices since primary school. Similar competencies should be disseminated to everyone through sources that are selected and validated for their capability of reporting evidence based health information about the effects of treatments.</td>
</tr>
<tr class="even">
<td align="left">32658841</td>
<td align="left">Development of a hyperimmune equine serum therapy for COVID-19 in Argentina.</td>
<td align="left"><MedlineTA>Medicina (B Aires)</MedlineTA></td>
<td align="left">2020</td>
<td align="left">The disease named COVID-19, caused by the SARS-CoV-2 coronavirus, is currently generating a global pandemic. Vaccine development is no doubt the best long-term immunological approach, but in the current epidemiologic and health emergency there is a need for rapid and effective solutions. Convalescent plasma is the only antibody-based therapy available for COVID-19 patients to date. Equine polyclonal antibodies (EpAbs) put forward a sound alternative. The new generation of processed and purified EpAbs containing highly purified F(ab’)2 fragments demonstrated to be safe and well tolerated. EpAbs are easy to manufacture allowing a fast development and scaling up for a treatment. Based on these ideas, we present a new therapeutic product obtained after immunization of horses with the receptor-binding domain of the viral Spike glycoprotein. Our product shows around 50 times more potency in in vitro seroneutralization assays than the average of convalescent plasma. This result may allow us to test the safety and efficacy of this product in a phase 2/3 clinical trial to be conducted in July 2020 in the metropolitan area of Buenos Aires, Argentina.</td>
</tr>
<tr class="odd">
<td align="left">32653511</td>
<td align="left">Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19.</td>
<td align="left"><MedlineTA>Free Radic Biol Med</MedlineTA></td>
<td align="left">2020 08 20</td>
<td align="left">Studies have shown that infection, excessive coagulation, cytokine storm, leukopenia, lymphopenia, hypoxemia and oxidative stress have also been observed in critically ill Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) patients in addition to the onset symptoms. There are still no approved drugs or vaccines. Dietary supplements could possibly improve the patient’s recovery. Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), present an anti-inflammatory effect that could ameliorate some patients need for intensive care unit (ICU) admission. EPA and DHA replace arachidonic acid (ARA) in the phospholipid membranes. When oxidized by enzymes, EPA and DHA contribute to the synthesis of less inflammatory eicosanoids and specialized pro-resolving lipid mediators (SPMs), such as resolvins, maresins and protectins. This reduces inflammation. In contrast, some studies have reported that EPA and DHA can make cell membranes more susceptible to non-enzymatic oxidation mediated by reactive oxygen species, leading to the formation of potentially toxic oxidation products and increasing the oxidative stress. Although the inflammatory resolution improved by EPA and DHA could contribute to the recovery of patients infected with SARS-CoV-2, Omega-3 fatty acids supplementation cannot be recommended before randomized and controlled trials are carried out. Copyright © 2020 Elsevier Inc. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32653463</td>
<td align="left">Vaccines for COVID-19: The current state of play.</td>
<td align="left"><MedlineTA>Paediatr Respir Rev</MedlineTA></td>
<td align="left">2020 Sep</td>
<td align="left">There is a strong consensus globally that a COVID-19 vaccine is likely the most effective approach to sustainably controlling the COVID-19 pandemic. An unprecedented research effort and global coordination has resulted in a rapid development of vaccine candidates and initiation of trials. Here, we review vaccine types, and progress with 10 vaccine candidates against SARS-CoV-2 - the virus that causes COVID-19 - currently undergoing early phase human trials. We also consider the many challenges of developing and deploying a new vaccine on a global scale, and recommend caution with respect to our expectations of the timeline that may be ahead. Copyright © 2020 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32653224</td>
<td align="left">BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?</td>
<td align="left"><MedlineTA>Allergol Immunopathol (Madr)</MedlineTA></td>
<td align="left">2020 Sep - Oct</td>
<td align="left">The impact of COVID-19 is changing with country wise and depend on universal immunization policies. COVID-19 badly affects countries that did not have universal immunization policies or having them only for the selective population of countries (highly prominent population) like Italy, USA, UK, Netherland, etc. Universal immunization of BCG can provide great protection against the COVID-19 infection because the BCG vaccine gives broad protection against respiratory infections. BCG vaccine induces expressions of the gene that are involved in the antiviral innate immune response against viral infections with long-term maintenance of BCG vaccine-induced cellular immunity. COVID-19 cases are reported very much less in the countries with universal BCG vaccination policies such as India, Afghanistan, Nepal, Bhutan, Bangladesh, Israel, Japan, etc. as compared to without BCG implemented countries such as the USA, Italy, Spain, Canada, UK, etc. BCG vaccine provides protection for 50-60 years of immunization, so the elderly population needs to be revaccinated with BCG. Several countries started clinical trials of the BCG vaccine for health care workers and elderly people. BCG can be uses as a prophylactic treatment until the availability of the COVID-19 vaccine. Copyright © 2020 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32648899</td>
<td align="left">Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.</td>
<td align="left"><MedlineTA>JAMA</MedlineTA></td>
<td align="left">2020 Aug 25</td>
<td align="left"><AbstractText Label="Importance" NlmCategory="UNASSIGNED">The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial increase in hospitalizations for pneumonia with multiorgan disease. This review discusses current evidence regarding the pathophysiology, transmission, diagnosis, and management of COVID-19. <AbstractText Label="Observations" NlmCategory="UNASSIGNED">SARS-CoV-2 is spread primarily via respiratory droplets during close face-to-face contact. Infection can be spread by asymptomatic, presymptomatic, and symptomatic carriers. The average time from exposure to symptom onset is 5 days, and 97.5% of people who develop symptoms do so within 11.5 days. The most common symptoms are fever, dry cough, and shortness of breath. Radiographic and laboratory abnormalities, such as lymphopenia and elevated lactate dehydrogenase, are common, but nonspecific. Diagnosis is made by detection of SARS-CoV-2 via reverse transcription polymerase chain reaction testing, although false-negative test results may occur in up to 20% to 67% of patients; however, this is dependent on the quality and timing of testing. Manifestations of COVID-19 include asymptomatic carriers and fulminant disease characterized by sepsis and acute respiratory failure. Approximately 5% of patients with COVID-19, and 20% of those hospitalized, experience severe symptoms necessitating intensive care. More than 75% of patients hospitalized with COVID-19 require supplemental oxygen. Treatment for individuals with COVID-19 includes best practices for supportive management of acute hypoxic respiratory failure. Emerging data indicate that dexamethasone therapy reduces 28-day mortality in patients requiring supplemental oxygen compared with usual care (21.6% vs 24.6%; age-adjusted rate ratio, 0.83 [95% CI, 0.74-0.92]) and that remdesivir improves time to recovery (hospital discharge or no supplemental oxygen requirement) from 15 to 11 days. In a randomized trial of 103 patients with COVID-19, convalescent plasma did not shorten time to recovery. Ongoing trials are testing antiviral therapies, immune modulators, and anticoagulants. The case-fatality rate for COVID-19 varies markedly by age, ranging from 0.3 deaths per 1000 cases among patients aged 5 to 17 years to 304.9 deaths per 1000 cases among patients aged 85 years or older in the US. Among patients hospitalized in the intensive care unit, the case fatality is up to 40%. At least 120 SARS-CoV-2 vaccines are under development. Until an effective vaccine is available, the primary methods to reduce spread are face masks, social distancing, and contact tracing. Monoclonal antibodies and hyperimmune globulin may provide additional preventive strategies. <AbstractText Label="Conclusions and Relevance" NlmCategory="UNASSIGNED">As of July 1, 2020, more than 10 million people worldwide had been infected with SARS-CoV-2. Many aspects of transmission, infection, and treatment remain unclear. Advances in prevention and effective management of COVID-19 will require basic and clinical investigation and public health and clinical interventions.</td>
</tr>
<tr class="odd">
<td align="left">32646869</td>
<td align="left">Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.</td>
<td align="left"><MedlineTA>CMAJ</MedlineTA></td>
<td align="left">2020 08 24</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32645630</td>
<td align="left">Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.</td>
<td align="left"><MedlineTA>Int Immunopharmacol</MedlineTA></td>
<td align="left">2020 Sep</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is no vaccine or specific antiviral treatment for HCoVs infection. The use of type I interferons for coronavirus is still under great debate in clinical practice. <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A literature search of all relevant studies published on PubMed, Cochrane library, Web of Science database, Science Direct, Wanfang Data, and China National Knowledge Infrastructure (CNKI) until February 2020 was performed. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 1081 identified articles, only 15 studies were included in the final analysis. Comorbidities and delay in diagnosis were significantly associated with case mortality. Type I interferons seem to improve respiratory distress, relieve lung abnormalities, present better saturation, reduce needs for supplemental oxygen support. Type I interferons seem to be well tolerated, and don’t increase life threating adverse effects. Data on IFNs in HCoVs are limited, heterogenous and mainly observational. <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Current data do not allow making regarding robust commendations for the use of IFNs in HCoVs in general or in specific subtype. But we still recommend type I interferons serving as first-line antivirals in HCoVs infections within local protocols, and interferons may be adopted to the treatments of the SARS-CoV-2 as well. Well-designed large-scale prospective randomized control trials are greatly needed to provide more robust evidence on this topic. Copyright © 2020. Published by Elsevier B.V.</td>
</tr>
<tr class="odd">
<td align="left">32636754</td>
<td align="left">A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic.</td>
<td align="left"><MedlineTA>Front Pharmacol</MedlineTA></td>
<td align="left">2020</td>
<td align="left">A novel coronavirus SARS-CoV-2 causing Coronavirus disease 2019 (COVID-19) has entered the human population and has spread rapidly around the world in the first half of 2020 causing a global pandemic. The virus uses its spike glycoprotein receptor-binding domain to interact with host cell angiotensin-converting enzyme 2 (ACE2) sites to initiate a cascade of events that culminate in severe acute respiratory syndrome in some individuals. In efforts to curtail viral spread, authorities initiated far-reaching lockdowns that have disrupted global economies. The scientific and medical communities are mounting serious efforts to limit this pandemic and subsequent waves of viral spread by developing preventative vaccines and repurposing existing drugs as potential therapies. In this review, we focus on the latest developments in COVID-19 vaccine development, including results of the first Phase I clinical trials and describe a number of the early candidates that are emerging in the field. We seek to provide a balanced coverage of the seven main platforms used in vaccine development that will lead to a desired target product profile for the “ideal” vaccine. Using tales of past vaccine discovery efforts that have taken many years or that have failed, we temper over exuberant enthusiasm with cautious optimism that the global medical community will reach the elusive target to treat COVID-19 and end the pandemic. Copyright © 2020 Funk, Laferrière and Ardakani.</td>
</tr>
<tr class="even">
<td align="left">32632960</td>
<td align="left">Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.</td>
<td align="left"><MedlineTA>Drug Dev Res</MedlineTA></td>
<td align="left">2020 Jul 06</td>
<td align="left">Coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is one of the most contagious diseases in human history that has already affected millions of lives worldwide. To date, no vaccines or effective therapeutics have been discovered yet that may successfully treat COVID-19 patients or contain the transmission of the virus. Scientific communities across the globe responded rapidly and have been working relentlessly to develop drugs and vaccines, which may require considerable time. In this uncertainty, repurposing the existing antiviral drugs could be the best strategy to speed up the discovery of effective therapeutics against SARS-CoV-2. Moreover, drug repurposing may leave some vital information on druggable targets that could be capitalized in target-based drug discovery. Information on possible drug targets and the progress on therapeutic and vaccine development also needs to be updated. In this review, we revisited the druggable targets that may hold promise in the development of the anti-SARS-CoV-2 agent. Progresses on the development of potential therapeutics and vaccines that are under the preclinical studies and clinical trials have been highlighted. We anticipate that this review will provide valuable information that would help to accelerate the development of therapeutics and vaccines against SARS-CoV-2 infection. © 2020 Wiley Periodicals, LLC.</td>
</tr>
<tr class="odd">
<td align="left">32628748</td>
<td align="left">Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development.</td>
<td align="left"><MedlineTA>Clin Infect Dis</MedlineTA></td>
<td align="left">2020 Jul 06</td>
<td align="left">Human challenge trials (HCTs) have been proposed as a means to accelerate SARS-CoV-2 vaccine development. We identify and discuss three potential use cases of HCTs in the current pandemic: evaluating efficacy, converging on correlates of protection, and improving understanding of pathogenesis and the human immune response. We outline the limitations of HCTs and find that HCTs are likely to be most useful for vaccine candidates currently in preclinical stages of development. We conclude that, while currently limited in their application, there are scenarios in which HCTs would be extremely beneficial. Therefore, the option of conducting HCTs to accelerate SARS-CoV-2 vaccine development should be preserved. As HCTs require many months of preparation, we recommend an immediate effort to (1) establish guidelines for HCTs for COVID-19; (2) take the first steps toward HCTs, including preparing challenge virus and making preliminary logistical arrangements; and (3) commit to periodically re-evaluating the utility of HCTs. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="even">
<td align="left">32624257</td>
<td align="left">Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective.</td>
<td align="left"><MedlineTA>J Allergy Clin Immunol</MedlineTA></td>
<td align="left">2020 08</td>
<td align="left">The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help of another host protein, transmembrane protease serine S1 member 2. Several factors likely contribute to the efficient transmission of SARS-CoV-2. The receptor-binding domain of SARS-CoV-2 has a 10- to 20-fold higher receptor-binding capacity compared with previous pandemic coronaviruses. In addition, because asymptomatic persons infected with SARS-CoV-2 have high viral loads in their nasal secretions, they can silently and efficiently spread the disease. PCR-based tests have emerged as the criterion standard for the diagnosis of infection. Caution must be exercised in interpreting antibody-based tests because they have not yet been validated, and may give a false sense of security of being “immune” to SARS-CoV-2. We discuss how the development of some symptoms in allergic rhinitis can serve as clues for new-onset COVID-19. There are mixed reports that asthma is a risk factor for severe COVID-19, possibly due to differences in asthma endotypes. The rapid spread of COVID-19 has focused the efforts of scientists on repurposing existing Food and Drug Administration-approved drugs that inhibit viral entry, endocytosis, genome assembly, translation, and replication. Numerous clinical trials have been launched to identify effective treatments for COVID-19. Initial data from a placebo-controlled study suggest faster time to recovery in patients on remdesivir; it is now being evaluated in additional controlled studies. As discussed in this review, till effective vaccines and treatments emerge, it is important to understand the scientific rationale of pandemic-mitigation strategies such as wearing facemasks and social distancing, and implement them. Copyright © 2020 American Academy of Allergy, Asthma &amp; Immunology. Published by Elsevier Inc. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32620409</td>
<td align="left">Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.</td>
<td align="left"><MedlineTA>Transfus Apher Sci</MedlineTA></td>
<td align="left">2020 Jun 27</td>
<td align="left"><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Convalescent Plasma (CP) therapy is of interest as no vaccine or specific treatment is available for emerging viruses such as severe acute respiratory syndrome coronavirus 2 causing Covid-19. It was aimed to report the results of our patients who underwent CP in the treatment of Covid-19. <AbstractText Label="METHODS" NlmCategory="METHODS">CP treatment was applied to 26 Covid-19 patients in intensive care unit who had quantitative reverse transcriptase-polymerase chain reaction positive Sars-Cov-2 infection. Plasma was collected at least 14 days after complete recovery from patients who had mild or moderate infection with Sars-Cov-2 infection. The collected CP (200cc) were applied to severe Covid-19 patients. Laboratory values of patients just before CP and after 7 days were compared. <AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no statistically significant differences in leukocyte, neutrophil, lymphocyte, platelet, CRP, ferritin, LDH, ALT, AST, sO2 and total bilirubin values just before and after 1 week of CP. A statistically significant difference was found between age and lymphocyte values of living and dying patients. The patients who died were determined to have older age (74,6 vs 61,85, p = 0,018) and more severe lymphopenia (0,47 vs 1,18, p = 0,001). <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">CP therapy has the potential to provide immediate and promising treatment options before specific vaccines and treatments are developed. In early stage Covid-19 patients who do not need mechanical ventilation, CP treatment may be a curative treatment option. Copyright © 2020 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32615862</td>
<td align="left">Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry.</td>
<td align="left"><MedlineTA>Emerg Microbes Infect</MedlineTA></td>
<td align="left">2020 Dec</td>
<td align="left">The COVID-19 pandemic has caused a global public health crisis. There is a pressing need for evidence-based interventions to address the devastating clinical and public health effects of the COVID-19 pandemic. The Chinese scientists supported by private and government resources have adopted extensive efforts to identify effective drugs against the virus. To date, a large number of clinical trials addressing various aspects of COVID19 have been registered in the Chinese Clinical Trial Registry (ChiCTR), including more than 200 interventional studies. Under such an urgent circumstance, the scope and quality of these clinical studies vary significantly. Hence, this review aims to make a comprehensive analysis on the profiles of COVID-19 clinical trials registered in the ChiCTR, including a wide range of characteristics. Our findings will provide a useful summary on these clinical studies since most of these studies will encounter major challenges from the design to completion. It will be a long road for the outcomes of these studies to be published and international collaboration will help the ultimate goals of developing new vaccines and anti-viral drugs.</td>
</tr>
<tr class="odd">
<td align="left">32591957</td>
<td align="left">Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19.</td>
<td align="left"><MedlineTA>Eur J Health Econ</MedlineTA></td>
<td align="left">2020 Sep</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32584199</td>
<td align="left">Human and novel coronavirus infections in children: a review.</td>
<td align="left"><MedlineTA>Paediatr Int Child Health</MedlineTA></td>
<td align="left">2020 Jun 25</td>
<td align="left">Coronaviruses, seven of which are known to infect humans, can cause a spectrum of clinical presentations ranging from asymptomatic infection to severe illness and death. Four human coronaviruses (hCoVs)-229E, HKU1, NL63 and OC43-circulate globally, commonly infect children and typically cause mild upper respiratory tract infections. Three novel coronaviruses of zoonotic origin have emerged during the past two decades: severe acute respiratory syndrome coronavirus (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS-CoV) and the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is the cause of the ongoing coronavirus disease 2019 (COVID-19) pandemic. These novel coronaviruses are known to cause severe illness and death predominantly in older adults and those with underlying comorbidities. Consistent with what has been observed during the outbreaks of SARS and MERS, children with COVID-19 are more likely to be asymptomatic or to have mild-to-moderate illness, with few deaths reported in children globally thus far. Clinical symptoms and laboratory and radiological abnormalities in children have been similar to those reported in adults but are generally less severe. A rare multisystem inflammatory syndrome in children (MIS-C) which has resulted in critical illness and some deaths has recently been described. Clinical trials for therapeutics and vaccine development should include paediatric considerations. Children may play an important role in the transmission of infection and outbreak dynamics and could be a key target population for effective measures to control outbreaks. The unintended consequences of the unprecedented scale and duration of pandemic control measures for children and families around the world should be carefully examined. <AbstractText Label="ABBREVIATIONS" NlmCategory="BACKGROUND">2019-nCoV, 2019 novel coronavirus; ADEM, acute demyelinating encephalomyelitis; AAP, American Academy of Pediatrics; ACE-2, angiotensin-converting enzyme 2; ARDS, acute respiratory distress syndrome; BCG, bacillus Calmette-Guérin; BNP, brain natriuretic peptide; CDC, Centers for Disease Control and Prevention; CRP, C-reactive protein; CSF, cerebrospinal fluid; COVID-19, coronavirus disease 2019; CT, computed tomography; CXR, chest X-ray; DOL, day of life; hCoV, human coronavirus; ICU, intensive care unit; IL, interleukin; IVIG, intravenous immunoglobulin; KD, Kawasaki disease; LDH, lactate dehydrogenase; MERS, Middle East respiratory syndrome; MERS-CoV, Middle East respiratory syndrome coronavirus; MEURI, monitored emergency use of unregistered and experimental interventions; MIS-C, multi-system inflammatory syndrome in children; PCR, polymerase chain reaction; PICU, paediatric intensive care unit; RNA, ribonucleic acid; RCT, randomised-controlled trial; RSV, respiratory syncytial virus; SARS, severe acute respiratory syndrome; SARS-CoV-1, severe acute respiratory syndrome coronavirus 1; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TNF-alpha, tumour necrosis factor alpha; UK United Kingdom; UNICEF, United Nations Children’s Fund; USA, United States of America; WHO, World Health Organization.</td>
</tr>
<tr class="odd">
<td align="left">32577634</td>
<td align="left">SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.</td>
<td align="left"><MedlineTA>bioRxiv</MedlineTA></td>
<td align="left">2020 Jun 11</td>
<td align="left">A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation.</td>
</tr>
<tr class="even">
<td align="left">32574236</td>
<td align="left">Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?</td>
<td align="left"><MedlineTA>Front Pharmacol</MedlineTA></td>
<td align="left">2020</td>
<td align="left">The novel coronavirus strain, severe acute respiratory syndrome coronavirus-2, the causative agent of COVID-19 emerged in Wuhan, China, in December 2019 and is skyrocketing throughout the globe and become a global public health emergency. Despite promising preventive measures being taken, there is no vaccine or drug therapy officially approved to prevent or treat the infection. Everybody is waiting the findings of ongoing clinical trials in various chemical and biological products. This review is specifically aimed to summarize the available evidence and ongoing clinical trials of remdesivir as a potential therapeutic option for COVID-19. Remdesivir is an investigational drug having broad spectrum antiviral activity with its target RNA dependent RNA polymerase. It has not yet been officially approved for Ebola and Coronaviruses. Several studies showed that remdesivir had promising in vitro and in vivo antiviral activities against SARS-CoV-1 and MERS-CoV strains. On the top of this, it exhibited a promising in vitro activity against SARS-CoV-2 strains though there are no published studies that substantiate its activity in vivo until the time of this review. There are few phase 3 randomized double-blind placebo controlled trials on the way to investigate the safety and efficacy of remdesivir. Of which, one completed double blind, placebo controlled trial showed that remdesivir showed faster time to clinical improvement in severe COVID-19 patients compared to placebo though not found statistically significant. In addition, two phase 3 randomized open label clinical trials coordinated by Gilead Sciences are being conducted. In addition, WHO Solidarity trial and INSERM DisCoVeRy trials (randomized open labels) were launched recently. Copyright © 2020 Sisay.</td>
</tr>
<tr class="odd">
<td align="left">32571773</td>
<td align="left">Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018.</td>
<td align="left"><MedlineTA>Br J Gen Pract</MedlineTA></td>
<td align="left">2020 07</td>
<td align="left"><AbstractText Label="BACKGROUND">Patients infected with the novel coronavirus (SARS-CoV-2) are being treated empirically with oseltamivir, but there is little evidence from randomised controlled trials to support the treatment of coronavirus infections with oseltamivir. <AbstractText Label="AIM">To determine whether adding oseltamivir to usual care reduces time to recovery in symptomatic patients who have tested positive for coronavirus (not including SARS-CoV-2). <AbstractText Label="DESIGN AND SETTING">Exploratory analysis of data from an open-label, pragmatic, randomised controlled trial during three influenza seasons, from 2016 to 2018, in primary care research networks, in 15 European countries. <AbstractText Label="METHOD">Patients aged ≥1 year presenting to primary care with influenza-like illness (ILI), and who tested positive for coronavirus (not including SARS-CoV-2), were randomised to usual care or usual care plus oseltamivir. The primary outcome was time to recovery defined as a return to usual activities, with minor or absent fever, headache, and muscle ache. <AbstractText Label="RESULTS">Coronaviruses (CoV-229E, CoV-OC43, CoV-KU1 and CoV-NL63) were identified in 308 (9%) out of 3266 randomised participants in the trial; 153 of these were allocated to usual care and 155 to usual care plus oseltamivir; the primary outcome was ascertained in 136 and 147 participants, respectively. The median time to recovery was shorter in patients randomised to oseltamivir: 4 days (interquartile range [IQR] 3-6) versus 5 days (IQR 3-8; hazard ratio 1.31; 95% confidence interval = 1.03 to 1.66; P = 0.026). <AbstractText Label="CONCLUSION">Primary care patients with ILI testing positive for coronavirus (not including SARS-CoV-2) recovered sooner when oseltamivir was added to usual care compared with usual care alone. This may be of relevance to the primary care management of COVID-19. ©The Authors.</td>
</tr>
<tr class="even">
<td align="left">32565096</td>
<td align="left">Anticipating Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Testing, Licensure, and Recommendations for Use.</td>
<td align="left"><MedlineTA>J Pediatr</MedlineTA></td>
<td align="left">2020 09</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32563940</td>
<td align="left">Analyzing barriers for implementation of public health and social measures to prevent the transmission of COVID-19 disease using DEMATEL method.</td>
<td align="left"><MedlineTA>Diabetes Metab Syndr</MedlineTA></td>
<td align="left">2020 Sep - Oct</td>
<td align="left"><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">COVID-19 is a contagious disease caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Till now there are no vaccines and explicit medicines available for the treatment of COVID-19 disease, therefore the initiatives like public health and social measures are helpful in limiting the quantity of contaminations and saving lives. Keeping this in view, an attempt has been made in the present work to identify the barriers which hinder the implementation of these public health and social measures METHODS: The barriers to implement public health and social measures for preventing transmission of COVID-19 are identified using systematic literature review and these barriers are then categorized using Decision-making trial and evaluation laboratory (DEMATEL) method. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Results reveal that among ten identified barriers, Lack of resources for implementing public health and social measures is found to be the most influential barrier to implement public health and social measures for preventing transmission of COVID-19. <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The successful implementation of public health and social measures depends on the adequate availability of resources which include medical equipment, personnel and financial dealings. The outcome of this research work will benefit and motivate the higher authorities to consider and overcome various challenges to prevent the transmission of COVID-19. Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32562594</td>
<td align="left">Pregnant Women in Trials of Covid-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.</td>
<td align="left"><MedlineTA>Ethics Hum Res</MedlineTA></td>
<td align="left">2020 Jul</td>
<td align="left">Ethical issues abound during this unprecedented international public health crisis of Covid-19. While the trade-off between societal and individual interests that occurs at the intersection of public health ethics and clinical ethics affects all populations, this calculus has particular relevance for pregnant women and the question of when they will have access to new Covid-19 therapies and vaccines. Pregnant women are a “scientifically complex” population whose inclusion in clinical research must be done with consideration of the unique state of pregnancy. Yet research on the impact of Covid-19 on pregnant women is lagging. In a rush to prevent and treat SARS-CoV-2 infection, it is crucial that the interests of pregnant women be prioritized to enable them to make autonomous, informed decisions about participating in clinical trials. The global pandemic calls for a revisiting of frameworks for the inclusion of pregnant women in research, as these women have an important stake in the prevention and treatment of Covid-19. © 2020 by The Hastings Center. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32561657</td>
<td align="left">Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?</td>
<td align="left"><MedlineTA>mBio</MedlineTA></td>
<td align="left">2020 06 19</td>
<td align="left">We propose the concept that administration of an unrelated live attenuated vaccine, such as MMR (measles, mumps, rubella), could serve as a preventive measure against the worst sequelae of coronavirus disease 2019 (COVID-19). There is mounting evidence that live attenuated vaccines provide nonspecific protection against lethal infections unrelated to the target pathogen of the vaccine by inducing “trained” nonspecific innate immune cells for improved host responses against subsequent infections. Mortality in COVID-19 cases is strongly associated with progressive lung inflammation and eventual sepsis. Vaccination with MMR in immunocompetent individuals has no contraindications and may be especially effective for health care workers who can easily be exposed to COVID-19. Following the lead of other countries conducting clinical trials with the live attenuated Mycobacterium bovis BCG (BCG) vaccine under a similar concept, a clinical trial with MMR in high-risk populations may provide a “low-risk-high-reward” preventive measure in saving lives during this unprecedented COVID-19 pandemic. Copyright © 2020 Fidel and Noverr.</td>
</tr>
<tr class="even">
<td align="left">32548679</td>
<td align="left">Calling for an exponential escalation scheme in vaccine development for COVID-19.</td>
<td align="left"><MedlineTA>Eur J Clin Pharmacol</MedlineTA></td>
<td align="left">2020 Oct</td>
<td align="left"><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">COVID-19 as a pandemic calls for rapid development of vaccines. <AbstractText Label="METHODS" NlmCategory="METHODS">Here a proposal of a seamless, adaptive, phase 1-3 trial for accelerated vaccine development is described. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Starting at 10, the number of vaccinated volunteers would exponentially increase by tenfold at an interval of 2 weeks; close surveillance of antibody responses, safety and efficacy is necessary. After only 16 weeks, general vaccination would be feasible if supply meets the demand. <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A COVID-19 vaccine would be rapidly available at a slightly increased risk for undetected late side effects or insufficient efficacy if compared with standard vaccine development schemes.</td>
</tr>
<tr class="odd">
<td align="left">32544799</td>
<td align="left">Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.</td>
<td align="left"><MedlineTA>Eur J Cancer</MedlineTA></td>
<td align="left">2020 08</td>
<td align="left">While confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease’s damage. Although no proven effective therapies for treating patients with COVID-19 or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome coronavirus 2 and its interplay with hosts provides a significant number of potential drug targets and the potential to repurpose drugs already tested in other diseases. Herein, we report the biological rationale of immune-activating drugs and a brief summary of literature data on the potential therapeutic value of immune checkpoint inhibitors that have been recently tested beyond cancer treatment for their potential to restore cellular immunocompetence. Copyright © 2020 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32540733</td>
<td align="left">Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies.</td>
<td align="left"><MedlineTA>Diabetes Metab Syndr</MedlineTA></td>
<td align="left">2020 Sep - Oct</td>
<td align="left"><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Many patients with coronavirus disease 2019 (COVID-19) have comorbidities related to metabolic syndrome (MS) during the disease course. Its presence in different ethnicities and continents places MS as an important risk factor for COVID-19. Adequate understanding of the interplay between MS, COVID-19 and proposed therapies is required for optimum management of these patients. <AbstractText Label="METHODS" NlmCategory="METHODS">We systematically searched the PubMed and Google Scholar databases until June 1st, 2020 and accessed the full text on COVID-19 and MS to prepare a narrative review on this topic. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with metabolic disorders like obesity, diabetes, cardiovascular and liver disease may face a higher risk of infection of COVID-19, greatly affecting the development and prognosis of the disease, being associated with significantly worse outcome in these patients. The proposed drugs that are in clinical trial for COVID-19 treatment must be carefully considered for clinical use, especially in patients with MS. <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MS is a risk factor influencing the progression and prognosis of COVID-2019. The drugs currently evaluated for the infection treatment are promising but need further studies to prove their efficacy and safety, due to the adverse effects may be exacerbated by combination therapy or due to viral infection. The development of a vaccine for immunization is still the best long-term solution. Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32535032</td>
<td align="left">Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.</td>
<td align="left"><MedlineTA>J Steroid Biochem Mol Biol</MedlineTA></td>
<td align="left">2020 09</td>
<td align="left">Coronavirus infection is a serious health problem awaiting an effective vaccine and/or antiviral treatment. The major complication of coronavirus disease 2019 (COVID-19), the Acute Respiratory Distress syndrome (ARDS), is due to a variety of mechanisms including cytokine storm, dysregulation of the renin-angiotensin system, neutrophil activation and increased (micro)coagulation. Based on many preclinical studies and observational data in humans, ARDS may be aggravated by vitamin D deficiency and tapered down by activation of the vitamin D receptor. Several randomized clinical trials using either oral vitamin D or oral Calcifediol (25OHD) are ongoing. Based on a pilot study, oral calcifediol may be the most promising approach. These studies are expected to provide guidelines within a few months. Copyright © 2020 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32527823</td>
<td align="left">Aggregating data from COVID-19 trials.</td>
<td align="left"><MedlineTA>Science</MedlineTA></td>
<td align="left">2020 06 12</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32525830</td>
<td align="left">A vaccine is not too far for COVID-19.</td>
<td align="left"><MedlineTA>J Infect Dev Ctries</MedlineTA></td>
<td align="left">2020 May 31</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32520683</td>
<td align="left">Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.</td>
<td align="left"><MedlineTA>Curr Drug Metab</MedlineTA></td>
<td align="left">2020</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As the number of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infected people is greatly increasing worldwide, the international medical situation becomes very serious. Potential therapeutic drugs, vaccine and stem cell replacement methods are emerging, so it is urgent to find specific therapeutic drugs and the best treatment regimens. After the publications on hydroxychloroquine (HCQ) with anti- SARS-COV-2 activity in vitro, a small, non-randomized, open-label clinical trial showed that HCQ treatment was significantly associated with reduced viral load in patients with coronavirus disease-19 (COVID-19). Meanwhile, a large prophylaxis study of HCQ sulfate for COVID-19 has been initiated in the United States. HCQ offered a promising efficacy in the treatment of COVID-19, but the optimal administration is still being explored. <AbstractText Label="METHODS" NlmCategory="METHODS">We used the keyword “hydroxychloroquine” to conduct a literature search in PubMed to collect relevant literature on the mechanism of action of HCQ, its clinical efficacy and safety, pharmacokinetic characteristics, precautions for clinical use and drug interactions to extract and organize information. <AbstractText Label="RESULTS" NlmCategory="RESULTS">This paper reviews the mechanism, clinical efficacy and safety, pharmacokinetic characteristics, exposureresponse relationship and precautions and drug interactions of HCQ, and summarizes dosage recommendations for HCQ sulfate. <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">It has been proved that HCQ, which has an established safety profile, is effective against SARS-CoV-2 with sufficient pre-clinical rationale and evidence. Data from high-quality clinical trials are urgently needed worldwide. Copyright© Bentham Science Publishers; For any queries, please email at <a href="mailto:epub@benthamscience.net" class="email">epub@benthamscience.net</a>.</td>
</tr>
<tr class="odd">
<td align="left">32515404</td>
<td align="left">Comprehensive overview of COVID-19 clinical trials.</td>
<td align="left"><MedlineTA>J Pak Med Assoc</MedlineTA></td>
<td align="left">2020 May</td>
<td align="left">Here, we present an overview of the clinical trials that are currently being conducted or have concluded to date on COVID-19 globally. A comprehensive search was conducted to present 16 trial registries from around the world. Collectively, there are 1,528 trials reported for COVID-19 to date. Out of them, 50 studies included paediatric age group from day 0 to less than or equal to 18 years of age. A few 18 studies involve only females and 20 only males. There are 2 trials currently underway in Bangladesh, 4 in Pakistan and 13 in India. Overall, 940 trials are related to medicines and/or interventions. They include standard of care for any viral illness, antivirals, anti-inflammatory and immune altering medications. Two out of 10 vaccine trials are novel vaccines. It is knowledgeable and resourceful to reach out to the concerned sponsor if a physician thinks his patient can benefit from the trials in the region.</td>
</tr>
<tr class="even">
<td align="left">32511340</td>
<td align="left">ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques.</td>
<td align="left"><MedlineTA>bioRxiv</MedlineTA></td>
<td align="left">2020 May 13</td>
<td align="left">Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in December 20191,2 and is responsible for the COVID-19 pandemic3. Vaccines are an essential countermeasure urgently needed to control the pandemic4. Here, we show that the adenovirus-vectored vaccine ChAdOx1 nCoV-19, encoding the spike protein of SARS-CoV-2, is immunogenic in mice, eliciting a robust humoral and cell-mediated response. This response was not Th2 dominated, as demonstrated by IgG subclass and cytokine expression profiling. A single vaccination with ChAdOx1 nCoV-19 induced a humoral and cellular immune response in rhesus macaques. We observed a significantly reduced viral load in bronchoalveolar lavage fluid and respiratory tract tissue of vaccinated animals challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated rhesus macaques. Importantly, no evidence of immune-enhanced disease following viral challenge in vaccinated animals was observed. ChAdOx1 nCoV-19 is currently under investigation in a phase I clinical trial. Safety, immunogenicity and efficacy against symptomatic PCR-positive COVID-19 disease will now be assessed in randomised controlled human clinical trials.</td>
</tr>
<tr class="odd">
<td align="left">32511333</td>
<td align="left">COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning.</td>
<td align="left"><MedlineTA>bioRxiv</MedlineTA></td>
<td align="left">2020 Mar 21</td>
<td align="left">To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. Our literature and clinical trial survey showed that the whole virus, as well as the spike (S) protein, nucleocapsid (N) protein, and membrane protein, have been tested for vaccine development against SARS and MERS. We further used the Vaxign reverse vaccinology tool and the newly developed Vaxign-ML machine learning tool to predict COVID-19 vaccine candidates. The N protein was found to be conserved in the more pathogenic strains (SARS/MERS/COVID-19), but not in the other human coronaviruses that mostly cause mild symptoms. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10) were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity. Besides the commonly used S protein, the nsp3 protein has not been tested in any coronavirus vaccine studies and was selected for further investigation. The nsp3 was found to be more conserved among SARS-CoV-2, SARS-CoV, and MERS-CoV than among 15 coronaviruses infecting human and other animals. The protein was also predicted to contain promiscuous MHC-I and MHC-II T-cell epitopes, and linear B-cell epitopes localized in specific locations and functional domains of the protein. Our predicted vaccine targets provide new strategies for effective and safe COVID-19 vaccine development.</td>
</tr>
<tr class="even">
<td align="left">32507409</td>
<td align="left">Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.</td>
<td align="left"><MedlineTA>Vaccine</MedlineTA></td>
<td align="left">2020 06 26</td>
<td align="left">A novel coronavirus (CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China and has since spread as a global pandemic. Safe and effective vaccines are thus urgently needed to reduce the significant morbidity and mortality of Coronavirus Disease 2019 (COVID-19) disease and ease the major economic impact. There has been an unprecedented rapid response by vaccine developers with now over one hundred vaccine candidates in development and at least six having reached clinical trials. However, a major challenge during rapid development is to avoid safety issues both by thoughtful vaccine design and by thorough evaluation in a timely manner. A syndrome of “disease enhancement” has been reported in the past for a few viral vaccines where those immunized suffered increased severity or death when they later encountered the virus or were found to have an increased frequency of infection. Animal models allowed scientists to determine the underlying mechanism for the former in the case of Respiratory syncytial virus (RSV) vaccine and have been utilized to design and screen new RSV vaccine candidates. Because some Middle East respiratory syndrome (MERS) and SARS-CoV-1 vaccines have shown evidence of disease enhancement in some animal models, this is a particular concern for SARS-CoV-2 vaccines. To address this challenge, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency vACcines (SPEAC) convened a scientific working meeting on March 12 and 13, 2020 of experts in the field of vaccine immunology and coronaviruses to consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for safety assessment of COVID-19 vaccine candidates in accelerated vaccine development. Copyright © 2020.</td>
</tr>
<tr class="odd">
<td align="left">32505245</td>
<td align="left">COVID-19 vaccine development pipeline gears up.</td>
<td align="left"><MedlineTA>Lancet</MedlineTA></td>
<td align="left">2020 06 06</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32503874</td>
<td align="left">Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials.</td>
<td align="left"><MedlineTA>BMJ Open</MedlineTA></td>
<td align="left">2020 06 04</td>
<td align="left"><AbstractText Label="BACKGROUND">Despite global containment measures to fight the coronavirus disease 2019 (COVID-19), the pandemic continued to rise, rapidly spread across the world, and resulting in 2.6 million confirmed cases and 185 061 deaths worldwide as of 23 April 2020. Yet, there are no approved vaccines or drugs to make the disease less deadly, while efforts are underway. Remdesivir, a nucleotide-analogue antiviral drug developed for Ebola, is determined to prevent and stop infections with COVID-19, while results are yet controversial. Here, we aim to conduct a systematic review and meta-analysis of randomised controlled trials (RCTs) to evaluate the efficacy of remdesivir in patients with COVID-19. <AbstractText Label="METHOD AND ANALYSIS">We will search MEDLINE-PubMed, Embase, Cochrane Library, ClinicalTrials.gov and Google scholar databases for articles published as of 30 June 2020 and we will complete the study on 30 August 2020. We will follow the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 guidelines for the design and reporting of the results. We will include RCTs that assessed the efficacy of remdesivir versus placebo or standard of care. The primary endpoint will be time to clinical recovery. The secondary endpoints will be proportion of participants relieved from clinical symptoms defined at the time (in hours) from initiation of the study treatment, all-cause mortality, discharged date, frequency of respiratory progression and treatment-emergent adverse events. RevMan V.5.3 software will be used for statistical analysis. Random effects model will be carried out to calculate mean differences for continuous outcome data and risk ratio for dichotomous outcome data between remdesivir and placebo or standard of care. <AbstractText Label="ETHICS AND DISSEMINATION">There are no ethical considerations associated with this study as we will use publicly available data from previously published studies. We plan to publish results in open-access peer-reviewed journals and present at international and national conferences. <AbstractText Label="PROSPERO REGISTRATION NUMBER">CRD42020177953. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="odd">
<td align="left">32503817</td>
<td align="left">Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.</td>
<td align="left"><MedlineTA>In Vivo</MedlineTA></td>
<td align="left">2020 Jun</td>
<td align="left">Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), initially termed 2019-new CoV (2019-nCoV), is a novel coronavirus responsible for the severe respiratory illness currently ongoing worldwide from the beginning of December 2019. This beta gene virus, very close to bat coronaviruses (bat-CoV-RaTG13) and bat-SL-CoVZC45, causes a severe disease, similar to those caused by Middle East respiratory syndrome (MERS)-CoV and SARS-CoV viruses, featured by low to moderate mortality rate. Unfortunately, the antiviral drugs commonly used in clinical practice to treat viral infections, are not applicable to SARS-Cov-2 and no vaccine is available. Thus, it is extremely necessary to identify new drugs suitable for the treatment of the 2019-nCoV outbreak. Different preclinical studies conducted on other coronaviruses suggested that promising clinical outcomes for 2019-nCoV should be obtained by using alpha-interferon, chloroquine phosphate, arabinol, remdesivir, lopinavir/ritonavir, and anti-inflammatory drugs. Moreover, clinical trials with these suitable drugs should be performed on patients affected by SARS-Cov-2 to prove their efficacy and safety. Finally, a very promising therapeutic drug, tocilizumab, is discussed; it is currently used to treat patients presenting COVID-19 pneumonia. Herein, we recapitulate these experimental studies to highlight the use of antiviral drugs for the treatment of SARS-Cov-2 disease. Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32503602</td>
<td align="left">Two Randomized Controlled Trials of Bacillus Calmette-Guérin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials.</td>
<td align="left"><MedlineTA>Trials</MedlineTA></td>
<td align="left">2020 Jun 05</td>
<td align="left"><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The objectives of these two separate trials are: (1) to reduce health care workers (HCWs) absenteeism; and (2) to reduce hospital admission among the elderly during the COVID-19 pandemic through BCG vaccination. <AbstractText Label="TRIAL DESIGN" NlmCategory="METHODS">Two separate multi-centre placebo-controlled parallel group randomized trials PARTICIPANTS: (1) Health care personnel working in the hospital or ambulance service where they will take care of patients with the COVID-19 infection and (2) elderly ≥60 years. The HCW trial is being undertaken in 9 hospitals. The elderly trial is being undertaken in locations in the community in Nijmegen, Utrecht, and Veghel, in the Netherlands, using senior citizen organisations to facilitate recruitment. <AbstractText Label="INTERVENTION AND COMPARATOR" NlmCategory="UNASSIGNED">For both trials the intervention group will be randomized to vaccination with 0.1 ml of the licensed BCG vaccine (Danish strain 1331, SSI, Denmark, equivalent to 0.075 mg attenuated M. bovis). The placebo group consists of 0.1 ml 0.9% NaCl, which is the same amount, and has the same colour and appearance as the suspended BCG vaccine. <AbstractText Label="MAIN OUTCOMES" NlmCategory="RESULTS">(1) Number of days of unplanned work absenteeism in HCWs for any reason which can be continuously measured on a bi-weekly basis, and (2) the cumulative incidence of hospital admission due to documented COVID-19. <AbstractText Label="RANDOMISATION" NlmCategory="UNASSIGNED">Participants will be randomized to BCG vaccine or placebo (1;1) centrally using a computer- based system, stratified by study centre. <AbstractText Label="BLINDING (MASKING)" NlmCategory="UNASSIGNED">Subjects, investigators, physicians and outcome assessors are blinded for the intervention. Only the pharmacist assistant that prepares- and research personnel that administers- study medicines are unblinded. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): (1) The sample size for the first trial is N=1500 HCWs randomised 1:1 to either BCG vaccine (n=750) and placebo (n=750) and (2) The sample size for the second trial is N=1600 elderly persons randomised to BCG vaccine (n=800) and the placebo group (n=800). <AbstractText Label="TRIAL STATUS" NlmCategory="UNASSIGNED">HCW: version 4.0, 24-04-2020. Recruitment began 25-03-2020 and was completed on the 23-04-2020. Elderly: version 3.0, 04-04-2020. Recruitment began 16-04- 2020 and is ongoing. <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">The HCWs trial was registered 31-03-2020 at clinicaltrials.gov (identifier: NCT04328441) and registered 20-03-2020 at the Dutch Trial Registry (trialregister.nl, identifier Trial NL8477). The elderly trial was registered 22-04-2020 at the Dutch trial registry with number NL8547. <AbstractText Label="FULL PROTOCOL" NlmCategory="UNASSIGNED">The full protocols will be attached as additional files, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.</td>
</tr>
<tr class="odd">
<td align="left">32499154</td>
<td align="left">Covid-19 Pandemic and Current Medical Interventions.</td>
<td align="left"><MedlineTA>Arch Med Res</MedlineTA></td>
<td align="left">2020 08</td>
<td align="left">First humanoid coronavirus was discovered in the middle of 1960s, the class of viruses are considered to be a huge threat. The first onset of human coronavirus, SARS (SARS-CoV) appeared in 2003 which spanned five continents having lethal effects on human population accompanied by The Middle East Respiratory Syndrome Coronavirus in 2012 with a death rate of 35%. The viruses remain a threat till date and are of serious concern since no vaccine or specified drug therapy has been approbated for treating human coronaviruses. The viruses became a pandemic worldwide with the emergence of Wuhan coronavirus (2019-nCoV). SARS-CoV2 viral manifestation poses a serious human life risk by causing acute lung injury and various respiratory outcomes and has become a global concern. High pathogenicity and transmission rate of the viral strain has become the spotlight of research community throughout the world. With the ongoing studies on viral structure and host interactions, the intricacy of the viral proteome structure and replication cycle proposes a need to explore our understanding of host factors playing role in viral multiplication cycle. This review provides insight into our prevalent perception of coronavirus-host interactions, structure of SARS-CoV2, receptor mediated entry of virus inside the human cells, ongoing clinical trials, drug therapies and treatments that are being used to combat COVID-19 targeting viral fusion, replication and its multiplication. Copyright © 2020 IMSS. Published by Elsevier Inc. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32498131</td>
<td align="left">Pandemic Best Regulatory Practices: An Urgent Need in the COVID-19 Pandemic.</td>
<td align="left"><MedlineTA>Clin Pharmacol Ther</MedlineTA></td>
<td align="left">2020 10</td>
<td align="left">As large numbers of candidate drugs and vaccines for potential use in the coronavirus disease 2019 (COVID-19) pandemic are being investigated, medicine regulators globally must now make urgent, informed, contextually risk-1based decisions regarding clinical trials and marketing authorizations. They must do this with the flexibility demanded by the pandemic while maintaining their core risk assessment and public safety functions. We lay out the critical role of regulators in the current crisis and offer eight “pandemic best regulatory practices.” These should support both the regulatory public heath imperative and assure timely patient access to effective, safe, quality products worldwide during this emergency-thus contributing to ending this pandemic as quickly, effectively, and safely as possible. © 2020 The Authors. Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</td>
</tr>
<tr class="odd">
<td align="left">32496238</td>
<td align="left">COVID-19 vaccine development and the way forward.</td>
<td align="left"><MedlineTA>Indian J Public Health</MedlineTA></td>
<td align="left">2020 Jun</td>
<td align="left">The whole globe is reeling under the COVID-19 pandemic now. With the scale and severity of infection, number of deaths and lack of any definite therapeutic armamentarium, the vaccine development has been accelerated at a never-before pace. A wide variety of vaccine technologies and platforms are being attempted. Out of the over 108 efforts, 100 are in preclinical and eight in Phase 1 or 2 trial stage. While the availability of newer technologies has facilitated development, there are several challenges on the way including limited understanding of the pathophysiology, targeting humoral or mucosal immunity, lack of suitable animal model, poor success of human severe acute respiratory syndrome/Middle East Respiratory Syndrome vaccines, limited efficacy of influenza vaccines, and immune exaggeration with animal coronavirus vaccines. With the current scenario with political, funding, research, and regulatory supports, if everything sails through smoothly, the successful vaccine is expected in 12-18 months. Modestly efficacious vaccine may be also a good achievement.</td>
</tr>
<tr class="even">
<td align="left">32495979</td>
<td align="left">Emergence of novel coronavirus and progress toward treatment and vaccine.</td>
<td align="left"><MedlineTA>Rev Med Virol</MedlineTA></td>
<td align="left">2020 07</td>
<td align="left">In late December 2019, a group of patients was observed with pneumonia-like symptoms that were linked with a wet market in Wuhan, China. The patients were found to have a novel coronavirus genetically related to a bat coronavirus that was termed SARS-CoV-2. The virus gradually spread worldwide and was declared a pandemic by WHO. Scientists have started trials on potential preventive and treatment options. Currently, there is no specific approved treatment for SARS-CoV-2, and various clinical trials are underway to explore better treatments. Some previously approved antiviral and other drugs have shown some in vitro activity. Here we summarize the fight against this novel coronavirus with particular focus on the different treatment options and clinical trials exploring treatment as well as work done toward development of vaccines. © 2020 John Wiley &amp; Sons, Ltd.</td>
</tr>
<tr class="odd">
<td align="left">32495226</td>
<td align="left">Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?</td>
<td align="left"><MedlineTA>Clin Rheumatol</MedlineTA></td>
<td align="left">2020 Aug</td>
<td align="left">The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical ventilation and to decrease mortality from coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine are among the proposed drugs and are the most widely used so far, despite the lack of robust evidence on their usefulness. The objective of this article is to review and discuss the possible role of these drugs in the therapy of COVID-19.</td>
</tr>
<tr class="even">
<td align="left">32494546</td>
<td align="left">Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials.</td>
<td align="left"><MedlineTA>Cureus</MedlineTA></td>
<td align="left">2020 May 28</td>
<td align="left">The ongoing novel coronavirus disease 2019 (COVID-19) pandemic has been responsible for millions of infections and hundreds of thousands of deaths. To date, there is no approved targeted treatment, and many investigational therapeutic agents and vaccine candidates are being considered for the treatment of COVID-19. To extract and summarize information on potential vaccines and therapeutic agents against COVID-19 at different stages of clinical trials from January to March 2020, we reviewed major clinical trial databases such as ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP), and other primary registries between January and March 15, 2020. Interventional studies at different phases under the COVID-19 pipeline were included. A total of 249 clinical trials were identified between January to March 15, 2020. After filtering observational studies (194 studies), a total of 56 interventional trials were considered. The majority of clinical trials have been conducted on chloroquine (n=10) and traditional Chinese medications (TCMs; n=10), followed by antivirals (n=8), anti-inflammatory/immunosuppressants (n=9), cellular therapies (n=4), combinations of different antivirals therapies (n=3), antibacterial (n=1), and other therapies (n=5). Five vaccines are under phase I, and there are a couple of phase III trials on the Bacillus Calmette-Guérin (BCG) vaccine under investigation among healthcare workers. Many novel compounds and vaccines against COVID-19 are currently under investigation. Some candidates have been tested for other viral infections and are listed for clinical trials against the COVID-19 pipeline. Currently, there are no effective specific antivirals or drug combinations available for the treatment of COVID-19. Copyright © 2020, Bhagavathula et al.</td>
</tr>
<tr class="odd">
<td align="left">32493494</td>
<td align="left">Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.</td>
<td align="left"><MedlineTA>Trials</MedlineTA></td>
<td align="left">2020 Jun 03</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SARS-CoV-2 infection presents a high transmission in the group of health professionals in Spain (12-15% infected). Currently there is no accepted chemoprophylaxis but hydroxychloroquine (HDQ) is known to inhibit the coronavirus in vitro. Our hypothesis is that oral administration of hydroxychloroquine to healthcare professionals can reduce the incidence and prevalence of infection as well as its severity in this group. <AbstractText Label="METHODS" NlmCategory="METHODS">Design: Prospective, single center, double blind, randomised, controlled trial (RCT). <AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Adult health-care professionals (18-65 years) working in areas of high exposure and high risk of transmission of SARS-COV-2 (COVID areas, Intensive Care Unit -ICUs-, Emergency, Anesthesia and all those performing aerosol-generating procedures) will be included. Exclusion criteria include previous infection with SARS CoV2 (positive SARS-CoV-2 PCR or IgG serology), pregnancy or lactation, any contraindication to hydroxychloroquine or evidence of unstable or clinically significant systemic disease. <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Patients will be randomized (1:1) to receive once-daily oral Hydroxychloroquine 200mg for two months (HC group) or placebo (P group) in addition to the protective measures appropriate to the level of exposure established by the hospital. A serological evaluation will be carried out every 15 days with PCR in case of seroconversion, symptoms or risk exposure. Primary outcome is the percentage of subjects presenting infection (seroconversion and/or PCR +ve) by the SARS-Cov-2 virus during the observation period. Additionally, both the percentage of subjects in each group presenting Pneumonia with severity criteria (Curb 65 ≥2) and that of subjects requiring admission to ICU will be determined. <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">While awaiting a vaccine, hygiene measures, social distancing and personal protective equipment are the only primary prophylaxis measures against SARS-CoV-2, but they have not been sufficient to protect our healthcare professionals. Some evidence of the in vitro efficacy of hydroxychloroquine against this virus is known, along with some clinical data that would support the study of this drug in the chemoprophylaxis of infection. However, there are still no data from controlled clinical trials in this regard. If our hypothesis is confirmed, hydroxychloroquine can help professionals fight this infection with more guarantees. <AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">This is a single-center study that will be carried out at the Marqués de Valdecilla University Hospital. 450 health professionals working at the Hospital Universitario Marqués de Valdecilla in areas of high exposure and high risk of transmission of SARS COV2 (COVID hospital areas, Intensive Care Unit, Emergency, Anesthesia and all those performing aerosol-generating procedures) will be included. <AbstractText Label="INCLUSION CRITERIA" NlmCategory="METHODS">1) Health professionals aged between 18 and 65 years (inclusive) at the time of the first screening visit; 2) They must provide signed written informed consent and agree to comply with the study protocol; 3) Active work in high exposure areas during the last two weeks and during the following weeks. <AbstractText Label="EXCLUSION CRITERIA" NlmCategory="METHODS">1) Previous infection with SARS CoV2 (positive coronavirus PCR or positive serology with SARS Cov2 negative PCR and absence of symptoms); 2) Current treatment with hydroxychloroquine or chloroquine; 3) Hypersensitivity, allergy or any contraindication for taking hydroxychloroquine, in the technical sheet; 4) Previous or current treatment with tamoxifen or raloxifene; 5) Previous eye disease, especially maculopathy; 6) Known heart failure (Grade III to IV of the New York Heart Association classification) or prolonged QTc; 7) Any type of cancer (except basal cell) in the last 5 years; 6) Refusal to give informed consent; 8) Evidence of any other unstable or clinically significant untreated immune, endocrine, hematological, gastrointestinal, neurological, neoplastic or psychiatric illness; 9) Antibodies positive for the human immunodeficiency virus; 10) Significant kidney or liver disease; 11) Pregnancy or lactation. <AbstractText Label="INTERVENTION AND COMPARATOR" NlmCategory="UNASSIGNED">Two groups will be analyzed with a 1: 1 randomization rate. 1)Intervention: (n = 225): One 200 mg hydroxychloroquine sulfate coated tablet once daily for two months.2)Comparator (control group) (n = 225): One hydroxychloroquine placebo tablet (identical to that of the drug) once daily for two months MAIN OUTCOMES: The primary outcome of this study will be to evaluate: number and percentage of healthcare personnel presenting symptomatic and asymptomatic infection (see “Diagnosis of SARS CoV2 infection” below) by the SARS-Cov2 virus during the study observation period (8 weeks) in both treatment arms;number and percentage of healthcare personnel in each group presenting with Pneumonia with severity criteria (Curb 65 ≥2) and number and percentage of healthcare personnel requiring admission to the Intensive Care Unit (ICU) in both treatment arms. DIAGNOSIS OF SARS COV2 INFECTION: Determination of IgA, IgM and IgG type antibodies against SARS-CoV-2 using the Anti-SARS-CoV-2 ELISA kit (EUROIMMUN Medizinische Labordiagnostika AG, Germany) every two weeks. In cases of seroconversion, a SARS-CoV-2 PCR will be performed to rule out / confirm an active infection (RT-PCR in One Step: RT performed with mastermix (Takara) and IDT probes, following protocol published and validated by the CDC Evaluation of COVID-19 in case of SARS-CoV-2 infection RANDOMISATION: Participants will be allocated to intervention and comparator groups according to a balanced randomization scheme (1: 1). The assignment will be made through a computer-generated numeric sequence for all participants BLINDING (MASKING): Both participants and investigators responsible for recruiting and monitoring participants will be blind to the assigned arm. <AbstractText Label="NUMBERS TO BE RANDOMISED (SAMPLE SIZE)" NlmCategory="UNASSIGNED">Taking into account the current high prevalence of infection in healthcare personnel in Spain (up to 15%), to detect a difference equal to or greater than 8% in the percentage estimates through a two-tailed 95% CI, with a statistical power of 80% and a dropout rate of 5%, a total of 450 participants will need to be included (250 in each arm). <AbstractText Label="TRIAL STATUS" NlmCategory="UNASSIGNED">The protocol approved by the health authorities in Spain (Spanish Agency for Medicines and Health Products “AEMPS”) and the Ethics and Research Committee of Cantabria (CEIm Cantabria) corresponds to version 1.1 of April 2, 2020. Currently, recruitment has not yet started, with the start scheduled for the second week of May 2020. <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Eudra CT number: 2020-001704-42 (Registered on 29 March 2020) FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).</td>
</tr>
<tr class="even">
<td align="left">32493478</td>
<td align="left">Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.</td>
<td align="left"><MedlineTA>Trials</MedlineTA></td>
<td align="left">2020 Jun 03</td>
<td align="left"><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Primary Objective • To test the efficacy of Hydroxychloroquine (HCQ) (400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days, to complete 14 days) to prevent incident SARS-CoV-2 infection, compared to ascorbic acid among contacts of persons with SARS-CoV-2 infection Secondary objectives • To determine the safety and tolerability of HCQ as SARS-CoV-2 Post-exposure Prophylaxis (PEP) in adults • To test the efficacy of HCQ (400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days, to complete 14 days) to prevent incident SARS-CoV-2 infection 2 weeks after completing therapy, compared to ascorbic acid among contacts of persons with SARS-CoV-2 infection • To test the efficacy of HCQ to shorten the duration of SARS-CoV-2 shedding among those with SARS-CoV-2 infection in the HCQ PEP group • To test the efficacy of HCQ to prevent incident COVID-19 TRIAL DESIGN: This is a randomized, multi-center, placebo-equivalent (ascorbic acid) controlled, blinded study of HCQ PEP for the prevention of SARS-CoV-2 infection in adults exposed to the virus. <AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">This study will enroll up to 2000 asymptomatic adults 18 to 80 years of age (inclusive) at baseline who are close contacts of persons with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 or clinically suspected COVID-19 and a pending SARS-CoV-2 PCR test. This multisite trial will be conducted at seven sites in Seattle (UW), Los Angeles (UCLA), New Orleans (Tulane), Baltimore (UMB), New York City (NYU), Syracuse (SUNY-Upstate), and Boston (BMC). Inclusion criteria Participants are eligible to be included in the study only if all of the following criteria apply: 1.Men or women 18 to 80 years of age inclusive, at the time of signing the informed consent2.Willing and able to provide informed consent3.Had a close contact of a person (index) with known PCR-confirmed SARS-CoV-2 infection or index who is currently being assessed for COVID-19 Close contact is defined as: a.Household contact (i.e., residing with the index case in the 14 days prior to index diagnosis or prolonged exposure within a residence/vehicle/enclosed space without maintaining social distance)b.Medical staff, first responders, or other care persons who cared for the index case without personal protection (mask and gloves)4.Less than 4 days since last exposure (close contact with a person with SARS-CoV-2 infection) to the index case5.Access to device and internet for Telehealth visits6.Not planning to take HCQ in addition to the study medication Exclusion criteria Participants are excluded from the study if any of the following criteria apply: 1.Known hypersensitivity to HCQ or other 4-aminoquinoline compounds2.Currently hospitalized3.Symptomatic with subjective fever, cough, or shortness of breath4.Current medications exclude concomitant use of HCQ5.Concomitant use of other anti-malarial treatment or chemoprophylaxis, including chloroquine, mefloquine, artemether, or lumefantrine.6.History of retinopathy of any etiology7.Psoriasis8.Porphyria9.Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes &lt;1500) or thrombocytopenia (&lt;100 K)10.Concomitant use of digoxin, cyclosporin, cimetidine, amiodarone, or tamoxifen11.Known moderate or severe liver disease12.Known long QT syndrome13.Severe renal impairment14.Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of the study drugs or planned use during the study period INTERVENTION AND COMPARATOR: Households will be randomized 1:1 (at the level of household), with close contact participants receiving one of the following therapies: •HCQ 400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days •Placebo-like control (ascorbic acid) 500 mg orally daily for 3 days then 250 mg orally daily for 11 days MAIN OUTCOMES: The primary outcome of the study is the incidence of SARS-CoV-2 infection through day 14 among participants who are SARS-CoV-2 negative at baseline by randomization group. <AbstractText Label="RANDOMISATION" NlmCategory="UNASSIGNED">Participants will be randomized in a 1:1 ratio to HCQ or ascorbic acid at the level of the household (all eligible participants in 1 household will receive the same intervention). The randomization code and resulting allocation list will be generated and maintained by the Study Statistician. The list will be blocked and stratified by site and contact type (household versus healthcare worker). <AbstractText Label="BLINDING (MASKING)" NlmCategory="UNASSIGNED">This is a blinded study. HCQ and ascorbic acid will appear similar, and taste will be partially masked as HCQ can be bitter and ascorbic acid will be sour. The participants will be blinded to their randomization group once assigned. Study team members, apart from the Study Pharmacist and the unblinded statistical staff, will be blinded. Laboratory staff are blinded to the group allocation. <AbstractText Label="NUMBERS TO BE RANDOMISED (SAMPLE SIZE)" NlmCategory="UNASSIGNED">The sample size for the study is N=2 000 participants randomized 1:1 to either HCZ (n=1 000) and ascorbic acid (n=1 000). <AbstractText Label="TRIAL STATUS" NlmCategory="UNASSIGNED">Protocol version: 1.2 05 April 2020 Recruitment is ongoing, started March 31 and anticipated end date is September 30, 2020. <AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov, Protocol Registry Number: NCT04328961 Date of registration: April 1, 2020, retrospectively registered FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.</td>
</tr>
<tr class="odd">
<td align="left">32474009</td>
<td align="left">COVID-19: Transmission, prevention, and potential therapeutic opportunities.</td>
<td align="left"><MedlineTA>Clin Chim Acta</MedlineTA></td>
<td align="left">2020 Sep</td>
<td align="left">The novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Despite intense research efforts worldwide, an effective vaccine and viable treatment options have eluded investigators. Therefore, infection prevention, early viral detection and identification of successful treatment protocols provide the best approach in controlling disease spread. In this review, current therapeutic options, preventive methods and transmission routes of COVID-19 are discussed. Copyright © 2020 Elsevier B.V. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32466392</td>
<td align="left">Model for Taking Care of Patients with Early Childhood Caries during the SARS-Cov-2 Pandemic.</td>
<td align="left"><MedlineTA>Int J Environ Res Public Health</MedlineTA></td>
<td align="left">2020 May 26</td>
<td align="left">Pending the availability of vaccines to contain the SARS-CoV-2 pandemic, the current solution is “social distancing” with a reduction of dental treatments to those assessed as urgent and emergency cases. These treatments also involve Early Childhood Caries (ECC) due to the fact that this disease affects preschool children (a vulnerable population) and, in addition, shows a propensity to evolve into more serious complications (dental pain, infections). A narrative review was carried out to support a protocol for treating ECC with efficacious and safe (in terms of SARS-CoV-2 transmission) procedures. Protocol involves criteria for patients’ selection remotely (telemedicine), and well-detailed criteria/equipment and hygiene procedures to combat against SARS-CoV-2 transmission. Moreover, the protocol proposes innovative caries treatments, named Minimally Invasive Treatments (MITs), well known in pedodontics for their high level of children’s acceptance during dental care. MITs allow for caries removal (particularly in primary teeth) without any high-speed rotating instrument cooled with nebulized air-water spray (with high risk of virus environmental diffusion), usually adopted during traditional treatments. For evaluating MITs effectiveness in caries management, only Systematic Review and Randomized Controlled Trials (RCTs) were included in our study, without any risk of bias assessment. The indications proposed in this protocol could support clinicians for the temporary management of ECC until the SARS-CoV-2 pandemic ends.</td>
</tr>
<tr class="odd">
<td align="left">32460358</td>
<td align="left">The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.</td>
<td align="left"><MedlineTA>Immunology</MedlineTA></td>
<td align="left">2020 07</td>
<td align="left">Since the first World Health Organization notification on 31 December 2019, coronavirus disease 2019 (COVID-19), the respiratory disease caused by the coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been responsible for over four million confirmed infections and almost 300 000 deaths worldwide. The pandemic has led to over half of the world’s population living under lockdown conditions. To allow normal life to resume, public health interventions will be needed to prevent further waves of infections as lockdown measures are lifted. As one of the most effective countermeasures against infectious diseases, an efficacious vaccine is considered crucial to containing the COVID-19 pandemic. Following the publication of the genome sequence of SARS-CoV-2, vaccine development has accelerated at an unprecedented pace across the world. Here we review the different platforms employed to develop vaccines, the standard timelines of development and how they can be condensed in a pandemic situation. We focus on vaccine development in the UK and vaccines that have entered clinical trials around the world. © 2020 The Authors. Immunology published by John Wiley &amp; Sons Ltd.</td>
</tr>
<tr class="even">
<td align="left">32459832</td>
<td align="left">Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.</td>
<td align="left"><MedlineTA>Clin Infect Dis</MedlineTA></td>
<td align="left">2020 May 27</td>
<td align="left">Pediatric patients are excluded from most COVID-19 therapeutic trials. We outline a rationale for the inclusion of children in COVID-19 therapeutic trials with enabled us to include children of all ages in a therapeutic COVID-19 trial at our institution. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="odd">
<td align="left">32459574</td>
<td align="left">The world is waiting, use sequential analysis and get us the evidence-based treatment we need for COVID-19.</td>
<td align="left"><MedlineTA>Libyan J Med</MedlineTA></td>
<td align="left">2020 Dec</td>
<td align="left">In spite of the relatively high morbidity and mortality, there is no approved medication yet for COVID-19. There are more than 200 ongoing trials on different drugs or vaccines, but new medications may take until 2021 to develop. Defining the optimal number of patients to be included in a study is a considerable challenge in these interventional researches. Ethical considerations prompt researchers to minimize the number of patients included in a trial. This gains particular importance when the disease is rare or lethal which is particularly so in the case of COVID-19. It is of paramount importance to explore some of the available tools that could help accelerate the adoption of any or some of the many proposed modalities for the treatment of diseases. These tools should be effective, yet efficient, for rapid testing of such treatments. Sequential analysis has not been frequently used in many clinical trials where it should have been used. None of the authors in published literature, as far as we know, used sequential analysis techniques to test potential drugs for COVID-19. In addition to its usefulness when the results of new forms of treatment are quickly needed, other important benefit of sequential analysis includes the ability to reach a similar conclusion about the utility of a new drug without unduly exposing more patients to the side effect of the old drug, in particularly, for the treatment of a rare disease.</td>
</tr>
<tr class="even">
<td align="left">32456404</td>
<td align="left">The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.</td>
<td align="left"><MedlineTA>Panminerva Med</MedlineTA></td>
<td align="left">2020 May 26</td>
<td align="left"><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Since December 2019, there has been an outbreak of a novel beta-coronavirus (SARS-CoV-2) in Wuhan, China. On March the 11th the World Health Organization (WHO) declared COVID-19 as a pandemic, with over 118,000 cases in more than 110 countries around the world. In response to the global coronavirus disease 2019 (COVID-19) emergency, clinical trial research assessing the efficacy and safety of experimental vaccines to prevent COVID-19 are emerging at an unprecedented rate. The aim of this systematic review is to summarize the preliminary experiences and ongoing clinical trials of the major candidates and challenges of the vaccine strategies in humans. <AbstractText Label="EVIDENCE ACQUISITION" NlmCategory="METHODS">After a priori protocol registration with PROSPERO (181483), a systematic research of the published literature was conducted on 24 April 2020 using Medline (via PubMed), Embase (via Ovid), and WHO databases. Moreover, to explore the more recent literature we also searched the preprint server medRxiv. Finally, we scrutinized the Cochrane COVID-19 study register and the COVID-19 section of ClinicalTrials.gov database for identifying relevant ongoing clinical trials. Thereafter we selected the articles according to the PRISMA guidelines. Animal or in-vitro experimental studies were excluded. Moreover editorials, commentaries, abstracts, reviews, book chapters, and articles not in English were not included. <AbstractText Label="EVIDENCE SYNTHESIS" NlmCategory="RESULTS">Our search identified 1359 published papers, 478 pre-print articles and 367 ongoing clinical trials. Finally, only ten ongoing clinical trials met the inclusion criteria. Specifically, seven developed vaccines for the S protein of SARS-CoV-2 and three clinical trials assessed the protective role of BCG vaccine against COVID-19. The first group included phase I/II trials with different types of molecules (DNA or mRNA vaccine, bacterial plasmid or viral vectors), the latter were phase III/IV trials designed on the basis of a heterologous lymphocyte activation by the BCG vaccine. <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This new disease is pushing the scientific community to develop swiftly a safe and effective vaccine. Notwithstanding the limitations of our analysis, given by the absence of available results, we try to provide a comprehensive view of the ongoing clinical trials in humans. Our analysis reveals a worldwide effort of both scientists and enterprises to achieve one of the most challenging goals of our century.</td>
</tr>
<tr class="odd">
<td align="left">32453605</td>
<td align="left">Rapid and robust bioanalytical assays are critical for SARS-CoV-2 therapeutic and vaccine development and beyond.</td>
<td align="left"><MedlineTA>Bioanalysis</MedlineTA></td>
<td align="left">2020 09</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32452350</td>
<td align="left">Understanding immune effects of oestrogens to explain the reduced morbidity and mortality in female versus male COVID-19 patients. Comparisons with autoimmunity and vaccination.</td>
<td align="left"><MedlineTA>Clin Exp Rheumatol</MedlineTA></td>
<td align="left">2020 May-Jun</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32450106</td>
<td align="left">Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.</td>
<td align="left"><MedlineTA>Lancet</MedlineTA></td>
<td align="left">2020 06 13</td>
<td align="left"><AbstractText Label="BACKGROUND">A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain. <AbstractText Label="METHODS">We did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. Healthy adults aged between 18 and 60 years were sequentially enrolled and allocated to one of three dose groups (5 × 1010, 1 × 1011, and 1·5 × 1011 viral particles) to receive an intramuscular injection of vaccine. The primary outcome was adverse events in the 7 days post-vaccination. Safety was assessed over 28 days post-vaccination. Specific antibodies were measured with ELISA, and the neutralising antibody responses induced by vaccination were detected with SARS-CoV-2 virus neutralisation and pseudovirus neutralisation tests. T-cell responses were assessed by enzyme-linked immunospot and flow-cytometry assays. This study is registered with ClinicalTrials.gov, NCT04313127. <AbstractText Label="FINDINGS">Between March 16 and March 27, 2020, we screened 195 individuals for eligibility. Of them, 108 participants (51% male, 49% female; mean age 36·3 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. All enrolled participants were included in the analysis. At least one adverse reaction within the first 7 days after the vaccination was reported in 30 (83%) participants in the low dose group, 30 (83%) participants in the middle dose group, and 27 (75%) participants in the high dose group. The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. No serious adverse event was noted within 28 days post-vaccination. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination. <AbstractText Label="INTERPRETATION">The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation. <AbstractText Label="FUNDING">National Key R&amp;D Program of China, National Science and Technology Major Project, and CanSino Biologics. Copyright © 2020 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32444382</td>
<td align="left">Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.</td>
<td align="left"><MedlineTA>mBio</MedlineTA></td>
<td align="left">2020 05 22</td>
<td align="left">Due to the urgent need of a therapeutic treatment for coronavirus (CoV) disease 2019 (COVID-19) patients, a number of FDA-approved/repurposed drugs have been suggested as antiviral candidates at clinics, without sufficient information. Furthermore, there have been extensive debates over antiviral candidates for their effectiveness and safety against severe acute respiratory syndrome CoV 2 (SARS-CoV-2), suggesting that rapid preclinical animal studies are required to identify potential antiviral candidates for human trials. To this end, the antiviral efficacies of lopinavir-ritonavir, hydroxychloroquine sulfate, and emtricitabine-tenofovir for SARS-CoV-2 infection were assessed in the ferret infection model. While the lopinavir-ritonavir-, hydroxychloroquine sulfate-, or emtricitabine-tenofovir-treated group exhibited lower overall clinical scores than the phosphate-buffered saline (PBS)-treated control group, the virus titers in nasal washes, stool specimens, and respiratory tissues were similar between all three antiviral-candidate-treated groups and the PBS-treated control group. Only the emtricitabine-tenofovir-treated group showed lower virus titers in nasal washes at 8 days postinfection (dpi) than the PBS-treated control group. To further explore the effect of immune suppression on viral infection and clinical outcome, ferrets were treated with azathioprine, an immunosuppressive drug. Compared to the PBS-treated control group, azathioprine-immunosuppressed ferrets exhibited a longer period of clinical illness, higher virus titers in nasal turbinate, delayed virus clearance, and significantly lower serum neutralization (SN) antibody titers. Taken together, all antiviral drugs tested marginally reduced the overall clinical scores of infected ferrets but did not significantly affect in vivo virus titers. Despite the potential discrepancy of drug efficacies between animals and humans, these preclinical ferret data should be highly informative to future therapeutic treatment of COVID-19 patients.IMPORTANCE The SARS-CoV-2 pandemic continues to spread worldwide, with rapidly increasing numbers of mortalities, placing increasing strain on health care systems. Despite serious public health concerns, no effective vaccines or therapeutics have been approved by regulatory agencies. In this study, we tested the FDA-approved drugs lopinavir-ritonavir, hydroxychloroquine sulfate, and emtricitabine-tenofovir against SARS-CoV-2 infection in a highly susceptible ferret infection model. While most of the drug treatments marginally reduced clinical symptoms, they did not reduce virus titers, with the exception of emtricitabine-tenofovir treatment, which led to diminished virus titers in nasal washes at 8 dpi. Further, the azathioprine-treated immunosuppressed ferrets showed delayed virus clearance and low SN titers, resulting in a prolonged infection. As several FDA-approved or repurposed drugs are being tested as antiviral candidates at clinics without sufficient information, rapid preclinical animal studies should proceed to identify therapeutic drug candidates with strong antiviral potential and high safety prior to a human efficacy trial. Copyright © 2020 Park et al.</td>
</tr>
<tr class="odd">
<td align="left">32442040</td>
<td align="left">SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties.</td>
<td align="left"><MedlineTA>Expert Opin Drug Saf</MedlineTA></td>
<td align="left">2020 Jul</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32441894</td>
<td align="left">Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.</td>
<td align="left"><MedlineTA>Ethics Hum Res</MedlineTA></td>
<td align="left">2020 Jul</td>
<td align="left">Human challenge trials to test the efficacy of vaccine candidates against SARS-CoV-2, the novel coronavirus behind Covid-19, could save considerable time and many lives. But they may initially seem unethical because they expose healthy volunteers to a live virus that is killing many people and for which no cure exists. This article argues that this is not the correct test of their ethics. The correct test is comparative. And in the special circumstances of the Covid-19 pandemic, human challenge trials meet the correct test better than standard efficacy testing would. © 2020 by The Hastings Center. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32437659</td>
<td align="left">Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection.</td>
<td align="left"><MedlineTA>Cell</MedlineTA></td>
<td align="left">2020 05 28</td>
<td align="left">SARS-CoV-2 infection is mild in the majority of individuals but progresses into severe pneumonia in a small proportion of patients. The increased susceptibility to severe disease in the elderly and individuals with co-morbidities argues for an initial defect in anti-viral host defense mechanisms. Long-term boosting of innate immune responses, also termed “trained immunity,” by certain live vaccines (BCG, oral polio vaccine, measles) induces heterologous protection against infections through epigenetic, transcriptional, and functional reprogramming of innate immune cells. We propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2. Copyright © 2020 Elsevier Inc. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32437587</td>
<td align="left">COVID-19 vaccines: Knowing the unknown.</td>
<td align="left"><MedlineTA>Eur J Immunol</MedlineTA></td>
<td align="left">2020 07</td>
<td align="left">Vaccine development against SARS-CoV-2 has drawn attention around the globe due to the exploding pandemic. Although COVID-19 is caused by a new coronavirus, SARS-CoV-2, previous research on other coronavirus vaccines, such as FIPV, SARS, and MERS, has provided valuable information for the rapid development of COVID-19 vaccine. However, important knowledge gaps remain - some are specific to SARS-CoV-2, others are fundamental to immunology and vaccinology. Here, we discuss areas that need to be addressed for COVID-19 vaccine development, and what can be learned from examples of vaccine development in the past. Since the beginning of the outbreak, the research progress on COVID-19 has been remarkable. We are therefore optimistic about the rapid development of COVID-19 vaccine. © 2020 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</td>
</tr>
<tr class="odd">
<td align="left">32434788</td>
<td align="left">COVID-19 and lung cancer: risks, mechanisms and treatment interactions.</td>
<td align="left"><MedlineTA>J Immunother Cancer</MedlineTA></td>
<td align="left">2020 05</td>
<td align="left">Cases of the 2019 novel coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. To date, there is no effective treatment. Clinical management is largely symptomatic, with organ support in intensive care for critically ill patients. The first phase I trial to test the efficacy of a vaccine has recently begun, but in the meantime there is an urgent need to decrease the morbidity and mortality of severe cases. It is known that patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments. Therefore, these patients might be at increased risk of pulmonary complications from COVID-19. The SARS-CoV-2 could in some case induce excessive and aberrant non-effective host immune responses that are associated with potentially fatal severe lung injury and patients can develop acute respiratory distress syndrome (ARDS). Cytokine release syndrome and viral ARDS result from uncontrolled severe acute inflammation. Acute lung injury results from inflammatory monocyte and macrophage activation in the pulmonary luminal epithelium which lead to a release of proinflammatory cytokines including interleukin (IL)-6, IL-1 and tumor necrosis factor-α. These cytokines play a crucial role in immune-related pneumonitis, and could represent a promising target when the infiltration is T cell predominant or there are indirect signs of high IL-6-related inflammation, such as elevated C-reactive protein. A monoclonal anti-IL-6 receptor antibody, tocilizumab has been administered in a number of cases in China and Italy. Positive clinical and radiological outcomes have been reported. These early findings have led to an ongoing randomized controlled clinical trial in China and Italy. While data from those trials are eagerly awaited, patients’ management will continue to rely for the vast majority on local guidelines. Among many other aspects, this crisis has proven that different specialists must join forces to deliver the best possible care to patients. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="even">
<td align="left">32425638</td>
<td align="left">Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.</td>
<td align="left"><MedlineTA>Int J Infect Dis</MedlineTA></td>
<td align="left">2020 Jul</td>
<td align="left">As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated over 500 COVID-19 clinical trials on a range of antiviral drug regimens and repurposed drugs in various combinations. A paradigm shift is underway from the current focus of drug development targeting the pathogen, to advancing cellular Host-Directed Therapies (HDTs) for tackling the aberrant host immune and inflammatory responses which underlie the pathogenesis of SARS-CoV-2 and high COVID-19 mortality rates. We focus this editorial specifically on the background to, and the rationale for, the use and evaluation of mesenchymal stromal (Stem) cells (MSCs) in treatment trials of patients with severe COVID-19 disease. Currently, the ClinicalTrials.gov and the WHO Clinical Trials Registry Platform (WHO ICTRP) report a combined 28 trials exploring the potential of MSCs or their products for treatment of COVID-19. MSCs should also be trialed for treatment of other circulating WHO priority Blueprint pathogens such as MERS-CoV which causes upto 34% mortality rates. It’s about time funding agencies invested more into development MSCs per se, and also for a range of other HDTs, in combination with other therapeutic interventions. MSC therapy could turn out to be an important contribution to bringing an end to the high COVID-19 death rates and preventing long-term functional disability in those who survive disease. Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32423342</td>
<td align="left">COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?</td>
<td align="left"><MedlineTA>Pharm Dev Technol</MedlineTA></td>
<td align="left">2020 07</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32420637</td>
<td align="left">Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.</td>
<td align="left"><MedlineTA>Drug Dev Res</MedlineTA></td>
<td align="left">2020 May 18</td>
<td align="left">Since its outbreak in late 2019, the SARS-Cov-2 pandemic already infected over 3.7 million people and claimed more than 250,000 lives globally. At least 1 year may take for an approved vaccine to be in place, and meanwhile millions more could be infected, some with fatal outcome. Over thousand clinical trials with COVID-19 patients are already listed in ClinicalTrials.com, some of them for assessing the utility of therapeutics approved for other conditions. However, clinical trials take many months, and are typically done with small cohorts. A much faster and by far more efficient method for rapidly identifying approved therapeutics that can be repurposed for treating COVID-19 patients is data mining their past and current electronic health and prescription records for identifying drugs that may protect infected individuals from severe COVID-19 symptoms. Examples are discussed for applying health and prescription records for assessing the potential repurposing (repositioning) of angiotensin receptor blockers, estradiol, or antiandrogens for reducing COVID-19 morbidity and fatalities. Data mining of prescription records of COVID-19 patients will not cancel the need for conducting controlled clinical trials, but could substantially assist in trial design, drug choice, inclusion and exclusion criteria, and prioritization. This approach requires a strong commitment of health provides for open collaboration with the biomedical research community, as health provides are typically the sole owners of retrospective drug prescription records. © 2020 Wiley Periodicals, Inc.</td>
</tr>
<tr class="odd">
<td align="left">32414757</td>
<td align="left">Ethical considerations for epidemic vaccine trials.</td>
<td align="left"><MedlineTA>J Med Ethics</MedlineTA></td>
<td align="left">2020 07</td>
<td align="left">Vaccines are a powerful measure to protect the health of individuals and to combat outbreaks such as the COVID-19 pandemic. An ethical dilemma arises when one effective vaccine has been successfully developed against an epidemic disease and researchers seek to test the efficacy of another vaccine for the same pathogen in clinical trials involving human subjects. On the one hand, there are compelling reasons why it would be unethical to trial a novel vaccine when an effective product exists already. First, it is a firm principle of medical ethics that an effective treatment or vaccine should not be withheld from patients if their life may depend on it. Second, since epidemic outbreaks often emerge in settings with less-resourced health systems, there is a pronounced risk that any trial withholding an effective vaccine would disproportionately affect the vulnerable populations that historically have been exploited for biomedical research. Third, clinical trials for novel vaccines may be at odds with efforts to control active outbreaks. On the other hand, it may be justified to conduct a trial for a candidate vaccine if it is expected to have certain advantages compared with the existing product. This essay discusses key factors for comparing vaccines against epidemic pathogens, including immunological, logistical and economic considerations. Alongside a case study of the development of vaccines for Ebola, the essay seeks to establish a general framework that should be expanded and populated by immunologists, epidemiologists, economists and bioethicists, and ultimately could be applied to the case of COVID-19 vaccines. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.</td>
</tr>
<tr class="even">
<td align="left">32410772</td>
<td align="left">Emerging pharmacotherapies for COVID-19.</td>
<td align="left"><MedlineTA>Biomed Pharmacother</MedlineTA></td>
<td align="left">2020 Aug</td>
<td align="left">Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2020. As of 10th April 2020, more than 1.5 million people are affected globally with around 95,000 deaths. Vaccines for this deadly virus are currently under development and many drugs used for other indications have been repurposed and investigated for prophylaxis and treatment of COVID 19. As per SOLIDARITY trial by WHO, some of the most promising candidates include chloroquine phosphate and hydroxychloroquine which are anti-malarial medications, Remdesivir, Lopinavir-Ritonavir combination with or without interferon which are anti-HIV drugs and convalescent plasma therapy. The current evidence of efficacy and ongoing research has been elaborated in the article. Besides, there has been evidence regarding inflammatory pathogenesis of this virus leading to cytokine storm in susceptible individuals. Thus, anti-proinflammatory cytokine drugs like Anakinra and Tocilizumab are undergoing multiple trials and some results are encouraging. Similarly, use of anti-inflammatory cytokines like IL-37 and IL-38 is hypothesised to be useful and is under research. The situation is still evolving and hence there is yet no definitive therapy but to conclude the use of repurposed medications can be a boon till a definitive therapy and vaccines are developed. Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32410758</td>
<td align="left">Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.</td>
<td align="left"><MedlineTA>Lancet</MedlineTA></td>
<td align="left">2020 05 23</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32407706</td>
<td align="left">SARS-CoV-2: A New Song Recalls an Old Melody.</td>
<td align="left"><MedlineTA>Cell Host Microbe</MedlineTA></td>
<td align="left">2020 05 13</td>
<td align="left">The viruses causing the SARS outbreak of 2002-2003 and current COVID-19 pandemic are related betacoronaviruses. What insights were learned from SARS that can inform SARS-CoV-2 vaccine development? Focusing on important lessons from SARS vaccine development and two SARS vaccines evaluated in humans may guide SARS-CoV-2 vaccine design, testing, and implementation. Copyright © 2020 Elsevier Inc. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32407539</td>
<td align="left">Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?</td>
<td align="left"><MedlineTA>Clin Pharmacol Ther</MedlineTA></td>
<td align="left">2020 10</td>
<td align="left">The scientific community has risen to the coronavirus disease 2019 (COVID-19) challenge, coming up with an impressive list of candidate drugs and vaccines targeting an array of pharmacological and immunological mechanisms. Yet, generating clinical evidence of efficacy and safety of these candidate treatments may be frustrated by the absence of comprehensive trial coordination mechanisms. Many small stand-alone trials and observational studies of single-agent interventions are currently running or in planning; many of these will likely not deliver robust results that could support regulatory and patient-level treatment decisions. In this paper, we discuss actions that all stakeholders in the clinical trial ecosystem need to take to ensure that the window of opportunity during this pandemic will not shut, both for patients in need of treatment and for researchers to conduct decision-relevant clinical trials. © 2020 The Authors. Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</td>
</tr>
<tr class="even">
<td align="left">32406317</td>
<td align="left">Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach.</td>
<td align="left"><MedlineTA>J Biomol Struct Dyn</MedlineTA></td>
<td align="left">2020 May 25</td>
<td align="left">The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which was first reported in Wuhan province of China, has become a deadly pandemic causing alarmingly high morbidity and mortality. In the absence of new targeted drugs and vaccines against SARS-CoV-2 at present, the choices for effective treatments are limited. Therefore, considering the exigency of the situation, we focused on identifying the available approved drugs as potential inhibitor against the promising Coronavirus drug target, the Main Protease, using computer-aided methods. We created a library of U. S. Food and Drug Administration approved anti-microbial drugs and virtually screened it against the available crystal structures of Main Protease of the virus. The study revealed that Viomycin showed the highest -CDocker energy after docking at the active site of SARS-CoV-2 Main Protease. It is noteworthy that Viomycin showed higher -CDocker energy as compared to the drugs currently under clinical trial for SARS-CoV-2 treatment viz. Ritonavir and Lopinavir. Additionally, Viomycin formed higher number of H-bonds with SARS-CoV-2 Main Protease than its co-crystallised inhibitor compound N3. Molecular dynamics simulation further showed that Viomycin embedded deeply inside the binding pocket and formed robust binding with SARS-CoV-2 Main Protease. Therefore, we propose that Viomycin may act as a potential inhibitor of the Main Protease of SARS-CoV-2. Further optimisations with the drug may support the much-needed rapid response to mitigate the pandemic.Communicated by Ramaswamy H. Sarma.</td>
</tr>
<tr class="odd">
<td align="left">32406253</td>
<td align="left">Bacillus Calmette Guérin (BCG) vaccination use in the fight against COVID-19 - what’s old is new again?</td>
<td align="left"><MedlineTA>Future Oncol</MedlineTA></td>
<td align="left">2020 Jul</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32404020</td>
<td align="left">COVID-19: The race for a vaccine.</td>
<td align="left"><MedlineTA>J Renin Angiotensin Aldosterone Syst</MedlineTA></td>
<td align="left">2020 Apr-Jun</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32393664</td>
<td align="left">Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.</td>
<td align="left"><MedlineTA>J Rheumatol</MedlineTA></td>
<td align="left">2020 May 11</td>
<td align="left"><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To characterize hydroxychloroquine (HCQ) exposure in patients with rheumatic disease receiving longterm HCQ compared to target concentrations with reported antiviral activity against the coronavirus disease 2019 caused by SARS-CoV-2 (COVID-19). <AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated total HCQ concentrations in serum and plasma from published literature values, frozen serum samples from a pediatric systemic lupus erythematosus trial, and simulated concentrations using a published pharmacokinetic model during pregnancy. For each source, we compared observed or predicted HCQ concentrations to target concentrations with reported antiviral activity against SARS-CoV-2. <AbstractText Label="RESULTS" NlmCategory="RESULTS">The average total serum/plasma HCQ concentrations were below the lowest SARS-CoV-2 target of 0.48 mg/l in all studies. Assuming the highest antiviral target exposure (total plasma concentration of 4.1 mg/l), all studies had about one-tenth the necessary concentration for in vitro viral inhibition. Pharmacokinetic model simulations confirmed that pregnant adults receiving common dosing for rheumatic diseases did not achieve target exposures; however, the models predict that a dosage of 600 mg once a day during pregnancy would obtain the lowest median target exposure for most patients after the first dose. <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We found that the average patient receiving treatment with HCQ for rheumatic diseases, including children and non-pregnant/pregnant adults, are unlikely to achieve total serum or plasma concentrations shown to inhibit SARS-CoV-2 in vitro. Nevertheless, patients receiving HCQ long term may have tissue concentrations far exceeding that of serum/plasma. Because the therapeutic window for HCQ in the setting of SARS-CoV-2 is unknown, well-designed clinical trials that include patients with rheumatic disease are urgently needed to characterize the efficacy, safety, and target exposures for HCQ.</td>
</tr>
<tr class="even">
<td align="left">32393526</td>
<td align="left">A strategic approach to COVID-19 vaccine R&amp;D.</td>
<td align="left"><MedlineTA>Science</MedlineTA></td>
<td align="left">2020 05 29</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32387332</td>
<td align="left">Current development of COVID-19 diagnostics, vaccines and therapeutics.</td>
<td align="left"><MedlineTA>Microbes Infect</MedlineTA></td>
<td align="left">2020 Jul - Aug</td>
<td align="left">A novel coronavirus, designated as SARS-CoV-2, first emerged in Wuhan City, Hubei Province, China, in late December 2019. The rapidly increasing number of cases has caused worldwide panic. In this review, we describe some currently applied diagnostic approaches, as well as therapeutics and vaccines, to prevent, treat and control further outbreaks of SARS-CoV-2 infection. Copyright © 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32387041</td>
<td align="left">COVID-19 and Moral Imperialism in Multinational Clinical Research.</td>
<td align="left"><MedlineTA>Arch Med Res</MedlineTA></td>
<td align="left">2020 08</td>
<td align="left">A TV debate in April 2020 between two French doctors regarding the benefits of testing a coronavirus vaccine in Africa where there are no masks or treatments available has led to international criticism. This case highlights a problematic ethical double standard in multinational clinical research: trials that would be considered unethical in high income countries (e.g., placebo-controlled where there is an existing treatment) are nonetheless justified in low-and-middle-income countries because the existing standards of care are less (i.e., no access to a treatment). Underlying this ethical double standard in some multinational clinical trials is a moral imperialism and persistent colonialist thinking that must be rejected. © 2020 IMSS. Published by Elsevier Inc.</td>
</tr>
<tr class="odd">
<td align="left">32387011</td>
<td align="left">Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development.</td>
<td align="left"><MedlineTA>Vaccine</MedlineTA></td>
<td align="left">2020 06 02</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32381692</td>
<td align="left">Combination prevention for COVID-19.</td>
<td align="left"><MedlineTA>Science</MedlineTA></td>
<td align="left">2020 05 08</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32380316</td>
<td align="left">Convalescent plasma in Covid-19: Possible mechanisms of action.</td>
<td align="left"><MedlineTA>Autoimmun Rev</MedlineTA></td>
<td align="left">2020 Jul</td>
<td align="left">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality. Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32378805</td>
<td align="left">COVID-19 and toxicity from potential treatments: Panacea or poison.</td>
<td align="left"><MedlineTA>Emerg Med Australas</MedlineTA></td>
<td align="left">2020 08</td>
<td align="left">Since December 2019, coronavirus disease (COVID-19) has been increasingly spreading from its origin in Wuhan, China to many countries around the world eventuating in morbidity and mortality affecting millions of people. This pandemic has proven to be a challenge given that there is no immediate cure, no vaccine is currently available and medications or treatments being used are still undergoing clinical trials. There have already been examples of self-medication and overdose. Clearly, there is a need to further define the efficacy of treatments used in the management of COVID-19. This evidence needs to be backed by large randomised-controlled clinical trials. In the meantime, there will no doubt be further off-label use of these medications by patients and practitioners and possibly related toxicity. © 2020 Australasian College for Emergency Medicine.</td>
</tr>
<tr class="odd">
<td align="left">32376359</td>
<td align="left">Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2.</td>
<td align="left"><MedlineTA>Microb Pathog</MedlineTA></td>
<td align="left">2020 Aug</td>
<td align="left">Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. In the absence of any antiviral or immunomodulatory therapies, the disease is spreading at an alarming rate. A possibility of a resurgence of COVID-19 in places where lockdowns have already worked is also developing. Thus, for controlling COVID-19, vaccines may be a better option than drugs. An mRNA-based anti-COVID-19 candidate vaccine has entered a phase 1 clinical trial. However, its efficacy and potency have to be evaluated and validated. Since vaccines have high failure rates, as an alternative, we are presenting a new, designed multi-peptide subunit-based epitope vaccine against COVID-19. The recombinant vaccine construct comprises an adjuvant, cytotoxic T-lymphocyte (CTL), helper T-lymphocyte (HTL), and B-cell epitopes joined by linkers. The computational data suggest that the vaccine is non-toxic, non-allergenic, thermostable, with the capability to elicit a humoral and cell-mediated immune response. The stabilization of the vaccine construct is validated with molecular dynamics simulation studies. This unique vaccine is made up of 33 highly antigenic epitopes from three proteins that have a prominent role in host-receptor recognition, viral entry, and pathogenicity. We advocate this vaccine must be synthesized and tested urgently as a public health priority. Copyright © 2020 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32366816</td>
<td align="left">An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.</td>
<td align="left"><MedlineTA>Med Sci Monit</MedlineTA></td>
<td align="left">2020 May 05</td>
<td align="left">The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US). The production of mRNA-based vaccines is a promising recent development in the production of vaccines. However, there remain significant challenges in the development and testing of vaccines as rapidly as possible to control COVID-19, which requires international collaboration. This review aims to describe the background to the rationale for the development of mRNA-based SARS-CoV-2 vaccines and the current status of the mRNA-1273 vaccine.</td>
</tr>
<tr class="odd">
<td align="left">32365191</td>
<td align="left">Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.</td>
<td align="left"><MedlineTA>J Infect Dis</MedlineTA></td>
<td align="left">2020 06 29</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32359402</td>
<td align="left">Considering BCG vaccination to reduce the impact of COVID-19.</td>
<td align="left"><MedlineTA>Lancet</MedlineTA></td>
<td align="left">2020 05 16</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32355008</td>
<td align="left">COVID-19 shot protects monkeys.</td>
<td align="left"><MedlineTA>Science</MedlineTA></td>
<td align="left">2020 05 01</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32350686</td>
<td align="left">Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.</td>
<td align="left"><MedlineTA>Adv Ther</MedlineTA></td>
<td align="left">2020 06</td>
<td align="left">The World Health Organization (WHO) called the outbreak of coronavirus infectious disease-2019 (COVID-19) a “Public Health Emergency of International Concern” (PHEIC). According to the WHO, Centers for Disease Control and Prevention (CDC), and the US Food and Drug Administration (FDA), currently there are no medicines or vaccines that have been claimed to be useful in the prevention or treatment of COVID-19. Several existing antiviral drugs, previously developed or used as treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), human immunodeficiency virus (HIV), and malaria, are being investigated as COVID-19 treatments and some of them are being used in clinical trials. According to the CDC and Chinese treatment guidelines for COVID-19, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and one of the investigational agents (remdesivir) are recommended in critically ill older patients. The use of other potential drugs reported in different studies may be considered if treatment with first-line drugs is ineffective. There are currently no complete data available from large randomized clinical trials (RCTs) to provide clinical guidance on the use, dosing, or duration to validate the effective role, safety profile, and adverse effects of all of the trial drugs for prophylaxis or treatment of COVID-19. Until now, it is still unclear which drug can successfully fight against the disease. Therefore, for the better safety of patients with COVID-19, further clinical trials and large randomized controlled studies are needed to validate the effective role, safety profile, and adverse effects of all the potential drugs. Such a measure requires action at the global level.</td>
</tr>
<tr class="odd">
<td align="left">32348598</td>
<td align="left">Review article: prevention, diagnosis and management of COVID-19 in the IBD patient.</td>
<td align="left"><MedlineTA>Aliment Pharmacol Ther</MedlineTA></td>
<td align="left">2020 07</td>
<td align="left"><AbstractText Label="BACKGROUND">The current COVID-19 pandemic, caused by SARS-CoV-2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune-based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications including those from COVID-19. <AbstractText Label="AIM">To summarise the scale of the COVID-19 pandemic, review unique concerns regarding IBD management and infection risk during the pandemic and assess COVID-19 management options and drug interactions in the IBD population. <AbstractText Label="METHODS">A literature review on IBD, SARS-CoV-2 and COVID-19 was undertaken and relevant literature was summarised and critically examined. <AbstractText Label="RESULTS">IBD patients do not appear to be more susceptible to SARS-CoV-2 infection and there is no evidence of an association between IBD therapies and increased risk of COVID-19. IBD medication adherence should be encouraged to prevent disease flare but where possible high-dose systemic corticosteroids should be avoided. Patients should exercise social distancing, optimise co-morbidities and be up to date with influenza and pneumococcal vaccines. If a patient develops COVID-19, immune suppressing medications should be withheld until infection resolution and if trial medications for COVID-19 are being considered, potential drug interactions should be checked. <AbstractText Label="CONCLUSIONS">IBD patient management presents a challenge in the current COVID-19 pandemic. The primary focus should remain on keeping bowel inflammation controlled and encouraging medication adherence. © 2020 John Wiley &amp; Sons Ltd.</td>
</tr>
<tr class="even">
<td align="left">32346094</td>
<td align="left">COVID-19 vaccine design: the Janus face of immune enhancement.</td>
<td align="left"><MedlineTA>Nat Rev Immunol</MedlineTA></td>
<td align="left">2020 06</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32344202</td>
<td align="left">Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.</td>
<td align="left"><MedlineTA>EBioMedicine</MedlineTA></td>
<td align="left">2020 May</td>
<td align="left">The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis. Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32343658</td>
<td align="left">Medication for COVID-19-an Overview of Approaches Currently Under Study.</td>
<td align="left"><MedlineTA>Dtsch Arztebl Int</MedlineTA></td>
<td align="left">2020 03 27</td>
<td align="left"><AbstractText Label="BACKGROUND">With the worldwide spread of SARS-CoV-2 infection, it is becoming increasingly urgent to develop a vaccine to prevent COVID-19, as well as effective drugs to treat it. <AbstractText Label="METHODS">This article is based on a selective literature search in PubMed and ClinicalTrials.gov, followed by an assessment of the ongoing clinical trials that were revealed by the search. <AbstractText Label="RESULTS">A number of substances have been found to prevent the reproduction of SARS-CoV-2 in vitro. These include virustatic agents that have already been approved for the treatment of other types of viral infection, as well as drugs that are currently used for entirely different purposes. High in vitro activity has been found for the nucleotide analogue remdesivir, for the antimalarial drug chloroquine, and for nitazoxanide, a drug used to treat protozoan infections. Because the virus enters human cells by way of the membrane-associated angiotensin converting enzyme 2 (ACE2), keeping the virus from docking to this receptor is a conceivable treatment approach. Transmembrane protease serine 2 (TMPRSS2) plays a role in the fusion of the virus with cells; inhibitors of this enzyme are known as well. The potential therapeutic efficacy and tolerability of these and other active substances remain to be investigated in clinical trials. At present, more than 80 trials on COVID-10 have already been registered with Clinical- Trials.gov. Some initial findings should already be available in late April 2020. <AbstractText Label="CONCLUSION">Clinical trials are now indispensable in order to determine the true clinical benefits and risks of the substances that have been found to be active against SARSCoV- 2 in vitro. There is not yet any recommendation for the therapeutic use of any particular agent beyond standard supportive treatment.</td>
</tr>
<tr class="odd">
<td align="left">32341531</td>
<td align="left">Could BCG be used to protect against COVID-19?</td>
<td align="left"><MedlineTA>Nat Rev Urol</MedlineTA></td>
<td align="left">2020 06</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32338347</td>
<td align="left">COVID-19 in Children: Clinical Approach and Management.</td>
<td align="left"><MedlineTA>Indian J Pediatr</MedlineTA></td>
<td align="left">2020 06</td>
<td align="left">COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major public health crisis threatening humanity at this point in time. Transmission of the infection occurs by inhalation of infected droplets or direct contact with soiled surfaces and fomites. It should be suspected in all symptomatic children who have undertaken international travel in the last 14 d, all hospitalized children with severe acute respiratory illness, and asymptomatic direct and high-risk contacts of a confirmed case. Clinical symptoms are similar to any acute respiratory viral infection with less pronounced nasal symptoms. Disease seems to be milder in children, but situation appears to be changing. Infants and young children had relatively more severe illness than older children. The case fatality rate is low in children. Diagnosis can be confirmed by Reverse transcriptase - Polymerase chain reaction (RT-PCR) on respiratory specimen (commonly nasopharyngeal and oropharyngeal swab). Rapid progress is being made to develop rapid diagnostic tests, which will help ramp up the capacity to test and also reduce the time to getting test results. Management is mainly supportive care. In severe pneumonia and critically ill children, trial of hydroxychloroquine or lopinavir/ritonavir should be considered. As per current policy, children with mild disease also need to be hospitalized; if this is not feasible, these children may be managed on ambulatory basis with strict home isolation. Pneumonia, severe disease and critical illness require admission and aggressive management for acute lung injury and shock and/or multiorgan dysfunction, if present. An early intubation is preferred over non-invasive ventilation or heated, humidified, high flow nasal cannula oxygen, as these may generate aerosols increasing the risk of infection in health care personnel. To prevent post discharge dissemination of infection, home isolation for 1-2 wk may be advised. As of now, no vaccine or specific chemotherapeutic agents are approved for children.</td>
</tr>
<tr class="odd">
<td align="left">32330122</td>
<td align="left">Panic prescribing has become omnipresent during the COVID-19 pandemic.</td>
<td align="left"><MedlineTA>J Clin Invest</MedlineTA></td>
<td align="left">2020 Jun 01</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32320592</td>
<td align="left">Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.</td>
<td align="left"><MedlineTA>N Engl J Med</MedlineTA></td>
<td align="left">2020 04 23</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32318706</td>
<td align="left">Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2.</td>
<td align="left"><MedlineTA>J Pediatric Infect Dis Soc</MedlineTA></td>
<td align="left">2020 Apr 22</td>
<td align="left"><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although Coronavirus Disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develops severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics. <AbstractText Label="METHODS" NlmCategory="METHODS">A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of best available evidence and expert opinion. <AbstractText Label="RESULTS" NlmCategory="RESULTS">Given the typically mild course of pediatric COVID-19, supportive care alone is suggested for the overwhelming majority of cases. The panel suggests a decision-making framework for antiviral therapy that weighs risks and benefits based on disease severity as indicated by respiratory support needs, with consideration on a case-by-case basis of potential pediatric risk factors for disease progression. If an antiviral is used, the panel suggests remdesivir as the preferred agent. Hydroxychloroquine could be considered for patients who are not candidates for remdesivir or when remdesivir is not available. Antivirals should preferably be used as part of a clinical trial if available. <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Antiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For those rare children who develop severe or critical disease, this guidance offer an approach for decision-making regarding antivirals, informed by available data. As evidence continues to evolve rapidly, the need for updates to the guidance is anticipated. © The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: <a href="mailto:journals.permissions@oup.com" class="email">journals.permissions@oup.com</a>.</td>
</tr>
<tr class="even">
<td align="left">32313823</td>
<td align="left">One month of the novel coronavirus 2019 outbreak: Is it still a threat?</td>
<td align="left"><MedlineTA>Virusdisease</MedlineTA></td>
<td align="left">2020 Apr 20</td>
<td align="left">The novel coronavirus 2019 disease (COVID-19) is now in an outbreak not only in China but also around the world, suspected to be originated from a wet market in Wuhan, Hubei province, China. The flare-up of COVID-19, it has already been infected 78,811 people with 2462 fatalities in 1 month window. The most alarming issue is the virus can transmit from host to host and still asymptomatic. Currently, 24 counties with 505 confirmed cases have been reported. Presently, there is no specific treatment or vaccine but physicians are battling with the use of antibiotics, steroid, anti-viral and anti-HIV drugs and some of the infected cases are testified improved. WHO and China National health Commission are cooperatively striving to come up with elucidation but it will take a minimum of 3 to 4 months at least to undergo a phase-1 trial. However, the soaring rates of spreading each day has become much stable which might even improve within the next few weeks in China but not for some other countries. Healthy peoples are instructed to avoid public gathering, always wearing the mask and frequently wash hands. Currently, China has able to hold up more than 97.7% infection within China but a scientific breakthrough is crucial before it’s too late. © Indian Virological Society 2020.</td>
</tr>
<tr class="odd">
<td align="left">32306836</td>
<td align="left">Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment.</td>
<td align="left"><MedlineTA>J Biomol Struct Dyn</MedlineTA></td>
<td align="left">2020 Apr 30</td>
<td align="left">In the past two decades, the world has faced several infectious disease outbreaks. Ebola, Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms of economic disruption, the strain on local and global public health. Most recently, the global outbreak of novel coronavirus 2019 (SARS-CoV-2) that causes COVID-19 is a newly discovered virus from the coronavirus family in Wuhan city, China, known to be a great threat to the public health systems. As of 15 April 2020, The Johns Hopkins University estimated that the COVID-19 affected more than two million people, resulting in a death toll above 130,000 around the world. Infected people in Europe and America correspond about 40% and 30% of the total reported cases respectively. At this moment only few Asian countries have controlled the disease, but a second wave of new infections is expected. Predicting inhibitor and target to the COVID-19 is an urgent need to protect human from the disease. Therefore, a protocol to identify anti-COVID-19 candidate based on computer-aided drug design is urgently needed. Thousands of compounds including approved drugs and drugs in the clinical trial are available in the literature. In practice, experimental techniques can measure the time and space average properties but they cannot be captured the structural variation of the COVID-19 during the interaction of inhibitor. Computer simulation is particularly suitable to complement experiments to elucidate conformational changes at the molecular level which are related to inhibition process of the COVID-19. Therefore, computational simulation is essential tool to elucidate the phenomenon. The structure-based virtual screening computational approach will be used to filter the best drugs from the literature, the investigate the structural variation of COVID-19 with the interaction of the best inhibitor is a fundamental step to design new drugs and vaccines which can combat the coronavirus. This mini-review will address novel coronavirus structure, mechanism of action, and trial test of antiviral drugs in the lab and patients with COVID-19.</td>
</tr>
<tr class="even">
<td align="left">32305089</td>
<td align="left">Sarah Gilbert: carving a path towards a COVID-19 vaccine.</td>
<td align="left"><MedlineTA>Lancet</MedlineTA></td>
<td align="left">2020 04 18</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32304435</td>
<td align="left">The Impact of the COVID-19 Pandemic on Cancer Patients.</td>
<td align="left"><MedlineTA>Am J Clin Oncol</MedlineTA></td>
<td align="left">2020 06</td>
<td align="left">In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19). Severe complications have been reported to occur in 33% of patients with COVID-19 and include acute respiratory distress syndrome, acute renal failure, acute respiratory injury, septic shock, and severe pneumonia. Currently, there is no specific treatment or approved vaccine against COVID-19 and many clinical trials are currently investigating potential medications to treat COVID-19. The immunosuppressed status of some cancer patients (whether caused by the disease itself or the treatment) increases their risk of infection compared with the general population. This short review aims to focus on the impact of COVID-19 on a cancer patient and discuss management options and recommendation in addition to highlighting the currently available clinical guidelines and resources.</td>
</tr>
<tr class="even">
<td align="left">32303704</td>
<td align="left">The race against COVID-19.</td>
<td align="left"><MedlineTA>Nat Nanotechnol</MedlineTA></td>
<td align="left">2020 04</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32302280</td>
<td align="left">Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.</td>
<td align="left"><MedlineTA>West J Emerg Med</MedlineTA></td>
<td align="left">2020 Mar 31</td>
<td align="left">As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.2 We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective.</td>
</tr>
<tr class="even">
<td align="left">32300051</td>
<td align="left">Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.</td>
<td align="left"><MedlineTA>J Immunother Cancer</MedlineTA></td>
<td align="left">2020 04</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32297723</td>
<td align="left">COVID-2019: update on epidemiology, disease spread and management.</td>
<td align="left"><MedlineTA>Monaldi Arch Chest Dis</MedlineTA></td>
<td align="left">2020 Apr 16</td>
<td align="left">With each passing day, more cases of Coronavirus disease (COVID-2019) are being detected and unfortunately the fear of novel corona virus 2019 (2019-nCoV) becoming a pandemic disease has come true. Constant efforts at individual, national, and international level are being made in order to understand the genomics, hosts, modes of transmission and epidemiological link of nCoV-2019. As of now, whole genome sequence of the newly discovered coronavirus has already been decoded. Genomic characterization nCoV-2019 have shown close homology with bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21. Structural analysis of the receptor binding site has confirmed that 2019-nCoV binds with the same ACE 2 receptor protein as human SARS virus. Compared to the previous coronavirus outbreaks, the overall mortality rate is relatively low for COVID-2019 (2-3%). Suspected cases must be quarantined till their test comes positive or they clear infection. At present, treatment of COVID-2019 is mostly based on the knowledge gained from the SARS and MERS outbreaks. Remdesivir, originally develop as a treatment for Ebola virus disease and Marburg virus infections, is being studied for it effectiveness against 2019-nCoV infection. Many other antiviral agents and vaccines are being tested but most of them are in phase I or II and hence unlikely to be of any benefit immediately with regards to current outbreak. Hence, the standard infection control techniques and preventive steps for healthy individuals and supportive care for the confirmed cases is the best available strategy to deal with current viral outbreak. .</td>
</tr>
<tr class="even">
<td align="left">32295694</td>
<td align="left">COVID-19 vaccination clinical trials should consider multiple doses of BCG.</td>
<td align="left"><MedlineTA>Pharmazie</MedlineTA></td>
<td align="left">2020 04 06</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32292113</td>
<td align="left">Stem Cell-Based Therapy for Coronavirus Disease 2019.</td>
<td align="left"><MedlineTA>Stem Cells Dev</MedlineTA></td>
<td align="left">2020 06 01</td>
<td align="left">The novel coronavirus disease 2019 (COVID-19) has grown to be a global public-health emergency since patients were first detected in Wuhan, China, in December 2019. As of April 9, 2020, the novel coronavirus (named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses on February 11) has infected 83,251 and 1,484,811 patients in China and the world, respectively. However, we have neither confirmed effective antiviral medications nor vaccines available to deal with this emergency. In this commentary, we offer an alternative promising therapy for COVID-19, that is, mesenchymal stem cell transplantation.</td>
</tr>
<tr class="even">
<td align="left">32290293</td>
<td align="left">A Review of SARS-CoV-2 and the Ongoing Clinical Trials.</td>
<td align="left"><MedlineTA>Int J Mol Sci</MedlineTA></td>
<td align="left">2020 Apr 10</td>
<td align="left">The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy. Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking. In this article, we present a succinct overview of the epidemiology, clinical features, and molecular characteristics of SARS-CoV-2. We summarize the current epidemiological and clinical data from the initial Wuhan studies, and emphasize several features of SARS-CoV-2, which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), such as high variability of disease presentation. We systematize the current clinical trials that have been rapidly initiated after the outbreak of COVID-19 pandemic. Whereas the trials on SARS-CoV-2 genome-based specific vaccines and therapeutic antibodies are currently being tested, this solution is more long-term, as they require thorough testing of their safety. On the other hand, the repurposing of the existing therapeutic agents previously designed for other virus infections and pathologies happens to be the only practical approach as a rapid response measure to the emergent pandemic, as most of these agents have already been tested for their safety. These agents can be divided into two broad categories, those that can directly target the virus replication cycle, and those based on immunotherapy approaches either aimed to boost innate antiviral immune responses or alleviate damage induced by dysregulated inflammatory responses. The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including favipiravir, a broad-spectrum antiviral drug that interferes with the viral replication, and hydroxychloroquine, the repurposed antimalarial drug that interferes with the virus endosomal entry pathway. We speculate that the current pandemic emergency will be a trigger for more systematic drug repurposing design approaches based on big data analysis.</td>
</tr>
<tr class="odd">
<td align="left">32282303</td>
<td align="left">Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.</td>
<td align="left"><MedlineTA>Curr Top Med Chem</MedlineTA></td>
<td align="left">2020</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32282038</td>
<td align="left">The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19.</td>
<td align="left"><MedlineTA>Clin Infect Dis</MedlineTA></td>
<td align="left">2020 07 28</td>
<td align="left">Since the COVID-19 pandemic first hit Wuhan, China, in December 2019, scientists have been racing to develop and test novel vaccines to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The speed of scientific discovery related to COVID-19 is unprecedented. With several vaccine candidates already being tested in clinical trials, we pose the question: what will the vaccine hesitant do in the face of this pandemic? © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.</td>
</tr>
<tr class="odd">
<td align="left">32273621</td>
<td align="left">If a coronavirus vaccine arrives, can the world make enough?</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 04</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32273591</td>
<td align="left">The COVID-19 vaccine development landscape.</td>
<td align="left"><MedlineTA>Nat Rev Drug Discov</MedlineTA></td>
<td align="left">2020 05</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32259480</td>
<td align="left">SARS-CoV-2 Vaccines: Status Report.</td>
<td align="left"><MedlineTA>Immunity</MedlineTA></td>
<td align="left">2020 04 14</td>
<td align="left">SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population. Copyright © 2020 Elsevier Inc. All rights reserved.</td>
</tr>
<tr class="even">
<td align="left">32251618</td>
<td align="left">Current Drugs with Potential for Treatment of COVID-19: A Literature Review.</td>
<td align="left"><MedlineTA>J Pharm Pharm Sci</MedlineTA></td>
<td align="left">2020</td>
<td align="left"><AbstractText Label="PURPOSE">SARS-CoV-2 first emerged in China in December 2019 and rapidly spread worldwide. No vaccine or approved drug is available to eradicate the virus, however, some drugs that are indicated for other afflictions seems to be potentially beneficial to treat the infection albeit without unequivocal evidence. The aim of this article is to review the published background on the effectiveness of these drugs against COVID-19 Methods: A thorough literature search was conducted on recently published studies which have published between January 1 to March 25, 2020. PubMed, Google Scholar and Science Direct databases were searched Results: A total 22 articles were found eligible. 8 discuss about treatment outcomes from their applied drugs during treatment of COVID-19 patients, 4 report laboratory tests, one report animal trial and other 9 articles discuss recommendations and suggestions based on the treatment process and clinical outcomes of other diseases such as malaria, ebola, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). The data and/or recommendations are categorized in 4 classes: (a) anti-viral and anti-inflammatory drugs, (b) anti-malaria drugs, (c) traditional Chinese drugs and (d) other treatments/drugs. <AbstractText Label="CONCLUSION">All examined treatments, although potentiality effective against COVID-19, need either appropriate drug development or clinical trial to be suitable for clinical use.</td>
</tr>
<tr class="odd">
<td align="left">32247193</td>
<td align="left">Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.</td>
<td align="left"><MedlineTA>J Neurol Sci</MedlineTA></td>
<td align="left">2020 05 15</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32243270</td>
<td align="left">Potential therapeutic agents against COVID-19: What we know so far.</td>
<td align="left"><MedlineTA>J Chin Med Assoc</MedlineTA></td>
<td align="left">2020 06</td>
<td align="left">The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.</td>
</tr>
<tr class="odd">
<td align="left">32241928</td>
<td align="left">Vaccine designers take first shots at COVID-19.</td>
<td align="left"><MedlineTA>Science</MedlineTA></td>
<td align="left">2020 04 03</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32234468</td>
<td align="left">The epidemiology, diagnosis and treatment of COVID-19.</td>
<td align="left"><MedlineTA>Int J Antimicrob Agents</MedlineTA></td>
<td align="left">2020 May</td>
<td align="left">In December 2019, the outbreak of the novel coronavirus disease (COVID-19) in China spread worldwide, becoming an emergency of major international concern. SARS-CoV-2 infection causes clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus. Human-to-human transmission via droplets, contaminated hands or surfaces has been described, with incubation times of 2-14 days. Early diagnosis, quarantine, and supportive treatments are essential to cure patients. This paper reviews the literature on all available information about the epidemiology, diagnosis, isolation and treatments of COVID-19. Treatments, including antiviral agents, chloroquine and hydroxychloroquine, corticosteroids, antibodies, convalescent plasma transfusion and vaccines, are discussed in this article. In addition, registered trials investigating treatment options for COVID-19 infection are listed. Copyright © 2020 Elsevier Ltd. All rights reserved.</td>
</tr>
<tr class="odd">
<td align="left">32232474</td>
<td align="left">Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.</td>
<td align="left"><MedlineTA>J Infect Dis</MedlineTA></td>
<td align="left">2020 05 11</td>
<td align="left">Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine evaluation, could reduce the global burden of coronavirus-related mortality and morbidity. Volunteers in such studies could autonomously authorize the risks to themselves, and their net risk could be acceptable if participants comprise healthy young adults, who are at relatively low risk of serious disease following natural infection, if they have a high baseline risk of natural infection, and if during the trial they receive frequent monitoring and, following any infection, the best available care. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.</td>
</tr>
<tr class="even">
<td align="left">32232214</td>
<td align="left">Potential Treatments for COVID-19; a Narrative Literature Review.</td>
<td align="left"><MedlineTA>Arch Acad Emerg Med</MedlineTA></td>
<td align="left">2020</td>
<td align="left">SARS-CoV-2 is a newly emerging human infectious coronavirus that causes COVID-19, which has been recognized as a pandemic by the World Health Organization (WHO) on March 11th. There is still no vaccine or definitive treatment for this virus because its pathogenesis and proliferation pathways are still unknown. Therefore, in this article, new potential COVID-19 therapies are briefly reviewed.</td>
</tr>
<tr class="odd">
<td align="left">32231348</td>
<td align="left">Emerging prophylaxis strategies against COVID-19.</td>
<td align="left"><MedlineTA>Monaldi Arch Chest Dis</MedlineTA></td>
<td align="left">2020 Mar 30</td>
<td align="left">The Novel corona virus 2019 which started as an outbreak in China in December 2019 has rapidly spread all over the world, such that on 11th March 2020 WHO declared this disease as pandemic. The emergency that the world faces today demands that we develop urgent and effective measures to protect people at high risk of transmission. WHO has accelerated research in diagnostics, vaccines and therapeutics for this novel coronavirus.</td>
</tr>
<tr class="even">
<td align="left">32229574</td>
<td align="left">News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine.</td>
<td align="left"><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA></td>
<td align="left">2020 04 14</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32227757</td>
<td align="left">Developing Covid-19 Vaccines at Pandemic Speed.</td>
<td align="left"><MedlineTA>N Engl J Med</MedlineTA></td>
<td align="left">2020 May 21</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32226288</td>
<td align="left">Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective.</td>
<td align="left"><MedlineTA>Int J Biol Sci</MedlineTA></td>
<td align="left">2020</td>
<td align="left">Currently, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, formerly known as 2019-nCoV, the causative pathogen of Coronavirus Disease 2019 (COVID-19)) has rapidly spread across China and around the world, causing an outbreak of acute infectious pneumonia. No specific anti-virus drugs or vaccines are available for the treatment of this sudden and lethal disease. The supportive care and non-specific treatment to ameliorate the symptoms of the patient are the only options currently. At the top of these conventional therapies, greater than 85% of SARS-CoV-2 infected patients in China are receiving Traditional Chinese Medicine (TCM) treatment. In this article, relevant published literatures are thoroughly reviewed and current applications of TCM in the treatment of COVID-19 patients are analyzed. Due to the homology in epidemiology, genomics, and pathogenesis of the SARS-CoV-2 and SARS-CoV, and the widely use of TCM in the treatment of SARS-CoV, the clinical evidence showing the beneficial effect of TCM in the treatment of patients with SARS coronaviral infections are discussed. Current experiment studies that provide an insight into the mechanism underlying the therapeutic effect of TCM, and those studies identified novel naturally occurring compounds with anti-coronaviral activity are also introduced. © The author(s).</td>
</tr>
<tr class="odd">
<td align="left">32205459</td>
<td align="left">Underpromise, overdeliver.</td>
<td align="left"><MedlineTA>Science</MedlineTA></td>
<td align="left">2020 03 27</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32203367</td>
<td align="left">Coronavirus vaccines: five key questions as trials begin.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 03</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">32179860</td>
<td align="left">Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees.</td>
<td align="left"><MedlineTA>Nature</MedlineTA></td>
<td align="left">2020 03</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">32108352</td>
<td align="left">Clinical trial analysis of 2019-nCoV therapy registered in China.</td>
<td align="left"><MedlineTA>J Med Virol</MedlineTA></td>
<td align="left">2020 06</td>
<td align="left">So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primary endpoints included symptom improvement and virus nucleic acid turning negative, but the optimal endpoint has not been determined. Although the final results of studies will take a long time to complete, the interim research data may provide some help for the current urgent demand for drug treatment. Compared with that of during SARS period in 2003, China has the stronger capability to carry out clinical trials of new drugs in emergency period. © 2020 Wiley Periodicals, Inc.</td>
</tr>
<tr class="odd">
<td align="left">32001631</td>
<td align="left">New coronavirus threat galvanizes scientists.</td>
<td align="left"><MedlineTA>Science</MedlineTA></td>
<td align="left">2020 01 31</td>
<td align="left">NA</td>
</tr>
</tbody>
</table>
<p>##Text Mining</p>
<ol style="list-style-type: decimal">
<li>Tokenize the abstracts and count the number of each token. Do you see anything interesting? Does removing stop words change what tokens appear as the most frequent? What are the 5 most common tokens for each search term after removing stopwords?</li>
</ol>
<pre class="r"><code>data &lt;- read_csv(&quot;https://raw.githubusercontent.com/USCbiostats/data-science-data/master/03_pubmed/pubmed.csv&quot;)</code></pre>
<pre><code>## Parsed with column specification:
## cols(
##   abstract = col_character(),
##   term = col_character()
## )</code></pre>
<pre class="r"><code>data %&gt;%
  unnest_tokens(token, abstract)%&gt;%
  count(token, sort=TRUE)%&gt;%
  top_n(n=20, wt=n)%&gt;%
  ggplot(aes(x=n, y=fct_reorder(token, n)))+
  geom_col()</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<p>Except for ‘covid’/‘19’, ‘patients’, ‘cancer’, and ‘prostate’, other words are stop words.</p>
<pre class="r"><code>data %&gt;%
  unnest_tokens(token, abstract) %&gt;%
  filter(!(token %in% stop_words$word)) %&gt;%
  count(token, sort = TRUE)%&gt;%
  top_n(n=20, wt=n)%&gt;%
  ggplot(aes(x=n, y=fct_reorder(token, n)))+
  geom_col()</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>tokens &lt;- data %&gt;%
  unnest_tokens(token, abstract) %&gt;%
  filter(!(token %in% stop_words$word)) %&gt;%
  group_by(term) %&gt;%
  count(token, sort = TRUE) %&gt;%
  top_n(5, n) %&gt;%
  arrange(term, desc(n))

knitr::kable(tokens, caption = &quot;Table 1: The 5 most common tokens for each search term&quot;)</code></pre>
<table>
<caption>Table 1: The 5 most common tokens for each search term</caption>
<thead>
<tr class="header">
<th align="left">term</th>
<th align="left">token</th>
<th align="right">n</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">covid</td>
<td align="left">covid</td>
<td align="right">7275</td>
</tr>
<tr class="even">
<td align="left">covid</td>
<td align="left">19</td>
<td align="right">7035</td>
</tr>
<tr class="odd">
<td align="left">covid</td>
<td align="left">patients</td>
<td align="right">2293</td>
</tr>
<tr class="even">
<td align="left">covid</td>
<td align="left">disease</td>
<td align="right">943</td>
</tr>
<tr class="odd">
<td align="left">covid</td>
<td align="left">pandemic</td>
<td align="right">800</td>
</tr>
<tr class="even">
<td align="left">cystic fibrosis</td>
<td align="left">fibrosis</td>
<td align="right">867</td>
</tr>
<tr class="odd">
<td align="left">cystic fibrosis</td>
<td align="left">cystic</td>
<td align="right">862</td>
</tr>
<tr class="even">
<td align="left">cystic fibrosis</td>
<td align="left">cf</td>
<td align="right">625</td>
</tr>
<tr class="odd">
<td align="left">cystic fibrosis</td>
<td align="left">patients</td>
<td align="right">586</td>
</tr>
<tr class="even">
<td align="left">cystic fibrosis</td>
<td align="left">disease</td>
<td align="right">400</td>
</tr>
<tr class="odd">
<td align="left">meningitis</td>
<td align="left">patients</td>
<td align="right">446</td>
</tr>
<tr class="even">
<td align="left">meningitis</td>
<td align="left">meningitis</td>
<td align="right">429</td>
</tr>
<tr class="odd">
<td align="left">meningitis</td>
<td align="left">meningeal</td>
<td align="right">219</td>
</tr>
<tr class="even">
<td align="left">meningitis</td>
<td align="left">csf</td>
<td align="right">206</td>
</tr>
<tr class="odd">
<td align="left">meningitis</td>
<td align="left">clinical</td>
<td align="right">187</td>
</tr>
<tr class="even">
<td align="left">preeclampsia</td>
<td align="left">pre</td>
<td align="right">2038</td>
</tr>
<tr class="odd">
<td align="left">preeclampsia</td>
<td align="left">eclampsia</td>
<td align="right">2005</td>
</tr>
<tr class="even">
<td align="left">preeclampsia</td>
<td align="left">preeclampsia</td>
<td align="right">1863</td>
</tr>
<tr class="odd">
<td align="left">preeclampsia</td>
<td align="left">women</td>
<td align="right">1196</td>
</tr>
<tr class="even">
<td align="left">preeclampsia</td>
<td align="left">pregnancy</td>
<td align="right">969</td>
</tr>
<tr class="odd">
<td align="left">prostate cancer</td>
<td align="left">cancer</td>
<td align="right">3840</td>
</tr>
<tr class="even">
<td align="left">prostate cancer</td>
<td align="left">prostate</td>
<td align="right">3832</td>
</tr>
<tr class="odd">
<td align="left">prostate cancer</td>
<td align="left">patients</td>
<td align="right">934</td>
</tr>
<tr class="even">
<td align="left">prostate cancer</td>
<td align="left">treatment</td>
<td align="right">926</td>
</tr>
<tr class="odd">
<td align="left">prostate cancer</td>
<td align="left">disease</td>
<td align="right">652</td>
</tr>
</tbody>
</table>
<p>After removing stop words, ‘Covid’ and ‘19’ become the two most frequent tokens having almost the same frequency (perhaps because they are linked words), with ‘patients’, ‘cancer’ and ‘prostate’ following.</p>
<ol start="2" style="list-style-type: decimal">
<li>Tokenize the abstracts into bigrams. Find the 10 most common bigram and visualize them with ggplot2.</li>
</ol>
<pre class="r"><code>data %&gt;%
  unnest_ngrams(output= bigram, input= abstract, n=2) %&gt;%
  anti_join(stop_words, by = c(&quot;bigram&quot; = &quot;word&quot;)) %&gt;%
  count(bigram, sort = TRUE)%&gt;%
  top_n(n=10, wt=n)%&gt;%
  ggplot(aes(x=n, y=fct_reorder(bigram, n)))+
  geom_col()</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code># Getting rid of stop words in bigram
data2&lt;- data%&gt;%
  unnest_ngrams(output= bigram, input= abstract, n=2) %&gt;%
  separate(col=bigram, into=c(&quot;word1&quot;, &quot;word2&quot;), sep = &quot; &quot;)%&gt;%
  select(word1, word2)

data2 %&gt;%
  anti_join(
    tidytext::stop_words %&gt;% select(word), by = c(&quot;word1&quot; = &quot;word&quot;)
  )%&gt;%
  anti_join(
    tidytext::stop_words %&gt;% select(word), by = c(&quot;word2&quot; = &quot;word&quot;)
  )%&gt;%
  count(word1, word2, sort=TRUE)%&gt;%
  top_n(n=10, wt=n)</code></pre>
<pre><code>## # A tibble: 10 x 3
##    word1       word2         n
##    &lt;chr&gt;       &lt;chr&gt;     &lt;int&gt;
##  1 covid       19         6969
##  2 prostate    cancer     3222
##  3 pre         eclampsia  1854
##  4 cystic      fibrosis    860
##  5 19          patients    448
##  6 19          pandemic    419
##  7 coronavirus disease     361
##  8 95          ci          322
##  9 sars        cov         317
## 10 cov         2           299</code></pre>
<p>After removing the stop words, the most frequent bigrams are “covid 19”, “prostate cancer”, “pre eclampsia”, “cystic fibrosis”, and “coronavirus disease”.</p>
<ol start="3" style="list-style-type: decimal">
<li>Calculate the TF-IDF value for each word-search term combination. (here you want the search term to be the “document”) What are the 5 tokens from each search term with the highest TF-IDF value? How are the results different from the answers you got in question 1?</li>
</ol>
<pre class="r"><code>tf_idf &lt;- data %&gt;%
  unnest_tokens(token, abstract) %&gt;%
  filter(!(token %in% stop_words$word)) %&gt;%
  group_by(term) %&gt;%
  count(token, sort = TRUE) %&gt;%
  bind_tf_idf(token, term, n) %&gt;%
  top_n(5, n) %&gt;%
  arrange(term, desc(tf_idf)) 

knitr::kable(tf_idf[, c(1:3,6)],
            caption = &quot;Table 2: Top 5 tokens with the highest TF-IDF from each term &quot;)</code></pre>
<table>
<caption>Table 2: Top 5 tokens with the highest TF-IDF from each term</caption>
<thead>
<tr class="header">
<th align="left">term</th>
<th align="left">token</th>
<th align="right">n</th>
<th align="right">tf_idf</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">covid</td>
<td align="left">covid</td>
<td align="right">7275</td>
<td align="right">0.1041177</td>
</tr>
<tr class="even">
<td align="left">covid</td>
<td align="left">pandemic</td>
<td align="right">800</td>
<td align="right">0.0114494</td>
</tr>
<tr class="odd">
<td align="left">covid</td>
<td align="left">19</td>
<td align="right">7035</td>
<td align="right">0.0000000</td>
</tr>
<tr class="even">
<td align="left">covid</td>
<td align="left">patients</td>
<td align="right">2293</td>
<td align="right">0.0000000</td>
</tr>
<tr class="odd">
<td align="left">covid</td>
<td align="left">disease</td>
<td align="right">943</td>
<td align="right">0.0000000</td>
</tr>
<tr class="even">
<td align="left">cystic fibrosis</td>
<td align="left">cf</td>
<td align="right">625</td>
<td align="right">0.0214528</td>
</tr>
<tr class="odd">
<td align="left">cystic fibrosis</td>
<td align="left">fibrosis</td>
<td align="right">867</td>
<td align="right">0.0165906</td>
</tr>
<tr class="even">
<td align="left">cystic fibrosis</td>
<td align="left">cystic</td>
<td align="right">862</td>
<td align="right">0.0164949</td>
</tr>
<tr class="odd">
<td align="left">cystic fibrosis</td>
<td align="left">patients</td>
<td align="right">586</td>
<td align="right">0.0000000</td>
</tr>
<tr class="even">
<td align="left">cystic fibrosis</td>
<td align="left">disease</td>
<td align="right">400</td>
<td align="right">0.0000000</td>
</tr>
<tr class="odd">
<td align="left">meningitis</td>
<td align="left">meningitis</td>
<td align="right">429</td>
<td align="right">0.0263883</td>
</tr>
<tr class="even">
<td align="left">meningitis</td>
<td align="left">meningeal</td>
<td align="right">219</td>
<td align="right">0.0134709</td>
</tr>
<tr class="odd">
<td align="left">meningitis</td>
<td align="left">csf</td>
<td align="right">206</td>
<td align="right">0.0072141</td>
</tr>
<tr class="even">
<td align="left">meningitis</td>
<td align="left">patients</td>
<td align="right">446</td>
<td align="right">0.0000000</td>
</tr>
<tr class="odd">
<td align="left">meningitis</td>
<td align="left">clinical</td>
<td align="right">187</td>
<td align="right">0.0000000</td>
</tr>
<tr class="even">
<td align="left">preeclampsia</td>
<td align="left">eclampsia</td>
<td align="right">2005</td>
<td align="right">0.0410837</td>
</tr>
<tr class="odd">
<td align="left">preeclampsia</td>
<td align="left">preeclampsia</td>
<td align="right">1863</td>
<td align="right">0.0381741</td>
</tr>
<tr class="even">
<td align="left">preeclampsia</td>
<td align="left">pregnancy</td>
<td align="right">969</td>
<td align="right">0.0063020</td>
</tr>
<tr class="odd">
<td align="left">preeclampsia</td>
<td align="left">pre</td>
<td align="right">2038</td>
<td align="right">0.0000000</td>
</tr>
<tr class="even">
<td align="left">preeclampsia</td>
<td align="left">women</td>
<td align="right">1196</td>
<td align="right">0.0000000</td>
</tr>
<tr class="odd">
<td align="left">prostate cancer</td>
<td align="left">prostate</td>
<td align="right">3832</td>
<td align="right">0.0906033</td>
</tr>
<tr class="even">
<td align="left">prostate cancer</td>
<td align="left">cancer</td>
<td align="right">3840</td>
<td align="right">0.0000000</td>
</tr>
<tr class="odd">
<td align="left">prostate cancer</td>
<td align="left">patients</td>
<td align="right">934</td>
<td align="right">0.0000000</td>
</tr>
<tr class="even">
<td align="left">prostate cancer</td>
<td align="left">treatment</td>
<td align="right">926</td>
<td align="right">0.0000000</td>
</tr>
<tr class="odd">
<td align="left">prostate cancer</td>
<td align="left">disease</td>
<td align="right">652</td>
<td align="right">0.0000000</td>
</tr>
</tbody>
</table>
<ul>
<li>As for the term ‘covid’, ‘covid’ and ‘pandemic’ have the highest TF-IDF value, with the TF-IDF values of ‘19’, ‘patients’, and ‘disease’ being 0.<br />
</li>
<li>As for the term ‘cystic fibrosis’, ‘cf’ becomes the first term instead of ‘fibrosis’.<br />
</li>
<li>As for the term ‘meningitis’, ‘patients; and ’clinical’ are excluded (with TF-IDF = 0).<br />
</li>
<li>As for the term ‘preeclampsia’, TF-IDF values of ‘pre’ and ‘woman’ are 0.<br />
</li>
<li>As for the term ‘prostate cancer’, only one token – ‘prostate’ has the non-zero TF-IDF value.</li>
</ul>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open')
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
